

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp269

Request ID: cder_mpl1r_wp269

Request Description: In this query, we evaluated trends in utilization of dupilumab in the MarketScan Research Databases.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 12.2.1

Data Source: This request was run against the Merative™ MarketScan® Research Database on September 15, 2023. The study period included data from January 1, 2017 to September 30, 2022. Please see Appendix A for the dates of available data used in this report.

Study Design: We identified individuals with use of dupilumab, overall and by dupilumab indication, and then characterized use and dispensing patterns by examining all episodes of use occurring after the initial exposure. This is a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposure of Interest: We defined the exposure of interest, dupilumab, using National Drug Codes (NDCs). The date of the qualifying dupilumab dispensing was defined as the index date. We created exposure episodes based on the number of days of product supplied per dispensing in the outpatient pharmacy dispensing data. We assessed two versions of each cohort of interest, one version where we bridged together episodes less than seven days apart, and one version where we did not apply any treatment gap allowance. Individuals were allowed to contribute more than one dupilumab use episode to the analyses over the cohort selection period; no incidence washout was enforced. Please see Appendix B for a list of generic and brand names of medical products used to define exposures in this request.

Cohort Eligibility Criteria: We required members to be continuously enrolled in health plans with medical and drug coverage for at least 183 days prior to their index dispensing date. A gap in enrollment of up to 45 days was allowed and treated as continuous enrollment. The following age groups were defined: 0-<6 months, 6 months-<6 years, 6-<12 years, 12-<18 years, 18-<80 years, and 80+ years.

Inclusion Criteria: We assessed cohorts of dupilumab users overall, and among those with a prior history of a dupilumab indication. We separately assessed the following indication cohorts: any indication, atopic dermatitis, asthma, chronic rhinosinusitis, eosinophilic esophagitis, and prurigo nodularis. For these indication-based cohorts, we required evidence of the indication in the 183 days prior to and including the date of the first valid index-defining exposure. We defined the indications used International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. Please see Appendix C for a list of diagnosis codes used to define inclusions in this request.

Baseline Characteristics: We evaluated the following demographic characteristics on the index date: age, year, sex, race and ethnicity. We evaluated the following clinical characteristics in the 183 days prior to the index date: combined comorbidity score, any dupilumab indication, individual dupilumab indications (atopic dermatitis, asthma, chronic rhinosinusitis, eosinophilic esophagitis, prurigo nodularis), no evidence of dupilumab indication, and health service utilization intensity metrics. We evaluated the following treatments over three time periods, from 183 days prior to index date to 31 days prior to index date, from 30 days prior to index date to one day prior to index date, and from index date to 30 days after the index date: use of topical glucocorticoids, topical calcineurin inhibitors, other topical prescription therapies, systemic therapies for atopic dermatitis, asthma biologics, oral azithromycin, exacerbation asthma inhalers (short-acting beta agonists (SABA) or short-acting muscarinic-antagonist (SAMA)), oral glucocorticoids, zileuton, montelukast, maintenance asthma inhalers (inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), or long-acting muscarinic-antagonist (LAMA)), proton pump inhibitors, IL-5 mAbs, purine analogues, IL-13 mAbs, systemic non-oral or injectable glucocorticoids, topical capsaicin, topical vitamin D analogues, systemic therapies for prurigo nodularis, and local nasal glucocorticoids. Please see Appendix D for a list of generic and brand names of medical products and Appendix E for a list of ICD-10-CM diagnosis codes used to define baseline characteristics in this request.

Please see Appendices F, G, and H for the specifications of parameters used in this request and a design diagram.

Limitations: Algorithms to define exposures, inclusion criteria, and characteristics are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

Overview for Request: cder_mpl1r_wp269

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

Overview for Request: cder_mpl1r_wp269

Request ID: cder_mpl1r_wp269

Request Description: In this query, we evaluated trends in utilization of dupilumab in the MarketScan Research Databases.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 12.2.1

Data Source: This request was run against the Merative™ MarketScan® Research Database on September 15, 2023. The study period included data from January 1, 2017 to September 30, 2022. Please see Appendix A for a the dates of available data used in this report.

Study Design: We identified individuals with use of dupilumab, overall and by dupilumab indication, and then characterized use and dispensing patterns by examining all episodes of use occurring after the initial exposure. This is a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposure of Interest: We defined the exposure of interest, dupilumab, using National Drug Codes (NDCs). The date of the qualifying dupilumab dispensing was defined as the index date. We created exposure episodes based on the number of days of product supplied per dispensing in the outpatient pharmacy dispensing data. We assessed two versions of each cohort of interest, one version where we bridged together episodes less than seven days apart, and one version where we did not apply any treatment gap allowance. Individuals were allowed to contribute more than one dupilumab use episode to the analyses over the cohort selection period; no incidence washout was enforced. Please see Appendix B for a list of generic and brand names of medical products used to define exposures in this request.

Cohort Eligibility Criteria: We required members to be continuously enrolled in health plans with medical and drug coverage for at least 183 days prior to their index dispensing date. A gap in enrollment of up to 45 days was allowed and treated as continuous enrollment. The following age groups were defined: 0-<6 months, 6 months-<6 years, 6-<12 years, 12-<18 years, 18-<80 years, and 80+ years.

Inclusion Criteria: We assessed cohorts of dupilumab users overall, and among those with a prior history of a dupilumab indication. We separately assessed the following indication cohorts: any indication, atopic dermatitis, asthma, chronic rhinosinusitis, eosinophilic esophagitis, and prurigo nodularis. For these indication-based cohorts, we required evidence of the indication in the 183 days prior to and including the date of the first valid index-defining exposure. We defined the indications used International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. Please see Appendix C for a list of diagnosis codes using to define inclusions in this request.

Baseline Characteristics: We evaluated the following demographic characteristics on the index date: age, year, sex, race and ethnicity. We evaluated the following clinical characteristics in the 183 days prior to the index date: combined comorbidity score, any dupilumab indication, individual dupilumab indications (atopic dermatitis, asthma, chronic rhinosinusitis, eosinophilic esophagitis, prurigo nodularis), no evidence of dupilumab indication, and health service utilization intensity metrics. We evaluated the following treatments over three time periods, from 183 days prior to index date to 31 days prior to index date, from 30 days prior to index date to one days prior to index date, and from index date to 30 days after the index date: use of topical glucocorticoids, topical calcineurin inhibitors, other topical prescription therapies, systemic therapies for atopic dermatitis, asthma biologics, oral azithromycin, exacerbation asthma inhalers (short-acting beta agonists (SABA) or short-acting muscarinic-antagonist (SAMA)), oral glucocorticoids, zileuton, montelukast, maintenance asthma inhalers (inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), or long-acting muscarinic-antagonist (LAMA)), proton pump inhibitors, IL-5 mAbs, purine analogues, IL-13 mAbs, systemic non-oral or injectable glucocorticoids, topical capsaicin, topical vitamin D analogues, systemic therapies for prurigo nodularis, and local nasal glucocorticoids. Please see Appendix D for a list of generic and brand names of medical products and Appendix E for a list of ICD-10-CM diagnosis codes used to define baseline characteristics in this request.

Please see Appendices F, G, and H for the specifications of parameters used in this request and a design diagram.

Limitations: Algorithms to define exposures, inclusion criteria, and characteristics are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

Table of Contents

<u>Glossary</u>	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
<u>Table 1a</u>	Characteristics of Dupilumab Use with a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1b</u>	Characteristics of Dupilumab Use with Any Indication and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1c</u>	Characteristics of Dupilumab Use with Atopic Dermatitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1d</u>	Characteristics of Dupilumab Use with Asthma and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1e</u>	Characteristics of Dupilumab Use with Chronic Rhinosinusitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1f</u>	Characteristics of Dupilumab Use with Eosinophilic Esophagitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1g</u>	Characteristics of Dupilumab Use with Prurigo Nodularis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1h</u>	Characteristics of Dupilumab Use with a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1i</u>	Characteristics of Dupilumab Use with Any Indication and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1j</u>	Characteristics of Dupilumab Use with Atopic Dermatitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1k</u>	Characteristics of Dupilumab Use with Asthma and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1l</u>	Characteristics of Dupilumab Use with Chronic Rhinosinusitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1m</u>	Characteristics of Dupilumab Use with Eosinophilic Esophagitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 1n</u>	Characteristics of Dupilumab Use with Prurigo Nodularis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 2a</u>	Continuous Summary of Days Supplied per Dispensing for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 2b</u>	Continuous Summary of Days Supplied per Dispensing for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex
<u>Table 2c</u>	Continuous Summary of Days Supplied per Dispensing for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group
<u>Table 3a</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Table of Contents

<u>Table 3b</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex
<u>Table 3c</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group
<u>Table 3d</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month
<u>Table 4a</u>	Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 4b</u>	Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex
<u>Table 4c</u>	Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group
<u>Table 4d</u>	Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month
<u>Table 5a</u>	Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 5b</u>	Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex
<u>Table 5c</u>	Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group
<u>Table 5d</u>	Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month
<u>Table 6a</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 6b</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex
<u>Table 6c</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group
<u>Table 6d</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month
<u>Table 7a</u>	Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 7b</u>	Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex
<u>Table 7c</u>	Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group
<u>Table 7d</u>	Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Table of Contents

<u>Table 8a</u>	Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 8b</u>	Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex
<u>Table 8c</u>	Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group
<u>Table 8d</u>	Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month
<u>Table 9a</u>	Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 9b</u>	Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex
<u>Table 9c</u>	Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group
<u>Table 9d</u>	Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month
<u>Table 10</u>	Summary of Reasons First Treatment Episodes Ended for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 11</u>	Summary of Reasons Treatment Episodes Ended for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Table 12</u>	Summary of Patient Level Cohort Attrition in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date
<u>Appendix B</u>	List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request
<u>Appendix C</u>	List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inclusion Criteria in this Request
<u>Appendix D</u>	List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request
<u>Appendix E</u>	List of Healthcare Common Procedure Coding System, Level II (HCPCS and ICD-10) Codes Used to Define Baseline Characteristics in this Request
<u>Appendix F</u>	Specifications Defining Parameters for this Request
<u>Appendix G</u>	Specifications Used to Define Baseline Characteristic Parameters in this Request
<u>Appendix H</u>	Design Diagram of Cohort Entry Requirements

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Characteristics of Dupilumab Use with a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

No Indication Requirement		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	39,944	N/A
Demographic Characteristics		
Age (years)	40.0	18.2
Age		
0-5 months	0	0.0%
6 months-5 years	315	0.8%
6-11 years	1,500	3.8%
12-17 years	3,721	9.3%
18-79 years	34,006	85.1%
≥ 80 years	402	1.0%
Sex		
Female	22,463	56.2%
Male	17,481	43.8%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	39,944	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	39,944	100.0%
Year		
2017	2,114	5.3%
2018	3,406	8.5%
2019	6,995	17.5%
2020	8,628	21.6%
2021	10,053	25.2%
2022	8,748	21.9%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	35,184	88.1%
Atopic Dermatitis	26,007	65.1%
Asthma	11,492	28.8%

Table 1a. Characteristics of Dupilumab Use with a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

No Indication Requirement		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Chronic Rhinosinusitis	7,059	17.7%
Eosinophilic Esophagitis	1,512	3.8%
Prurigo Nodularis	637	1.6%
No Dupilumab Indication	4,760	11.9%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	19,959	50.0%
Topical Calcineurin Inhibitors	5,746	14.4%
Other Topical Prescription Therapies	108	0.3%
Systemic Therapies for Atopic Dermatitis	1,990	5.0%
Asthma Biologics	1,579	4.0%
Oral Azithromycin	3,412	8.5%
Exacerbation Asthma Inhalers (SABA or SAMA)	9,025	22.6%
Oral Glucocorticoids	15,401	38.6%
Zileuton	93	0.2%
Montelukast	8,275	20.7%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	9,800	24.5%
Proton Pump Inhibitors	4,701	11.8%
IL-5 mAbs	757	1.9%
Purine Analogues	153	0.4%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	7,308	18.3%
Topical Capsaicin	1	0.0%
Topical Vitamin D Analogues	276	0.7%
Systemic Therapies for Prurigo Nodularis	11,020	27.6%
Local Nasal Glucocorticoids	4,354	10.9%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	13,225	33.1%
Topical Calcineurin Inhibitors	4,043	10.1%
Other Topical Prescription Therapies	107	0.3%
Systemic Therapies for Atopic Dermatitis	1,429	3.6%
Asthma Biologics	986	2.5%
Oral Azithromycin	904	2.3%
Exacerbation Asthma Inhalers (SABA or SAMA)	5,055	12.7%
Oral Glucocorticoids	7,516	18.8%
Zileuton	76	0.2%
Montelukast	6,839	17.1%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	7,687	19.2%

Table 1a. Characteristics of Dupilumab Use with a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

No Indication Requirement		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Proton Pump Inhibitors	3,802	9.5%
IL-5 mAbs	447	1.1%
Purine Analogues	103	0.3%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	2,484	6.2%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	121	0.3%
Systemic Therapies for Prurigo Nodularis	8,858	22.2%
Local Nasal Glucocorticoids	2,710	6.8%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	10,769	27.0%
Topical Calcineurin Inhibitors	2,888	7.2%
Other Topical Prescription Therapies	107	0.3%
Systemic Therapies for Atopic Dermatitis	1,164	2.9%
Asthma Biologics	586	1.5%
Oral Azithromycin	834	2.1%
Exacerbation Asthma Inhalers (SABA or SAMA)	4,666	11.7%
Oral Glucocorticoids	4,912	12.3%
Zileuton	71	0.2%
Montelukast	6,617	16.6%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	7,465	18.7%
Proton Pump Inhibitors	3,821	9.6%
IL-5 mAbs	246	0.6%
Purine Analogues	81	0.2%
IL-13 mAbs	2	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	1,268	3.2%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	96	0.2%
Systemic Therapies for Prurigo Nodularis	8,491	21.3%
Local Nasal Glucocorticoids	2,590	6.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.4	9.1
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.0	4.4
Mean number of filled prescriptions	14.4	13.4

Table 1a. Characteristics of Dupilumab Use with a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

No Indication Requirement		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of generics dispensed	7.2	5.2
Mean number of unique drug classes dispensed	6.5	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 1b. Characteristics of Dupilumab Use with Any Indication and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	36,986	N/A
Demographic Characteristics		
Age (years)	39.7	18.2
Age		
0-5 months	0	0.0%
6 months-5 years	307	0.8%
6-11 years	1,446	3.9%
12-17 years	3,541	9.6%
18-79 years	31,346	84.8%
≥ 80 years	346	0.9%
Sex		
Female	20,805	56.3%
Male	16,181	43.7%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	36,986	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	36,986	100.0%
Year		
2017	1,913	5.2%
2018	3,097	8.4%
2019	6,528	17.6%
2020	7,951	21.5%
2021	9,349	25.3%
2022	8,148	22.0%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	36,986	100.0%
Atopic Dermatitis	27,470	74.3%
Asthma	11,804	31.9%
Chronic Rhinosinusitis	7,198	19.5%
Eosinophilic Esophagitis	1,573	4.3%

Table 1b. Characteristics of Dupilumab Use with Any Indication and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	659	1.8%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	18,472	49.9%
Topical Calcineurin Inhibitors	5,426	14.7%
Other Topical Prescription Therapies	107	0.3%
Systemic Therapies for Atopic Dermatitis	1,790	4.8%
Asthma Biologics	1,553	4.2%
Oral Azithromycin	3,275	8.9%
Exacerbation Asthma Inhalers (SABA or SAMA)	8,767	23.7%
Oral Glucocorticoids	14,624	39.5%
Zileuton	89	0.2%
Montelukast	8,019	21.7%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	9,562	25.9%
Proton Pump Inhibitors	4,452	12.0%
IL-5 mAbs	753	2.0%
Purine Analogues	132	0.4%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	6,962	18.8%
Topical Capsaicin	1	0.0%
Topical Vitamin D Analogues	240	0.6%
Systemic Therapies for Prurigo Nodularis	10,527	28.5%
Local Nasal Glucocorticoids	4,190	11.3%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	12,214	33.0%
Topical Calcineurin Inhibitors	3,739	10.1%
Other Topical Prescription Therapies	104	0.3%
Systemic Therapies for Atopic Dermatitis	1,280	3.5%
Asthma Biologics	976	2.6%
Oral Azithromycin	874	2.4%
Exacerbation Asthma Inhalers (SABA or SAMA)	4,955	13.4%
Oral Glucocorticoids	7,032	19.0%
Zileuton	72	0.2%
Montelukast	6,604	17.9%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	7,528	20.4%
Proton Pump Inhibitors	3,614	9.8%
IL-5 mAbs	448	1.2%
Purine Analogues	87	0.2%
IL-13 mAbs	0	0.0%

Table 1b. Characteristics of Dupilumab Use with Any Indication and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	2,317	6.3%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	104	0.3%
Systemic Therapies for Prurigo Nodularis	8,457	22.9%
Local Nasal Glucocorticoids	2,617	7.1%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	9,890	26.7%
Topical Calcineurin Inhibitors	2,693	7.3%
Other Topical Prescription Therapies	100	0.3%
Systemic Therapies for Atopic Dermatitis	1,048	2.8%
Asthma Biologics	580	1.6%
Oral Azithromycin	791	2.1%
Exacerbation Asthma Inhalers (SABA or SAMA)	4,539	12.3%
Oral Glucocorticoids	4,599	12.4%
Zileuton	69	0.2%
Montelukast	6,393	17.3%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	7,299	19.7%
Proton Pump Inhibitors	3,625	9.8%
IL-5 mAbs	247	0.7%
Purine Analogues	69	0.2%
IL-13 mAbs	3	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	1,194	3.2%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	84	0.2%
Systemic Therapies for Prurigo Nodularis	8,102	21.9%
Local Nasal Glucocorticoids	2,486	6.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.7	9.1
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.0	4.5
Mean number of filled prescriptions	14.6	13.5
Mean number of generics dispensed	7.3	5.2
Mean number of unique drug classes dispensed	6.6	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1c. Characteristics of Dupilumab Use with Atopic Dermatitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	28,055	N/A
Demographic Characteristics		
Age (years)	37.3	18.4
Age		
0-5 months	0	0.0%
6 months-5 years	297	1.1%
6-11 years	1,368	4.9%
12-17 years	3,241	11.6%
18-79 years	22,870	81.5%
≥ 80 years	279	1.0%
Sex		
Female	15,820	56.4%
Male	12,235	43.6%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	28,055	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	28,055	100.0%
Year		
2017	1,845	6.6%
2018	2,940	10.5%
2019	4,910	17.5%
2020	5,595	19.9%
2021	6,945	24.8%
2022	5,820	20.7%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	28,055	100.0%
Atopic Dermatitis	28,055	100.0%
Asthma	4,964	17.7%
Chronic Rhinosinusitis	1,579	5.6%
Eosinophilic Esophagitis	717	2.6%

Table 1c. Characteristics of Dupilumab Use with Atopic Dermatitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	534	1.9%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	17,381	62.0%
Topical Calcineurin Inhibitors	5,287	18.8%
Other Topical Prescription Therapies	103	0.4%
Systemic Therapies for Atopic Dermatitis	1,653	5.9%
Asthma Biologics	405	1.4%
Oral Azithromycin	1,646	5.9%
Exacerbation Asthma Inhalers (SABA or SAMA)	4,386	15.6%
Oral Glucocorticoids	9,024	32.2%
Zileuton	8	0.0%
Montelukast	3,563	12.7%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	3,456	12.3%
Proton Pump Inhibitors	2,314	8.2%
IL-5 mAbs	74	0.3%
Purine Analogues	108	0.4%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	4,983	17.8%
Topical Capsaicin	1	0.0%
Topical Vitamin D Analogues	216	0.8%
Systemic Therapies for Prurigo Nodularis	5,697	20.3%
Local Nasal Glucocorticoids	1,839	6.6%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	11,669	41.6%
Topical Calcineurin Inhibitors	3,639	13.0%
Other Topical Prescription Therapies	101	0.4%
Systemic Therapies for Atopic Dermatitis	1,175	4.2%
Asthma Biologics	249	0.9%
Oral Azithromycin	391	1.4%
Exacerbation Asthma Inhalers (SABA or SAMA)	2,210	7.9%
Oral Glucocorticoids	4,095	14.6%
Zileuton	4	0.0%
Montelukast	2,754	9.8%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	2,416	8.6%
Proton Pump Inhibitors	1,834	6.5%
IL-5 mAbs	43	0.2%
Purine Analogues	69	0.2%
IL-13 mAbs	0	0.0%

Table 1c. Characteristics of Dupilumab Use with Atopic Dermatitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	1,756	6.3%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	95	0.3%
Systemic Therapies for Prurigo Nodularis	4,296	15.3%
Local Nasal Glucocorticoids	1,028	3.7%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	9,391	33.5%
Topical Calcineurin Inhibitors	2,613	9.3%
Other Topical Prescription Therapies	98	0.3%
Systemic Therapies for Atopic Dermatitis	949	3.4%
Asthma Biologics	183	0.7%
Oral Azithromycin	386	1.4%
Exacerbation Asthma Inhalers (SABA or SAMA)	2,045	7.3%
Oral Glucocorticoids	2,551	9.1%
Zileuton	4	0.0%
Montelukast	2,648	9.4%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	2,365	8.4%
Proton Pump Inhibitors	1,840	6.6%
IL-5 mAbs	33	0.1%
Purine Analogues	55	0.2%
IL-13 mAbs	2	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	796	2.8%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	81	0.3%
Systemic Therapies for Prurigo Nodularis	4,048	14.4%
Local Nasal Glucocorticoids	998	3.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.7	8.7
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	1.7	3.9
Mean number of filled prescriptions	12.6	11.5
Mean number of generics dispensed	6.5	4.6
Mean number of unique drug classes dispensed	5.9	4.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1d. Characteristics of Dupilumab Use with Asthma and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	13,372	N/A
Demographic Characteristics		
Age (years)	41.1	17.8
Age		
0-5 months	0	0.0%
6 months-5 years	56	0.4%
6-11 years	533	4.0%
12-17 years	1,285	9.6%
18-79 years	11,418	85.4%
≥ 80 years	80	0.6%
Sex		
Female	7,812	58.4%
Male	5,560	41.6%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	13,372	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	13,372	100.0%
Year		
2017	449	3.4%
2018	791	5.9%
2019	2,598	19.4%
2020	3,187	23.8%
2021	3,400	25.4%
2022	2,947	22.0%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	13,372	100.0%
Atopic Dermatitis	5,738	42.9%
Asthma	13,372	100.0%
Chronic Rhinosinusitis	4,779	35.7%
Eosinophilic Esophagitis	772	5.8%

Table 1d. Characteristics of Dupilumab Use with Asthma and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	91	0.7%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	4,552	34.0%
Topical Calcineurin Inhibitors	1,253	9.4%
Other Topical Prescription Therapies	19	0.1%
Systemic Therapies for Atopic Dermatitis	427	3.2%
Asthma Biologics	1,421	10.6%
Oral Azithromycin	2,115	15.8%
Exacerbation Asthma Inhalers (SABA or SAMA)	7,245	54.2%
Oral Glucocorticoids	7,064	52.8%
Zileuton	89	0.7%
Montelukast	5,880	44.0%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	8,161	61.0%
Proton Pump Inhibitors	2,487	18.6%
IL-5 mAbs	745	5.6%
Purine Analogues	38	0.3%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	2,765	20.7%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	51	0.4%
Systemic Therapies for Prurigo Nodularis	6,538	48.9%
Local Nasal Glucocorticoids	2,634	19.7%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	2,696	20.2%
Topical Calcineurin Inhibitors	799	6.0%
Other Topical Prescription Therapies	14	0.1%
Systemic Therapies for Atopic Dermatitis	292	2.2%
Asthma Biologics	887	6.6%
Oral Azithromycin	634	4.7%
Exacerbation Asthma Inhalers (SABA or SAMA)	4,453	33.3%
Oral Glucocorticoids	3,589	26.8%
Zileuton	72	0.5%
Montelukast	5,006	37.4%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	6,639	49.6%
Proton Pump Inhibitors	2,036	15.2%
IL-5 mAbs	438	3.3%
Purine Analogues	26	0.2%
IL-13 mAbs	0	0.0%

Table 1d. Characteristics of Dupilumab Use with Asthma and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	828	6.2%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	25	0.2%
Systemic Therapies for Prurigo Nodularis	5,512	41.2%
Local Nasal Glucocorticoids	1,741	13.0%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	2,256	16.9%
Topical Calcineurin Inhibitors	587	4.4%
Other Topical Prescription Therapies	15	0.1%
Systemic Therapies for Atopic Dermatitis	253	1.9%
Asthma Biologics	521	3.9%
Oral Azithromycin	511	3.8%
Exacerbation Asthma Inhalers (SABA or SAMA)	3,954	29.6%
Oral Glucocorticoids	2,481	18.6%
Zileuton	68	0.5%
Montelukast	4,860	36.3%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	6,427	48.1%
Proton Pump Inhibitors	2,034	15.2%
IL-5 mAbs	241	1.8%
Purine Analogues	23	0.2%
IL-13 mAbs	3	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	538	4.0%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	20	0.1%
Systemic Therapies for Prurigo Nodularis	5,334	39.9%
Local Nasal Glucocorticoids	1,623	12.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.1	10.0
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.7	5.2
Mean number of filled prescriptions	20.0	15.9
Mean number of generics dispensed	9.4	5.8
Mean number of unique drug classes dispensed	8.7	5.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 1e. Characteristics of Dupilumab Use with Chronic Rhinosinusitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	8,142	N/A
Demographic Characteristics		
Age (years)	45.7	15.4
Age		
0-5 months	0	0.0%
6 months-5 years	21	0.3%
6-11 years	93	1.1%
12-17 years	302	3.7%
18-79 years	7,666	94.2%
≥ 80 years	60	0.7%
Sex		
Female	4,444	54.6%
Male	3,698	45.4%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	8,142	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	8,142	100.0%
Year		
2017	121	1.5%
2018	295	3.6%
2019	1,438	17.7%
2020	2,073	25.5%
2021	2,244	27.6%
2022	1,971	24.2%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	8,142	100.0%
Atopic Dermatitis	1,986	24.4%
Asthma	4,956	60.9%
Chronic Rhinosinusitis	8,142	100.0%
Eosinophilic Esophagitis	410	5.0%

Table 1e. Characteristics of Dupilumab Use with Chronic Rhinosinusitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	40	0.5%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	1,813	22.3%
Topical Calcineurin Inhibitors	400	4.9%
Other Topical Prescription Therapies	11	0.1%
Systemic Therapies for Atopic Dermatitis	173	2.1%
Asthma Biologics	722	8.9%
Oral Azithromycin	1,338	16.4%
Exacerbation Asthma Inhalers (SABA or SAMA)	3,300	40.5%
Oral Glucocorticoids	4,878	59.9%
Zileuton	66	0.8%
Montelukast	3,601	44.2%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	4,579	56.2%
Proton Pump Inhibitors	1,583	19.4%
IL-5 mAbs	426	5.2%
Purine Analogues	15	0.2%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	1,736	21.3%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	23	0.3%
Systemic Therapies for Prurigo Nodularis	3,947	48.5%
Local Nasal Glucocorticoids	2,257	27.7%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	974	12.0%
Topical Calcineurin Inhibitors	257	3.2%
Other Topical Prescription Therapies	5	0.1%
Systemic Therapies for Atopic Dermatitis	119	1.5%
Asthma Biologics	461	5.7%
Oral Azithromycin	380	4.7%
Exacerbation Asthma Inhalers (SABA or SAMA)	1,889	23.2%
Oral Glucocorticoids	2,404	29.5%
Zileuton	53	0.7%
Montelukast	3,076	37.8%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	3,757	46.1%
Proton Pump Inhibitors	1,300	16.0%
IL-5 mAbs	264	3.2%
Purine Analogues	13	0.2%
IL-13 mAbs	0	0.0%

Table 1e. Characteristics of Dupilumab Use with Chronic Rhinosinusitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	479	5.9%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	8	0.1%
Systemic Therapies for Prurigo Nodularis	3,357	41.2%
Local Nasal Glucocorticoids	1,508	18.5%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	813	10.0%
Topical Calcineurin Inhibitors	193	2.4%
Other Topical Prescription Therapies	4	0.0%
Systemic Therapies for Atopic Dermatitis	110	1.4%
Asthma Biologics	279	3.4%
Oral Azithromycin	313	3.8%
Exacerbation Asthma Inhalers (SABA or SAMA)	1,669	20.5%
Oral Glucocorticoids	1,621	19.9%
Zileuton	53	0.7%
Montelukast	2,955	36.3%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	3,615	44.4%
Proton Pump Inhibitors	1,305	16.0%
IL-5 mAbs	151	1.9%
Purine Analogues	14	0.2%
IL-13 mAbs	1	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	341	4.2%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	7	0.1%
Systemic Therapies for Prurigo Nodularis	3,226	39.6%
Local Nasal Glucocorticoids	1,412	17.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.8	10.0
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.8	5.5
Mean number of filled prescriptions	19.5	15.4
Mean number of generics dispensed	9.4	5.8
Mean number of unique drug classes dispensed	8.7	5.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1f. Characteristics of Dupilumab Use with Eosinophilic Esophagitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	2,453	N/A
Demographic Characteristics		
Age (years)	42.2	18.0
Age		
0-5 months	0	0.0%
6 months-5 years	17	0.7%
6-11 years	76	3.1%
12-17 years	205	8.4%
18-79 years	2,120	86.4%
≥ 80 years	35	1.4%
Sex		
Female	1,427	58.2%
Male	1,026	41.8%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	2,453	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	2,453	100.0%
Year		
2017	58	2.4%
2018	161	6.6%
2019	382	15.6%
2020	460	18.8%
2021	616	25.1%
2022	776	31.6%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	2,453	100.0%
Atopic Dermatitis	1,180	48.1%
Asthma	1,079	44.0%
Chronic Rhinosinusitis	535	21.8%
Eosinophilic Esophagitis	2,453	100.0%

Table 1f. Characteristics of Dupilumab Use with Eosinophilic Esophagitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	31	1.3%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	927	37.8%
Topical Calcineurin Inhibitors	243	9.9%
Other Topical Prescription Therapies	4	0.2%
Systemic Therapies for Atopic Dermatitis	106	4.3%
Asthma Biologics	137	5.6%
Oral Azithromycin	308	12.6%
Exacerbation Asthma Inhalers (SABA or SAMA)	715	29.1%
Oral Glucocorticoids	964	39.3%
Zileuton	8	0.3%
Montelukast	664	27.1%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	912	37.2%
Proton Pump Inhibitors	1,099	44.8%
IL-5 mAbs	60	2.4%
Purine Analogues	8	0.3%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	539	22.0%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	17	0.7%
Systemic Therapies for Prurigo Nodularis	889	36.2%
Local Nasal Glucocorticoids	348	14.2%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	506	20.6%
Topical Calcineurin Inhibitors	123	5.0%
Other Topical Prescription Therapies	3	0.1%
Systemic Therapies for Atopic Dermatitis	69	2.8%
Asthma Biologics	84	3.4%
Oral Azithromycin	87	3.5%
Exacerbation Asthma Inhalers (SABA or SAMA)	380	15.5%
Oral Glucocorticoids	442	18.0%
Zileuton	3	0.1%
Montelukast	540	22.0%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	681	27.8%
Proton Pump Inhibitors	940	38.3%
IL-5 mAbs	40	1.6%
Purine Analogues	4	0.2%
IL-13 mAbs	0	0.0%

Table 1f. Characteristics of Dupilumab Use with Eosinophilic Esophagitis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	185	7.5%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	6	0.2%
Systemic Therapies for Prurigo Nodularis	706	28.8%
Local Nasal Glucocorticoids	230	9.4%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	454	18.5%
Topical Calcineurin Inhibitors	89	3.6%
Other Topical Prescription Therapies	4	0.2%
Systemic Therapies for Atopic Dermatitis	59	2.4%
Asthma Biologics	53	2.2%
Oral Azithromycin	71	2.9%
Exacerbation Asthma Inhalers (SABA or SAMA)	350	14.3%
Oral Glucocorticoids	348	14.2%
Zileuton	3	0.1%
Montelukast	514	21.0%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	652	26.6%
Proton Pump Inhibitors	910	37.1%
IL-5 mAbs	20	0.8%
Purine Analogues	6	0.2%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	125	5.1%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	5	0.2%
Systemic Therapies for Prurigo Nodularis	670	27.3%
Local Nasal Glucocorticoids	229	9.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.0	11.4
Mean number of emergency room encounters	0.6	1.3
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.9	7.7
Mean number of filled prescriptions	21.8	18.3
Mean number of generics dispensed	10.4	6.7
Mean number of unique drug classes dispensed	9.5	5.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 1g. Characteristics of Dupilumab Use with Prurigo Nodularis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	828	N/A
Demographic Characteristics		
Age (years)	50.6	16.8
Age		
0-5 months	0	0.0%
6 months-5 years	2	0.2%
6-11 years	12	1.4%
12-17 years	35	4.2%
18-79 years	756	91.3%
≥ 80 years	23	2.8%
Sex		
Female	493	59.5%
Male	335	40.5%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	828	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	828	100.0%
Year		
2017	35	4.2%
2018	69	8.3%
2019	152	18.4%
2020	159	19.2%
2021	204	24.6%
2022	209	25.2%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	828	100.0%
Atopic Dermatitis	661	79.8%
Asthma	98	11.8%
Chronic Rhinosinusitis	39	4.7%
Eosinophilic Esophagitis	23	2.8%

Table 1g. Characteristics of Dupilumab Use with Prurigo Nodularis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	828	100.0%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	591	71.4%
Topical Calcineurin Inhibitors	136	16.4%
Other Topical Prescription Therapies	1	0.1%
Systemic Therapies for Atopic Dermatitis	67	8.1%
Asthma Biologics	8	1.0%
Oral Azithromycin	62	7.5%
Exacerbation Asthma Inhalers (SABA or SAMA)	117	14.1%
Oral Glucocorticoids	257	31.0%
Zileuton	1	0.1%
Montelukast	93	11.2%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	96	11.6%
Proton Pump Inhibitors	123	14.9%
IL-5 mAbs	2	0.2%
Purine Analogues	7	0.8%
IL-13 mAbs	1	0.1%
Systemic Non-Oral or Injectable Glucocorticoids	259	31.3%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	14	1.7%
Systemic Therapies for Prurigo Nodularis	231	27.9%
Local Nasal Glucocorticoids	71	8.6%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	382	46.1%
Topical Calcineurin Inhibitors	109	13.2%
Other Topical Prescription Therapies	1	0.1%
Systemic Therapies for Atopic Dermatitis	49	5.9%
Asthma Biologics	6	0.7%
Oral Azithromycin	18	2.2%
Exacerbation Asthma Inhalers (SABA or SAMA)	49	5.9%
Oral Glucocorticoids	96	11.6%
Zileuton	1	0.1%
Montelukast	74	8.9%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	73	8.8%
Proton Pump Inhibitors	96	11.6%
IL-5 mAbs	2	0.2%
Purine Analogues	3	0.4%
IL-13 mAbs	1	0.1%

Table 1g. Characteristics of Dupilumab Use with Prurigo Nodularis and a 0-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	105	12.7%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	6	0.7%
Systemic Therapies for Prurigo Nodularis	186	22.5%
Local Nasal Glucocorticoids	35	4.2%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	334	40.3%
Topical Calcineurin Inhibitors	78	9.4%
Other Topical Prescription Therapies	1	0.1%
Systemic Therapies for Atopic Dermatitis	37	4.5%
Asthma Biologics	3	0.4%
Oral Azithromycin	17	2.1%
Exacerbation Asthma Inhalers (SABA or SAMA)	50	6.0%
Oral Glucocorticoids	88	10.6%
Zileuton	1	0.1%
Montelukast	72	8.7%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	75	9.1%
Proton Pump Inhibitors	99	12.0%
IL-5 mAbs	1	0.1%
Purine Analogues	2	0.2%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	73	8.8%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	3	0.4%
Systemic Therapies for Prurigo Nodularis	182	22.0%
Local Nasal Glucocorticoids	38	4.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.3	10.3
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.4	3.9
Mean number of filled prescriptions	19.2	16.1
Mean number of generics dispensed	9.1	5.6
Mean number of unique drug classes dispensed	8.2	5.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1h. Characteristics of Dupilumab Use with a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

No Indication Requirement		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	38,506	N/A
Demographic Characteristics		
Age (years)	39.9	18.2
Age		
0-5 months	0	0.0%
6 months-5 years	314	0.8%
6-11 years	1,471	3.8%
12-17 years	3,630	9.4%
18-79 years	32,712	85.0%
≥ 80 years	379	1.0%
Sex		
Female	21,653	56.2%
Male	16,853	43.8%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	38,506	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	38,506	100.0%
Year		
2017	2,076	5.4%
2018	3,241	8.4%
2019	6,856	17.8%
2020	8,300	21.6%
2021	9,629	25.0%
2022	8,404	21.8%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	34,020	88.3%
Atopic Dermatitis	25,121	65.2%

Table 1h. Characteristics of Dupilumab Use with a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	No Indication Requirement	
	Number/Mean	Percent/ Standard Deviation ¹
Asthma	11,122	28.9%
Chronic Rhinosinusitis	6,850	17.8%
Eosinophilic Esophagitis	1,466	3.8%
Prurigo Nodularis	627	1.6%
No Dupilumab Indication	4,486	11.7%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	19,420	50.4%
Topical Calcineurin Inhibitors	5,591	14.5%
Other Topical Prescription Therapies	106	0.3%
Systemic Therapies for Atopic Dermatitis	1,937	5.0%
Asthma Biologics	1,552	4.0%
Oral Azithromycin	3,320	8.6%
Exacerbation Asthma Inhalers (SABA or SAMA)	8,723	22.7%
Oral Glucocorticoids	15,014	39.0%
Zileuton	91	0.2%
Montelukast	8,010	20.8%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	9,489	24.6%
Proton Pump Inhibitors	4,562	11.8%
IL-5 mAbs	750	1.9%
Purine Analogues	148	0.4%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	7,116	18.5%
Topical Capsaicin	1	0.0%
Topical Vitamin D Analogues	273	0.7%
Systemic Therapies for Prurigo Nodularis	10,674	27.7%
Local Nasal Glucocorticoids	4,232	11.0%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	13,034	33.8%
Topical Calcineurin Inhibitors	4,000	10.4%
Other Topical Prescription Therapies	110	0.3%
Systemic Therapies for Atopic Dermatitis	1,407	3.7%
Asthma Biologics	981	2.5%
Oral Azithromycin	884	2.3%
Exacerbation Asthma Inhalers (SABA or SAMA)	4,919	12.8%
Oral Glucocorticoids	7,427	19.3%
Zileuton	75	0.2%
Montelukast	6,614	17.2%

Table 1h. Characteristics of Dupilumab Use with a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	No Indication Requirement	
	Number/Mean	Percent/ Standard Deviation ¹
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	7,449	19.3%
Proton Pump Inhibitors	3,675	9.5%
IL-5 mAbs	447	1.2%
Purine Analogues	101	0.3%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	2,467	6.4%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	122	0.3%
Systemic Therapies for Prurigo Nodularis	8,585	22.3%
Local Nasal Glucocorticoids	2,618	6.8%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	10,607	27.5%
Topical Calcineurin Inhibitors	2,851	7.4%
Other Topical Prescription Therapies	104	0.3%
Systemic Therapies for Atopic Dermatitis	1,145	3.0%
Asthma Biologics	580	1.5%
Oral Azithromycin	810	2.1%
Exacerbation Asthma Inhalers (SABA or SAMA)	4,548	11.8%
Oral Glucocorticoids	4,845	12.6%
Zileuton	70	0.2%
Montelukast	6,386	16.6%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	7,226	18.8%
Proton Pump Inhibitors	3,679	9.6%
IL-5 mAbs	245	0.6%
Purine Analogues	79	0.2%
IL-13 mAbs	2	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	1,231	3.2%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	96	0.2%
Systemic Therapies for Prurigo Nodularis	8,210	21.3%
Local Nasal Glucocorticoids	2,511	6.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.4	9.1
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.0	4.5

Table 1h. Characteristics of Dupilumab Use with a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

No Indication Requirement		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	14.3	13.4
Mean number of generics dispensed	7.2	5.2
Mean number of unique drug classes dispensed	6.5	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1i. Characteristics of Dupilumab Use with Any Indication and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	35,371	N/A
Demographic Characteristics		
Age (years)	39.5	18.2
Age		
0-5 months	0	0.0%
6 months-5 years	305	0.9%
6-11 years	1,410	4.0%
12-17 years	3,439	9.7%
18-79 years	29,900	84.5%
≥ 80 years	317	0.9%
Sex		
Female	19,925	56.3%
Male	15,446	43.7%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	35,371	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	35,371	100.0%
Year		
2017	1,856	5.2%
2018	2,911	8.2%
2019	6,356	18.0%
2020	7,614	21.5%
2021	8,860	25.0%
2022	7,774	22.0%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	35,371	100.0%
Atopic Dermatitis	26,246	74.2%
Asthma	11,346	32.1%
Chronic Rhinosinusitis	6,950	19.6%
Eosinophilic Esophagitis	1,510	4.3%

Table 1i. Characteristics of Dupilumab Use with Any Indication and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	645	1.8%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	17,791	50.3%
Topical Calcineurin Inhibitors	5,225	14.8%
Other Topical Prescription Therapies	103	0.3%
Systemic Therapies for Atopic Dermatitis	1,717	4.9%
Asthma Biologics	1,527	4.3%
Oral Azithromycin	3,189	9.0%
Exacerbation Asthma Inhalers (SABA or SAMA)	8,470	23.9%
Oral Glucocorticoids	14,155	40.0%
Zileuton	86	0.2%
Montelukast	7,736	21.9%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	9,244	26.1%
Proton Pump Inhibitors	4,286	12.1%
IL-5 mAbs	747	2.1%
Purine Analogues	126	0.4%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	6,712	19.0%
Topical Capsaicin	1	0.0%
Topical Vitamin D Analogues	233	0.7%
Systemic Therapies for Prurigo Nodularis	10,131	28.6%
Local Nasal Glucocorticoids	4,043	11.4%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	11,923	33.7%
Topical Calcineurin Inhibitors	3,684	10.4%
Other Topical Prescription Therapies	104	0.3%
Systemic Therapies for Atopic Dermatitis	1,252	3.5%
Asthma Biologics	971	2.7%
Oral Azithromycin	850	2.4%
Exacerbation Asthma Inhalers (SABA or SAMA)	4,793	13.6%
Oral Glucocorticoids	6,914	19.5%
Zileuton	70	0.2%
Montelukast	6,369	18.0%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	7,284	20.6%
Proton Pump Inhibitors	3,466	9.8%
IL-5 mAbs	448	1.3%
Purine Analogues	87	0.2%
IL-13 mAbs	0	0.0%

Table 1i. Characteristics of Dupilumab Use with Any Indication and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	2,282	6.5%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	105	0.3%
Systemic Therapies for Prurigo Nodularis	8,152	23.0%
Local Nasal Glucocorticoids	2,513	7.1%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	9,636	27.2%
Topical Calcineurin Inhibitors	2,635	7.4%
Other Topical Prescription Therapies	98	0.3%
Systemic Therapies for Atopic Dermatitis	1,021	2.9%
Asthma Biologics	573	1.6%
Oral Azithromycin	765	2.2%
Exacerbation Asthma Inhalers (SABA or SAMA)	4,389	12.4%
Oral Glucocorticoids	4,513	12.8%
Zileuton	66	0.2%
Montelukast	6,152	17.4%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	7,048	19.9%
Proton Pump Inhibitors	3,458	9.8%
IL-5 mAbs	245	0.7%
Purine Analogues	70	0.2%
IL-13 mAbs	2	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	1,155	3.3%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	83	0.2%
Systemic Therapies for Prurigo Nodularis	7,787	22.0%
Local Nasal Glucocorticoids	2,404	6.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.7	9.2
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.0	4.5
Mean number of filled prescriptions	14.5	13.5
Mean number of generics dispensed	7.3	5.2
Mean number of unique drug classes dispensed	6.6	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1j. Characteristics of Dupilumab Use with Atopic Dermatitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	26,674	N/A
Demographic Characteristics		
Age (years)	37.1	18.4
Age		
0-5 months	0	0.0%
6 months-5 years	295	1.1%
6-11 years	1,336	5.0%
12-17 years	3,132	11.7%
18-79 years	21,656	81.2%
≥ 80 years	255	1.0%
Sex		
Female	15,069	56.5%
Male	11,605	43.5%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	26,674	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	26,674	100.0%
Year		
2017	1,783	6.7%
2018	2,754	10.3%
2019	4,741	17.8%
2020	5,328	20.0%
2021	6,558	24.6%
2022	5,510	20.7%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	26,674	100.0%
Atopic Dermatitis	26,674	100.0%
Asthma	4,683	17.6%
Chronic Rhinosinusitis	1,471	5.5%
Eosinophilic Esophagitis	689	2.6%

Table 1j. Characteristics of Dupilumab Use with Atopic Dermatitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	520	1.9%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	16,706	62.6%
Topical Calcineurin Inhibitors	5,080	19.0%
Other Topical Prescription Therapies	99	0.4%
Systemic Therapies for Atopic Dermatitis	1,587	5.9%
Asthma Biologics	384	1.4%
Oral Azithromycin	1,593	6.0%
Exacerbation Asthma Inhalers (SABA or SAMA)	4,178	15.7%
Oral Glucocorticoids	8,668	32.5%
Zileuton	7	0.0%
Montelukast	3,377	12.7%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	3,286	12.3%
Proton Pump Inhibitors	2,201	8.3%
IL-5 mAbs	70	0.3%
Purine Analogues	102	0.4%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	4,756	17.8%
Topical Capsaicin	1	0.0%
Topical Vitamin D Analogues	209	0.8%
Systemic Therapies for Prurigo Nodularis	5,418	20.3%
Local Nasal Glucocorticoids	1,749	6.6%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	11,366	42.6%
Topical Calcineurin Inhibitors	3,578	13.4%
Other Topical Prescription Therapies	104	0.4%
Systemic Therapies for Atopic Dermatitis	1,149	4.3%
Asthma Biologics	241	0.9%
Oral Azithromycin	373	1.4%
Exacerbation Asthma Inhalers (SABA or SAMA)	2,103	7.9%
Oral Glucocorticoids	4,018	15.1%
Zileuton	4	0.0%
Montelukast	2,596	9.7%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	2,278	8.5%
Proton Pump Inhibitors	1,736	6.5%
IL-5 mAbs	41	0.2%
Purine Analogues	68	0.3%
IL-13 mAbs	0	0.0%

Table 1j. Characteristics of Dupilumab Use with Atopic Dermatitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	1,715	6.4%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	97	0.4%
Systemic Therapies for Prurigo Nodularis	4,079	15.3%
Local Nasal Glucocorticoids	968	3.6%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	9,129	34.2%
Topical Calcineurin Inhibitors	2,552	9.6%
Other Topical Prescription Therapies	98	0.4%
Systemic Therapies for Atopic Dermatitis	924	3.5%
Asthma Biologics	176	0.7%
Oral Azithromycin	372	1.4%
Exacerbation Asthma Inhalers (SABA or SAMA)	1,945	7.3%
Oral Glucocorticoids	2,497	9.4%
Zileuton	4	0.0%
Montelukast	2,485	9.3%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	2,238	8.4%
Proton Pump Inhibitors	1,729	6.5%
IL-5 mAbs	32	0.1%
Purine Analogues	55	0.2%
IL-13 mAbs	2	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	766	2.9%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	80	0.3%
Systemic Therapies for Prurigo Nodularis	3,821	14.3%
Local Nasal Glucocorticoids	951	3.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.7	8.6
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	1.7	3.9
Mean number of filled prescriptions	12.5	11.4
Mean number of generics dispensed	6.5	4.6
Mean number of unique drug classes dispensed	5.8	4.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1k. Characteristics of Dupilumab Use with Asthma and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	12,473	N/A
Demographic Characteristics		
Age (years)	41.1	17.8
Age		
0-5 months	0	0.0%
6 months-5 years	55	0.4%
6-11 years	515	4.1%
12-17 years	1,206	9.7%
18-79 years	10,625	85.2%
≥ 80 years	72	0.6%
Sex		
Female	7,304	58.6%
Male	5,169	41.4%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	12,473	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	12,473	100.0%
Year		
2017	414	3.3%
2018	709	5.7%
2019	2,500	20.0%
2020	2,960	23.7%
2021	3,154	25.3%
2022	2,736	21.9%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	12,473	100.0%
Atopic Dermatitis	5,260	42.2%
Asthma	12,473	100.0%
Chronic Rhinosinusitis	4,545	36.4%
Eosinophilic Esophagitis	736	5.9%

Table 1k. Characteristics of Dupilumab Use with Asthma and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	81	0.6%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	4,238	34.0%
Topical Calcineurin Inhibitors	1,158	9.3%
Other Topical Prescription Therapies	17	0.1%
Systemic Therapies for Atopic Dermatitis	396	3.2%
Asthma Biologics	1,396	11.2%
Oral Azithromycin	2,018	16.2%
Exacerbation Asthma Inhalers (SABA or SAMA)	6,880	55.2%
Oral Glucocorticoids	6,771	54.3%
Zileuton	86	0.7%
Montelukast	5,587	44.8%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	7,789	62.4%
Proton Pump Inhibitors	2,371	19.0%
IL-5 mAbs	736	5.9%
Purine Analogues	37	0.3%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	2,642	21.2%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	47	0.4%
Systemic Therapies for Prurigo Nodularis	6,195	49.7%
Local Nasal Glucocorticoids	2,519	20.2%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	2,577	20.7%
Topical Calcineurin Inhibitors	762	6.1%
Other Topical Prescription Therapies	15	0.1%
Systemic Therapies for Atopic Dermatitis	280	2.2%
Asthma Biologics	881	7.1%
Oral Azithromycin	589	4.7%
Exacerbation Asthma Inhalers (SABA or SAMA)	4,153	33.3%
Oral Glucocorticoids	3,441	27.6%
Zileuton	70	0.6%
Montelukast	4,741	38.0%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	6,321	50.7%
Proton Pump Inhibitors	1,932	15.5%
IL-5 mAbs	436	3.5%
Purine Analogues	26	0.2%
IL-13 mAbs	0	0.0%

Table 1k. Characteristics of Dupilumab Use with Asthma and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	795	6.4%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	22	0.2%
Systemic Therapies for Prurigo Nodularis	5,209	41.8%
Local Nasal Glucocorticoids	1,660	13.3%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	2,150	17.2%
Topical Calcineurin Inhibitors	562	4.5%
Other Topical Prescription Therapies	15	0.1%
Systemic Therapies for Atopic Dermatitis	243	1.9%
Asthma Biologics	513	4.1%
Oral Azithromycin	479	3.8%
Exacerbation Asthma Inhalers (SABA or SAMA)	3,727	29.9%
Oral Glucocorticoids	2,394	19.2%
Zileuton	66	0.5%
Montelukast	4,586	36.8%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	6,095	48.9%
Proton Pump Inhibitors	1,920	15.4%
IL-5 mAbs	237	1.9%
Purine Analogues	23	0.2%
IL-13 mAbs	1	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	511	4.1%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	19	0.2%
Systemic Therapies for Prurigo Nodularis	5,028	40.3%
Local Nasal Glucocorticoids	1,547	12.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.3	10.0
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.8	5.3
Mean number of filled prescriptions	19.9	16.0
Mean number of generics dispensed	9.5	5.8
Mean number of unique drug classes dispensed	8.7	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1I. Characteristics of Dupilumab Use with Chronic Rhinosinusitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	7,627	N/A
Demographic Characteristics		
Age (years)	45.7	15.3
Age		
0-5 months	0	0.0%
6 months-5 years	21	0.3%
6-11 years	87	1.1%
12-17 years	275	3.6%
18-79 years	7,188	94.2%
≥ 80 years	56	0.7%
Sex		
Female	4,143	54.3%
Male	3,484	45.7%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	7,627	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	7,627	100.0%
Year		
2017	112	1.5%
2018	260	3.4%
2019	1,372	18.0%
2020	1,965	25.8%
2021	2,069	27.1%
2022	1,849	24.2%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	7,627	100.0%
Atopic Dermatitis	1,761	23.1%
Asthma	4,693	61.5%
Chronic Rhinosinusitis	7,627	100.0%
Eosinophilic Esophagitis	385	5.0%

Table 1I. Characteristics of Dupilumab Use with Chronic Rhinosinusitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	32	0.4%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	1,659	21.8%
Topical Calcineurin Inhibitors	365	4.8%
Other Topical Prescription Therapies	10	0.1%
Systemic Therapies for Atopic Dermatitis	160	2.1%
Asthma Biologics	695	9.1%
Oral Azithromycin	1,262	16.5%
Exacerbation Asthma Inhalers (SABA or SAMA)	3,111	40.8%
Oral Glucocorticoids	4,648	60.9%
Zileuton	64	0.8%
Montelukast	3,422	44.9%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	4,351	57.0%
Proton Pump Inhibitors	1,478	19.4%
IL-5 mAbs	414	5.4%
Purine Analogues	14	0.2%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	1,664	21.8%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	20	0.3%
Systemic Therapies for Prurigo Nodularis	3,743	49.1%
Local Nasal Glucocorticoids	2,153	28.2%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	918	12.0%
Topical Calcineurin Inhibitors	247	3.2%
Other Topical Prescription Therapies	4	0.1%
Systemic Therapies for Atopic Dermatitis	115	1.5%
Asthma Biologics	453	5.9%
Oral Azithromycin	358	4.7%
Exacerbation Asthma Inhalers (SABA or SAMA)	1,783	23.4%
Oral Glucocorticoids	2,303	30.2%
Zileuton	52	0.7%
Montelukast	2,917	38.2%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	3,561	46.7%
Proton Pump Inhibitors	1,208	15.8%
IL-5 mAbs	262	3.4%
Purine Analogues	12	0.2%
IL-13 mAbs	0	0.0%

Table 1I. Characteristics of Dupilumab Use with Chronic Rhinosinusitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	464	6.1%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	7	0.1%
Systemic Therapies for Prurigo Nodularis	3,175	41.6%
Local Nasal Glucocorticoids	1,428	18.7%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	774	10.1%
Topical Calcineurin Inhibitors	182	2.4%
Other Topical Prescription Therapies	7	0.1%
Systemic Therapies for Atopic Dermatitis	106	1.4%
Asthma Biologics	270	3.5%
Oral Azithromycin	305	4.0%
Exacerbation Asthma Inhalers (SABA or SAMA)	1,569	20.6%
Oral Glucocorticoids	1,562	20.5%
Zileuton	52	0.7%
Montelukast	2,799	36.7%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	3,415	44.8%
Proton Pump Inhibitors	1,209	15.9%
IL-5 mAbs	148	1.9%
Purine Analogues	13	0.2%
IL-13 mAbs	1	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	324	4.2%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	6	0.1%
Systemic Therapies for Prurigo Nodularis	3,047	40.0%
Local Nasal Glucocorticoids	1,342	17.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.9	10.1
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.8	5.6
Mean number of filled prescriptions	19.4	15.4
Mean number of generics dispensed	9.4	5.8
Mean number of unique drug classes dispensed	8.7	5.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1m. Characteristics of Dupilumab Use with Eosinophilic Esophagitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	2,155	N/A
Demographic Characteristics		
Age (years)	41.7	18.2
Age		
0-5 months	0	0.0%
6 months-5 years	17	0.8%
6-11 years	72	3.3%
12-17 years	189	8.8%
18-79 years	1,849	85.8%
≥ 80 years	28	1.3%
Sex		
Female	1,246	57.8%
Male	909	42.2%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	2,155	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	2,155	100.0%
Year		
2017	52	2.4%
2018	141	6.5%
2019	344	16.0%
2020	390	18.1%
2021	527	24.5%
2022	701	32.5%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	2,155	100.0%
Atopic Dermatitis	1,021	47.4%
Asthma	949	44.0%
Chronic Rhinosinusitis	460	21.3%
Eosinophilic Esophagitis	2,155	100.0%

Table 1m. Characteristics of Dupilumab Use with Eosinophilic Esophagitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	26	1.2%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	804	37.3%
Topical Calcineurin Inhibitors	212	9.8%
Other Topical Prescription Therapies	4	0.2%
Systemic Therapies for Atopic Dermatitis	94	4.4%
Asthma Biologics	128	5.9%
Oral Azithromycin	276	12.8%
Exacerbation Asthma Inhalers (SABA or SAMA)	643	29.8%
Oral Glucocorticoids	847	39.3%
Zileuton	8	0.4%
Montelukast	580	26.9%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	831	38.6%
Proton Pump Inhibitors	1,001	46.5%
IL-5 mAbs	57	2.6%
Purine Analogues	8	0.4%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	485	22.5%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	17	0.8%
Systemic Therapies for Prurigo Nodularis	778	36.1%
Local Nasal Glucocorticoids	302	14.0%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	469	21.8%
Topical Calcineurin Inhibitors	121	5.6%
Other Topical Prescription Therapies	2	0.1%
Systemic Therapies for Atopic Dermatitis	63	2.9%
Asthma Biologics	82	3.8%
Oral Azithromycin	72	3.3%
Exacerbation Asthma Inhalers (SABA or SAMA)	330	15.3%
Oral Glucocorticoids	402	18.7%
Zileuton	3	0.1%
Montelukast	474	22.0%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	615	28.5%
Proton Pump Inhibitors	831	38.6%
IL-5 mAbs	39	1.8%
Purine Analogues	4	0.2%
IL-13 mAbs	0	0.0%

Table 1m. Characteristics of Dupilumab Use with Eosinophilic Esophagitis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	169	7.8%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	6	0.3%
Systemic Therapies for Prurigo Nodularis	623	28.9%
Local Nasal Glucocorticoids	193	9.0%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	415	19.3%
Topical Calcineurin Inhibitors	88	4.1%
Other Topical Prescription Therapies	3	0.1%
Systemic Therapies for Atopic Dermatitis	52	2.4%
Asthma Biologics	51	2.4%
Oral Azithromycin	64	3.0%
Exacerbation Asthma Inhalers (SABA or SAMA)	320	14.8%
Oral Glucocorticoids	316	14.7%
Zileuton	3	0.1%
Montelukast	457	21.2%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	586	27.2%
Proton Pump Inhibitors	783	36.3%
IL-5 mAbs	20	0.9%
Purine Analogues	6	0.3%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	113	5.2%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	5	0.2%
Systemic Therapies for Prurigo Nodularis	599	27.8%
Local Nasal Glucocorticoids	200	9.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.1	11.4
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	4.0	8.1
Mean number of filled prescriptions	21.4	18.3
Mean number of generics dispensed	10.3	6.7
Mean number of unique drug classes dispensed	9.5	6.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1n. Characteristics of Dupilumab Use with Prurigo Nodularis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	767	N/A
Demographic Characteristics		
Age (years)	50.6	16.7
Age		
0-5 months	0	0.0%
6 months-5 years	2	0.3%
6-11 years	10	1.3%
12-17 years	32	4.2%
18-79 years	701	91.4%
≥ 80 years	22	2.9%
Sex		
Female	459	59.8%
Male	308	40.2%
Other	0	0.0%
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	767	100.0%
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	767	100.0%
Year		
2017	33	4.3%
2018	65	8.5%
2019	140	18.3%
2020	147	19.2%
2021	185	24.1%
2022	197	25.7%
Baseline Dupilumab Indications [-183, 0]:		
Any Dupilumab Indication	767	100.0%
Atopic Dermatitis	611	79.7%
Asthma	92	12.0%
Chronic Rhinosinusitis	33	4.3%
Eosinophilic Esophagitis	21	2.7%

Table 1n. Characteristics of Dupilumab Use with Prurigo Nodularis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Prurigo Nodularis	767	100.0%
No Dupilumab Indication	0	0.0%
Prior Treatments [-183, -31]:		
Topical Glucocorticoids	551	71.8%
Topical Calcineurin Inhibitors	128	16.7%
Other Topical Prescription Therapies	1	0.1%
Systemic Therapies for Atopic Dermatitis	66	8.6%
Asthma Biologics	8	1.0%
Oral Azithromycin	61	8.0%
Exacerbation Asthma Inhalers (SABA or SAMA)	107	14.0%
Oral Glucocorticoids	242	31.6%
Zileuton	1	0.1%
Montelukast	88	11.5%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	90	11.7%
Proton Pump Inhibitors	113	14.7%
IL-5 mAbs	2	0.3%
Purine Analogues	8	1.0%
IL-13 mAbs	1	0.1%
Systemic Non-Oral or Injectable Glucocorticoids	239	31.2%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	11	1.4%
Systemic Therapies for Prurigo Nodularis	223	29.1%
Local Nasal Glucocorticoids	66	8.6%
Recent Treatments [-30, -1]:		
Topical Glucocorticoids	360	46.9%
Topical Calcineurin Inhibitors	102	13.3%
Other Topical Prescription Therapies	1	0.1%
Systemic Therapies for Atopic Dermatitis	49	6.4%
Asthma Biologics	6	0.8%
Oral Azithromycin	16	2.1%
Exacerbation Asthma Inhalers (SABA or SAMA)	46	6.0%
Oral Glucocorticoids	87	11.3%
Zileuton	1	0.1%
Montelukast	68	8.9%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	69	9.0%
Proton Pump Inhibitors	90	11.7%
IL-5 mAbs	2	0.3%
Purine Analogues	4	0.5%
IL-13 mAbs	1	0.1%

Table 1n. Characteristics of Dupilumab Use with Prurigo Nodularis and a 7-day Treatment Gap in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Systemic Non-Oral or Injectable Glucocorticoids	97	12.6%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	5	0.7%
Systemic Therapies for Prurigo Nodularis	175	22.8%
Local Nasal Glucocorticoids	32	4.2%
Concomitant Treatments [0, 30]:		
Topical Glucocorticoids	322	42.0%
Topical Calcineurin Inhibitors	73	9.5%
Other Topical Prescription Therapies	1	0.1%
Systemic Therapies for Atopic Dermatitis	37	4.8%
Asthma Biologics	3	0.4%
Oral Azithromycin	17	2.2%
Exacerbation Asthma Inhalers (SABA or SAMA)	50	6.5%
Oral Glucocorticoids	82	10.7%
Zileuton	1	0.1%
Montelukast	66	8.6%
Maintenance Asthma Inhalers (ICS, LABA or LAMA)	74	9.6%
Proton Pump Inhibitors	89	11.6%
IL-5 mAbs	1	0.1%
Purine Analogues	2	0.3%
IL-13 mAbs	0	0.0%
Systemic Non-Oral or Injectable Glucocorticoids	72	9.4%
Topical Capsaicin	0	0.0%
Topical Vitamin D Analogues	3	0.4%
Systemic Therapies for Prurigo Nodularis	173	22.6%
Local Nasal Glucocorticoids	36	4.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.4	10.3
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.4	4.0
Mean number of filled prescriptions	19.2	16.4
Mean number of generics dispensed	9.1	5.7
Mean number of unique drug classes dispensed	8.2	5.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 2a. Continuous Summary of Days Supplied per Dispensing for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	465,244	1	28	28	28	364	29.3	13.3
<i>Any Indication</i>	432,266	1	28	28	28	364	29.3	13.3
<i>Atopic Dermatitis</i>	335,709	1	28	28	28	364	29.3	13.2
<i>Asthma</i>	159,931	1	28	28	28	350	29.5	13.6
<i>Chronic Rhinosinusitis</i>	91,809	1	28	28	28	350	29.3	13.1
<i>Eosinophilic Esophagitis</i>	23,810	1	28	28	28	252	29.3	13.1
<i>Prurigo Nodularis</i>	9,534	1	28	28	28	350	29.5	13.6
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	448,998	1	28	28	28	364	29.3	13.4
<i>Any Indication</i>	413,523	1	28	28	28	350	29.3	13.4
<i>Atopic Dermatitis</i>	319,336	1	28	28	28	350	29.4	13.3
<i>Asthma</i>	148,672	1	28	28	28	350	29.5	13.8
<i>Chronic Rhinosinusitis</i>	85,396	1	28	28	28	350	29.4	13.2
<i>Eosinophilic Esophagitis</i>	20,664	1	28	28	28	252	29.3	13.4
<i>Prurigo Nodularis</i>	8,775	1	28	28	28	350	29.4	13.6

Table 2b. Continuous Summary of Days Supplied per Dispensing for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	465,244	1	28	28	28	364	29.3	13.3
Female	259,206	1	28	28	28	364	29.2	13.3
Male	206,038	1	28	28	28	350	29.4	13.4
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	432,266	1	28	28	28	364	29.3	13.3
Female	241,277	1	28	28	28	364	29.2	13.3
Male	190,989	1	28	28	28	350	29.4	13.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	335,709	1	28	28	28	364	29.3	13.2
Female	186,339	1	28	28	28	364	29.3	13.3
Male	149,370	1	28	28	28	350	29.4	13.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	159,931	1	28	28	28	350	29.5	13.6
Female	92,591	1	28	28	28	336	29.4	13.6
Male	67,340	1	28	28	28	350	29.6	13.7
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	91,809	1	28	28	28	350	29.3	13.1
Female	50,819	1	28	28	28	336	29.2	12.7
Male	40,990	1	28	28	28	350	29.5	13.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	23,810	1	28	28	28	252	29.3	13.1
Female	14,110	1	28	28	28	252	29.1	12.5
Male	9,700	1	28	28	28	252	29.5	13.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	9,534	1	28	28	28	350	29.5	13.6
Female	5,696	1	28	28	28	280	29.7	13.6
Male	3,838	1	28	28	28	350	29.1	13.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	448,998	1	28	28	28	364	29.3	13.4

Table 2b. Continuous Summary of Days Supplied per Dispensing for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	250,176	1	28	28	28	364	29.2	13.4
Male	198,822	1	28	28	28	350	29.4	13.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	<i>413,523</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>28</i>	<i>350</i>	<i>29.3</i>	<i>13.4</i>
Female	231,114	1	28	28	28	336	29.2	13.4
Male	182,409	1	28	28	28	350	29.4	13.4
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	<i>319,336</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>28</i>	<i>350</i>	<i>29.4</i>	<i>13.3</i>
Female	177,769	1	28	28	28	336	29.3	13.4
Male	141,567	1	28	28	28	350	29.4	13.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	<i>148,672</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>28</i>	<i>350</i>	<i>29.5</i>	<i>13.8</i>
Female	86,298	1	28	28	28	336	29.4	13.8
Male	62,374	1	28	28	28	350	29.6	13.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	<i>85,396</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>28</i>	<i>350</i>	<i>29.4</i>	<i>13.2</i>
Female	46,849	1	28	28	28	336	29.2	12.9
Male	38,547	1	28	28	28	350	29.6	13.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	<i>20,664</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>28</i>	<i>252</i>	<i>29.3</i>	<i>13.4</i>
Female	12,108	1	28	28	28	252	29.1	12.7
Male	8,556	1	28	28	28	252	29.6	14.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	<i>8,775</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>28</i>	<i>350</i>	<i>29.4</i>	<i>13.6</i>
Female	5,192	1	28	28	28	280	29.7	13.7
Male	3,583	1	28	28	28	350	29.1	13.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2c. Continuous Summary of Days Supplied per Dispensing for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	465,244	1	28	28	28	364	29.3	13.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	1,025	1	28	28	31	112	32.0	14.9
6-11 years	13,554	1	28	28	28	308	30.6	14.3
12-17 years	45,630	1	28	28	28	350	29.2	13.5
18-79 years	401,870	1	28	28	28	364	29.2	13.3
≥ 80 years	3,165	1	28	28	28	285	29.4	13.8
<i>Any Indication</i>	432,266	1	28	28	28	364	29.3	13.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	979	1	28	28	31	112	31.9	15.0
6-11 years	13,125	1	28	28	28	308	30.6	14.4
12-17 years	43,701	1	28	28	28	350	29.3	13.6
18-79 years	371,777	1	28	28	28	364	29.3	13.2
≥ 80 years	2,684	1	28	28	28	285	29.3	13.3
<i>Atopic Dermatitis</i>	335,709	1	28	28	28	364	29.3	13.2
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	935	1	28	28	31	112	32.3	15.2
6-11 years	12,623	1	28	28	28	308	30.6	14.3
12-17 years	40,803	1	28	28	28	336	29.2	13.3
18-79 years	279,225	1	28	28	28	364	29.3	13.2
≥ 80 years	2,123	1	28	28	28	285	29.5	13.9
<i>Asthma</i>	159,931	1	28	28	28	350	29.5	13.6
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	164	2	28	29	56	84	33.4	16.9
6-11 years	4,939	1	28	28	28	280	30.6	14.9
12-17 years	16,529	1	28	28	28	350	29.6	13.9
18-79 years	137,631	1	28	28	28	336	29.4	13.5
≥ 80 years	668	1	28	28	28	84	29.4	12.6
<i>Chronic Rhinosinusitis</i>	91,809	1	28	28	28	350	29.3	13.1
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 2c. Continuous Summary of Days Supplied per Dispensing for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
6-71 months	67	2	28	28	31	84	32.5	18.0
6-11 years	716	1	28	28	28	210	29.8	15.4
12-17 years	3,493	1	28	28	28	350	29.7	14.8
18-79 years	87,092	1	28	28	28	336	29.3	13.0
≥ 80 years	441	1	28	28	28	84	30.9	14.4
<i>Eosinophilic Esophagitis</i>	23,810	1	28	28	28	252	29.3	13.1
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	87	2	28	28	28	84	29.8	14.6
6-11 years	559	1	28	28	28	210	31.2	18.5
12-17 years	2,015	1	28	28	28	92	28.9	12.2
18-79 years	20,908	1	28	28	28	252	29.3	13.0
≥ 80 years	241	1	28	28	28	84	29.0	12.1
<i>Prurigo Nodularis</i>	9,534	1	28	28	28	350	29.5	13.6
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	2	11	11	18	25	25	18.0	9.9
6-11 years	58	4	28	28	28	105	29.4	16.5
12-17 years	425	1	28	28	28	84	28.5	11.8
18-79 years	8,854	1	28	28	28	350	29.6	13.7
≥ 80 years	195	1	28	28	28	84	28.6	10.0
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	448,998	1	28	28	28	364	29.3	13.4
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	1,021	1	28	28	31	112	32.0	14.9
6-11 years	13,343	1	28	28	28	308	30.6	14.3
12-17 years	44,484	1	28	28	28	350	29.3	13.6
18-79 years	387,213	1	28	28	28	364	29.3	13.4
≥ 80 years	2,937	1	28	28	28	285	29.4	14.0
<i>Any Indication</i>	413,523	1	28	28	28	350	29.3	13.4
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	966	1	28	28	31	112	31.8	14.9
6-11 years	12,875	1	28	28	28	308	30.6	14.4

Table 2c. Continuous Summary of Days Supplied per Dispensing for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
12-17 years	42,373	1	28	28	28	350	29.3	13.6
18-79 years	354,913	1	28	28	28	350	29.3	13.3
≥ 80 years	2,396	1	28	28	28	285	29.3	13.7
<i>Atopic Dermatitis</i>	319,336	1	28	28	28	350	29.4	13.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	921	1	28	28	31	112	32.1	15.1
6-11 years	12,400	1	28	28	28	308	30.7	14.3
12-17 years	39,353	1	28	28	28	336	29.3	13.4
18-79 years	264,762	1	28	28	28	350	29.3	13.3
≥ 80 years	1,900	1	28	28	28	285	29.5	14.2
<i>Asthma</i>	148,672	1	28	28	28	350	29.5	13.8
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	163	2	28	28	56	84	33.2	16.8
6-11 years	4,767	1	28	28	28	280	30.6	14.9
12-17 years	15,398	1	28	28	28	350	29.5	14.1
18-79 years	127,773	1	28	28	28	336	29.5	13.7
≥ 80 years	571	1	28	28	28	84	29.0	12.1
<i>Chronic Rhinosinusitis</i>	85,396	1	28	28	28	350	29.4	13.2
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	67	2	28	28	31	84	32.5	18.0
6-11 years	694	1	28	28	28	210	29.9	15.5
12-17 years	3,187	1	28	28	28	350	29.6	14.8
18-79 years	81,038	1	28	28	28	336	29.3	13.1
≥ 80 years	410	1	28	28	28	84	30.0	12.9
<i>Eosinophilic Esophagitis</i>	20,664	1	28	28	28	252	29.3	13.4
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	87	2	28	28	28	84	29.8	14.6
6-11 years	499	1	28	28	30	210	31.4	19.4
12-17 years	1,907	1	28	28	28	92	28.4	11.4
18-79 years	17,986	1	28	28	28	252	29.3	13.4
≥ 80 years	185	1	28	28	28	84	29.6	13.4

Table 2c. Continuous Summary of Days Supplied per Dispensing for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Prurigo Nodularis</i>	8,775	1	28	28	28	350	29.4	13.6
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	2	11	11	18	25	25	18.0	9.9
6-11 years	56	4	28	28	28	105	29.4	16.8
12-17 years	388	1	28	28	28	84	28.7	12.1
18-79 years	8,158	1	28	28	28	350	29.5	13.7
≥ 80 years	171	1	28	28	28	84	28.7	10.6

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3a. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	39,944	1	88	229	489	1,984	341.0	335.6
<i>Any Indication</i>	36,986	1	91	233	490	1,984	342.6	335.5
<i>Atopic Dermatitis</i>	28,055	1	95	238	496	1,984	351.2	348.4
<i>Asthma</i>	13,372	1	98	252	518	1,984	352.7	330.2
<i>Chronic Rhinosinusitis</i>	8,142	1	96	239	484	1,977	330.9	301.6
<i>Eosinophilic Esophagitis</i>	2,453	1	60	182	403	1,824	284.1	298.4
<i>Prurigo Nodularis</i>	828	1	86	233	485	1,893	339.6	330.9
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	38,506	1	92	235	496	1,990	347.0	341.3
<i>Any Indication</i>	35,371	1	94	237	499	1,990	348.3	340.7
<i>Atopic Dermatitis</i>	26,674	1	98	240	505	1,990	357.1	353.7
<i>Asthma</i>	12,473	1	98	252	523	1,984	357.2	334.3
<i>Chronic Rhinosinusitis</i>	7,627	1	98	240	488	1,977	333.6	304.7
<i>Eosinophilic Esophagitis</i>	2,155	1	59	178	402	1,831	285.6	303.6
<i>Prurigo Nodularis</i>	767	1	86	233	485	1,923	341.8	336.2

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	39,944	1	88	229	489	1,984	341.0	335.6
Female	22,463	1	86	224	483	1,955	337.0	331.5
Male	17,481	1	92	236	493	1,984	346.2	340.7
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	36,986	1	91	233	490	1,984	342.6	335.5
Female	20,805	1	88	228	488	1,955	339.0	331.4
Male	16,181	1	95	238	492	1,984	347.1	340.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	28,055	1	95	238	496	1,984	351.2	348.4
Female	15,820	1	92	231	490	1,955	345.1	342.1
Male	12,235	1	98	239	504	1,984	359.1	356.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	13,372	1	98	252	518	1,984	352.7	330.2
Female	7,812	1	92	248	510	1,955	348.4	328.7
Male	5,560	1	100	253	526	1,984	358.8	332.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	8,142	1	96	239	484	1,977	330.9	301.6
Female	4,444	1	89	241	500	1,955	333.8	306.4
Male	3,698	1	99	239	476	1,977	327.4	295.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	2,453	1	60	182	403	1,824	284.1	298.4
Female	1,427	1	68	191	406	1,787	287.8	295.5
Male	1,026	1	56	168	392	1,824	279.1	302.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	828	1	86	233	485	1,893	339.6	330.9
Female	493	1	93	238	499	1,893	343.6	335.0
Male	335	2	84	227	466	1,752	333.8	325.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	38,506	1	92	235	496	1,990	347.0	341.3

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	21,653	1	91	230	491	1,967	343.0	337.3
Male	16,853	1	94	239	504	1,990	352.2	346.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	35,371	1	94	237	499	1,990	348.3	340.7
Female	19,925	1	92	234	494	1,967	344.6	336.5
Male	15,446	1	96	240	504	1,990	353.0	346.0
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	26,674	1	98	240	505	1,990	357.1	353.7
Female	15,069	1	96	236	499	1,967	351.3	347.3
Male	11,605	1	98	244	515	1,990	364.6	361.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	12,473	1	98	252	523	1,984	357.2	334.3
Female	7,304	1	96	248	516	1,958	352.9	333.7
Male	5,169	1	103	257	531	1,984	363.2	335.1
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	7,627	1	98	240	488	1,977	333.6	304.7
Female	4,143	1	91	236	500	1,955	334.8	309.2
Male	3,484	1	103	243	484	1,977	332.2	299.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	2,155	1	59	178	402	1,831	285.6	303.6
Female	1,246	1	66	183	396	1,805	287.1	300.9
Male	909	1	56	168	409	1,831	283.6	307.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	767	1	86	233	485	1,923	341.8	336.2
Female	459	1	86	231	488	1,923	340.7	338.8
Male	308	2	87	237	477	1,754	343.3	332.9
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3c. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	39,944	1	88	229	489	1,984	341.0	335.6
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	315	1	28	51	106	1,116	104.0	148.9
6-11 years	1,500	1	78	206	406	1,658	276.1	249.9
12-17 years	3,721	1	108	266	529	1,747	358.6	313.4
18-79 years	34,006	1	90	232	490	1,984	345.5	342.2
≥ 80 years	402	1	56	151	355	1,150	231.6	228.1
<i>Any Indication</i>	36,986	1	91	233	490	1,984	342.6	335.5
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	307	1	28	51	99	1,116	101.8	147.1
6-11 years	1,446	1	80	207	409	1,658	277.5	251.8
12-17 years	3,541	1	112	269	532	1,747	361.3	314.2
18-79 years	31,346	1	94	235	493	1,984	347.1	342.0
≥ 80 years	346	1	56	151	346	1,150	227.5	223.6
<i>Atopic Dermatitis</i>	28,055	1	95	238	496	1,984	351.2	348.4
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	297	1	28	51	96	1,116	101.5	145.5
6-11 years	1,368	1	84	211	418	1,658	282.8	253.8
12-17 years	3,241	1	114	280	538	1,747	368.2	314.7
18-79 years	22,870	1	98	238	504	1,984	357.6	358.9
≥ 80 years	279	1	56	150	333	1,150	224.7	221.4
<i>Asthma</i>	13,372	1	98	252	518	1,984	352.7	330.2
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	56	2	24	48	103	624	97.7	136.1
6-11 years	533	1	84	210	402	1,658	283.3	262.9
12-17 years	1,285	1	108	294	570	1,636	380.2	328.7
18-79 years	11,418	1	98	252	521	1,984	354.9	333.5
≥ 80 years	80	10	70	176	393	916	245.5	215.8
<i>Chronic Rhinosinusitis</i>	8,142	1	96	239	484	1,977	330.9	301.6
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 3c. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
6-71 months	21	2	30	56	148	624	103.8	135.5
6-11 years	93	1	54	147	322	1,045	229.4	236.6
12-17 years	302	7	107	263	463	1,636	343.8	306.8
18-79 years	7,666	1	98	243	488	1,977	333.0	302.4
≥ 80 years	60	14	56	147	329	916	226.8	225.9
<i>Eosinophilic Esophagitis</i>	2,453	1	60	182	403	1,824	284.1	298.4
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	17	2	34	64	151	639	152.3	199.8
6-11 years	76	1	58	147	324	1,015	229.7	232.9
12-17 years	205	1	53	168	462	1,258	283.7	291.1
18-79 years	2,120	1	65	183	403	1,824	288.6	302.7
≥ 80 years	35	5	46	109	319	757	199.9	199.1
<i>Prurigo Nodularis</i>	828	1	86	233	485	1,893	339.6	330.9
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	2	11	11	18	25	25	18.0	9.9
6-11 years	12	9	22	97	214	434	142.0	151.1
12-17 years	35	2	84	328	463	1,191	345.8	318.0
18-79 years	756	1	94	238	490	1,893	346.3	335.4
≥ 80 years	23	6	69	208	382	789	242.5	217.5
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	38,506	1	92	235	496	1,990	347.0	341.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	314	1	28	51	106	1,136	105.4	151.6
6-11 years	1,471	1	82	209	416	1,668	281.2	254.3
12-17 years	3,630	1	112	272	537	1,767	364.5	318.5
18-79 years	32,712	1	94	236	502	1,990	351.7	348.0
≥ 80 years	379	1	56	152	338	1,171	231.0	230.2
<i>Any Indication</i>	35,371	1	94	237	499	1,990	348.3	340.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	305	1	28	50	96	1,136	101.9	148.8
6-11 years	1,410	1	82	211	420	1,668	283.4	256.6

Table 3c. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
12-17 years	3,439	1	112	274	543	1,767	366.8	319.5
18-79 years	29,900	1	97	238	504	1,990	353.0	347.4
≥ 80 years	317	1	56	151	323	1,171	224.4	224.1
<i>Atopic Dermatitis</i>	26,674	1	98	240	505	1,990	357.1	353.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	295	1	28	51	96	1,136	101.5	147.0
6-11 years	1,336	1	84	218	422	1,668	288.7	258.4
12-17 years	3,132	1	120	284	550	1,767	373.6	319.3
18-79 years	21,656	1	98	240	513	1,990	363.9	364.6
≥ 80 years	255	1	56	151	323	1,171	222.7	223.4
<i>Asthma</i>	12,473	1	98	252	523	1,984	357.2	334.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	55	2	23	46	112	627	100.3	140.4
6-11 years	515	1	86	214	413	1,668	287.0	267.1
12-17 years	1,206	1	109	294	572	1,653	383.6	334.3
18-79 years	10,625	1	99	253	528	1,984	359.7	337.5
≥ 80 years	72	10	71	169	361	931	233.8	211.2
<i>Chronic Rhinosinusitis</i>	7,627	1	98	240	488	1,977	333.6	304.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	21	2	30	56	150	627	105.5	136.8
6-11 years	87	1	54	150	360	1,045	241.1	244.0
12-17 years	275	7	107	254	485	1,653	348.7	311.9
18-79 years	7,188	1	98	243	493	1,977	335.7	305.4
≥ 80 years	56	14	47	140	295	931	223.4	230.7
<i>Eosinophilic Esophagitis</i>	2,155	1	59	178	402	1,831	285.6	303.6
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	17	2	34	64	156	639	153.8	200.2
6-11 years	72	1	60	135	332	974	220.8	219.9
12-17 years	189	1	54	179	470	1,268	291.4	294.8
18-79 years	1,849	1	61	182	404	1,831	290.1	308.9
≥ 80 years	28	5	52	136	299	759	198.6	196.7

Table 3c. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Prurigo Nodularis</i>	767	1	86	233	485	1,923	341.8	336.2
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	2	11	11	18	25	25	18.0	9.9
6-11 years	10	9	16	128	254	437	166.8	158.0
12-17 years	32	2	91	315	496	1,199	354.8	325.8
18-79 years	701	1	92	240	490	1,923	348.2	340.9
≥ 80 years	22	6	69	190	308	808	226.5	205.7

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	39,944	1	88	229	489	1,984	341.0	335.6
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	713	713	713	713	713	713.0	NaN
April	88	13	243	670	1,349	1,984	853.4	649.3
May	241	14	220	568	1,300	1,977	765.4	617.0
June	236	4	185	561	1,121	1,940	711.5	590.1
July	248	5	154	518	1,077	1,910	660.9	565.3
August	288	14	129	406	987	1,879	617.8	572.1
September	247	13	110	425	1,078	1,842	629.5	577.5
October	274	14	98	423	966	1,817	599.5	544.7
November	279	14	60	380	1,010	1,779	563.5	533.4
December	212	6	42	280	865	1,752	510.1	547.4
2018								
January	182	14	139	433	1,010	1,721	605.0	519.4
February	215	14	207	472	1,032	1,690	622.8	521.2
March	256	14	185	510	1,184	1,675	663.8	536.8
April	197	4	218	541	1,092	1,619	652.0	501.0
May	200	14	187	527	1,117	1,607	633.2	511.0
June	200	10	182	470	933	1,580	594.9	482.1
July	378	2	129	331	778	1,536	471.4	422.4
August	386	10	119	322	798	1,503	494.0	454.0
September	310	4	103	350	765	1,479	488.9	448.0
October	381	10	107	387	826	1,459	509.9	440.4
November	367	5	133	419	860	1,429	537.7	442.8
December	334	1	98	378	784	1,394	511.9	451.6
2019								
January	410	14	210	504	915	1,363	576.0	422.3
February	401	1	238	518	882	1,332	573.2	403.0
March	415	6	210	462	868	1,306	541.2	393.4
April	561	8	196	490	899	1,276	543.9	401.4
May	503	4	182	477	912	1,237	534.7	393.7
June	511	12	168	417	854	1,215	497.5	382.5
July	710	2	154	377	809	1,186	474.7	368.7
August	743	2	126	434	851	1,156	491.4	381.2
September	637	1	112	388	732	1,123	448.6	355.7
October	741	1	98	406	782	1,096	463.8	352.3
November	672	5	86	406	783	1,061	458.9	355.1
December	691	1	74	350	770	1,034	429.6	356.4
2020								
January	598	1	210	406	784	1,003	475.7	313.9
February	655	2	172	364	780	970	455.8	315.0

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	657	4	154	329	698	941	425.7	300.6
April	465	3	190	386	700	913	431.8	282.6
May	462	3	154	309	687	879	403.5	286.9
June	571	7	171	331	658	852	397.5	272.4
July	1,067	14	151	360	644	817	390.4	264.6
August	853	1	127	374	642	789	386.4	261.7
September	828	1	116	376	626	760	376.4	248.1
October	872	2	98	336	596	730	350.2	244.4
November	815	1	84	322	560	698	332.6	234.5
December	785	1	84	336	558	669	324.5	232.0
2021								
January	683	11	182	360	546	634	356.8	198.4
February	673	5	182	378	542	607	357.0	187.5
March	776	2	182	370	521	579	345.7	181.5
April	751	2	154	336	485	547	314.2	172.3
May	712	2	154	323	464	516	298.3	165.7
June	715	2	168	323	439	487	294.3	151.8
July	1,016	5	152	288	403	457	269.4	135.7
August	1,100	1	133	288	379	424	255.6	130.9
September	897	9	112	270	354	394	239.3	121.4
October	948	4	98	259	327	365	221.3	114.5
November	919	2	84	224	298	334	194.9	108.9
December	863	1	94	216	275	304	183.4	101.0
2022								
January	811	1	126	219	248	271	184.7	76.8
February	748	12	113	196	220	242	166.2	67.8
March	912	1	112	172	193	214	150.1	55.4
April	884	6	112	148	163	183	129.9	46.1
May	835	1	98	124	137	152	112.7	34.0
June	869	7	80	95	107	122	88.4	26.0
July	1,212	14	56	68	78	92	64.9	17.5
August	1,366	1	31	40	51	61	40.8	12.0
September	1,111	1	8	14	21	30	13.8	8.4
<i>Any Indication</i>	<i>36,986</i>	<i>1</i>	<i>91</i>	<i>233</i>	<i>490</i>	<i>1,984</i>	<i>342.6</i>	<i>335.5</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	713	713	713	713	713	713.0	NaN
April	79	13	243	716	1,444	1,984	891.1	664.2
May	209	14	216	496	1,293	1,977	735.9	622.0
June	210	4	185	527	1,027	1,940	685.1	577.5
July	226	5	155	534	1,099	1,910	679.4	573.0
August	266	14	136	446	1,008	1,879	636.8	568.3
September	230	13	110	418	1,092	1,842	633.2	581.9

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
October	249	14	105	427	963	1,813	601.2	536.6
November	254	14	60	379	936	1,779	541.1	523.0
December	189	6	42	308	826	1,752	505.1	538.8
2018								
January	168	14	142	455	1,045	1,721	627.5	526.6
February	194	14	210	475	1,032	1,690	626.0	521.2
March	225	14	199	522	1,231	1,675	687.7	547.3
April	184	4	232	553	1,108	1,632	661.1	502.3
May	177	14	188	536	1,135	1,607	642.9	515.2
June	181	10	182	428	929	1,573	570.3	478.3
July	332	2	133	350	813	1,536	500.4	436.1
August	346	10	124	337	798	1,503	497.3	453.6
September	293	4	112	348	742	1,479	478.4	435.5
October	341	10	122	418	865	1,459	535.0	446.2
November	349	5	133	400	856	1,429	528.4	438.6
December	307	1	104	378	826	1,389	516.0	448.0
2019								
January	377	14	210	532	943	1,363	590.5	425.7
February	375	1	233	535	888	1,332	578.4	405.7
March	394	6	210	493	848	1,306	542.6	392.4
April	522	13	192	490	920	1,276	551.6	407.8
May	478	4	183	484	920	1,237	542.4	394.9
June	478	12	168	413	849	1,215	494.0	383.3
July	654	2	154	378	809	1,186	478.2	370.4
August	705	2	128	435	851	1,153	495.4	379.7
September	590	1	112	420	796	1,123	466.1	358.5
October	687	14	98	407	784	1,096	468.7	352.9
November	633	5	84	405	780	1,061	455.0	351.8
December	635	1	84	354	770	1,034	434.4	353.1
2020								
January	571	1	210	405	789	1,003	477.0	312.8
February	618	2	177	378	782	970	459.8	315.8
March	617	6	154	326	691	941	421.4	298.9
April	436	3	205	417	707	913	443.1	281.9
May	432	3	153	336	687	879	405.0	285.4
June	532	7	178	364	665	852	406.1	273.1
July	947	11	152	372	663	822	396.9	265.8
August	765	5	127	367	640	789	385.2	261.8
September	754	1	120	392	635	760	384.4	250.0
October	803	2	98	336	592	730	349.5	241.4
November	757	1	92	326	562	698	334.2	235.1
December	719	1	84	320	554	669	318.0	233.0
2021								
January	642	11	182	367	549	634	361.5	198.3

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
February	641	5	196	372	537	607	357.9	185.6
March	734	2	182	364	520	579	342.3	182.1
April	699	2	154	336	479	547	314.4	171.1
May	677	6	165	336	464	516	302.1	163.7
June	665	8	172	328	438	487	295.7	149.7
July	879	5	154	294	408	457	273.4	136.5
August	1,008	1	134	287	380	424	255.9	130.9
September	854	9	115	280	358	394	243.6	121.1
October	872	4	98	252	327	365	219.9	114.7
November	835	2	84	224	298	334	195.0	108.7
December	843	1	98	221	275	304	184.5	100.6
2022								
January	756	7	121	213	248	271	183.5	76.9
February	695	12	119	196	220	242	167.5	66.8
March	859	1	112	172	193	214	151.0	54.4
April	831	6	112	149	163	183	131.0	45.1
May	789	1	98	124	137	152	112.9	33.9
June	832	4	81	96	107	122	88.7	25.7
July	1,083	14	58	68	78	92	65.3	17.5
August	1,263	1	31	40	51	61	40.8	12.0
September	1,040	1	8	13	20	30	13.7	8.3
<i>Atopic Dermatitis</i>	<i>28,055</i>	<i>1</i>	<i>95</i>	<i>238</i>	<i>496</i>	<i>1,984</i>	<i>351.2</i>	<i>348.4</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	713	713	713	713	713	713.0	NaN
April	74	13	244	787	1,444	1,984	915.4	666.7
May	204	14	217	497	1,297	1,977	739.4	621.8
June	207	4	185	532	1,050	1,940	695.3	581.7
July	214	5	159	534	1,099	1,910	679.0	568.3
August	251	14	136	444	984	1,879	630.0	560.9
September	224	13	110	418	1,107	1,842	634.2	580.7
October	243	14	101	427	987	1,813	606.7	541.3
November	248	14	60	386	937	1,779	546.7	522.9
December	179	6	42	314	836	1,752	515.5	541.7
2018								
January	167	14	154	490	1,092	1,726	654.0	540.6
February	185	14	210	504	1,046	1,690	643.2	525.9
March	220	14	189	519	1,240	1,675	684.9	551.0
April	173	4	218	554	1,050	1,632	652.6	502.6
May	172	14	194	520	1,132	1,607	641.6	513.9
June	180	10	182	422	927	1,573	566.2	478.4
July	322	2	133	350	819	1,536	506.0	440.2
August	335	10	124	344	798	1,503	502.5	453.7

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	286	4	111	349	746	1,479	484.3	439.7
October	328	10	122	421	880	1,459	537.8	446.5
November	316	5	126	394	794	1,429	514.5	435.0
December	256	4	102	378	812	1,389	509.9	448.6
2019								
January	315	14	210	504	952	1,363	583.6	430.3
February	293	1	210	545	910	1,332	581.4	410.4
March	308	6	210	461	844	1,306	542.1	393.3
April	423	13	196	462	920	1,276	544.7	402.7
May	382	4	196	490	919	1,237	548.6	393.3
June	376	12	170	434	852	1,215	503.4	380.7
July	526	2	155	372	812	1,186	483.3	375.6
August	517	3	128	434	826	1,153	485.6	375.4
September	419	1	111	378	718	1,123	445.7	349.2
October	475	14	98	406	744	1,096	454.8	342.7
November	432	5	84	380	759	1,061	443.5	350.5
December	444	1	98	351	741	1,034	426.2	345.0
2020								
January	410	1	210	434	773	1,003	479.4	308.9
February	416	2	154	336	752	970	439.1	319.1
March	416	7	151	296	641	941	393.8	286.8
April	280	3	178	411	660	913	424.0	281.1
May	291	14	162	364	700	877	416.0	284.0
June	378	7	172	338	658	852	399.2	271.3
July	697	11	150	360	644	822	389.5	264.9
August	556	5	126	336	616	789	370.8	256.5
September	529	3	140	383	620	760	383.1	243.3
October	540	2	98	338	589	730	352.3	241.1
November	554	1	92	327	558	698	331.4	233.0
December	528	1	84	308	547	669	317.2	231.0
2021								
January	466	11	182	380	552	634	367.9	195.7
February	472	5	178	328	529	607	339.9	183.5
March	534	2	182	370	518	578	341.1	182.2
April	513	2	152	322	474	544	306.3	170.0
May	495	6	154	308	460	515	296.0	163.7
June	495	6	168	308	436	487	291.0	149.7
July	664	5	154	300	405	457	274.5	135.3
August	727	1	134	282	378	424	254.3	129.0
September	659	9	112	264	352	394	237.0	121.6
October	655	4	98	252	327	365	218.5	115.1
November	634	2	84	218	293	334	191.1	107.8
December	631	3	90	210	271	304	180.0	100.3
2022								

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	563	12	126	210	248	271	183.9	75.3
February	500	12	116	196	220	242	166.4	67.5
March	624	1	112	170	193	214	149.3	54.7
April	593	9	112	144	162	183	128.7	45.0
May	566	8	98	124	136	152	113.4	32.5
June	562	4	79	95	106	122	87.3	26.2
July	793	14	59	68	77	92	64.8	17.7
August	890	1	31	40	51	61	40.5	12.1
September	729	1	8	14	19	30	13.8	8.4
<i>Asthma</i>	<i>13,372</i>	<i>1</i>	<i>98</i>	<i>252</i>	<i>518</i>	<i>1,984</i>	<i>352.7</i>	<i>330.2</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	713	713	713	713	713	713.0	NaN
April	21	14	284	686	1,551	1,984	957.3	725.4
May	43	14	223	764	1,574	1,944	875.5	672.6
June	38	98	224	742	1,180	1,836	755.2	540.8
July	60	13	155	449	980	1,895	621.2	559.2
August	68	14	126	400	1,047	1,852	612.0	540.0
September	48	28	114	853	1,281	1,842	815.9	607.8
October	62	14	196	467	1,032	1,743	628.7	504.1
November	56	14	56	379	863	1,779	518.8	525.7
December	52	10	39	336	911	1,662	522.2	533.4
2018								
January	46	14	166	694	1,023	1,721	722.8	547.6
February	54	14	210	588	1,232	1,677	693.1	558.5
March	52	28	267	621	1,301	1,651	756.4	549.0
April	46	14	229	578	1,247	1,619	712.0	541.3
May	44	20	301	924	1,316	1,607	827.6	514.7
June	34	14	350	628	1,096	1,556	735.3	447.3
July	82	28	148	329	853	1,522	500.5	439.0
August	89	14	125	314	707	1,492	490.6	463.6
September	63	5	98	266	826	1,479	460.7	480.4
October	70	14	98	427	1,038	1,429	560.6	490.7
November	93	14	224	535	895	1,417	596.3	432.7
December	118	1	194	520	826	1,388	577.0	438.1
2019								
January	160	14	293	631	959	1,353	634.1	418.4
February	144	14	253	580	866	1,331	582.8	387.4
March	147	14	210	462	892	1,298	545.9	389.2
April	205	13	230	588	994	1,276	610.8	414.7
May	182	4	209	530	952	1,235	557.5	388.7
June	186	14	168	376	905	1,215	496.0	397.5
July	235	14	156	434	812	1,177	493.9	361.0

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	305	2	133	472	859	1,152	517.2	384.9
September	237	6	112	434	854	1,123	497.8	369.5
October	294	14	140	444	896	1,089	514.5	365.4
November	267	12	126	445	811	1,061	489.0	351.8
December	236	6	86	356	863	1,034	449.0	368.8
2020								
January	236	3	212	357	838	993	481.7	330.3
February	274	14	232	449	821	964	487.1	313.6
March	264	6	168	463	816	941	477.0	316.1
April	194	14	219	476	749	913	468.7	278.1
May	179	3	154	308	672	879	406.9	286.0
June	220	8	184	407	708	852	424.6	279.0
July	351	14	158	416	669	817	409.9	263.8
August	289	5	130	448	672	788	408.8	267.0
September	301	1	119	424	644	760	391.6	253.4
October	330	10	86	336	598	723	349.8	243.7
November	284	14	116	353	604	691	354.5	238.3
December	265	1	84	341	572	667	326.4	235.1
2021								
January	244	14	234	440	560	633	379.4	196.4
February	242	14	204	435	556	605	376.8	189.8
March	288	14	198	353	525	579	348.6	176.3
April	268	9	196	362	490	541	330.9	167.8
May	260	5	164	362	470	515	314.0	165.1
June	243	2	170	328	437	484	294.9	148.7
July	315	14	150	283	406	452	267.9	137.4
August	364	12	140	308	383	425	265.6	130.2
September	291	11	115	290	362	394	250.5	121.6
October	298	14	112	266	326	362	225.0	111.4
November	298	14	112	252	305	334	208.6	107.5
December	289	1	110	238	276	303	189.7	101.2
2022								
January	276	7	132	229	252	271	190.1	78.4
February	275	13	140	199	220	242	170.9	63.7
March	282	7	112	171	194	214	150.8	55.5
April	325	10	112	151	166	183	133.4	44.9
May	295	6	98	124	137	153	113.1	33.4
June	294	8	84	96	107	121	90.7	23.7
July	396	12	56	68	79	92	65.5	17.9
August	445	6	32	43	52	61	41.4	12.1
September	359	1	8	14	22	30	14.2	8.2
<i>Chronic Rhinosinusitis</i>	<i>8,142</i>	<i>1</i>	<i>96</i>	<i>239</i>	<i>484</i>	<i>1,977</i>	<i>330.9</i>	<i>301.6</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	5	251	1,078	1,330	1,444	1,551	1,130.8	522.3
May	14	14	126	997	1,636	1,977	929.0	791.9
June	16	14	157	396	1,226	1,871	705.9	653.9
July	13	42	70	168	672	1,910	445.8	549.8
August	25	30	187	378	921	1,856	626.8	578.9
September	9	98	448	761	1,581	1,775	966.1	657.1
October	13	14	266	322	963	1,106	496.7	397.6
November	12	42	266	815	1,328	1,648	809.8	598.7
December	14	13	42	137	862	1,668	473.4	566.6
2018								
January	17	14	294	695	789	1,204	550.7	387.9
February	20	14	205	404	1,135	1,677	663.9	579.8
March	17	56	292	643	1,052	1,629	734.2	503.1
April	18	28	238	482	865	986	529.3	332.8
May	19	42	98	266	865	1,547	499.4	451.2
June	10	14	235	463	546	1,548	525.0	435.4
July	27	14	159	476	868	1,316	516.8	387.5
August	31	14	314	498	820	1,485	582.7	403.9
September	23	70	161	393	948	1,470	562.2	459.6
October	22	42	168	453	1,033	1,389	614.3	468.7
November	35	17	210	434	979	1,391	568.2	465.4
December	56	1	217	499	861	1,388	564.6	430.9
2019								
January	64	14	140	578	850	1,349	565.8	421.7
February	52	14	246	688	1,036	1,331	679.6	424.3
March	62	14	154	489	798	1,298	506.7	398.2
April	94	14	260	606	981	1,276	642.4	411.3
May	79	14	182	448	966	1,235	545.7	411.9
June	87	14	177	364	929	1,202	508.5	409.1
July	112	14	148	452	870	1,185	526.3	390.7
August	166	10	140	494	924	1,151	536.8	391.2
September	166	6	112	432	824	1,123	492.4	364.7
October	185	14	91	406	824	1,089	477.6	366.0
November	191	14	88	448	795	1,060	483.0	355.0
December	180	5	77	377	862	1,034	448.0	369.3
2020								
January	154	3	280	397	812	983	490.2	307.5
February	174	14	233	391	756	964	467.7	300.9
March	182	14	218	418	758	940	454.6	302.6
April	136	14	210	418	778	913	468.1	288.1
May	117	5	140	352	689	879	405.8	289.2
June	153	8	184	448	682	849	428.1	284.1

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	212	28	158	417	686	817	417.5	270.7
August	182	5	130	391	682	788	402.8	273.5
September	187	1	108	364	644	760	374.1	260.0
October	208	9	85	307	588	725	334.5	241.5
November	179	12	56	308	574	689	328.7	243.6
December	189	1	66	362	568	667	325.1	239.8
2021								
January	164	14	247	389	560	634	375.5	189.1
February	173	28	282	471	562	607	409.6	174.3
March	161	14	224	424	534	578	370.8	176.6
April	177	9	164	353	487	547	321.1	176.2
May	177	14	182	392	465	516	323.4	158.0
June	168	14	185	367	446	487	308.0	153.3
July	205	28	168	313	415	452	287.5	134.6
August	223	14	150	308	382	424	270.4	126.9
September	182	14	168	301	362	394	261.8	115.1
October	210	14	140	277	327	362	231.4	111.1
November	187	14	84	252	305	333	206.5	111.0
December	217	9	107	233	277	304	190.1	99.5
2022								
January	197	14	155	224	250	271	193.3	70.1
February	193	13	140	201	224	242	173.0	64.9
March	216	7	121	176	196	214	155.7	52.6
April	222	10	124	154	164	183	134.5	44.5
May	222	1	96	124	137	152	111.6	37.4
June	224	14	84	99	108	122	92.2	24.1
July	221	18	56	68	79	92	65.6	17.2
August	265	6	32	43	52	61	41.9	11.5
September	211	1	6	12	21	30	13.5	8.4
<i>Eosinophilic Esophagitis</i>	2,453	1	60	182	403	1,824	284.1	298.4
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	114	114	1,526	1,551	1,551	1,063.7	822.5
May	6	14	42	132	215	1,315	308.3	499.1
June	5	98	155	156	185	188	156.4	36.2
July	9	210	648	905	1,106	1,824	970.9	543.4
August	8	70	154	343	905	1,680	569.1	612.8
September	8	86	133	372	1,097	1,787	634.5	632.8
October	1	202	202	202	202	202	202.0	NaN
November	8	42	80	518	1,332	1,593	686.6	652.0
December	10	6	14	279	601	1,596	482.4	613.7
2018								

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	6	70	139	647	1,247	1,704	742.3	635.1
February	13	14	56	210	364	1,386	340.9	416.8
March	12	61	161	550	868	1,486	565.9	438.5
April	6	42	100	294	588	1,106	404.0	393.9
May	8	28	155	222	703	1,140	415.9	392.3
June	15	27	221	515	807	1,295	517.9	358.2
July	17	28	154	403	853	1,383	530.4	439.5
August	14	56	133	293	871	1,468	504.2	466.8
September	9	28	168	320	448	736	346.6	260.6
October	19	14	140	387	696	1,359	444.7	372.8
November	17	32	126	464	896	1,402	580.2	489.8
December	25	5	165	686	1,190	1,375	630.1	500.4
2019								
January	19	14	252	588	1,120	1,342	627.3	435.7
February	17	28	154	560	661	1,331	561.2	471.9
March	24	14	112	246	689	1,250	401.6	394.5
April	30	14	154	290	595	1,258	419.8	367.3
May	31	14	224	490	761	1,236	520.3	351.0
June	19	14	98	479	929	1,188	501.4	420.4
July	39	15	140	378	812	1,174	503.6	380.0
August	43	9	131	437	616	1,129	421.0	343.4
September	38	6	178	392	812	1,093	487.4	347.5
October	46	9	83	420	644	1,048	414.8	331.3
November	41	14	280	504	982	1,055	544.3	374.5
December	35	2	86	379	710	998	434.7	330.4
2020								
January	39	14	196	448	896	982	513.9	337.8
February	53	14	154	414	669	956	441.4	307.4
March	39	14	181	336	715	926	426.3	293.6
April	24	135	236	571	765	879	516.3	275.7
May	26	14	196	306	532	858	361.4	255.4
June	33	13	112	207	476	842	307.5	265.3
July	37	14	150	364	507	795	365.9	242.7
August	34	28	130	350	662	768	379.1	255.9
September	39	28	94	239	470	744	299.3	223.5
October	35	14	84	355	532	719	339.5	236.4
November	45	14	56	336	578	683	334.6	247.3
December	56	3	27	102	430	646	216.0	227.1
2021								
January	50	28	140	331	528	633	320.6	198.8
February	36	42	238	374	556	603	371.0	185.0
March	42	28	182	352	500	576	335.8	170.9
April	38	28	166	378	477	526	317.8	172.2
May	49	39	168	288	416	512	287.3	147.0

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	40	28	178	278	428	471	288.5	146.1
July	51	14	117	224	376	442	244.1	134.8
August	59	28	142	322	379	418	272.8	120.1
September	51	24	112	297	352	395	246.5	120.2
October	58	14	196	302	337	362	252.9	109.6
November	74	14	140	235	297	329	212.8	96.7
December	68	9	112	244	273	295	199.4	90.1
2022								
January	53	14	112	192	254	271	177.4	81.4
February	42	14	118	187	220	236	168.9	60.9
March	56	64	136	181	195	214	164.6	40.5
April	52	28	106	154	164	179	135.7	39.4
May	57	1	98	123	134	148	109.9	35.6
June	73	28	78	95	107	122	87.7	26.6
July	109	28	56	66	78	92	65.5	15.7
August	180	19	32	44	52	61	42.3	10.9
September	154	1	5	11	22	30	13.1	8.8
<i>Prurigo Nodularis</i>	828	1	86	233	485	1,893	339.6	330.9
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	1,327	1,327	1,368	1,893	1,893	1,529.3	315.6
May	2	42	42	112	181	181	111.5	98.3
June	3	71	71	185	225	225	160.3	79.9
July	6	155	770	1,031	1,249	1,608	974.0	501.8
August	6	14	42	942	1,206	1,470	769.2	613.5
September	2	64	64	74	84	84	74.0	14.1
October	5	59	69	372	377	1,408	457.0	553.8
November	5	14	30	545	782	1,131	500.4	483.9
December	3	24	24	357	1,752	1,752	711.0	916.8
2018								
January	4	210	378	693	1,103	1,365	740.3	489.6
February	8	17	192	378	518	1,038	403.9	316.6
March	4	98	301	532	1,118	1,675	709.3	675.9
April	7	113	229	554	927	1,431	619.0	445.6
May	5	14	98	182	443	562	259.8	233.2
June	4	534	855	1,211	1,293	1,339	1,073.8	366.0
July	2	996	996	1,244	1,492	1,492	1,244.0	350.7
August	5	56	98	770	1,181	1,305	682.0	586.9
September	7	56	126	406	1,289	1,377	561.3	553.8
October	6	143	182	658	848	1,285	629.0	441.0
November	12	39	266	385	707	1,390	519.6	433.8
December	5	196	242	328	952	1,258	595.2	480.1

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2019								
January	5	126	364	907	1,176	1,204	755.4	487.5
February	11	14	126	315	938	1,306	520.8	467.4
March	10	14	70	101	252	1,123	243.1	343.1
April	10	14	98	197	462	840	291.5	280.7
May	14	154	224	344	490	1,209	404.3	276.8
June	15	56	420	761	1,102	1,191	724.1	394.0
July	14	111	182	351	644	1,114	441.6	307.0
August	13	84	478	851	994	1,124	705.5	393.0
September	14	56	140	391	862	1,117	488.1	390.8
October	15	28	224	681	912	1,088	565.3	368.9
November	15	15	124	322	666	912	397.7	295.8
December	16	14	133	440	693	983	444.4	329.5
2020								
January	19	14	168	331	476	983	376.4	297.3
February	9	126	304	364	822	940	497.7	291.6
March	9	14	56	294	420	782	306.1	295.9
April	6	14	322	642	803	809	538.7	326.8
May	8	33	64	440	693	830	407.1	321.4
June	9	163	210	336	462	672	357.9	173.5
July	17	28	84	395	704	799	392.7	300.9
August	17	85	280	490	663	752	449.6	245.0
September	11	42	339	585	672	739	489.9	226.6
October	13	32	196	308	504	617	322.8	191.7
November	27	22	57	397	584	682	335.5	245.3
December	14	11	18	476	580	642	362.1	256.5
2021								
January	15	56	252	476	597	623	416.7	192.9
February	14	28	280	457	528	569	411.4	159.2
March	20	56	231	428	517	570	367.3	178.0
April	9	70	168	406	435	536	317.0	166.2
May	11	105	196	443	488	505	367.7	149.6
June	19	84	154	436	466	485	334.5	162.3
July	20	10	105	329	432	452	272.4	164.6
August	19	14	84	138	252	423	166.9	123.2
September	21	14	240	336	360	393	277.2	114.7
October	16	61	99	250	329	362	220.4	110.9
November	19	14	45	154	231	319	153.9	102.6
December	21	3	112	255	288	303	191.5	114.5
2022								
January	25	14	182	233	249	261	194.8	80.7
February	24	14	84	200	222	240	160.4	77.5
March	13	84	140	175	192	212	159.6	41.7
April	22	6	136	156	167	177	141.7	39.2

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	24	1	107	129	142	148	118.4	34.0
June	25	24	78	93	101	120	86.3	23.8
July	23	14	56	68	76	92	62.7	20.0
August	27	14	28	40	52	60	38.7	15.1
September	26	2	11	17	25	29	17.4	8.3
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>								
	38,506	1	92	235	496	1,990	347.0	341.3
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	742	742	742	742	742	742.0	NaN
April	88	13	250	691	1,366	1,990	865.5	655.6
May	241	14	222	578	1,311	1,978	777.1	624.1
June	236	4	187	568	1,130	1,940	722.7	597.3
July	231	5	158	509	1,100	1,914	662.2	574.4
August	280	14	131	418	1,033	1,880	634.3	584.2
September	245	13	110	444	1,104	1,842	647.2	590.9
October	264	14	99	432	983	1,825	607.5	555.4
November	278	14	61	394	1,012	1,779	570.8	539.5
December	212	6	42	259	872	1,758	510.9	552.6
2018								
January	178	14	141	447	1,002	1,731	607.5	520.8
February	211	14	207	472	1,033	1,691	631.9	529.5
March	252	14	195	522	1,184	1,675	673.8	536.5
April	196	4	225	551	1,061	1,619	659.7	506.0
May	198	14	188	544	1,161	1,611	641.3	521.4
June	197	10	192	483	950	1,583	600.2	488.5
July	309	2	126	329	787	1,549	473.1	432.1
August	347	5	124	315	800	1,522	500.7	462.6
September	294	5	106	375	775	1,486	510.3	454.8
October	370	10	100	390	832	1,459	515.1	447.9
November	360	5	146	424	869	1,429	540.4	445.7
December	329	1	99	379	794	1,398	516.9	455.6
2019								
January	411	14	210	520	950	1,363	587.8	427.3
February	405	1	246	547	913	1,338	588.4	407.2
March	415	6	210	466	864	1,306	544.6	396.5
April	548	8	193	497	917	1,278	553.6	409.0
May	495	4	182	480	927	1,248	541.0	399.8
June	506	12	176	428	859	1,215	506.4	387.9
July	660	2	155	377	835	1,186	486.3	377.3
August	714	2	132	448	869	1,157	506.8	386.3
September	616	1	112	409	742	1,123	455.8	359.4

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
October	731	1	102	420	791	1,096	474.1	356.6
November	661	5	88	406	784	1,062	464.7	358.9
December	694	1	77	351	767	1,034	428.9	358.0
2020								
January	596	1	213	421	809	1,003	486.4	318.7
February	646	2	175	373	789	970	460.1	319.6
March	664	4	158	358	719	943	434.8	303.7
April	454	3	186	385	704	913	435.7	287.0
May	453	3	158	313	691	883	408.2	289.0
June	564	7	172	351	674	852	405.2	277.4
July	897	14	154	355	645	822	390.8	268.2
August	784	5	133	372	645	789	389.0	261.4
September	774	1	115	371	629	760	377.6	251.7
October	858	2	98	334	605	730	352.0	246.4
November	805	1	98	326	562	698	337.3	235.2
December	805	1	85	341	567	669	330.7	234.5
2021								
January	671	4	186	361	555	636	361.1	199.8
February	664	5	182	373	547	607	359.2	191.4
March	760	2	193	364	529	579	349.2	182.0
April	734	2	162	347	490	548	319.7	173.3
May	696	6	159	333	469	518	303.7	166.6
June	700	2	170	327	449	487	297.5	154.0
July	863	5	154	290	408	457	272.1	136.8
August	995	1	133	286	382	425	255.3	132.1
September	867	9	115	265	358	395	240.7	121.8
October	923	4	112	269	333	365	226.5	115.5
November	886	2	84	229	305	334	198.4	110.5
December	870	1	98	221	277	304	185.1	102.1
2022								
January	790	1	126	224	251	273	187.7	77.7
February	747	8	116	199	222	242	168.6	68.6
March	899	1	114	175	195	214	152.2	56.2
April	854	5	112	151	165	183	131.7	46.8
May	824	1	101	128	138	152	114.4	34.7
June	865	3	81	98	108	122	89.3	27.0
July	1,070	14	57	68	79	92	65.6	18.1
August	1,282	1	32	40	52	61	41.2	12.3
September	1,073	1	7	12	22	30	13.8	8.4
<i>Any Indication</i>	<i>35,371</i>	<i>1</i>	<i>94</i>	<i>237</i>	<i>499</i>	<i>1,990</i>	<i>348.3</i>	<i>340.7</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	742	742	742	742	742	742.0	NaN

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	79	13	250	733	1,491	1,990	903.5	670.4
May	208	14	221	501	1,307	1,978	750.3	628.8
June	208	4	186	528	1,023	1,940	689.3	583.2
July	211	5	159	535	1,108	1,914	680.9	581.3
August	252	14	138	462	1,084	1,880	658.1	582.0
September	223	13	110	425	1,127	1,842	646.9	591.7
October	237	14	106	432	967	1,822	604.8	543.6
November	251	14	60	384	935	1,779	547.7	527.2
December	186	6	42	259	843	1,758	497.1	544.4
2018								
January	158	14	146	454	1,045	1,731	619.4	522.6
February	187	14	207	472	1,050	1,691	638.2	532.9
March	218	14	210	536	1,238	1,675	698.7	544.1
April	181	4	243	576	1,135	1,632	684.2	505.8
May	175	14	185	545	1,188	1,611	648.5	527.7
June	176	10	190	448	945	1,583	582.2	488.1
July	273	2	126	336	794	1,549	489.5	439.4
August	297	5	126	320	821	1,522	509.8	471.1
September	277	5	117	372	770	1,486	508.4	448.8
October	332	10	128	431	882	1,459	548.2	450.6
November	338	5	144	405	871	1,429	535.5	441.3
December	299	1	105	378	794	1,397	515.2	448.4
2019								
January	377	14	215	536	970	1,363	598.6	430.9
February	373	1	238	574	921	1,338	593.7	409.7
March	385	6	201	465	851	1,306	539.5	397.3
April	512	13	189	494	949	1,278	559.1	414.9
May	465	4	192	484	940	1,248	549.5	400.1
June	465	12	172	429	857	1,215	502.9	388.2
July	607	2	155	376	823	1,186	482.3	376.2
August	672	2	133	464	870	1,157	513.2	386.1
September	566	1	113	421	813	1,123	471.1	361.4
October	677	14	103	423	792	1,096	478.5	356.4
November	622	5	90	406	787	1,062	463.6	357.1
December	635	1	84	354	768	1,034	434.4	355.9
2020								
January	562	1	215	421	804	1,003	484.8	317.7
February	599	2	176	378	804	970	466.1	321.4
March	614	6	155	341	710	943	430.2	301.9
April	423	3	198	420	702	913	445.8	285.2
May	417	3	155	322	695	883	408.7	289.4
June	518	7	177	371	687	852	411.1	279.2
July	820	11	154	366	664	822	396.0	269.5
August	707	5	132	363	645	789	388.0	262.0

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	705	1	119	388	640	760	383.1	252.6
October	779	2	98	339	604	730	353.9	244.2
November	735	1	98	340	567	698	341.1	235.7
December	735	1	84	331	567	669	325.8	235.3
2021								
January	620	13	191	376	559	636	366.5	198.6
February	624	5	196	373	547	607	361.8	188.9
March	707	2	190	364	529	579	349.7	182.6
April	676	2	160	341	489	548	318.4	172.3
May	647	6	163	336	467	518	305.1	165.4
June	647	14	172	322	446	487	297.0	152.2
July	756	5	157	296	414	457	276.6	136.7
August	917	1	135	286	383	425	256.6	131.9
September	812	9	116	274	360	395	243.8	121.8
October	837	4	100	266	333	365	225.2	115.9
November	797	2	84	229	305	334	199.0	110.4
December	820	1	98	222	277	304	185.8	102.2
2022								
January	741	7	121	222	250	273	186.9	78.0
February	683	12	126	201	225	242	170.5	67.6
March	836	1	117	175	196	214	153.6	54.8
April	794	6	112	151	165	183	132.6	45.7
May	762	1	101	128	138	152	115.0	34.4
June	816	3	81	98	108	122	89.6	26.6
July	959	14	59	68	79	92	65.7	18.4
August	1,193	1	32	40	52	61	41.3	12.3
September	990	1	8	12	21	30	13.8	8.4
<i>Atopic Dermatitis</i>	<i>26,674</i>	<i>1</i>	<i>98</i>	<i>240</i>	<i>505</i>	<i>1,990</i>	<i>357.1</i>	<i>353.7</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	742	742	742	742	742	742.0	NaN
April	74	13	251	802	1,491	1,990	927.9	673.1
May	202	14	221	518	1,309	1,978	755.6	629.7
June	205	4	186	536	1,051	1,940	699.6	587.5
July	199	5	160	535	1,108	1,914	681.1	575.0
August	237	14	138	465	1,021	1,880	652.0	574.6
September	215	13	110	425	1,151	1,842	651.7	592.2
October	229	14	104	432	975	1,822	607.2	549.7
November	245	14	61	391	932	1,779	548.2	524.6
December	176	6	44	282	854	1,758	508.5	547.9
2018								
January	158	14	157	481	1,056	1,732	638.6	532.7
February	179	14	210	501	1,100	1,691	656.6	536.6

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	213	14	196	526	1,238	1,675	695.7	547.8
April	169	4	239	567	1,054	1,632	671.2	507.6
May	169	14	189	502	1,161	1,611	643.1	525.5
June	173	10	186	448	939	1,583	579.4	490.8
July	263	2	121	336	799	1,549	491.7	443.0
August	289	5	126	336	836	1,522	518.9	472.5
September	270	5	119	375	771	1,486	512.9	451.4
October	318	10	126	435	906	1,459	554.8	454.1
November	306	5	129	400	796	1,429	520.5	438.0
December	247	4	99	371	758	1,396	500.8	445.3
2019								
January	313	14	210	504	974	1,363	592.8	436.1
February	292	1	225	575	931	1,335	593.7	412.2
March	298	6	201	450	849	1,306	535.4	397.5
April	412	13	189	466	920	1,278	550.3	411.1
May	369	4	201	489	935	1,248	556.3	399.9
June	364	12	177	450	863	1,215	509.7	385.4
July	480	2	156	378	836	1,186	492.4	381.9
August	489	3	133	463	855	1,157	503.0	381.8
September	398	1	112	377	725	1,123	445.7	351.6
October	468	14	105	418	757	1,096	463.1	345.5
November	415	5	84	392	754	1,062	448.8	354.3
December	443	1	90	350	743	1,034	423.1	346.3
2020								
January	399	1	206	442	806	1,003	488.3	316.5
February	398	2	156	343	782	970	445.8	326.6
March	415	7	154	308	658	943	406.6	290.5
April	271	3	174	406	660	913	424.3	281.4
May	282	14	166	349	714	883	421.7	288.2
June	367	7	171	352	667	852	403.8	277.5
July	599	11	148	350	649	822	388.2	269.0
August	516	5	130	340	633	789	376.1	257.2
September	498	3	129	386	629	760	386.5	247.1
October	519	2	112	346	598	729	359.3	242.8
November	527	1	102	343	560	698	337.7	232.5
December	537	1	84	313	561	669	323.7	234.0
2021								
January	444	13	193	392	562	634	373.8	194.9
February	456	5	173	330	533	607	344.5	187.2
March	509	2	193	382	528	579	350.3	182.6
April	500	2	154	320	482	547	308.8	171.1
May	468	6	154	303	464	518	297.1	166.3
June	475	6	169	303	445	487	293.0	150.7
July	571	5	158	308	412	457	280.2	135.4

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	661	1	136	283	382	425	256.5	130.2
September	630	9	112	261	353	395	238.2	122.1
October	630	4	98	261	333	365	224.9	116.0
November	605	2	84	224	302	334	195.2	109.9
December	609	3	88	212	276	304	181.1	101.6
2022								
January	553	12	121	215	250	271	186.2	77.1
February	484	12	119	200	224	242	168.9	68.8
March	608	1	115	173	194	214	151.2	55.8
April	557	9	110	148	163	183	130.1	45.7
May	544	8	102	128	138	152	115.4	32.8
June	553	3	79	96	107	122	88.5	27.1
July	699	14	59	68	78	92	65.1	18.4
August	825	1	31	40	51	61	40.8	12.4
September	687	1	7	12	19	30	13.7	8.4
<i>Asthma</i>	<i>12,473</i>	<i>1</i>	<i>98</i>	<i>252</i>	<i>523</i>	<i>1,984</i>	<i>357.2</i>	<i>334.3</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	742	742	742	742	742	742.0	NaN
April	21	14	292	707	1,559	1,984	971.2	728.9
May	43	14	223	775	1,592	1,957	889.5	680.8
June	38	101	224	742	1,183	1,847	767.0	548.5
July	54	13	160	407	807	1,906	596.3	551.0
August	64	14	131	412	1,110	1,858	638.0	555.2
September	43	28	110	813	1,279	1,842	773.8	612.3
October	49	14	225	729	1,114	1,772	718.9	539.4
November	51	14	56	418	907	1,779	539.6	517.7
December	50	4	28	270	902	1,692	496.9	542.0
2018								
January	40	14	159	713	1,105	1,727	719.8	551.3
February	50	14	207	441	1,201	1,677	666.0	557.7
March	48	56	349	678	1,349	1,651	813.2	531.0
April	38	14	182	494	1,262	1,619	666.7	539.2
May	41	20	274	848	1,331	1,611	811.3	541.7
June	34	14	355	593	1,106	1,566	722.1	455.6
July	63	40	153	339	869	1,543	497.7	427.8
August	71	14	119	281	707	1,494	475.4	462.4
September	59	5	98	280	883	1,486	509.9	499.5
October	68	14	96	432	898	1,438	545.6	487.6
November	86	14	216	532	916	1,417	598.8	442.2
December	111	1	167	506	897	1,397	579.0	447.5
2019								
January	151	14	295	654	974	1,359	642.0	415.1

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
February	141	14	257	611	887	1,338	598.5	396.4
March	143	14	218	476	912	1,305	556.5	393.9
April	194	13	243	612	1,022	1,278	633.3	422.6
May	179	4	210	536	956	1,237	557.2	399.3
June	185	14	159	372	908	1,215	499.0	403.3
July	221	14	156	407	833	1,186	490.9	365.1
August	295	2	134	469	884	1,157	524.9	390.1
September	232	6	140	441	865	1,123	512.4	369.1
October	282	14	172	453	913	1,089	526.0	369.7
November	252	12	140	453	815	1,062	499.4	355.9
December	225	6	84	353	871	1,034	448.8	372.8
2020								
January	222	3	210	363	855	1,000	488.0	336.8
February	265	14	232	458	850	967	494.8	318.2
March	247	6	154	445	800	943	466.5	321.7
April	179	14	226	485	764	912	478.2	279.5
May	170	3	146	274	658	883	398.6	287.4
June	202	8	190	418	739	852	444.1	283.6
July	295	14	162	418	681	822	414.2	268.8
August	268	5	132	439	673	788	410.5	268.2
September	274	1	113	419	640	760	390.9	257.7
October	304	10	88	314	610	729	347.3	246.3
November	271	14	126	360	606	696	362.3	241.0
December	263	1	84	360	580	669	331.8	237.8
2021								
January	235	14	210	383	551	636	371.0	196.5
February	229	14	202	424	567	607	376.2	195.2
March	267	14	202	356	530	579	351.3	176.9
April	246	9	204	364	494	548	339.3	165.9
May	243	5	168	363	477	515	318.1	167.1
June	237	2	179	327	443	485	297.2	150.1
July	270	14	140	280	405	456	265.1	138.8
August	327	12	142	302	384	425	263.4	131.3
September	265	11	116	293	362	395	250.6	123.2
October	278	14	112	277	330	362	229.3	113.3
November	281	14	112	247	308	334	208.5	108.7
December	276	1	107	239	280	304	191.9	103.0
2022								
January	264	7	129	232	254	273	191.7	79.3
February	263	13	144	204	225	242	176.3	63.0
March	269	7	120	175	196	214	154.6	54.5
April	312	10	112	155	166	183	135.0	45.1
May	272	6	98	128	138	152	114.5	34.4
June	283	8	84	97	107	122	91.2	24.2

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	334	14	60	71	81	92	66.5	18.8
August	397	6	32	42	52	61	41.5	12.2
September	342	1	8	14	22	30	14.5	8.4
<i>Chronic Rhinosinusitis</i>	<i>7,627</i>	<i>1</i>	<i>98</i>	<i>240</i>	<i>488</i>	<i>1,977</i>	<i>333.6</i>	<i>304.7</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	5	251	1,120	1,354	1,491	1,559	1,155.0	532.5
May	14	14	136	1,012	1,653	1,977	941.1	799.2
June	16	14	158	410	1,247	1,895	722.8	671.5
July	11	42	56	70	674	1,914	419.9	591.3
August	24	30	175	373	1,024	1,880	630.3	595.4
September	9	104	452	774	1,615	1,802	982.4	669.1
October	9	14	267	326	350	1,116	390.7	338.0
November	11	42	210	692	1,566	1,654	802.5	629.6
December	13	13	42	129	611	1,476	387.0	473.9
2018								
January	14	14	70	388	721	1,022	457.1	353.9
February	15	14	288	489	1,290	1,677	758.6	627.7
March	13	56	183	637	852	1,630	671.3	533.3
April	16	28	326	601	867	971	589.7	315.4
May	18	42	99	263	711	1,555	467.3	432.3
June	11	14	154	423	556	1,557	471.7	448.3
July	24	14	187	496	741	1,177	514.4	353.7
August	26	14	266	528	893	1,488	615.6	444.5
September	22	70	161	425	858	1,471	577.7	460.0
October	18	42	288	513	1,157	1,398	673.1	477.1
November	33	17	216	434	756	1,401	539.2	457.9
December	50	1	210	479	794	1,397	551.6	434.0
2019								
January	59	14	150	532	822	1,351	547.3	405.4
February	49	14	256	689	1,080	1,331	688.1	433.5
March	59	14	112	436	819	1,305	505.3	414.3
April	83	14	251	613	995	1,278	645.3	419.1
May	76	14	140	484	964	1,235	552.3	416.7
June	82	14	188	437	932	1,205	529.8	410.6
July	104	14	142	440	877	1,186	515.9	399.5
August	159	10	133	505	940	1,153	546.4	399.4
September	162	6	119	446	837	1,123	498.6	367.1
October	184	14	92	423	894	1,089	495.5	373.8
November	189	14	90	428	784	1,058	481.6	357.4
December	166	5	80	372	839	1,034	447.7	370.6

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2020								
January	152	3	273	360	817	989	491.4	311.9
February	172	14	228	405	769	964	477.4	306.5
March	176	14	202	413	751	942	452.6	306.3
April	126	14	213	391	771	912	466.4	287.3
May	115	5	140	353	695	879	407.0	291.4
June	138	8	186	481	708	852	441.6	292.8
July	187	28	157	378	708	822	413.3	278.3
August	166	5	134	366	654	789	392.2	273.0
September	178	1	108	385	657	760	381.8	265.3
October	195	9	86	299	609	730	341.4	247.0
November	175	12	60	314	589	696	335.8	245.1
December	185	1	70	369	580	668	333.7	242.1
2021								
January	154	14	258	401	578	634	383.5	193.7
February	160	27	278	473	573	607	409.7	177.5
March	154	14	202	431	537	578	372.6	177.9
April	158	9	183	357	494	548	328.2	176.1
May	165	14	194	382	472	516	328.0	159.0
June	161	14	179	371	450	487	303.9	155.1
July	171	28	168	319	423	457	291.6	136.5
August	209	14	144	308	384	424	266.9	129.7
September	165	14	153	308	365	395	260.1	117.9
October	191	14	144	277	333	362	234.4	112.8
November	169	14	91	269	310	334	212.4	112.5
December	212	9	112	240	278	304	193.9	98.1
2022								
January	182	14	153	229	254	271	195.8	72.3
February	191	14	144	210	225	242	177.7	62.4
March	210	7	122	180	198	214	158.0	52.9
April	208	10	123	155	166	183	134.9	46.1
May	215	1	98	129	140	152	112.4	38.9
June	212	14	84	100	110	122	92.4	25.1
July	181	18	60	68	79	92	66.4	17.2
August	247	6	32	44	53	61	42.5	11.9
September	203	1	6	12	19	30	13.4	8.3
<i>Eosinophilic Esophagitis</i>								
	2,155	1	59	178	402	1,831	285.6	303.6
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	114	114	1,538	1,559	1,559	1,070.3	828.3
May	6	14	42	134	227	1,324	312.5	502.1

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	5	105	158	159	188	209	163.8	39.2
July	8	217	534	995	1,437	1,831	997.5	579.5
August	8	71	161	349	912	1,693	575.9	616.5
September	6	90	105	384	883	1,805	608.3	654.3
October	1	202	202	202	202	202	202.0	NaN
November	6	42	103	531	1,260	1,624	681.8	650.4
December	9	6	14	206	417	1,615	366.7	514.8
2018								
January	5	56	70	141	625	1,704	519.2	702.6
February	10	14	56	168	301	1,428	285.7	421.1
March	11	61	183	637	952	1,521	613.2	445.5
April	5	42	100	284	329	1,139	378.8	441.7
May	9	28	166	265	595	1,188	439.6	380.6
June	13	27	235	490	745	1,295	498.1	374.7
July	15	56	163	403	849	1,333	511.3	387.0
August	10	56	98	302	1,072	1,479	521.3	524.7
September	9	84	320	754	771	1,413	641.9	428.3
October	17	14	140	402	549	1,359	448.6	387.0
November	15	32	133	413	902	1,402	526.1	458.7
December	22	5	252	699	1,246	1,378	692.7	501.6
2019								
January	18	14	220	549	1,120	1,342	601.6	470.8
February	16	28	107	583	697	1,331	538.0	465.8
March	23	14	88	259	762	1,265	419.6	410.4
April	24	14	137	240	586	1,268	391.3	356.1
May	24	14	206	513	693	1,248	512.8	330.8
June	20	14	95	481	787	1,190	493.2	423.3
July	35	15	140	389	974	1,186	511.3	398.0
August	40	14	138	460	744	1,130	473.1	378.8
September	32	6	174	368	802	1,049	461.8	336.2
October	40	14	88	426	708	1,067	434.7	337.4
November	38	14	284	511	1,023	1,058	559.2	379.7
December	34	13	224	391	757	998	474.0	324.6
2020								
January	36	14	200	493	910	986	530.2	342.1
February	48	14	151	372	660	950	434.5	309.0
March	41	14	182	305	728	943	424.0	298.3
April	19	147	312	610	837	891	551.5	262.9
May	21	14	219	322	665	878	396.1	282.2
June	29	13	116	212	496	841	304.5	259.8
July	30	14	148	273	464	801	325.0	234.5
August	29	32	183	377	588	786	407.1	241.4
September	25	28	112	327	487	751	338.0	233.0
October	25	14	88	441	556	710	356.2	256.5

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	42	14	47	273	579	696	317.1	248.1
December	45	3	25	154	490	649	249.7	240.5
2021								
January	47	28	105	333	480	634	312.4	197.7
February	30	46	231	350	580	603	367.9	188.9
March	36	28	180	352	504	569	338.4	172.3
April	30	28	197	375	459	527	318.2	166.9
May	44	22	168	293	438	506	291.8	152.5
June	37	28	177	270	414	485	273.2	140.6
July	41	14	112	200	371	442	234.1	136.1
August	46	28	137	255	359	415	254.8	119.1
September	38	31	100	259	359	383	238.0	124.6
October	53	14	217	314	343	362	262.4	113.1
November	63	14	141	230	305	333	213.6	98.9
December	62	9	112	247	277	296	200.4	93.9
2022								
January	47	14	104	186	256	270	175.8	81.7
February	36	14	119	186	220	241	165.8	65.1
March	51	56	120	181	194	213	161.5	44.6
April	51	28	107	157	166	180	139.3	37.8
May	51	1	93	124	135	150	109.5	37.8
June	62	28	78	96	109	122	89.4	27.2
July	93	28	57	68	79	92	66.9	16.5
August	164	19	32	44	53	61	42.9	11.1
September	146	1	5	11	22	30	13.0	8.8
<i>Prurigo Nodularis</i>	767	1	86	233	485	1,923	341.8	336.2
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	1,331	1,331	1,378	1,923	1,923	1,544.0	329.1
May	2	43	43	114	185	185	114.0	100.4
June	3	71	71	185	233	233	163.0	83.2
July	5	156	780	894	1,262	1,695	957.4	573.3
August	6	14	45	951	1,217	1,480	776.3	616.8
September	2	64	64	74	84	84	74.0	14.1
October	5	59	69	378	398	1,428	466.4	561.5
November	4	14	22	288	847	1,148	434.3	536.0
December	3	24	24	374	1,754	1,754	717.3	914.7
2018								
January	4	216	389	708	1,115	1,376	751.8	490.9
February	7	115	281	466	594	1,038	466.6	296.4
March	2	98	98	887	1,675	1,675	886.5	1,115.1
April	6	113	229	522	623	935	490.7	294.0

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	5	14	100	189	449	564	263.2	234.1
June	4	1,189	1,233	1,325	1,375	1,377	1,303.8	89.6
July	3	420	420	1,014	1,502	1,502	978.7	541.9
August	5	56	98	770	1,224	1,308	691.2	597.1
September	7	56	129	406	1,337	1,391	571.1	567.4
October	6	151	193	677	848	1,331	646.0	449.6
November	12	39	279	389	721	1,401	525.9	435.7
December	4	196	273	652	1,137	1,320	705.0	524.5
2019								
January	5	139	364	942	1,185	1,241	774.2	496.6
February	9	14	170	675	981	1,306	606.9	485.6
March	10	14	70	101	259	1,156	248.7	353.3
April	10	14	100	197	472	856	296.8	287.6
May	12	155	241	351	481	602	363.7	153.6
June	13	56	470	786	1,081	1,199	755.1	370.1
July	14	124	182	316	644	1,150	434.4	327.1
August	11	84	141	506	1,078	1,131	604.0	408.8
September	14	60	149	401	865	1,123	493.4	391.4
October	14	28	224	566	806	1,090	536.3	360.5
November	14	15	171	348	682	935	428.7	304.5
December	14	14	201	461	619	994	449.2	311.8
2020								
January	19	14	168	332	571	987	413.3	328.1
February	10	126	336	670	840	946	595.9	304.7
March	9	14	56	294	721	818	354.0	343.1
April	3	14	14	337	488	488	279.7	242.1
May	7	33	58	447	658	845	369.0	323.0
June	6	163	168	314	475	519	325.3	162.9
July	14	28	83	290	733	808	362.4	321.4
August	16	92	204	632	698	756	485.9	260.9
September	11	48	196	427	662	740	424.1	237.7
October	11	38	201	308	513	623	323.9	196.6
November	29	22	60	400	574	682	353.9	244.4
December	12	11	100	489	561	600	368.2	240.9
2021								
January	13	56	252	476	574	623	408.6	202.9
February	13	168	293	456	535	577	419.8	139.5
March	20	56	220	432	525	576	366.0	185.9
April	9	73	171	415	439	536	319.6	165.9
May	13	105	271	417	491	508	362.0	138.9
June	18	84	154	448	467	485	333.6	167.6
July	17	10	89	294	432	457	258.8	171.6
August	14	14	98	157	255	423	184.1	127.4
September	22	14	204	303	362	393	262.9	117.7

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
October	9	66	82	269	331	362	229.7	122.0
November	17	14	45	156	224	308	145.8	101.0
December	20	3	79	241	293	303	191.3	117.5
2022								
January	25	14	182	243	254	261	197.6	81.9
February	23	14	76	206	225	240	165.7	78.6
March	14	84	112	179	199	214	158.3	48.7
April	17	6	118	150	162	177	131.6	49.4
May	21	1	114	129	145	151	123.3	34.0
June	24	24	81	94	105	120	89.1	22.4
July	21	14	51	68	78	92	61.4	22.5
August	27	14	28	40	52	60	39.3	14.7
September	25	2	10	17	24	30	17.1	8.6

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4a. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	164,198	1	28	28	84	1,984	83.0	125.3
<i>Any Indication</i>	152,714	1	28	28	84	1,984	83.0	125.4
<i>Atopic Dermatitis</i>	120,523	1	28	28	84	1,984	81.7	125.9
<i>Asthma</i>	56,197	1	28	28	84	1,984	83.9	125.2
<i>Chronic Rhinosinusitis</i>	31,403	1	28	28	84	1,977	85.8	123.4
<i>Eosinophilic Esophagitis</i>	9,260	1	28	28	84	1,584	75.3	111.0
<i>Prurigo Nodularis</i>	3,273	1	28	30	84	1,675	85.9	122.9
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	99,869	1	28	63	163	1,990	133.8	183.8
<i>Any Indication</i>	92,172	1	28	63	162	1,990	133.6	183.6
<i>Atopic Dermatitis</i>	72,490	1	28	61	154	1,990	131.4	184.8
<i>Asthma</i>	33,025	1	28	63	168	1,984	134.9	183.1
<i>Chronic Rhinosinusitis</i>	18,396	1	28	72	169	1,977	138.3	178.6
<i>Eosinophilic Esophagitis</i>	5,269	1	28	57	140	1,801	116.8	160.7
<i>Prurigo Nodularis</i>	1,878	1	28	78	172	1,754	139.6	180.0

Table 4b. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	164,198	1	28	28	84	1,984	83.0	125.3
Female	91,709	1	28	28	84	1,955	82.5	124.3
Male	72,489	1	28	28	84	1,984	83.5	126.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	152,714	1	28	28	84	1,984	83.0	125.4
Female	85,381	1	28	28	84	1,955	82.6	124.3
Male	67,333	1	28	28	84	1,984	83.4	126.7
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	120,523	1	28	28	84	1,984	81.7	125.9
Female	67,108	1	28	28	84	1,955	81.3	124.3
Male	53,415	1	28	28	84	1,984	82.2	127.9
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	56,197	1	28	28	84	1,984	83.9	125.2
Female	32,376	1	28	28	84	1,842	84.1	125.4
Male	23,821	1	28	28	84	1,984	83.8	125.0
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	31,403	1	28	28	84	1,977	85.8	123.4
Female	17,465	1	28	28	84	1,955	84.9	123.8
Male	13,938	1	28	28	84	1,977	86.9	123.0
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	9,260	1	28	28	84	1,584	75.3	111.0
Female	5,396	1	28	28	84	1,428	76.1	110.6
Male	3,864	1	28	28	84	1,584	74.1	111.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	3,273	1	28	30	84	1,675	85.9	122.9
Female	1,979	1	28	42	84	1,675	85.6	122.6
Male	1,294	1	28	28	84	1,486	86.4	123.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	99,869	1	28	63	163	1,990	133.8	183.8

Table 4b. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	56,131	1	28	63	158	1,955	132.3	181.6
Male	43,738	1	28	63	168	1,990	135.7	186.7
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	92,172	1	28	63	162	1,990	133.6	183.6
Female	51,901	1	28	63	158	1,955	132.3	180.9
Male	40,271	1	28	63	168	1,990	135.4	186.9
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	72,490	1	28	61	154	1,990	131.4	184.8
Female	40,740	1	28	61	152	1,955	129.9	181.3
Male	31,750	1	28	61	156	1,990	133.3	189.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	33,025	1	28	63	168	1,984	134.9	183.1
Female	19,222	1	28	62	165	1,906	134.1	182.7
Male	13,803	1	28	63	168	1,984	136.0	183.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	18,396	1	28	72	169	1,977	138.3	178.6
Female	10,216	1	28	66	168	1,955	135.8	177.3
Male	8,180	1	28	80	174	1,977	141.5	180.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	5,269	1	28	57	140	1,801	116.8	160.7
Female	3,087	1	28	58	140	1,477	115.9	159.1
Male	2,182	1	28	57	142	1,801	118.1	162.9
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	1,878	1	28	78	172	1,754	139.6	180.0
Female	1,135	1	28	84	170	1,675	137.8	176.1
Male	743	2	28	69	181	1,754	142.3	185.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4c. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	164,198	1	28	28	84	1,984	83.0	125.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	698	1	28	30	56	695	46.9	63.9
6-11 years	5,746	1	28	30	79	1,222	72.1	98.6
12-17 years	16,824	1	28	28	84	1,520	79.3	116.9
18-79 years	139,800	1	28	28	84	1,984	84.0	127.5
≥ 80 years	1,130	1	28	41	90	822	82.4	106.3
<i>Any Indication</i>	152,714	1	28	28	84	1,984	83.0	125.4
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	673	1	28	30	56	695	46.5	64.3
6-11 years	5,556	1	28	30	79	1,222	72.2	99.2
12-17 years	16,027	1	28	28	84	1,520	79.8	117.8
18-79 years	129,496	1	28	28	84	1,984	84.0	127.6
≥ 80 years	962	1	28	40	84	759	81.8	104.5
<i>Atopic Dermatitis</i>	120,523	1	28	28	84	1,984	81.7	125.9
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	655	1	28	30	56	695	46.0	63.8
6-11 years	5,339	1	28	30	81	1,222	72.5	99.5
12-17 years	14,836	1	28	28	84	1,520	80.4	118.6
18-79 years	98,929	1	28	28	84	1,984	82.7	128.7
≥ 80 years	764	1	28	42	85	753	82.1	103.0
<i>Asthma</i>	56,197	1	28	28	84	1,984	83.9	125.2
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	125	2	28	30	56	476	43.8	50.7
6-11 years	2,112	1	28	30	73	1,050	71.5	97.8
12-17 years	6,216	1	28	28	84	1,285	78.6	117.8
18-79 years	47,513	1	28	28	84	1,984	85.3	127.4
≥ 80 years	231	2	28	49	112	759	85.0	107.6
<i>Chronic Rhinosinusitis</i>	31,403	1	28	28	84	1,977	85.8	123.4
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 4c. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
6-71 months	42	2	28	30	56	476	51.9	73.8
6-11 years	296	1	28	30	65	780	72.1	108.6
12-17 years	1,381	1	28	28	84	1,177	75.2	111.1
18-79 years	29,513	1	28	28	84	1,977	86.5	124.2
≥ 80 years	171	1	28	28	84	703	79.6	104.3
<i>Eosinophilic Esophagitis</i>	9,260	1	28	28	84	1,584	75.3	111.0
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	34	2	28	41	84	476	76.1	100.5
6-11 years	287	1	28	30	56	728	60.8	81.0
12-17 years	740	1	28	28	84	1,160	78.6	114.5
18-79 years	8,103	1	28	28	84	1,584	75.5	111.8
≥ 80 years	96	2	28	28	84	522	72.9	95.8
<i>Prurigo Nodularis</i>	3,273	1	28	30	84	1,675	85.9	122.9
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	2	11	11	18	25	25	18.0	9.9
6-11 years	19	9	16	28	116	369	89.7	108.2
12-17 years	145	2	28	28	84	952	83.5	122.8
18-79 years	3,029	1	28	33	84	1,675	86.4	123.9
≥ 80 years	78	6	28	30	84	537	71.5	82.1
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	99,869	1	28	63	163	1,990	133.8	183.8
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	577	1	28	30	56	800	57.3	88.6
6-11 years	3,987	1	28	56	118	1,548	103.7	139.9
12-17 years	10,287	1	28	62	155	1,537	128.6	170.8
18-79 years	84,306	1	28	66	168	1,990	136.5	187.7
≥ 80 years	712	1	28	61	168	981	122.9	146.3
<i>Any Indication</i>	92,172	1	28	63	162	1,990	133.6	183.6
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	560	1	28	30	56	800	55.5	85.8
6-11 years	3,848	1	28	56	117	1,548	103.8	140.6

Table 4c. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
12-17 years	9,739	1	28	62	156	1,520	129.5	171.9
18-79 years	77,424	1	28	66	168	1,990	136.3	187.4
≥ 80 years	601	1	28	60	168	815	118.4	138.0
<i>Atopic Dermatitis</i>	72,490	1	28	61	154	1,990	131.4	184.8
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	545	1	28	30	56	800	54.9	85.7
6-11 years	3,697	1	28	56	118	1,548	104.3	141.5
12-17 years	8,968	1	28	62	158	1,520	130.5	173.1
18-79 years	58,810	1	28	63	156	1,990	134.0	189.6
≥ 80 years	470	1	28	61	169	815	120.9	139.8
<i>Asthma</i>	33,025	1	28	63	168	1,984	134.9	183.1
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	97	2	28	30	62	619	56.9	89.9
6-11 years	1,443	1	28	56	116	1,548	102.4	138.5
12-17 years	3,642	1	28	60	148	1,285	127.0	171.7
18-79 years	27,702	1	28	66	168	1,984	138.0	186.7
≥ 80 years	141	2	28	70	165	725	119.4	132.0
<i>Chronic Rhinosinusitis</i>	18,396	1	28	72	169	1,977	138.3	178.6
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	31	2	28	31	84	619	71.5	112.2
6-11 years	213	1	28	42	90	844	98.5	141.3
12-17 years	853	2	28	58	135	1,269	112.4	152.2
18-79 years	17,192	1	28	75	172	1,977	140.4	180.4
≥ 80 years	107	1	28	60	150	703	116.9	132.2
<i>Eosinophilic Esophagitis</i>	5,269	1	28	57	140	1,801	116.8	160.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	24	2	22	56	145	619	108.9	142.4
6-11 years	195	1	28	31	84	874	81.5	116.4
12-17 years	460	1	28	57	146	1,268	119.7	165.3
18-79 years	4,543	1	28	58	141	1,801	118.1	161.9
≥ 80 years	47	5	28	57	140	687	118.3	150.7

Table 4c. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Prurigo Nodularis</i>	1,878	1	28	78	172	1,754	139.6	180.0
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	2	11	11	18	25	25	18.0	9.9
6-11 years	12	9	15	110	216	417	139.0	133.1
12-17 years	76	2	28	84	190	1,199	149.4	205.2
18-79 years	1,736	1	28	81	173	1,754	140.6	180.4
≥ 80 years	52	6	28	43	115	808	95.8	128.1

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	164,198	1	28	28	84	1,984	83.0	125.3
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	18	14	28	28	28	140	39.6	32.6
April	701	1	28	56	112	1,984	107.1	185.7
May	1,772	1	28	42	84	1,977	104.1	191.5
June	1,818	1	28	28	84	1,940	92.4	167.8
July	1,831	1	28	30	84	1,908	89.5	161.1
August	2,042	1	28	28	84	1,879	87.1	148.0
September	1,608	1	28	30	84	1,842	96.7	170.9
October	1,896	1	28	28	84	1,708	86.6	163.0
November	1,783	1	28	30	84	1,769	88.2	146.2
December	1,226	3	28	28	84	1,745	88.2	159.9
2018								
January	1,206	1	28	30	84	1,694	91.3	154.4
February	1,403	1	28	28	84	1,676	95.4	163.7
March	1,712	2	28	42	98	1,675	99.3	167.6
April	1,449	1	28	28	84	1,619	88.6	142.9
May	1,402	1	28	30	84	1,520	90.3	151.7
June	1,271	1	28	28	84	1,580	93.6	159.1
July	2,253	1	28	28	84	1,536	79.1	123.6
August	2,295	1	28	28	84	1,503	83.1	136.5
September	1,715	1	28	28	84	1,446	88.4	147.2
October	2,173	1	28	38	84	1,459	89.4	138.3
November	2,126	1	28	28	84	1,429	92.8	162.9
December	1,774	1	28	28	84	1,394	96.4	158.5
2019								
January	2,432	1	28	30	84	1,363	97.1	152.2
February	2,659	1	28	28	84	1,332	86.4	141.4

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	2,595	1	28	28	84	1,306	86.6	138.6
April	3,309	1	28	28	84	1,275	92.2	148.6
May	3,139	1	28	28	84	1,237	85.7	140.2
June	2,793	1	28	28	84	1,215	91.0	139.3
July	4,034	1	28	28	84	1,186	83.6	131.0
August	4,023	1	28	28	84	1,156	90.8	148.9
September	3,236	1	28	28	84	1,123	88.3	140.2
October	3,929	1	28	28	84	1,096	87.5	133.0
November	3,550	1	28	28	84	1,061	86.9	130.6
December	3,339	1	28	28	84	1,034	88.9	137.5
2020								
January	3,184	1	28	28	84	1,003	89.3	130.0
February	3,024	1	28	39	112	970	98.7	145.3
March	3,178	1	28	28	84	941	88.0	130.4
April	2,261	1	28	40	84	913	88.8	125.7
May	2,136	1	28	28	84	879	87.3	126.7
June	2,660	1	28	28	84	852	85.3	123.4
July	5,210	1	28	28	84	817	80.0	113.1
August	3,930	1	28	28	84	789	83.9	119.6
September	3,906	1	28	28	84	760	79.8	108.0
October	3,552	1	28	29	84	730	86.0	120.0
November	3,236	1	28	30	84	698	83.8	114.3
December	3,127	1	28	29	84	669	81.5	105.5
2021								
January	2,908	1	28	28	84	634	83.8	108.1
February	2,753	1	28	30	84	607	87.3	114.3
March	3,058	1	28	34	98	579	87.7	111.6
April	2,865	1	28	31	98	544	82.4	98.9
May	2,575	1	28	30	84	516	82.5	102.7
June	2,460	1	28	42	112	487	85.5	100.3
July	3,695	1	28	28	84	457	74.1	85.8

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	3,704	1	28	30	84	424	75.9	85.7
September	2,717	1	28	31	93	394	79.0	87.4
October	2,880	1	28	30	84	365	72.8	78.3
November	2,574	1	28	28	84	334	69.6	75.9
December	2,252	1	28	30	84	304	70.3	73.0
2022								
January	2,084	1	28	37	92	271	71.9	69.4
February	1,775	1	28	31	93	242	70.0	65.2
March	2,058	1	28	31	84	214	66.5	59.3
April	1,868	1	28	30	86	183	61.5	51.3
May	1,654	1	28	30	84	152	56.9	43.8
June	1,573	1	28	28	81	122	48.8	34.1
July	1,872	1	28	30	65	92	42.0	24.3
August	1,812	1	17	28	43	61	30.8	15.6
September	1,145	1	5	12	19	30	13.4	8.3
<i>Any Indication</i>	<i>152,714</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>84</i>	<i>1,984</i>	<i>83.0</i>	<i>125.4</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	18	14	28	28	28	140	39.6	32.6
April	635	1	28	56	112	1,984	110.9	192.8
May	1,463	1	28	42	84	1,977	105.1	195.7
June	1,591	1	28	28	84	1,940	90.4	166.7
July	1,719	1	28	28	84	1,908	89.3	162.4
August	1,907	1	28	30	84	1,879	88.8	149.9
September	1,525	1	28	30	84	1,842	95.5	172.0
October	1,692	1	28	28	84	1,683	88.5	164.2
November	1,600	1	28	28	84	1,769	85.9	145.6
December	1,096	3	28	28	84	1,744	87.1	155.1
2018								
January	1,211	2	28	28	84	1,694	87.1	141.8

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
February	1,245	1	28	28	84	1,676	97.5	168.7
March	1,455	2	28	56	112	1,675	106.3	178.2
April	1,366	1	28	28	84	1,632	89.0	147.0
May	1,241	1	28	42	84	1,520	91.7	152.7
June	1,135	1	28	28	84	1,526	90.9	151.6
July	2,083	1	28	28	84	1,536	79.8	125.1
August	2,078	1	28	28	84	1,503	82.8	136.2
September	1,632	1	28	28	84	1,446	85.9	146.3
October	2,084	1	28	28	84	1,459	87.5	139.9
November	1,990	1	28	28	84	1,429	92.7	163.5
December	1,653	1	28	28	84	1,388	95.8	155.1
2019								
January	2,295	1	28	28	84	1,363	97.0	154.9
February	2,496	1	28	28	84	1,332	86.9	143.1
March	2,498	1	28	28	84	1,306	85.6	135.6
April	3,085	1	28	28	84	1,275	93.3	150.4
May	3,003	1	28	28	84	1,237	86.3	141.8
June	2,545	1	28	30	84	1,215	92.8	142.0
July	3,737	1	28	28	84	1,186	83.7	130.6
August	3,871	1	28	28	84	1,153	90.2	148.3
September	3,098	1	28	28	84	1,123	88.8	140.6
October	3,700	1	28	28	84	1,096	87.0	132.0
November	3,362	1	28	28	84	1,061	85.7	128.5
December	3,149	1	28	28	84	1,034	87.6	136.5
2020								
January	3,062	1	28	28	84	1,003	89.0	129.1
February	2,833	1	28	42	112	970	100.3	147.4
March	2,958	1	28	28	84	941	87.9	130.0
April	2,176	1	28	38	84	913	88.8	126.8
May	1,994	1	28	28	84	879	87.7	123.8
June	2,572	1	28	28	84	852	84.0	123.2

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	4,598	1	28	28	84	822	81.7	114.5
August	3,492	1	28	28	84	789	84.4	119.1
September	3,585	1	28	28	84	760	80.9	110.8
October	3,317	1	28	28	84	730	84.6	118.8
November	3,004	1	28	30	84	698	84.2	115.6
December	2,799	1	28	28	84	669	81.7	105.0
2021								
January	2,743	1	28	28	84	634	84.6	109.2
February	2,697	1	28	28	84	607	85.1	111.5
March	2,892	1	28	33	98	579	86.9	110.1
April	2,731	1	28	30	84	544	80.5	97.3
May	2,526	1	28	28	84	516	81.0	101.1
June	2,358	1	28	30	98	487	83.4	98.5
July	3,123	1	28	28	84	457	76.9	89.1
August	3,365	1	28	30	84	424	76.6	86.7
September	2,577	1	28	31	98	394	80.7	89.4
October	2,640	1	28	30	84	365	72.6	78.1
November	2,346	1	28	28	84	334	69.4	75.0
December	2,214	1	28	29	84	304	70.3	73.3
2022								
January	1,958	1	28	31	84	271	70.8	68.4
February	1,679	1	28	30	87	242	69.4	64.4
March	1,965	1	28	31	84	214	66.0	58.8
April	1,774	1	28	30	84	183	61.4	51.0
May	1,558	1	28	30	84	152	57.2	44.0
June	1,505	1	28	28	81	122	49.0	34.1
July	1,672	1	28	30	65	92	42.3	24.5
August	1,670	1	17	28	43	61	30.9	15.6
September	1,073	1	5	12	19	30	13.3	8.3
<i>Atopic Dermatitis</i>	<i>120,523</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>84</i>	<i>1,984</i>	<i>81.7</i>	<i>125.9</i>
2017								

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	18	14	28	28	28	140	39.6	32.6
April	610	1	28	56	112	1,984	111.0	194.4
May	1,447	1	28	42	84	1,977	104.2	195.7
June	1,590	1	28	28	84	1,940	90.5	166.9
July	1,618	1	28	29	84	1,908	89.8	159.2
August	1,782	1	28	30	84	1,879	88.7	149.3
September	1,500	1	28	30	84	1,842	94.7	170.7
October	1,660	1	28	28	84	1,683	88.8	168.3
November	1,583	1	28	28	84	1,769	85.7	145.6
December	1,071	3	28	28	84	1,744	86.2	154.0
2018								
January	1,204	2	28	28	84	1,694	90.7	150.6
February	1,213	1	28	28	84	1,676	98.1	170.4
March	1,411	2	28	56	112	1,675	106.8	179.9
April	1,250	1	28	28	84	1,632	90.3	146.1
May	1,181	1	28	42	84	1,520	93.4	155.0
June	1,120	1	28	30	84	1,526	91.0	151.0
July	2,039	1	28	28	84	1,536	79.9	125.7
August	2,004	1	28	28	84	1,503	84.0	138.2
September	1,586	1	28	28	84	1,446	87.3	148.2
October	2,024	1	28	28	84	1,459	87.2	140.1
November	1,814	2	28	28	84	1,429	89.6	156.2
December	1,381	1	28	28	84	1,388	94.5	155.8
2019								
January	1,911	1	28	29	84	1,363	96.2	155.6
February	1,969	1	28	28	84	1,332	86.5	145.3
March	1,917	1	28	28	84	1,306	87.1	141.9
April	2,526	1	28	28	84	1,275	91.2	146.7
May	2,507	1	28	28	84	1,237	83.6	139.3

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	2,125	2	28	28	84	1,215	89.1	138.5
July	3,004	1	28	28	84	1,186	84.6	135.5
August	2,922	1	28	28	84	1,153	85.9	140.6
September	2,202	1	28	28	84	1,123	84.8	132.8
October	2,578	1	28	28	84	1,096	83.8	127.3
November	2,321	1	28	28	84	1,061	82.6	126.9
December	2,288	1	28	28	84	1,034	82.7	127.4
2020								
January	2,358	1	28	28	84	1,003	83.3	124.8
February	1,938	1	28	30	86	970	94.3	142.4
March	1,977	1	28	28	84	940	82.9	120.0
April	1,358	1	28	28	84	913	87.4	133.1
May	1,362	1	28	28	84	877	88.9	125.9
June	1,806	1	28	28	84	852	83.5	118.9
July	3,434	1	28	28	84	822	79.1	112.1
August	2,557	1	28	28	84	789	80.6	112.5
September	2,615	1	28	28	84	760	77.5	105.5
October	2,343	1	28	28	84	730	81.2	113.4
November	2,214	1	28	30	84	698	82.9	113.3
December	2,076	1	28	28	84	669	80.7	105.0
2021								
January	1,987	1	28	30	98	634	86.3	108.8
February	1,991	1	28	28	84	607	80.6	104.9
March	2,122	1	28	31	86	578	85.8	109.2
April	2,071	1	28	29	84	544	75.9	91.1
May	1,851	1	28	30	84	515	79.2	98.0
June	1,787	1	28	30	88	487	80.6	95.7
July	2,443	1	28	28	84	457	74.6	87.5
August	2,517	1	28	28	84	424	73.5	84.1
September	2,025	1	28	30	84	394	77.1	86.8
October	1,950	1	28	30	84	365	73.4	80.0

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	1,786	1	28	28	84	334	67.8	74.0
December	1,682	1	28	28	84	304	67.5	70.0
2022								
January	1,529	1	28	30	84	271	67.7	65.7
February	1,243	1	28	28	84	242	66.9	62.3
March	1,454	1	28	31	84	214	64.1	56.8
April	1,327	1	28	28	84	183	57.5	48.1
May	1,145	1	28	28	84	152	56.0	43.3
June	1,037	1	28	28	72	122	47.3	33.2
July	1,229	1	28	30	65	92	41.8	24.4
August	1,180	1	15	28	42	61	30.5	15.5
September	753	1	5	12	19	30	13.3	8.3
<i>Asthma</i>	<i>56,197</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>84</i>	<i>1,984</i>	<i>83.9</i>	<i>125.2</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	18	14	28	28	28	140	39.6	32.6
April	163	2	28	42	92	1,984	123.3	267.7
May	361	4	28	28	84	1,712	104.3	196.3
June	311	6	28	28	84	1,526	92.3	182.4
July	431	5	28	28	84	1,559	86.5	154.8
August	512	1	28	30	84	1,362	81.3	119.8
September	363	3	28	30	84	1,842	107.9	191.0
October	465	4	28	28	84	1,486	83.8	141.9
November	326	4	28	28	84	1,597	89.1	157.6
December	363	5	28	28	84	1,080	74.8	107.1
2018								
January	330	2	28	42	84	1,304	100.8	162.8
February	335	2	28	32	112	1,663	111.7	212.6
March	372	5	28	42	112	1,651	105.7	177.5
April	370	3	28	47	84	1,619	88.5	135.6

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	451	1	28	28	84	1,397	80.7	126.4
June	212	1	28	56	133	1,317	117.9	185.4
July	552	3	28	28	84	1,092	74.3	113.4
August	552	5	28	28	84	1,366	79.1	128.1
September	371	1	28	28	84	1,397	78.2	125.8
October	450	5	28	28	84	1,288	87.2	143.1
November	641	1	28	28	84	1,417	86.5	164.9
December	676	1	28	30	84	1,383	100.7	162.6
2019								
January	1,063	2	28	30	84	1,339	95.4	148.4
February	979	1	28	28	84	1,331	85.7	140.4
March	1,021	1	28	28	84	1,297	78.6	121.8
April	1,300	1	28	28	84	1,269	96.3	157.9
May	1,177	1	28	28	84	1,235	86.2	142.1
June	942	1	28	42	98	1,215	97.9	146.1
July	1,386	1	28	28	84	1,177	83.7	129.1
August	1,671	1	28	28	84	1,152	94.4	155.9
September	1,261	2	28	28	84	1,123	93.6	145.4
October	1,663	1	28	30	84	1,089	91.0	135.3
November	1,486	1	28	28	84	1,054	87.9	130.9
December	1,083	1	28	28	84	1,034	97.8	161.1
2020								
January	1,156	1	28	28	112	983	98.3	141.1
February	1,282	2	28	42	112	964	104.1	148.2
March	1,371	1	28	28	84	941	91.9	134.8
April	1,061	1	28	37	84	913	85.7	116.8
May	855	2	28	28	84	879	85.2	120.9
June	1,129	1	28	28	84	852	82.7	123.4
July	1,719	1	28	28	84	815	83.7	116.3
August	1,427	1	28	28	84	788	82.8	118.4
September	1,473	1	28	28	84	760	80.0	110.1

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
October	1,353	1	28	30	84	722	85.3	117.9
November	1,188	2	28	28	84	691	84.8	115.5
December	1,081	1	28	28	84	663	80.0	106.4
2021								
January	1,168	1	28	28	84	631	79.2	107.6
February	1,005	1	28	42	98	605	90.7	115.8
March	1,156	1	28	39	98	579	86.8	107.8
April	1,060	1	28	30	84	541	83.7	102.9
May	1,042	1	28	28	84	515	78.4	99.2
June	895	2	28	28	84	484	80.1	92.7
July	1,088	1	28	30	85	452	77.6	86.1
August	1,250	1	28	30	84	425	77.3	86.7
September	869	1	28	30	104	394	83.9	93.9
October	958	1	28	29	84	362	70.0	74.5
November	827	1	28	37	84	334	75.2	79.8
December	769	1	28	30	84	303	71.3	74.3
2022								
January	707	1	28	40	84	271	74.2	72.3
February	663	2	28	30	93	242	70.9	66.5
March	631	1	28	28	94	214	67.4	61.5
April	666	1	28	28	110	183	65.1	54.7
May	581	1	28	30	84	153	57.4	43.9
June	529	1	28	28	84	121	50.4	35.3
July	621	1	28	28	64	92	41.8	24.6
August	588	1	17	28	45	61	31.4	16.1
September	372	1	8	14	20	30	13.7	8.2
<i>Chronic Rhinosinusitis</i>	<i>31,403</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>84</i>	<i>1,977</i>	<i>85.8</i>	<i>123.4</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	57	14	28	56	112	539	99.2	117.5
May	105	4	28	56	84	1,977	123.9	280.0
June	140	1	28	28	84	588	80.7	102.9
July	76	14	28	30	56	1,796	76.3	206.9
August	185	2	28	28	70	1,362	84.7	151.6
September	77	10	28	56	140	986	112.9	156.3
October	86	14	28	28	84	660	75.1	103.0
November	73	3	28	56	112	1,330	133.1	234.4
December	63	13	28	28	84	989	105.2	179.6
2018								
January	141	3	28	28	56	545	66.4	88.3
February	115	14	28	28	84	1,663	115.5	245.6
March	123	12	28	56	112	775	101.5	139.7
April	157	14	28	28	56	392	60.7	60.7
May	142	9	28	28	70	1,386	66.8	129.5
June	62	14	28	28	84	932	84.7	143.6
July	169	3	28	28	84	778	82.6	105.8
August	200	2	28	28	84	1,275	90.3	155.7
September	141	14	28	56	84	1,372	91.7	150.4
October	125	3	28	56	115	1,120	108.1	156.0
November	227	3	28	28	84	1,216	87.6	156.1
December	280	1	28	56	112	1,316	112.9	167.9
2019								
January	334	2	28	56	112	1,335	108.4	155.7
February	412	2	28	28	84	1,331	85.8	141.9
March	382	1	28	35	84	1,022	82.2	120.6
April	594	1	28	28	84	1,275	101.7	169.4
May	441	1	28	28	96	1,235	97.8	160.3
June	411	9	28	56	112	1,174	107.6	158.1
July	667	1	28	28	84	1,177	88.4	142.3
August	904	1	28	28	84	1,151	98.6	163.4

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	917	3	28	28	84	1,123	89.1	148.5
October	924	1	28	42	96	1,089	95.6	134.5
November	982	3	28	28	84	1,046	93.9	136.7
December	879	1	28	28	84	1,034	91.7	145.1
2020								
January	785	1	28	42	112	956	96.2	130.0
February	814	1	28	36	112	964	100.0	139.1
March	874	1	28	28	84	929	94.7	143.8
April	700	1	28	56	111	913	91.0	120.8
May	536	2	28	28	84	879	88.6	129.4
June	768	1	28	28	84	844	85.3	127.6
July	986	1	28	44	84	817	89.8	121.1
August	865	1	28	28	84	788	84.8	123.9
September	771	1	28	28	107	760	90.7	121.6
October	775	1	28	42	84	725	89.8	123.7
November	717	1	28	28	84	689	82.1	107.1
December	733	1	28	28	84	662	83.8	105.9
2021								
January	758	1	28	28	84	634	81.2	109.1
February	738	1	28	32	112	607	96.0	121.9
March	647	2	28	42	112	578	92.3	115.3
April	663	1	28	28	84	541	85.7	107.1
May	696	2	28	28	84	516	82.2	102.5
June	605	2	28	28	98	487	85.5	101.3
July	710	1	28	28	98	452	83.0	96.5
August	708	1	28	42	112	424	85.2	94.5
September	595	1	28	30	98	394	80.1	86.6
October	687	1	28	28	84	362	70.7	74.2
November	534	1	28	28	84	333	72.3	79.3
December	560	3	28	31	84	304	73.7	74.4
2022								

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	497	1	28	45	112	271	76.6	71.3
February	441	3	28	53	112	242	75.7	68.2
March	485	2	28	28	110	214	69.4	61.8
April	456	1	28	30	112	183	65.5	53.5
May	429	1	28	35	84	152	57.7	43.8
June	389	1	28	33	84	122	53.1	35.4
July	325	1	28	30	68	92	44.6	24.5
August	346	1	25	28	44	61	32.1	15.0
September	219	1	5	12	19	30	13.0	8.3
<i>Eosinophilic Esophagitis</i>	9,260	1	28	28	84	1,584	75.3	111.0
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	16	28	38	98	336	616	199.4	203.0
May	18	5	14	28	84	1,161	102.8	266.1
June	15	6	14	28	87	182	52.1	56.8
July	65	9	28	30	112	1,584	134.4	274.6
August	50	14	28	28	84	672	91.1	133.6
September	55	12	28	56	112	644	92.3	118.4
October	2	56	56	101	146	146	101.0	63.6
November	53	28	28	56	84	866	103.6	155.0
December	66	6	28	29	84	392	73.1	75.0
2018								
January	48	14	28	28	78	976	92.8	173.7
February	73	14	28	28	56	336	60.7	60.2
March	69	14	28	56	112	814	98.4	131.2
April	55	14	28	28	56	252	44.1	35.1
May	51	12	28	28	56	580	65.2	95.0
June	98	14	28	28	84	1,295	79.3	149.9
July	108	6	28	28	84	1,014	83.5	140.4

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	94	14	28	28	84	1,006	75.1	123.8
September	56	14	28	51	56	252	55.7	47.8
October	91	2	28	28	84	1,178	92.8	155.7
November	108	14	28	28	56	1,402	91.3	195.7
December	170	5	28	30	112	1,263	92.7	132.7
2019								
January	113	10	28	42	84	1,342	105.5	193.3
February	60	5	28	56	126	1,331	159.0	269.5
March	128	12	28	28	84	1,064	75.3	118.5
April	144	9	28	28	84	1,160	87.5	147.8
May	210	5	28	28	84	560	76.8	86.7
June	102	5	28	28	84	1,174	93.4	153.5
July	268	5	28	28	84	670	73.3	98.8
August	202	9	28	28	84	947	89.6	135.1
September	257	2	28	28	84	588	72.1	89.4
October	264	1	28	28	79	1,010	72.3	107.4
November	205	1	28	28	84	1,048	108.9	183.9
December	191	1	28	28	84	840	79.7	109.5
2020								
January	194	5	28	55	137	977	103.3	142.1
February	314	2	28	28	56	888	74.5	113.7
March	210	5	28	28	84	728	79.2	102.1
April	145	14	28	56	84	630	85.4	103.0
May	112	12	28	56	84	784	83.9	105.6
June	129	13	28	28	84	841	78.7	120.0
July	162	3	28	28	100	588	83.6	108.5
August	172	1	28	28	84	504	74.9	95.4
September	166	2	28	28	56	744	70.3	96.2
October	168	10	28	28	56	719	70.7	111.8
November	185	1	28	28	84	683	81.4	112.0
December	171	3	28	28	84	476	70.7	85.0

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2021								
January	207	2	28	28	84	616	77.4	110.6
February	150	4	28	28	84	603	89.0	122.9
March	201	1	28	28	84	576	70.2	93.3
April	163	13	28	28	84	522	74.1	86.8
May	207	3	28	28	84	430	68.0	67.5
June	150	4	28	56	90	470	76.9	81.1
July	179	11	28	28	74	442	69.5	81.6
August	197	12	28	34	84	418	81.7	90.7
September	185	3	28	28	84	395	68.0	73.6
October	212	2	28	28	83	362	69.2	78.3
November	244	1	28	28	84	327	64.5	67.4
December	208	1	28	28	84	291	65.2	67.3
2022								
January	145	2	28	28	66	271	64.8	67.3
February	120	4	28	28	74	232	59.1	57.2
March	136	1	28	31	84	214	67.8	59.2
April	115	11	28	30	84	179	61.4	48.9
May	117	1	28	30	84	148	53.6	40.9
June	130	5	28	28	82	122	49.3	33.2
July	177	1	28	28	57	92	40.4	23.4
August	229	1	28	28	46	61	33.2	15.3
September	155	1	5	11	22	30	13.0	8.7
<i>Prurigo Nodularis</i>	3,273	1	28	30	84	1,675	85.9	122.9
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	34	28	28	56	140	1,023	134.9	218.3
May	8	14	21	28	28	55	27.9	12.7
June	7	14	14	57	112	185	68.7	64.1

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	81	14	28	56	84	686	72.1	93.9
August	33	14	28	98	196	483	139.8	131.3
September	3	28	28	56	64	64	49.3	18.9
October	25	13	28	28	112	387	91.4	109.3
November	17	14	28	56	140	584	147.2	188.7
December	9	24	28	30	196	1,486	237.0	475.5
2018								
January	38	14	28	28	84	518	77.9	111.5
February	33	14	28	42	84	1,038	97.9	183.7
March	8	84	84	91	364	1,675	354.6	558.0
April	34	14	28	98	168	476	127.4	117.0
May	24	14	28	28	56	308	54.1	59.9
June	51	2	28	56	84	504	84.2	99.6
July	33	28	28	50	56	532	75.4	107.5
August	30	14	28	28	56	842	113.7	199.7
September	51	14	28	28	84	448	77.0	96.0
October	65	14	28	28	56	532	58.1	84.2
November	52	9	28	28	126	1,124	119.9	190.6
December	39	12	28	28	56	840	76.3	140.7
2019								
January	58	14	28	28	56	420	65.1	82.0
February	53	14	28	42	98	1,180	108.1	196.9
March	36	14	28	56	84	308	67.5	63.3
April	42	14	28	34	98	280	69.4	64.9
May	61	5	28	42	112	616	92.8	122.8
June	101	5	28	56	84	1,106	107.5	161.7
July	99	3	28	28	84	420	62.5	65.1
August	73	8	28	56	142	812	125.6	168.2
September	52	2	28	56	133	1,103	131.4	209.7
October	74	14	28	56	112	826	114.6	159.4
November	89	1	28	28	84	560	67.0	83.2

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December 2020	73	14	28	30	112	588	97.4	126.8
January	56	8	28	70	145	983	127.7	174.2
February	55	1	28	28	84	786	81.4	143.2
March	33	2	28	28	112	364	83.5	104.2
April	36	12	28	56	112	434	89.8	99.8
May	48	14	28	30	70	448	67.9	82.4
June	40	14	28	56	105	369	80.5	77.0
July	73	3	28	56	112	537	91.5	106.9
August	85	14	28	28	98	588	89.9	110.2
September	69	10	28	28	84	683	78.1	106.3
October	51	4	28	28	84	504	82.3	110.0
November	101	3	28	39	84	682	89.7	116.0
December	72	1	28	28	77	504	70.4	89.4
2021								
January	62	14	28	50	84	623	100.8	140.8
February	87	14	28	28	84	490	66.2	72.9
March	75	1	28	56	112	556	97.9	121.2
April	37	14	28	28	56	536	77.1	111.9
May	36	14	28	84	168	493	112.4	104.4
June	56	14	28	56	116	485	113.5	126.9
July	64	10	28	28	105	442	85.1	109.1
August	54	5	28	54	79	423	58.7	61.3
September	73	2	28	42	84	393	79.8	90.2
October	44	5	28	41	85	362	80.2	91.2
November	56	9	28	28	63	224	52.2	49.1
December	47	3	28	56	112	303	85.6	86.2
2022								
January	68	3	28	51	100	261	71.6	63.9
February	49	14	28	28	112	240	78.6	72.6
March	28	14	28	46	114	199	74.1	63.5

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	45	6	28	56	105	177	69.3	52.5
May	50	1	28	28	86	145	56.8	43.7
June	45	1	28	28	84	120	48.0	33.8
July	33	5	20	44	68	92	43.7	26.3
August	32	10	14	31	47	60	32.7	17.1
September	27	2	11	17	24	29	16.8	7.8
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>								
	99,869	1	28	63	163	1,990	133.8	183.8
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	10	14	28	42	118	241	74.2	72.1
April	379	1	30	84	229	1,990	201.0	313.1
May	1,007	1	28	84	197	1,978	186.0	301.9
June	1,072	1	28	59	168	1,940	159.1	258.3
July	968	1	28	62	164	1,914	158.0	270.2
August	1,116	3	28	63	172	1,880	159.2	252.4
September	937	1	28	81	182	1,842	169.2	257.8
October	1,087	1	28	59	140	1,825	147.6	254.9
November	1,074	1	28	60	168	1,769	147.8	221.4
December	728	3	28	58	168	1,758	148.8	249.0
2018								
January	702	2	28	62	171	1,731	154.0	235.9
February	808	1	28	71	184	1,691	165.0	252.4
March	972	4	28	84	210	1,675	174.7	238.6
April	804	3	28	84	195	1,619	160.8	231.0
May	802	2	28	84	173	1,611	158.3	233.9
June	758	3	28	70	169	1,583	156.0	240.1
July	1,084	1	28	59	144	1,549	134.9	205.8
August	1,275	3	28	59	148	1,522	136.3	206.3

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	1,067	3	28	63	154	1,486	140.6	217.3
October	1,306	1	28	76	168	1,459	145.9	211.2
November	1,297	1	28	57	168	1,429	150.0	234.3
December	1,021	1	28	70	196	1,398	166.5	243.6
2019								
January	1,473	1	28	84	198	1,363	164.0	224.7
February	1,574	1	28	84	169	1,338	151.4	216.7
March	1,541	1	28	84	171	1,306	146.7	207.5
April	1,930	1	28	73	169	1,278	157.2	228.1
May	1,839	1	28	63	168	1,248	145.6	207.8
June	1,675	2	28	72	181	1,215	153.0	211.4
July	2,310	1	28	63	159	1,186	138.9	196.5
August	2,424	1	28	60	161	1,157	149.3	217.5
September	1,922	1	28	77	168	1,123	146.1	200.9
October	2,355	1	28	77	172	1,096	147.2	194.3
November	2,113	1	28	60	170	1,062	145.4	197.6
December	2,092	1	28	58	168	1,034	142.3	200.9
2020								
January	1,935	1	28	84	194	1,003	149.8	188.8
February	1,781	1	28	84	203	970	166.9	212.5
March	1,985	1	28	61	174	943	145.4	192.6
April	1,353	1	28	84	186	913	146.2	178.5
May	1,249	1	28	84	182	883	148.1	184.6
June	1,612	1	28	82	175	852	141.8	175.0
July	2,649	1	28	60	164	822	132.3	168.8
August	2,288	1	28	63	151	789	133.3	168.7
September	2,292	1	28	62	154	760	127.5	154.5
October	2,191	1	28	73	168	730	137.8	166.1
November	2,101	1	28	61	168	698	129.2	152.7
December	2,104	1	28	60	168	669	126.5	150.5
2021								

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	1,761	1	28	84	177	636	137.6	152.0
February	1,667	1	28	84	183	607	143.1	158.7
March	1,848	1	28	84	188	579	143.6	154.6
April	1,799	1	28	84	172	548	130.4	135.9
May	1,660	2	28	70	170	518	127.3	136.3
June	1,573	1	28	79	191	487	132.4	135.4
July	2,049	1	28	61	158	457	114.6	118.4
August	2,189	1	28	61	161	425	116.0	117.8
September	1,798	1	28	72	168	395	116.1	112.9
October	1,841	1	28	74	168	365	113.5	105.3
November	1,662	1	28	59	163	334	105.8	99.4
December	1,518	1	28	63	163	304	106.1	95.4
2022								
January	1,372	1	28	84	177	273	108.1	88.3
February	1,205	1	28	84	190	242	104.5	80.7
March	1,415	1	28	84	173	214	96.7	71.1
April	1,304	1	28	71	156	183	86.3	60.6
May	1,166	1	28	84	131	152	80.8	50.7
June	1,160	1	28	68	102	122	66.6	38.2
July	1,313	1	28	64	75	92	53.5	25.8
August	1,430	1	28	38	50	61	37.0	15.4
September	1,077	1	7	12	22	30	13.8	8.4
Any Indication	92,172	1	28	63	162	1,990	133.6	183.6
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	10	14	28	42	118	241	74.2	72.1
April	333	1	30	84	248	1,990	214.3	328.4
May	833	1	28	84	199	1,978	187.3	307.1
June	926	1	28	58	159	1,940	154.8	253.4
July	904	1	28	61	164	1,914	158.9	272.7

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	1,020	3	28	78	176	1,880	162.6	250.3
September	880	1	28	70	170	1,842	163.9	257.6
October	959	1	28	58	140	1,822	149.5	255.8
November	953	1	28	59	165	1,769	144.3	219.7
December	636	3	28	57	168	1,758	145.4	241.0
2018								
January	672	2	28	60	168	1,731	145.6	224.3
February	737	12	28	62	169	1,691	161.9	255.8
March	807	4	34	93	232	1,675	188.7	250.8
April	774	3	28	84	193	1,632	160.0	233.1
May	705	2	28	84	183	1,611	161.0	235.5
June	670	3	28	84	168	1,583	152.9	235.8
July	997	1	28	58	140	1,549	134.0	205.7
August	1,079	3	28	62	154	1,522	140.3	212.7
September	1,039	3	28	60	143	1,486	135.6	215.5
October	1,256	1	28	72	168	1,459	144.9	208.9
November	1,193	1	28	58	168	1,429	151.7	237.2
December	941	1	28	70	196	1,397	163.7	235.2
2019								
January	1,379	1	28	84	197	1,363	163.6	227.2
February	1,444	1	28	84	168	1,338	153.4	219.9
March	1,447	1	28	73	169	1,306	143.5	203.4
April	1,820	1	28	70	168	1,278	157.3	230.2
May	1,757	1	28	63	168	1,248	145.4	208.5
June	1,520	2	28	84	182	1,215	153.8	210.8
July	2,109	1	28	62	157	1,186	138.8	196.8
August	2,290	1	28	61	161	1,157	150.6	218.2
September	1,835	1	28	81	168	1,123	145.3	200.7
October	2,215	1	28	81	171	1,096	146.3	191.8
November	2,033	1	28	59	168	1,062	141.8	193.0
December	1,944	1	28	57	168	1,034	141.9	200.8

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2020								
January	1,845	1	28	74	187	1,003	147.7	187.3
February	1,649	1	28	84	207	970	169.3	215.1
March	1,830	1	28	61	172	943	144.3	189.6
April	1,300	1	28	84	180	913	145.1	179.4
May	1,162	1	28	84	181	883	146.7	181.1
June	1,509	1	28	74	175	852	141.1	175.3
July	2,386	1	28	62	168	822	136.1	171.5
August	2,062	1	28	63	149	789	133.0	168.8
September	2,074	1	28	63	164	760	130.2	157.1
October	1,996	1	28	74	169	730	138.1	166.0
November	1,923	1	28	60	168	698	130.4	155.1
December	1,886	1	28	60	168	669	127.0	151.7
2021								
January	1,665	1	28	84	178	636	136.5	151.3
February	1,603	1	28	84	180	607	140.8	156.6
March	1,730	1	28	84	185	579	142.9	154.0
April	1,698	1	28	77	168	548	126.8	133.8
May	1,567	1	28	68	168	518	126.0	134.8
June	1,473	1	28	78	186	487	130.4	132.9
July	1,760	1	28	63	168	457	118.8	120.8
August	2,019	1	28	61	161	425	116.6	118.2
September	1,675	1	28	73	168	395	118.2	114.5
October	1,678	1	28	74	165	365	112.4	104.9
November	1,499	1	28	59	165	334	105.8	99.2
December	1,437	1	28	62	163	304	106.0	96.1
2022								
January	1,293	1	28	84	175	273	107.1	87.7
February	1,104	1	28	84	191	242	105.5	80.7
March	1,344	1	28	75	173	214	95.5	71.0
April	1,219	1	28	71	156	183	86.4	60.6

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	1,076	1	28	84	131	152	81.4	50.9
June	1,097	1	28	68	102	122	66.6	38.0
July	1,167	1	28	64	75	92	54.0	25.9
August	1,335	1	28	37	50	61	36.9	15.5
September	994	1	7	12	21	30	13.7	8.4
<i>Atopic Dermatitis</i>	<i>72,490</i>	<i>1</i>	<i>28</i>	<i>61</i>	<i>154</i>	<i>1,990</i>	<i>131.4</i>	<i>184.8</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	10	14	28	42	118	241	74.2	72.1
April	320	1	30	84	233	1,990	214.6	332.4
May	822	1	28	84	197	1,978	185.7	305.5
June	919	1	28	58	159	1,940	156.1	257.2
July	848	1	28	62	168	1,914	159.8	269.6
August	951	3	28	80	178	1,880	162.5	248.0
September	859	1	28	70	170	1,842	163.1	257.2
October	928	1	28	58	136	1,822	149.8	261.6
November	932	1	28	59	160	1,769	144.1	220.9
December	618	3	28	56	161	1,758	144.8	240.6
2018								
January	672	2	28	61	168	1,732	150.2	234.0
February	720	12	28	62	172	1,691	163.2	258.2
March	784	4	35	94	231	1,675	189.0	252.3
April	699	3	28	74	196	1,632	162.3	235.4
May	664	2	28	84	196	1,611	163.7	238.8
June	652	3	28	84	169	1,583	153.7	236.4
July	966	1	28	58	140	1,549	133.9	206.4
August	1,053	3	28	68	159	1,522	142.4	213.9
September	993	3	28	62	148	1,486	139.4	219.3
October	1,212	1	28	72	166	1,459	145.6	211.4
November	1,076	2	28	58	158	1,429	148.0	228.8

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December	768	1	28	62	181	1,396	161.1	236.4
2019								
January	1,148	1	28	84	195	1,363	161.6	226.8
February	1,158	1	28	84	166	1,335	149.7	216.4
March	1,100	1	28	80	161	1,306	145.0	212.8
April	1,510	1	28	66	168	1,278	150.1	215.8
May	1,478	1	28	61	147	1,248	138.9	204.2
June	1,254	2	28	71	174	1,215	148.0	202.7
July	1,676	1	28	63	157	1,186	141.0	202.1
August	1,707	1	28	60	153	1,157	144.1	208.2
September	1,319	1	28	69	154	1,123	134.5	185.0
October	1,549	2	28	74	168	1,096	139.9	182.7
November	1,366	1	28	57	160	1,062	136.3	189.9
December	1,445	1	28	56	141	1,034	129.7	186.0
2020								
January	1,413	1	28	62	172	1,003	137.9	178.0
February	1,147	1	28	62	176	970	154.7	212.0
March	1,272	1	28	61	168	943	132.7	170.8
April	829	2	28	70	168	913	138.7	180.8
May	823	1	28	84	176	883	144.5	179.3
June	1,053	1	28	79	177	852	140.7	171.8
July	1,791	1	28	58	163	822	129.8	167.4
August	1,547	1	28	60	142	789	125.4	160.1
September	1,551	1	28	59	141	760	124.1	154.1
October	1,424	1	28	66	154	729	131.0	162.0
November	1,421	1	28	60	168	698	125.2	149.5
December	1,397	1	28	60	166	669	124.4	149.6
2021								
January	1,188	1	28	84	187	634	139.7	151.0
February	1,215	1	28	63	163	607	129.3	147.8
March	1,258	1	28	84	178	579	141.7	152.8

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	1,301	1	28	63	156	547	118.7	127.0
May	1,139	1	28	62	159	518	122.1	132.2
June	1,134	1	28	66	172	487	122.7	129.0
July	1,373	1	28	62	157	457	116.5	119.6
August	1,517	1	28	59	148	425	111.8	116.0
September	1,329	1	28	63	155	395	112.9	112.0
October	1,261	1	28	72	168	365	112.4	105.6
November	1,153	1	28	58	151	334	102.4	96.8
December	1,091	1	28	59	147	304	101.1	93.4
2022								
January	997	1	28	72	166	271	103.3	86.4
February	793	1	28	76	184	242	103.1	80.7
March	990	1	28	71	162	214	92.9	70.1
April	895	1	28	60	142	183	81.0	59.0
May	785	1	28	84	130	152	80.0	50.5
June	758	1	28	61	101	122	64.6	37.7
July	855	1	28	64	74	92	53.2	25.8
August	925	1	28	37	50	61	36.4	15.4
September	689	1	6	12	19	30	13.6	8.4
<i>Asthma</i>	33,025	1	28	63	168	1,984	134.9	183.1
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	10	14	28	42	118	241	74.2	72.1
April	78	2	30	84	252	1,984	261.5	442.6
May	197	4	28	84	209	1,957	194.1	319.3
June	196	6	28	61	156	1,833	148.7	248.0
July	214	8	28	58	158	1,906	150.5	260.4
August	305	1	28	61	152	1,732	133.9	193.6
September	183	14	28	61	179	1,842	181.8	300.6
October	241	4	28	60	147	1,486	146.2	228.8

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	217	5	28	56	143	1,597	126.8	199.8
December	215	4	28	56	140	1,548	115.5	181.3
2018								
January	199	2	28	56	140	1,727	144.7	243.0
February	172	12	28	98	201	1,663	193.6	305.2
March	209	5	28	84	229	1,651	186.8	257.4
April	158	3	28	84	187	1,619	160.4	235.2
May	213	2	28	86	180	1,611	156.2	214.7
June	142	14	28	84	173	1,566	172.9	261.3
July	269	6	28	58	126	1,543	116.6	172.9
August	272	8	28	56	125	1,395	124.1	200.6
September	225	5	28	70	119	1,486	133.7	221.7
October	256	5	28	63	146	1,438	144.9	217.3
November	378	1	28	56	145	1,417	136.2	231.2
December	415	1	28	65	196	1,397	154.9	220.8
2019								
January	631	2	28	84	175	1,359	153.6	205.6
February	531	1	28	63	179	1,338	158.9	233.6
March	593	1	28	66	168	1,305	134.2	182.7
April	746	1	28	62	168	1,278	164.7	252.1
May	659	1	28	75	173	1,237	151.3	210.8
June	600	3	28	71	186	1,215	153.9	209.3
July	790	1	28	62	160	1,186	137.3	192.3
August	991	1	28	60	164	1,157	156.3	231.9
September	744	4	28	84	176	1,123	159.8	214.6
October	967	1	28	84	184	1,089	153.4	198.8
November	858	1	28	60	175	1,062	146.7	196.1
December	648	1	28	58	182	1,034	155.8	225.0
2020								
January	673	1	28	78	204	1,000	161.0	208.5
February	728	2	28	88	229	967	180.1	219.1

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	735	3	28	59	179	943	156.8	212.6
April	601	1	28	84	180	912	142.4	170.3
May	481	2	28	70	158	883	140.9	187.5
June	623	1	28	62	180	852	144.0	184.9
July	871	1	28	76	169	822	140.3	173.9
August	837	1	28	62	146	788	131.4	166.8
September	823	1	28	66	168	760	130.1	154.2
October	761	1	28	84	168	729	138.7	163.1
November	677	2	28	75	194	696	145.0	167.1
December	719	1	28	57	148	669	121.4	149.4
2021								
January	690	1	28	59	168	636	126.3	145.8
February	573	2	28	84	201	607	150.3	163.9
March	668	2	28	84	184	579	140.4	151.9
April	653	1	28	72	182	548	127.8	135.3
May	621	2	28	63	168	515	124.5	134.1
June	558	2	28	84	176	485	126.2	125.8
July	598	1	28	73	168	456	119.7	117.6
August	722	4	28	62	168	425	119.3	119.2
September	553	1	28	70	170	395	120.1	118.8
October	584	1	28	66	152	362	109.2	103.0
November	528	2	28	61	168	334	111.0	102.8
December	488	1	28	62	171	304	108.5	97.5
2022								
January	455	1	28	84	187	273	111.2	90.9
February	424	2	28	85	196	242	109.3	80.6
March	440	1	28	70	174	214	94.5	72.8
April	456	1	28	84	159	183	92.3	62.7
May	397	1	28	70	131	152	78.4	51.0
June	380	1	28	78	101	122	67.9	38.2
July	400	1	28	64	78	92	55.5	26.0

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	442	1	28	38	50	61	37.3	15.4
September	344	1	8	14	22	30	14.4	8.5
<i>Chronic</i>								
<i>Rhinosinusitis</i>	18,396	1	28	72	169	1,977	138.3	178.6
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	28	14	28	134	243	872	206.3	240.3
May	56	4	28	84	181	1,977	235.3	421.8
June	68	1	28	92	196	826	170.1	205.6
July	53	14	28	30	56	1,914	87.2	264.0
August	86	9	28	60	168	1,880	175.9	305.7
September	34	10	28	132	368	1,510	260.1	307.7
October	25	14	56	93	212	448	140.6	134.0
November	38	3	28	82	268	1,330	232.3	353.6
December	38	13	28	51	123	1,159	132.4	237.7
2018								
January	70	14	28	28	84	1,008	91.4	157.4
February	57	14	28	60	207	1,663	199.6	366.5
March	58	28	28	67	168	855	150.5	207.6
April	80	14	28	84	150	710	117.9	120.5
May	87	9	28	56	98	1,534	96.7	178.1
June	38	14	28	57	91	1,494	136.6	256.2
July	103	14	28	62	140	863	119.9	154.6
August	103	14	28	84	171	1,311	155.4	225.2
September	104	8	28	60	141	1,457	122.2	188.1
October	86	14	28	84	168	1,269	140.9	188.1
November	120	3	28	56	169	1,363	148.3	248.4
December	149	1	28	84	224	1,397	185.1	246.8
2019								

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	190	2	28	84	224	1,351	169.9	223.4
February	209	8	28	84	185	1,331	161.3	219.0
March	202	3	28	84	189	1,305	147.6	195.5
April	305	2	28	61	174	1,278	175.6	282.0
May	265	1	28	63	171	1,235	158.4	229.2
June	252	11	28	85	195	1,205	172.4	225.2
July	379	1	28	61	149	1,186	141.6	209.8
August	540	1	28	62	173	1,153	160.9	233.0
September	511	4	28	84	177	1,123	158.1	216.7
October	563	1	28	84	210	1,089	161.9	200.4
November	600	8	28	59	196	1,058	151.7	197.1
December	481	1	28	59	196	1,034	154.5	213.0
2020								
January	466	1	28	83	216	989	160.3	200.5
February	474	3	28	91	227	964	173.2	201.0
March	480	3	28	65	197	942	166.0	219.4
April	385	1	28	87	196	912	152.6	175.6
May	321	5	28	84	169	879	145.8	184.2
June	409	1	28	76	191	852	149.0	184.9
July	503	3	28	84	174	822	153.7	183.3
August	449	1	28	76	148	789	145.0	184.6
September	458	1	28	84	204	760	148.4	164.8
October	451	1	28	84	182	730	147.6	171.5
November	428	3	28	61	178	696	137.3	158.6
December	464	1	28	60	169	668	133.1	159.4
2021								
January	420	3	28	84	189	634	140.6	155.6
February	386	2	38	95	238	607	169.8	168.1
March	392	4	28	84	193	578	146.4	158.7
April	378	3	28	84	193	548	137.2	143.1
May	423	2	28	70	168	516	128.0	138.3

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	365	7	28	84	194	487	134.0	133.6
July	369	4	28	86	197	457	135.1	131.3
August	440	3	28	73	196	424	126.8	120.8
September	359	1	28	84	168	395	119.6	113.0
October	403	2	28	70	152	362	111.1	103.4
November	312	1	28	62	175	334	115.0	106.5
December	382	7	28	80	150	304	107.6	93.6
2022								
January	301	1	28	86	204	271	118.4	89.5
February	311	4	38	84	190	242	109.1	77.6
March	328	2	28	80	185	214	101.2	73.5
April	304	1	28	84	158	183	92.3	61.6
May	290	1	28	86	136	152	83.3	51.7
June	277	1	28	84	107	122	70.7	38.5
July	215	1	28	64	76	92	55.9	24.8
August	270	2	28	39	52	61	38.9	14.8
September	205	1	5	12	19	30	13.3	8.3
<i>Eosinophilic Esophagitis</i>	5,269	1	28	57	140	1,801	116.8	160.7
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	11	28	28	56	613	872	291.9	320.9
May	11	14	14	28	116	1,324	170.5	387.7
June	6	6	105	159	182	209	136.5	72.5
July	36	9	28	73	186	1,801	221.7	402.4
August	34	28	28	61	146	847	135.5	185.1
September	22	28	28	84	199	891	165.9	223.1
October	2	56	56	101	146	146	101.0	63.6
November	28	28	60	84	109	1,019	146.1	201.7

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December 2018	27	6	28	60	170	611	122.2	141.3
January	23	14	28	28	63	976	112.9	237.7
February	35	14	28	56	118	281	81.6	69.8
March	34	14	28	107	314	814	198.4	203.8
April	29	14	28	28	87	269	65.3	61.1
May	36	12	28	61	148	595	109.9	119.1
June	55	14	28	84	91	1,295	117.7	198.5
July	52	6	28	84	171	1,044	147.5	190.9
August	34	14	28	56	199	1,006	153.3	209.5
September	44	14	28	84	197	826	131.3	149.1
October	52	9	28	60	141	1,178	146.7	207.3
November	51	14	28	56	142	1,402	154.7	287.7
December	91	5	28	84	203	1,134	167.5	209.3
2019								
January	70	14	28	77	174	1,342	154.7	238.8
February	51	5	28	30	157	1,331	168.8	302.0
March	61	12	42	84	196	1,254	158.2	207.4
April	66	14	28	56	161	1,268	142.3	222.0
May	94	5	28	84	162	1,248	130.9	160.8
June	63	9	28	56	141	1,176	156.6	259.4
July	130	8	28	84	160	1,186	137.7	180.0
August	120	14	28	85	173	1,088	157.7	201.7
September	118	6	28	70	140	788	125.2	153.9
October	152	1	28	58	141	1,067	114.4	159.2
November	121	1	28	56	195	1,058	175.6	261.2
December	117	12	28	84	187	840	137.7	155.8
2020								
January	112	9	28	84	217	977	170.4	210.2
February	187	3	28	56	115	950	111.5	160.1
March	145	4	28	62	145	943	119.9	148.0

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	77	14	31	84	168	695	136.1	161.7
May	56	14	28	81	168	878	148.6	199.6
June	84	13	28	60	115	841	105.1	131.6
July	72	3	28	74	165	801	135.4	168.6
August	88	1	28	60	153	786	134.2	174.2
September	88	3	28	56	112	751	96.0	124.2
October	76	1	28	67	148	618	117.2	128.9
November	113	9	28	56	141	696	117.9	154.7
December	93	3	28	56	168	631	120.8	148.3
2021								
January	131	8	28	56	113	634	112.1	143.4
February	69	14	28	85	183	603	159.9	174.2
March	109	1	28	70	164	569	111.8	118.9
April	102	14	28	60	113	486	93.6	93.0
May	118	7	28	62	162	506	108.8	102.4
June	86	3	28	89	168	485	117.5	109.2
July	83	11	28	84	168	442	115.7	107.0
August	113	12	28	57	137	415	103.7	107.7
September	83	3	28	59	147	383	109.0	109.2
October	118	2	28	83	178	362	117.9	112.2
November	131	1	28	81	144	333	102.7	91.9
December	123	1	28	57	172	296	101.0	97.5
2022								
January	84	2	28	59	149	270	98.4	90.5
February	69	8	28	56	126	241	86.5	76.3
March	95	3	28	57	163	213	86.7	69.3
April	88	4	28	59	155	180	80.7	60.0
May	82	1	28	56	114	150	68.1	47.2
June	79	14	28	84	103	122	70.2	37.6
July	114	3	28	64	75	92	54.6	25.4
August	179	1	28	40	51	61	39.3	14.6

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	146	1	5	11	22	30	13.0	8.8
<i>Prurigo Nodularis</i>	1,878	1	28	78	172	1,754	139.6	180.0
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	17	28	56	88	476	1,023	272.5	325.6
May	5	28	43	45	55	57	45.6	11.6
June	5	14	15	57	185	218	97.8	96.9
July	20	14	29	107	412	766	239.4	265.4
August	20	14	98	199	323	706	232.9	177.0
September	3	28	28	56	64	64	49.3	18.9
October	11	13	28	118	378	682	212.0	219.2
November	11	14	28	56	112	1,148	157.9	330.7
December	4	24	78	187	999	1,754	538.0	815.6
2018								
January	24	14	28	74	160	606	125.3	150.1
February	20	14	35	90	181	1,038	163.3	232.9
March	2	98	98	887	1,675	1,675	886.5	1,115.1
April	16	14	29	99	340	609	184.0	196.8
May	17	14	28	57	114	308	77.4	74.1
June	31	9	56	112	254	618	168.2	151.4
July	25	28	44	62	86	1,252	117.4	239.8
August	20	14	28	56	157	842	172.8	258.7
September	31	14	28	84	143	535	129.0	140.0
October	32	14	28	61	151	610	121.1	150.4
November	32	14	28	84	351	1,387	197.2	272.1
December	12	12	70	158	304	840	235.0	251.6
2019								
January	31	14	28	56	140	790	124.9	168.9
February	27	14	42	126	194	1,180	202.3	255.2

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	21	14	42	70	116	537	118.4	130.7
April	27	14	28	84	162	472	109.9	108.0
May	26	14	28	100	239	602	167.8	179.2
June	50	9	56	113	252	1,199	196.3	248.8
July	56	3	28	72	129	568	108.6	118.1
August	24	8	28	123	435	1,131	276.8	341.8
September	32	14	49	89	207	1,123	215.8	284.5
October	41	23	28	84	245	1,090	183.1	235.6
November	45	1	45	91	170	626	133.4	142.2
December	38	14	28	84	259	619	165.5	183.3
2020								
January	41	8	42	140	252	983	191.5	210.3
February	46	12	28	42	172	946	129.5	185.3
March	30	2	28	28	228	385	106.2	114.9
April	6	14	14	55	267	434	139.8	172.5
May	22	14	28	56	140	456	117.4	135.3
June	18	14	37	84	168	417	108.4	101.5
July	25	14	28	112	280	808	202.9	238.7
August	47	14	40	98	257	597	165.4	163.4
September	29	10	28	62	280	740	160.9	171.9
October	26	14	28	73	260	504	137.0	142.6
November	75	8	28	84	194	682	136.8	151.1
December	46	11	28	57	119	454	96.0	103.2
2021								
January	32	14	37	84	205	623	166.0	186.0
February	50	14	28	83	127	490	109.1	115.4
March	48	1	35	98	204	576	152.5	159.0
April	28	14	28	54	87	536	102.7	133.6
May	37	14	28	61	168	508	127.2	138.8
June	29	14	56	141	383	485	207.0	177.2
July	33	10	28	61	196	457	133.3	136.7

Table 4d. Continuous Summary of All Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	35	5	28	56	89	423	73.6	77.1
September	55	11	28	42	112	393	105.2	121.5
October	20	14	28	57	174	362	103.4	102.3
November	32	14	28	49	114	305	77.5	70.9
December	29	3	28	86	276	303	131.9	120.7
2022								
January	44	3	28	71	189	261	112.3	89.5
February	32	14	28	98	210	240	119.1	84.6
March	19	28	56	105	193	214	116.6	67.5
April	26	6	28	62	144	177	86.0	57.7
May	28	1	35	107	144	151	92.5	53.0
June	33	14	28	74	95	120	64.8	36.8
July	25	5	28	56	72	92	51.6	27.4
August	31	10	16	36	47	60	34.2	16.5
September	25	2	10	17	24	30	17.1	8.6

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5a. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	39,944	1	14	32	99	1,984	94.7	152.7
<i>Any Indication</i>	36,986	1	14	36	106	1,984	95.6	153.4
<i>Atopic Dermatitis</i>	28,055	1	14	30	98	1,984	93.3	154.6
<i>Asthma</i>	13,372	1	24	42	112	1,984	101.7	157.9
<i>Chronic Rhinosinusitis</i>	8,142	1	28	42	126	1,977	105.9	153.1
<i>Eosinophilic Esophagitis</i>	2,453	1	28	30	84	1,402	81.8	123.5
<i>Prurigo Nodularis</i>	828	1	14	41	98	1,675	94.8	146.9
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	38,506	1	28	84	207	1,990	167.3	225.3
<i>Any Indication</i>	35,371	1	28	85	208	1,990	167.7	225.3
<i>Atopic Dermatitis</i>	26,674	1	28	84	202	1,990	167.2	231.5
<i>Asthma</i>	12,473	1	28	86	215	1,984	172.6	225.8
<i>Chronic Rhinosinusitis</i>	7,627	1	28	93	224	1,977	172.8	210.8
<i>Eosinophilic Esophagitis</i>	2,155	1	28	62	169	1,477	137.6	190.3
<i>Prurigo Nodularis</i>	767	1	28	86	218	1,754	164.1	214.8

Table 5b. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	39,944	1	14	32	99	1,984	94.7	152.7
Female	22,463	1	14	31	98	1,955	94.0	150.5
Male	17,481	1	14	33	102	1,984	95.6	155.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	36,986	1	14	36	106	1,984	95.6	153.4
Female	20,805	1	14	34	102	1,955	94.8	150.9
Male	16,181	1	14	37	108	1,984	96.6	156.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	28,055	1	14	30	98	1,984	93.3	154.6
Female	15,820	1	14	31	98	1,955	92.7	151.5
Male	12,235	1	14	30	98	1,984	94.0	158.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	13,372	1	24	42	112	1,984	101.7	157.9
Female	7,812	1	16	42	112	1,842	100.0	154.4
Male	5,560	1	28	42	112	1,984	104.0	162.7
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	8,142	1	28	42	126	1,977	105.9	153.1
Female	4,444	1	28	42	115	1,955	103.8	153.4
Male	3,698	1	28	45	131	1,977	108.6	152.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	2,453	1	28	30	84	1,402	81.8	123.5
Female	1,427	1	28	30	85	1,342	84.2	124.2
Male	1,026	1	28	30	84	1,402	78.6	122.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	828	1	14	41	98	1,675	94.8	146.9
Female	493	1	14	42	112	1,675	96.8	153.5
Male	335	2	14	30	98	1,106	91.7	136.9
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	38,506	1	28	84	207	1,990	167.3	225.3

Table 5b. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	21,653	1	28	84	202	1,955	165.0	223.1
Male	16,853	1	28	85	211	1,990	170.2	228.1
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	35,371	1	28	85	208	1,990	167.7	225.3
Female	19,925	1	28	84	203	1,955	165.4	222.3
Male	15,446	1	28	85	210	1,990	170.6	229.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	26,674	1	28	84	202	1,990	167.2	231.5
Female	15,069	1	28	84	197	1,955	164.5	227.2
Male	11,605	1	28	84	210	1,990	170.7	236.9
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	12,473	1	28	86	215	1,984	172.6	225.8
Female	7,304	1	28	85	212	1,906	170.2	224.5
Male	5,169	1	28	88	219	1,984	176.0	227.4
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	7,627	1	28	93	224	1,977	172.8	210.8
Female	4,143	1	28	89	222	1,955	168.6	208.3
Male	3,484	1	28	100	229	1,977	177.7	213.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	2,155	1	28	62	169	1,477	137.6	190.3
Female	1,246	1	28	70	173	1,477	139.3	190.5
Male	909	1	28	60	160	1,402	135.3	190.1
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	767	1	28	86	218	1,754	164.1	214.8
Female	459	1	28	96	203	1,675	160.3	207.3
Male	308	2	28	84	226	1,754	169.7	225.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5c. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	39,944	1	14	32	99	1,984	94.7	152.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	315	1	24	30	56	695	45.8	60.6
6-11 years	1,500	1	16	30	84	1,222	85.1	127.5
12-17 years	3,721	1	14	28	100	1,520	95.3	154.8
18-79 years	34,006	1	14	38	105	1,984	95.6	154.3
≥ 80 years	402	1	14	28	98	822	88.3	129.0
<i>Any Indication</i>	36,986	1	14	36	106	1,984	95.6	153.4
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	307	1	24	30	56	695	45.8	63.7
6-11 years	1,446	1	15	30	84	1,222	85.1	128.4
12-17 years	3,541	1	14	28	108	1,520	96.9	156.9
18-79 years	31,346	1	14	42	112	1,984	96.5	154.9
≥ 80 years	346	1	14	28	98	759	86.5	123.9
<i>Atopic Dermatitis</i>	28,055	1	14	30	98	1,984	93.3	154.6
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	297	1	25	30	56	695	46.2	64.5
6-11 years	1,368	1	15	30	84	1,222	84.9	128.3
12-17 years	3,241	1	14	29	112	1,520	98.7	158.6
18-79 years	22,870	1	14	33	98	1,984	93.7	156.5
≥ 80 years	279	1	14	28	85	703	84.8	122.0
<i>Asthma</i>	13,372	1	24	42	112	1,984	101.7	157.9
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	56	2	23	30	56	140	41.6	32.6
6-11 years	533	1	28	31	86	1,050	89.5	132.7
12-17 years	1,285	1	14	28	98	1,285	97.1	159.1
18-79 years	11,418	1	28	42	112	1,984	103.1	159.3
≥ 80 years	80	10	14	42	125	759	100.1	132.6
<i>Chronic Rhinosinusitis</i>	8,142	1	28	42	126	1,977	105.9	153.1
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 5c. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
6-71 months	21	2	28	31	56	140	48.9	37.8
6-11 years	93	1	28	42	84	780	89.2	129.0
12-17 years	302	7	15	30	98	1,177	95.7	145.9
18-79 years	7,666	1	28	42	126	1,977	106.7	153.9
≥ 80 years	60	1	28	35	126	703	102.5	142.7
<i>Eosinophilic Esophagitis</i>	2,453	1	28	30	84	1,402	81.8	123.5
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	17	2	28	42	56	140	49.3	39.7
6-11 years	76	1	28	30	84	402	73.9	85.0
12-17 years	205	1	24	33	75	584	73.5	96.9
18-79 years	2,120	1	28	30	84	1,402	83.3	127.7
≥ 80 years	35	5	25	28	84	522	74.2	101.3
<i>Prurigo Nodularis</i>	828	1	14	41	98	1,675	94.8	146.9
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	2	11	11	18	25	25	18.0	9.9
6-11 years	12	9	14	28	67	322	65.2	94.9
12-17 years	35	2	14	28	112	826	87.9	148.4
18-79 years	756	1	14	42	98	1,675	96.3	149.4
≥ 80 years	23	6	28	56	112	280	77.9	73.9
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	38,506	1	28	84	207	1,990	167.3	225.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	314	1	25	30	61	800	61.5	96.9
6-11 years	1,471	1	28	61	168	1,222	134.6	173.7
12-17 years	3,630	1	28	90	210	1,537	167.6	216.0
18-79 years	32,712	1	28	86	210	1,990	170.1	229.5
≥ 80 years	379	1	28	68	179	822	132.6	162.4
<i>Any Indication</i>	35,371	1	28	85	208	1,990	167.7	225.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	305	1	25	30	60	800	58.9	92.1
6-11 years	1,410	1	28	61	168	1,222	135.2	175.7

Table 5c. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
12-17 years	3,439	1	28	91	212	1,520	169.4	217.2
18-79 years	29,900	1	28	87	210	1,990	170.6	229.5
≥ 80 years	317	1	28	66	176	815	126.4	153.3
<i>Atopic Dermatitis</i>	26,674	1	28	84	202	1,990	167.2	231.5
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	295	1	25	30	60	800	60.5	95.4
6-11 years	1,336	1	28	61	169	1,222	136.6	177.3
12-17 years	3,132	1	28	98	219	1,520	172.9	220.1
18-79 years	21,656	1	28	85	205	1,990	170.2	237.5
≥ 80 years	255	1	28	60	183	815	126.9	155.3
<i>Asthma</i>	12,473	1	28	86	215	1,984	172.6	225.8
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	55	2	22	30	64	619	60.4	102.0
6-11 years	515	1	28	61	168	1,050	131.7	166.4
12-17 years	1,206	1	28	88	212	1,285	169.6	218.1
18-79 years	10,625	1	28	88	219	1,984	175.7	229.6
≥ 80 years	72	10	28	84	208	725	144.9	154.4
<i>Chronic Rhinosinusitis</i>	7,627	1	28	93	224	1,977	172.8	210.8
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	21	2	30	56	84	619	87.7	132.2
6-11 years	87	1	30	65	156	844	139.0	184.6
12-17 years	275	7	28	74	196	1,261	142.7	178.2
18-79 years	7,188	1	28	98	226	1,977	175.0	212.6
≥ 80 years	56	1	28	65	163	703	125.1	147.1
<i>Eosinophilic Esophagitis</i>	2,155	1	28	62	169	1,477	137.6	190.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	17	2	30	56	112	619	106.8	155.5
6-11 years	72	1	30	59	129	874	112.5	143.8
12-17 years	189	1	28	62	185	1,268	141.7	194.1
18-79 years	1,849	1	28	63	169	1,477	138.2	191.9
≥ 80 years	28	5	28	94	197	687	150.9	183.6

Table 5c. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Prurigo Nodularis</i>	767	1	28	86	218	1,754	164.1	214.8
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	2	11	11	18	25	25	18.0	9.9
6-11 years	10	9	14	128	254	417	147.9	145.0
12-17 years	32	2	28	74	238	1,199	189.7	284.9
18-79 years	701	1	28	87	214	1,754	164.0	213.5
≥ 80 years	22	6	30	84	224	808	151.1	178.4

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	39,944	1	14	32	99	1,984	94.7	152.7
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	88	1	14	30	91	1,984	134.5	309.7
May	241	1	14	42	98	1,977	121.4	276.3
June	236	1	14	42	98	1,940	107.9	233.1
July	248	5	14	30	91	1,908	88.0	181.5
August	288	1	14	30	70	1,879	88.6	185.3
September	247	1	14	30	98	1,842	116.1	255.0
October	274	14	14	30	74	1,708	96.6	224.0
November	279	14	14	42	70	1,769	95.7	189.7
December	212	4	14	25	42	1,745	72.7	195.7
2018								
January	182	14	14	42	98	1,694	114.7	241.3
February	215	14	14	42	126	1,636	118.2	202.8
March	256	14	14	42	126	1,675	116.8	218.8
April	197	4	14	42	126	1,619	116.0	205.5
May	200	12	14	42	127	1,520	113.2	196.2
June	200	1	14	42	126	1,580	117.7	207.8
July	378	1	14	28	90	1,536	86.1	146.0
August	386	10	14	28	98	1,503	89.8	145.6
September	310	4	14	36	98	952	87.1	135.4
October	381	1	14	42	91	1,459	96.0	179.5
November	367	1	14	28	84	1,429	109.0	230.2
December	334	1	14	28	70	1,394	93.0	199.6
2019								
January	410	1	14	42	126	1,363	115.4	199.4
February	401	1	14	28	112	1,332	100.5	186.9

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	415	2	14	28	98	1,306	101.8	193.8
April	561	1	14	28	98	1,275	106.6	191.5
May	503	1	14	28	112	1,237	112.7	205.4
June	511	12	14	28	98	1,215	101.4	180.8
July	710	2	14	42	112	1,186	104.1	183.8
August	743	1	14	28	112	1,156	106.7	196.2
September	637	1	14	28	103	1,123	107.1	192.4
October	741	1	14	42	90	1,096	112.8	195.9
November	672	1	14	28	70	1,061	100.7	188.9
December	691	1	14	28	56	1,034	91.9	178.0
2020								
January	598	1	14	28	154	1,003	120.9	184.0
February	655	2	14	42	168	970	134.2	198.8
March	657	4	14	42	154	941	132.3	199.4
April	465	1	28	56	154	913	123.4	173.1
May	462	3	14	38	126	879	115.0	176.4
June	571	1	14	42	126	852	113.6	175.8
July	1,067	1	28	42	126	817	107.4	155.0
August	853	1	28	56	140	789	127.9	180.9
September	828	1	20	42	112	760	100.5	148.9
October	872	2	14	56	126	730	115.5	163.8
November	815	1	14	39	112	698	107.5	160.3
December	785	1	14	28	98	669	91.5	136.9
2021								
January	683	11	14	42	140	634	115.1	153.0
February	673	1	14	42	126	607	112.9	156.5
March	776	2	14	42	140	579	114.6	149.8
April	751	2	14	42	140	544	104.5	132.1
May	712	2	14	42	126	516	108.1	140.9
June	715	2	14	42	154	487	110.7	135.3
July	1,016	5	28	42	128	457	96.4	112.1

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	1,100	1	28	42	126	424	93.2	109.5
September	897	9	28	56	112	394	96.9	109.5
October	948	4	28	42	112	365	87.4	99.1
November	919	2	28	42	112	334	86.1	96.6
December	863	1	14	28	84	304	75.4	87.7
2022								
January	811	1	28	56	126	271	87.9	85.9
February	748	12	28	56	154	242	87.3	79.7
March	912	1	28	56	154	214	83.4	71.7
April	884	1	28	42	140	183	72.2	60.4
May	835	1	28	46	127	152	68.2	50.8
June	869	7	28	55	99	122	58.8	38.3
July	1,212	14	28	56	72	92	49.1	25.1
August	1,366	1	28	32	46	61	35.3	14.2
September	1,111	1	8	14	19	30	13.6	8.3
<i>Any Indication</i>	<i>36,986</i>	<i>1</i>	<i>14</i>	<i>36</i>	<i>106</i>	<i>1,984</i>	<i>95.6</i>	<i>153.4</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	79	1	14	30	98	1,984	144.3	325.5
May	209	1	14	42	99	1,977	122.7	285.6
June	210	1	14	42	98	1,940	107.5	234.0
July	226	5	14	30	84	1,908	93.9	194.3
August	266	1	14	30	84	1,879	90.9	188.2
September	230	1	14	30	98	1,842	120.4	262.4
October	249	14	14	30	82	1,534	94.9	210.3
November	254	14	14	42	70	1,769	95.1	185.5
December	189	4	14	28	42	1,744	65.9	160.4
2018								
January	168	14	14	42	98	1,694	119.1	247.6

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
February	194	14	14	42	126	1,636	127.9	214.3
March	225	14	14	42	154	1,675	127.3	231.0
April	184	4	14	42	120	1,632	123.7	236.8
May	177	12	14	42	128	1,520	112.3	194.9
June	181	1	14	42	126	1,284	100.4	162.9
July	332	1	14	42	98	1,536	89.4	153.3
August	346	10	14	42	112	1,503	93.1	147.5
September	293	4	14	30	98	952	85.8	134.9
October	341	1	14	42	84	1,459	96.8	186.7
November	349	5	14	28	70	1,429	110.9	239.9
December	307	1	14	28	73	1,388	92.8	194.7
2019								
January	377	14	14	42	126	1,363	120.9	206.6
February	375	1	14	28	114	1,332	102.2	184.1
March	394	2	14	28	98	1,306	102.6	188.7
April	522	1	14	42	112	1,275	110.1	193.2
May	478	1	14	28	112	1,237	112.8	207.7
June	478	12	14	28	109	1,215	105.6	186.3
July	654	2	14	42	112	1,186	102.6	181.1
August	705	1	14	28	102	1,153	104.7	194.7
September	590	1	14	28	111	1,123	108.0	192.4
October	687	14	14	42	98	1,096	115.0	198.0
November	633	1	14	28	70	1,061	97.0	181.7
December	635	1	14	28	70	1,034	93.8	180.9
2020								
January	571	1	14	28	154	1,003	120.8	182.1
February	618	2	14	42	168	970	136.4	200.5
March	617	6	14	42	154	941	134.6	200.8
April	436	1	28	56	154	913	125.3	178.8
May	432	3	14	42	138	879	115.4	171.7
June	532	1	14	42	126	852	119.9	185.3

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	947	1	28	42	126	822	107.6	154.1
August	765	5	28	56	140	789	128.2	178.6
September	754	1	28	42	112	760	104.1	153.7
October	803	2	14	56	126	730	116.3	163.8
November	757	1	14	38	112	698	109.7	163.8
December	719	1	14	28	98	669	90.8	134.9
2021								
January	642	11	20	42	140	634	118.2	155.7
February	641	1	14	42	126	607	111.0	153.7
March	734	2	14	42	126	579	112.7	147.6
April	699	2	14	42	126	544	103.0	131.5
May	677	6	28	42	126	516	108.6	141.1
June	665	8	28	42	154	487	112.2	135.2
July	879	5	28	50	140	457	100.6	116.5
August	1,008	1	28	42	126	424	95.2	111.5
September	854	9	28	56	120	394	100.0	111.8
October	872	4	28	42	112	365	87.0	98.0
November	835	2	28	42	112	334	84.9	95.0
December	843	1	14	28	98	304	77.2	88.7
2022								
January	756	1	28	56	126	271	87.2	85.4
February	695	12	28	56	154	242	87.3	78.8
March	859	1	28	56	154	214	83.3	71.3
April	831	1	28	42	140	183	71.9	60.0
May	789	1	28	56	127	152	68.8	51.0
June	832	4	28	56	100	122	59.6	38.3
July	1,083	14	28	56	72	92	49.4	25.2
August	1,263	1	28	32	47	61	35.4	14.2
September	1,040	1	8	12	19	30	13.6	8.3
<i>Atopic Dermatitis</i>	<i>28,055</i>	<i>1</i>	<i>14</i>	<i>30</i>	<i>98</i>	<i>1,984</i>	<i>93.3</i>	<i>154.6</i>
2017								

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	74	1	14	30	98	1,984	147.3	335.2
May	204	1	14	42	99	1,977	122.5	288.4
June	207	1	14	42	98	1,940	107.6	235.4
July	214	5	14	30	98	1,908	97.7	199.2
August	251	1	14	30	84	1,879	94.2	193.1
September	224	1	14	30	98	1,842	122.4	265.6
October	243	14	14	30	82	1,534	93.1	207.6
November	248	14	14	42	77	1,769	95.9	186.4
December	179	4	14	28	42	1,744	65.8	164.1
2018								
January	167	14	14	42	112	1,694	125.9	252.4
February	185	14	14	42	126	1,636	130.0	218.6
March	220	14	14	42	154	1,675	128.4	233.3
April	173	4	14	42	114	1,632	116.7	213.3
May	172	12	14	42	147	1,520	114.6	197.6
June	180	1	14	42	120	1,284	99.3	162.7
July	322	1	14	42	98	1,536	89.5	154.6
August	335	10	14	42	112	1,503	94.4	149.3
September	286	4	14	36	98	952	87.3	136.4
October	328	1	14	42	84	1,459	97.3	188.5
November	316	5	14	28	70	1,429	105.7	233.9
December	256	1	14	28	70	1,388	86.6	185.0
2019								
January	315	14	14	42	140	1,363	129.9	217.0
February	293	1	14	42	112	1,332	101.3	180.1
March	308	2	14	42	126	1,306	113.2	201.5
April	423	1	14	42	112	1,275	108.7	192.1
May	382	4	14	28	112	1,237	117.8	214.9

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	376	12	14	28	112	1,215	110.0	196.7
July	526	2	14	35	112	1,186	104.9	191.4
August	517	3	14	28	102	1,153	101.1	188.0
September	419	1	14	28	98	1,123	95.5	177.1
October	475	14	14	42	84	1,096	105.7	186.9
November	432	5	14	28	69	1,061	93.4	183.5
December	444	1	14	28	70	1,034	90.1	173.0
2020								
January	410	1	14	28	154	1,003	124.3	194.7
February	416	2	14	42	140	970	122.7	194.2
March	416	7	14	42	154	940	118.6	178.3
April	280	3	22	42	154	913	122.0	188.6
May	291	14	14	42	140	877	121.5	179.8
June	378	7	14	42	126	852	114.2	172.3
July	697	1	28	42	126	822	107.0	156.2
August	556	5	20	56	135	789	119.6	168.1
September	529	3	14	42	112	760	102.2	149.2
October	540	2	14	42	112	730	108.7	158.3
November	554	1	14	39	112	698	107.2	160.7
December	528	1	14	28	98	669	87.7	134.4
2021								
January	466	11	14	56	140	634	116.0	151.3
February	472	1	14	29	126	607	102.5	145.4
March	534	2	14	42	126	578	109.3	144.7
April	513	2	14	42	126	544	94.4	123.8
May	495	6	14	42	126	515	105.6	139.9
June	495	6	14	42	140	487	106.8	133.9
July	664	5	28	42	112	457	95.8	115.9
August	727	1	28	42	112	424	90.4	110.2
September	659	9	28	53	112	394	93.3	106.5
October	655	4	28	42	112	365	87.7	100.3

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	634	2	14	39	112	334	82.7	93.2
December	631	1	14	28	84	304	72.8	84.1
2022								
January	563	1	28	42	121	271	83.3	82.2
February	500	12	28	42	126	242	81.4	76.1
March	624	1	28	42	126	214	78.1	69.6
April	593	1	28	28	112	183	64.9	57.0
May	566	8	28	43	126	152	67.8	50.5
June	562	4	28	42	96	122	56.6	38.1
July	793	14	28	56	71	92	48.5	25.2
August	890	1	28	31	46	61	34.8	14.3
September	729	1	8	14	19	30	13.6	8.3
<i>Asthma</i>	13,372	1	24	42	112	1,984	101.7	157.9
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	21	14	14	30	70	1,984	272.7	567.2
May	43	14	15	42	154	952	115.0	166.5
June	38	14	14	42	126	1,526	127.0	266.0
July	60	13	14	42	84	744	92.6	143.8
August	68	1	14	30	91	658	79.8	129.7
September	48	14	28	42	112	1,842	155.1	316.5
October	62	14	14	28	70	1,486	86.6	221.8
November	56	14	28	42	77	1,330	97.7	208.5
December	52	10	15	30	84	393	68.3	82.7
2018								
January	46	14	28	42	126	1,304	129.6	236.3
February	54	14	14	63	196	1,636	179.6	295.0
March	52	14	14	42	84	1,651	100.8	233.6
April	46	14	14	37	112	1,619	115.7	249.2

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	44	12	28	42	187	504	110.8	113.0
June	34	14	14	49	154	1,317	143.9	249.1
July	82	14	28	42	126	1,044	113.2	181.7
August	89	14	14	42	112	602	88.1	110.0
September	63	5	14	28	84	364	55.9	63.5
October	70	14	14	28	85	882	78.5	129.7
November	93	14	14	30	84	1,417	128.3	278.0
December	118	1	14	28	154	1,383	130.8	227.4
2019								
January	160	14	14	29	112	1,339	102.7	190.9
February	144	14	14	30	126	1,331	109.8	185.7
March	147	14	14	28	70	1,297	94.1	193.1
April	205	13	14	42	140	1,269	118.7	193.7
May	182	1	14	28	98	1,235	112.2	215.8
June	186	14	14	35	98	1,215	102.0	178.6
July	235	14	14	42	126	1,177	115.9	199.8
August	305	1	14	28	112	1,152	113.3	207.4
September	237	6	18	42	112	1,123	128.3	217.2
October	294	14	14	45	112	1,089	128.0	211.6
November	267	12	14	28	84	1,054	104.5	183.5
December	236	1	14	28	80	1,034	116.4	222.0
2020								
January	236	3	14	28	182	983	127.1	184.1
February	274	14	14	56	196	964	144.6	194.3
March	264	6	28	56	154	941	146.1	205.0
April	194	1	28	84	168	913	139.6	180.8
May	179	3	28	42	140	879	119.2	175.5
June	220	1	14	42	140	852	127.7	195.0
July	351	8	28	56	112	815	107.4	152.7
August	289	5	28	56	143	788	134.0	183.3
September	301	1	28	42	112	760	103.7	152.7

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
October	330	10	28	56	112	722	116.6	163.3
November	284	14	28	42	119	691	117.3	168.2
December	265	1	14	28	112	663	102.1	150.8
2021								
January	244	14	28	42	147	631	125.5	169.3
February	242	14	28	56	154	605	121.1	156.1
March	288	14	28	56	154	579	121.9	151.3
April	268	9	28	42	168	541	114.6	141.2
May	260	5	28	42	105	515	103.3	139.7
June	243	2	28	56	168	484	110.2	126.4
July	315	14	28	56	140	452	100.3	108.2
August	364	1	28	42	136	425	98.3	112.4
September	291	11	28	30	132	394	102.7	119.2
October	298	14	28	56	98	362	86.7	94.4
November	298	10	28	45	112	334	92.9	101.8
December	289	1	17	28	98	303	79.9	91.1
2022								
January	276	1	28	42	147	271	90.8	90.7
February	275	13	28	56	168	242	93.2	82.5
March	282	1	28	56	182	214	88.5	74.4
April	325	1	28	56	158	183	81.5	64.0
May	295	6	28	56	128	153	70.0	50.7
June	294	8	28	56	101	121	63.6	38.2
July	396	12	28	56	73	92	49.4	25.3
August	445	6	28	33	48	61	36.3	14.3
September	359	1	8	14	22	30	14.0	8.1
<i>Chronic Rhinosinusitis</i>	<i>8,142</i>	<i>1</i>	<i>28</i>	<i>42</i>	<i>126</i>	<i>1,977</i>	<i>105.9</i>	<i>153.1</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	5	14	14	70	251	434	156.6	183.1
May	14	14	14	71	234	1,977	365.4	686.0
June	16	1	15	36	119	210	72.1	70.0
July	13	14	28	49	114	308	91.3	96.1
August	25	9	28	42	70	658	98.5	169.0
September	9	14	28	29	98	266	79.8	94.2
October	13	14	28	42	84	660	100.5	172.4
November	12	14	21	46	262	1,330	244.9	414.2
December	14	13	14	22	28	168	36.9	43.8
2018								
January	17	14	14	56	84	168	60.1	53.7
February	20	14	14	35	175	330	98.9	109.7
March	17	14	28	56	112	196	74.3	56.6
April	18	14	28	44	126	280	84.4	81.8
May	19	12	14	42	140	254	75.8	74.9
June	10	14	14	14	84	238	54.6	73.3
July	27	14	28	70	126	778	115.6	169.2
August	31	14	14	28	140	496	93.7	115.8
September	23	14	14	56	154	858	107.6	175.5
October	22	14	14	42	84	420	64.2	86.8
November	35	14	14	28	126	700	91.5	148.5
December	56	1	14	28	84	952	111.7	198.2
2019								
January	64	14	14	35	140	910	97.1	147.7
February	52	14	14	28	70	1,331	85.8	197.9
March	62	1	14	28	84	1,022	96.6	180.3
April	94	14	14	42	154	1,275	155.2	261.8
May	79	1	14	42	112	1,235	135.0	242.0
June	87	14	14	42	98	756	91.1	131.4
July	112	14	14	42	112	1,177	126.5	208.2
August	166	10	14	28	126	1,151	125.5	230.1

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	166	6	28	29	119	1,123	133.8	226.9
October	185	14	28	56	140	1,089	132.1	198.4
November	191	14	28	42	84	1,046	110.3	181.7
December	180	1	21	28	56	1,034	97.9	184.1
2020								
January	154	1	28	28	140	832	103.2	145.5
February	174	4	28	56	210	964	146.0	184.3
March	182	14	28	42	224	929	160.1	227.4
April	136	14	28	56	168	913	136.4	186.2
May	117	5	28	28	135	879	107.2	164.2
June	153	8	28	56	140	844	131.0	191.2
July	212	8	28	56	158	817	120.3	152.7
August	182	5	28	56	136	788	138.0	194.7
September	187	1	28	42	120	760	111.4	155.0
October	208	9	28	66	158	725	135.2	174.6
November	179	12	28	28	112	689	95.2	138.9
December	189	1	25	28	140	662	105.4	147.9
2021								
January	164	14	28	56	196	634	144.6	172.6
February	173	14	28	56	196	607	143.0	172.4
March	161	14	28	56	168	578	138.0	164.5
April	177	9	28	56	168	541	120.5	144.7
May	177	14	28	56	168	516	127.4	149.5
June	168	14	28	56	172	487	122.4	135.8
July	205	14	28	56	168	452	118.0	124.1
August	223	1	28	56	154	424	113.2	120.8
September	182	14	28	56	120	394	104.5	116.6
October	210	14	28	42	112	362	87.0	92.2
November	187	10	28	42	112	333	93.6	103.0
December	217	9	28	42	112	304	88.5	94.4
2022								

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	197	1	28	56	154	271	96.4	89.6
February	193	13	28	56	196	242	102.4	81.8
March	216	7	28	56	178	214	94.2	73.2
April	222	1	28	56	158	183	83.1	61.7
May	222	1	28	56	129	152	71.3	50.3
June	224	14	28	56	103	122	66.7	37.3
July	221	14	28	56	74	92	52.6	24.2
August	265	6	28	32	47	61	36.7	13.1
September	211	1	5	12	20	30	13.3	8.3
<i>Eosinophilic Esophagitis</i>	2,453	1	28	30	84	1,402	81.8	123.5
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	30	30	70	182	182	94.0	78.8
May	6	14	14	14	14	90	26.7	31.0
June	5	14	14	14	15	182	47.8	75.0
July	9	14	14	28	58	308	75.1	105.1
August	8	14	14	28	70	266	63.0	86.6
September	8	14	29	36	70	196	60.0	60.4
October	1	146	146	146	146	146	146.0	NaN
November	8	42	42	52	91	308	89.9	90.8
December	10	6	14	21	30	128	36.2	39.1
2018								
January	6	14	28	91	196	728	191.3	271.0
February	13	14	42	42	70	336	82.9	97.2
March	12	14	28	98	168	299	110.5	90.6
April	6	14	14	42	84	100	49.3	35.7
May	8	14	21	28	91	192	60.8	64.5
June	15	14	27	56	168	1,295	178.7	343.6
July	17	14	28	28	56	280	49.4	61.2

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	14	14	28	49	133	196	79.6	64.5
September	9	14	28	56	56	84	45.1	21.9
October	19	14	28	56	140	1,178	164.5	278.8
November	17	14	28	42	145	1,402	202.9	369.0
December	25	5	14	28	56	322	67.9	92.9
2019								
January	19	14	14	42	98	1,342	195.6	376.1
February	17	14	28	42	308	1,331	185.6	325.3
March	24	14	14	28	63	187	49.4	45.9
April	30	14	14	28	51	271	66.2	85.6
May	31	14	14	42	140	266	78.8	76.3
June	19	14	14	28	84	476	74.9	113.3
July	39	14	15	42	84	434	69.0	80.7
August	43	9	28	28	84	301	57.4	58.1
September	38	6	28	28	84	588	77.9	120.8
October	46	9	28	42	84	440	88.6	105.1
November	41	14	28	28	84	1,048	126.2	234.7
December	35	2	14	28	84	379	82.9	110.0
2020								
January	39	14	28	28	139	977	102.2	169.5
February	53	14	28	56	146	888	110.5	154.8
March	39	14	14	42	154	728	129.3	175.4
April	24	14	28	70	112	630	117.1	158.4
May	26	14	28	50	140	297	85.1	81.3
June	33	13	28	28	84	841	102.3	164.4
July	37	14	28	30	112	518	86.0	104.4
August	34	14	28	56	168	504	123.3	138.9
September	39	14	28	56	112	744	99.2	131.4
October	35	14	28	66	170	719	144.5	188.0
November	45	14	28	28	98	683	109.7	167.5
December	56	3	14	28	56	389	51.1	62.8

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2021								
January	50	14	28	45	112	616	110.2	157.0
February	36	14	28	56	154	603	124.8	162.5
March	42	14	28	56	168	576	123.7	160.2
April	38	14	28	28	84	522	83.4	112.7
May	49	14	28	50	86	291	70.8	63.3
June	40	14	28	56	112	470	97.0	115.9
July	51	14	28	28	98	442	85.9	113.5
August	59	14	28	56	136	418	97.3	106.0
September	51	14	28	56	90	395	90.9	105.6
October	58	14	28	42	140	362	95.3	108.5
November	74	14	28	43	112	327	82.1	84.7
December	68	9	28	28	91	291	77.5	84.3
2022								
January	53	14	28	42	168	271	89.3	88.5
February	42	14	28	56	126	232	89.4	72.6
March	56	14	28	56	186	214	95.9	74.4
April	52	14	28	56	155	179	79.1	58.9
May	57	1	28	56	112	148	67.9	47.3
June	73	14	28	56	96	122	62.1	36.5
July	109	14	28	56	68	92	48.8	23.2
August	180	14	28	35	50	61	38.2	12.7
September	154	1	5	11	22	30	13.0	8.8
<i>Prurigo Nodularis</i>	828	1	14	41	98	1,675	94.8	146.9
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	28	28	42	855	855	308.3	473.5
May	2	14	14	14	14	14	14.0	0.0
June	3	14	14	14	185	185	71.0	98.7

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	6	14	14	29	70	686	140.3	268.1
August	6	14	14	35	98	98	49.0	41.3
September	2	28	28	46	64	64	46.0	25.5
October	5	14	31	69	112	126	70.4	48.9
November	5	14	15	30	41	560	132.0	239.5
December	3	24	24	30	70	70	41.3	25.0
2018								
January	4	14	14	14	266	518	140.0	252.0
February	8	14	14	23	42	1,038	151.1	358.6
March	4	84	91	329	1,118	1,675	604.3	747.3
April	7	14	14	28	56	113	40.1	36.0
May	5	14	28	42	42	84	42.0	26.2
June	4	14	14	175	420	504	217.0	244.2
July	2	28	28	217	406	406	217.0	267.3
August	5	14	15	56	182	714	196.2	297.5
September	7	14	14	28	98	126	52.0	46.2
October	6	14	14	21	42	266	63.0	100.1
November	12	14	14	28	59	398	88.3	141.3
December	5	14	28	28	28	168	53.2	64.5
2019								
January	5	14	14	28	28	28	22.4	7.7
February	11	14	14	42	126	194	68.5	59.5
March	10	14	14	28	56	103	38.3	30.0
April	10	14	14	14	84	267	63.9	86.1
May	14	14	14	42	112	589	99.1	151.8
June	15	14	14	28	84	1,106	132.5	284.9
July	14	14	14	35	131	420	87.4	114.8
August	13	14	28	56	182	812	192.9	254.4
September	14	14	28	35	98	518	97.0	143.2
October	15	14	28	71	154	826	142.6	218.2
November	15	1	14	15	98	560	96.1	166.1

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December 2020	16	14	14	28	71	280	67.6	89.6
January	19	14	15	84	238	983	164.2	223.3
February	9	14	28	28	84	126	54.4	41.1
March	9	14	14	28	168	294	93.4	117.1
April	6	14	14	196	336	434	198.3	177.0
May	8	14	14	38	77	140	51.4	45.8
June	9	14	28	70	98	280	90.2	86.0
July	17	14	28	56	84	322	85.6	92.5
August	17	14	14	28	109	378	80.5	103.0
September	11	14	14	28	280	350	108.2	142.4
October	13	14	28	42	168	406	118.0	130.0
November	27	14	28	42	112	682	113.4	160.6
December 2021	14	11	14	42	140	504	110.2	148.7
January 2021	15	14	14	84	126	623	141.2	187.5
February	14	14	14	28	98	490	81.0	124.5
March	20	14	14	35	98	364	84.5	106.1
April	9	14	14	28	56	536	109.3	176.9
May	11	14	42	84	168	493	125.6	138.1
June	19	14	56	84	198	485	162.6	164.0
July	20	10	28	63	112	442	112.1	130.9
August	19	14	14	28	84	423	65.6	93.3
September	21	14	28	84	112	393	116.1	125.4
October	16	14	28	69	168	362	118.4	119.3
November	19	14	14	28	98	224	62.3	65.6
December 2022	21	3	14	56	112	303	86.0	101.0
January 2022	25	14	28	28	112	261	77.8	78.9
February	24	14	14	42	180	240	92.3	89.3
March	13	14	28	56	140	199	89.6	70.3

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	22	6	28	56	157	177	86.8	62.3
May	24	1	28	28	107	145	60.0	49.5
June	25	14	24	28	93	120	55.7	38.6
July	23	14	28	56	72	92	52.1	26.2
August	27	14	14	37	51	60	35.2	16.9
September	26	2	11	17	24	29	16.8	8.0
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>								
	38,506	1	28	84	207	1,990	167.3	225.3
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	88	1	30	76	369	1,990	333.5	508.2
May	241	1	40	99	294	1,978	289.5	444.3
June	236	1	31	104	210	1,940	219.7	342.1
July	231	5	28	106	243	1,914	260.4	427.8
August	280	9	29	97	220	1,880	210.6	339.9
September	245	1	30	98	312	1,842	252.2	374.2
October	264	14	30	82	220	1,825	227.5	367.3
November	278	14	30	57	252	1,769	203.9	306.6
December	212	4	14	42	179	1,758	170.5	314.8
2018								
January	178	14	28	93	323	1,731	236.9	335.3
February	211	14	28	126	267	1,691	219.8	300.7
March	252	14	42	134	305	1,675	248.0	322.5
April	196	4	28	103	270	1,619	223.0	304.6
May	198	12	42	133	273	1,611	252.4	331.7
June	197	3	42	126	272	1,583	260.9	360.1
July	309	1	28	77	208	1,549	184.4	275.0
August	347	5	28	101	213	1,522	188.1	258.9

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	294	5	28	98	197	1,486	193.2	296.9
October	370	1	28	87	226	1,459	206.1	302.3
November	360	5	14	56	227	1,429	197.3	313.7
December	329	1	14	70	254	1,398	207.2	322.6
2019								
January	411	1	42	130	339	1,363	254.1	316.7
February	405	1	28	123	272	1,338	230.1	309.5
March	415	6	28	126	268	1,306	218.7	291.5
April	548	1	30	126	273	1,278	251.3	325.0
May	495	1	28	116	274	1,248	233.3	297.7
June	506	12	28	98	241	1,215	212.7	284.4
July	660	2	28	101	196	1,186	190.7	269.1
August	714	1	28	101	253	1,157	213.9	292.7
September	616	1	28	98	208	1,123	191.3	265.1
October	731	1	28	85	277	1,096	202.0	259.1
November	661	1	28	57	216	1,062	186.1	265.6
December	694	1	14	42	230	1,034	176.7	267.6
2020								
January	596	1	28	126	325	1,003	211.4	243.5
February	646	2	28	128	329	970	241.5	277.9
March	664	4	28	115	297	943	221.2	263.5
April	454	1	42	142	268	913	215.0	228.8
May	453	3	28	118	241	883	206.2	240.1
June	564	1	38	126	238	852	201.4	225.7
July	897	8	28	123	259	822	197.7	220.8
August	784	5	42	119	287	789	206.4	231.6
September	774	1	28	100	233	760	174.2	199.3
October	858	2	28	95	280	730	193.5	213.5
November	805	1	28	84	235	698	171.9	196.5
December	805	1	23	70	221	669	157.8	190.7
2021								

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	671	4	28	117	287	636	189.2	188.1
February	664	1	28	126	292	607	195.3	196.5
March	760	2	31	113	296	579	193.6	189.7
April	734	2	28	112	248	548	167.7	164.1
May	696	6	28	105	252	518	170.2	166.8
June	700	2	28	119	278	487	177.4	163.6
July	863	5	28	110	213	457	152.9	141.7
August	995	1	28	99	241	425	149.9	139.6
September	867	9	28	98	231	395	146.7	131.4
October	923	4	28	87	216	365	137.4	120.9
November	886	2	28	78	223	334	127.5	114.3
December	870	1	28	84	245	304	122.5	108.4
2022								
January	790	1	30	112	248	273	132.6	96.6
February	747	8	38	124	220	242	127.8	86.2
March	899	1	30	118	193	214	117.5	74.3
April	854	1	28	112	163	183	100.3	64.4
May	824	1	30	120	137	152	94.0	50.7
June	865	3	28	94	107	122	75.6	37.8
July	1,070	14	30	67	78	92	59.4	23.9
August	1,282	1	28	39	51	61	39.6	13.7
September	1,073	1	7	12	22	30	13.8	8.4
Any Indication	35,371	1	28	85	208	1,990	167.7	225.3
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	79	1	30	77	420	1,990	357.9	527.7
May	208	1	30	99	277	1,978	293.3	458.7
June	208	1	31	105	200	1,940	201.8	310.9
July	211	5	28	111	246	1,914	269.7	439.4

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	252	9	30	99	241	1,880	219.3	338.8
September	223	1	30	98	312	1,842	259.0	387.0
October	237	14	30	84	238	1,822	229.7	356.5
November	251	14	30	58	256	1,769	201.2	301.7
December	186	4	15	42	161	1,758	161.1	301.4
2018								
January	158	14	28	93	296	1,731	243.5	347.2
February	187	14	28	119	272	1,691	225.1	315.5
March	218	14	42	164	308	1,675	261.2	335.3
April	181	4	28	102	270	1,632	232.6	325.7
May	175	12	42	131	273	1,611	248.8	330.9
June	176	3	39	109	215	1,583	242.8	354.2
July	273	1	28	77	213	1,549	182.7	271.0
August	297	5	28	112	216	1,522	195.8	267.0
September	277	5	28	98	193	1,486	191.9	295.3
October	332	1	28	89	239	1,459	208.2	302.6
November	338	5	14	56	218	1,429	198.7	316.2
December	299	1	14	73	254	1,397	202.7	308.9
2019								
January	377	14	42	130	342	1,363	259.6	325.1
February	373	1	28	123	302	1,338	235.4	315.6
March	385	6	28	115	245	1,306	208.5	281.9
April	512	1	41	116	278	1,278	255.2	331.5
May	465	1	28	112	274	1,248	233.9	298.9
June	465	12	28	98	226	1,215	214.4	287.2
July	607	2	28	98	194	1,186	185.6	264.2
August	672	1	28	98	261	1,157	213.8	293.6
September	566	1	28	99	205	1,123	193.6	267.4
October	677	14	30	86	272	1,096	201.9	257.2
November	622	1	28	56	202	1,062	179.7	258.4
December	635	1	14	42	239	1,034	178.2	266.7

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2020								
January	562	1	28	127	327	1,003	210.0	240.9
February	599	2	28	126	330	970	242.3	278.5
March	614	6	28	113	295	943	215.6	258.3
April	423	1	39	140	269	913	217.1	235.6
May	417	3	28	113	241	883	200.8	234.1
June	518	1	42	127	239	852	205.7	228.8
July	820	8	28	129	269	822	202.0	222.3
August	707	5	42	118	281	789	205.6	231.2
September	705	1	28	102	252	760	181.2	203.1
October	779	2	42	98	278	730	194.6	212.7
November	735	1	28	85	252	698	176.9	199.3
December	735	1	22	70	233	669	159.5	192.2
2021								
January	620	7	30	117	287	636	188.8	187.6
February	624	1	28	126	293	607	194.9	194.9
March	707	2	40	113	294	579	193.4	189.9
April	676	2	28	112	238	548	163.6	162.1
May	647	6	28	112	252	518	171.0	166.2
June	647	14	28	126	271	487	177.2	161.7
July	756	5	28	112	215	457	154.8	142.9
August	917	1	28	99	252	425	150.9	140.2
September	812	9	28	98	252	395	150.0	133.0
October	837	4	28	86	219	365	137.9	120.6
November	797	2	28	74	220	334	126.8	114.2
December	820	1	28	84	257	304	124.3	109.2
2022								
January	741	1	28	112	247	273	131.6	95.9
February	683	12	42	126	221	242	129.5	85.7
March	836	1	30	115	193	214	116.9	74.8
April	794	1	28	112	163	183	101.3	64.3

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	762	1	28	123	137	152	94.6	51.0
June	816	3	28	94	107	122	76.0	37.4
July	959	14	31	67	79	92	59.8	23.8
August	1,193	1	28	39	51	61	39.6	13.7
September	990	1	8	12	21	30	13.7	8.4
<i>Atopic Dermatitis</i>	26,674	1	28	84	202	1,990	167.2	231.5
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	74	1	30	88	469	1,990	373.1	541.0
May	202	1	30	100	280	1,978	297.8	464.0
June	205	1	42	105	200	1,940	209.6	324.4
July	199	5	28	121	299	1,914	284.4	448.9
August	237	9	30	101	243	1,880	222.2	344.1
September	215	1	30	98	326	1,842	266.0	392.4
October	229	14	30	84	238	1,822	236.6	372.4
November	245	14	30	60	252	1,769	201.9	303.7
December	176	4	15	42	162	1,758	165.1	308.7
2018								
January	158	14	30	101	323	1,732	259.5	367.5
February	179	14	28	119	273	1,691	230.8	321.2
March	213	14	56	182	312	1,675	264.8	338.0
April	169	4	14	100	267	1,632	223.3	315.1
May	169	12	42	133	274	1,611	255.9	334.7
June	173	3	42	106	211	1,583	240.1	352.7
July	263	1	28	77	218	1,549	182.3	271.9
August	289	5	28	118	224	1,522	199.7	269.4
September	270	5	28	98	196	1,486	195.9	300.0
October	318	1	28	85	238	1,459	210.1	307.8
November	306	5	21	56	216	1,429	195.9	316.0

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December	247	1	14	73	231	1,396	194.4	304.9
2019								
January	313	14	42	140	343	1,363	265.3	325.2
February	292	1	28	113	269	1,335	229.3	318.9
March	298	6	28	121	245	1,306	218.1	297.0
April	412	1	30	109	272	1,278	243.1	316.0
May	369	4	28	112	274	1,248	235.4	302.9
June	364	12	28	99	245	1,215	220.9	291.9
July	480	2	28	99	195	1,186	192.1	274.5
August	489	3	28	98	238	1,157	209.6	287.7
September	398	1	28	97	174	1,123	169.5	240.7
October	468	14	35	84	238	1,096	185.3	242.5
November	415	5	28	56	200	1,062	179.3	263.2
December	443	1	14	42	216	1,034	173.2	260.0
2020								
January	399	1	28	119	300	1,003	199.7	235.3
February	398	2	28	112	312	970	228.3	282.5
March	415	7	28	112	259	943	193.4	235.4
April	271	3	30	134	267	913	219.1	248.1
May	282	14	36	113	249	883	206.4	237.8
June	367	7	42	131	238	852	201.9	222.0
July	599	11	28	127	252	822	197.0	222.2
August	516	5	35	113	261	789	192.8	220.4
September	498	3	28	101	247	760	179.6	204.4
October	519	2	28	98	266	729	189.6	213.5
November	527	1	28	84	224	698	169.2	195.0
December	537	1	17	58	222	669	151.0	187.7
2021								
January	444	7	42	126	299	634	192.2	186.7
February	456	1	28	109	266	607	178.1	186.7
March	509	2	28	112	294	579	188.7	188.7

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	500	2	28	103	214	547	151.6	153.7
May	468	6	28	103	248	518	164.4	165.8
June	475	6	28	113	253	487	169.9	160.2
July	571	5	28	112	215	457	155.4	144.0
August	661	1	28	88	241	425	145.6	139.9
September	630	9	28	98	224	395	145.1	131.1
October	630	4	30	85	214	365	136.7	121.1
November	605	2	28	80	204	334	124.3	111.1
December	609	1	28	84	214	304	117.7	106.7
2022								
January	553	1	30	112	246	271	130.5	94.9
February	484	12	29	119	220	242	125.7	86.8
March	608	1	28	112	193	214	114.1	74.8
April	557	1	28	87	162	183	94.9	63.9
May	544	8	28	120	137	152	93.6	50.8
June	553	3	28	93	106	122	73.5	38.0
July	699	14	30	67	78	92	59.1	23.8
August	825	1	28	39	51	61	39.0	14.0
September	687	1	7	12	19	30	13.7	8.4
<i>Asthma</i>	<i>12,473</i>	<i>1</i>	<i>28</i>	<i>86</i>	<i>215</i>	<i>1,984</i>	<i>172.6</i>	<i>225.8</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	21	14	30	77	623	1,984	494.9	685.1
May	43	14	42	145	269	1,957	332.1	507.6
June	38	14	42	114	187	1,526	192.7	284.2
July	54	13	42	130	208	1,906	255.8	413.6
August	64	14	21	68	157	906	150.1	197.9
September	43	14	42	112	466	1,842	365.6	489.9
October	49	14	28	79	193	1,486	211.1	333.1

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	51	14	30	50	182	1,330	154.6	246.6
December	50	4	26	39	130	693	108.9	156.2
2018								
January	40	14	28	70	332	1,727	240.8	359.5
February	50	14	28	158	322	1,636	265.7	347.5
March	48	14	42	131	344	1,651	259.3	346.9
April	38	14	31	119	266	1,619	250.8	364.9
May	41	12	42	126	239	1,611	218.8	305.0
June	34	14	56	117	520	1,566	322.9	403.9
July	63	14	28	71	251	1,543	179.3	261.8
August	71	14	28	108	192	1,114	165.7	202.8
September	59	5	14	98	154	1,486	181.3	330.4
October	68	14	14	73	246	1,438	201.0	307.1
November	86	14	14	51	218	1,417	179.0	303.7
December	111	1	21	105	300	1,397	234.2	324.3
2019								
January	151	14	28	119	337	1,359	238.7	309.3
February	141	14	28	126	321	1,338	246.4	318.7
March	143	14	28	127	248	1,305	201.2	264.0
April	194	13	42	142	384	1,278	297.1	372.9
May	179	1	28	104	266	1,237	233.0	303.8
June	185	14	28	84	196	1,215	185.5	258.1
July	221	14	28	104	196	1,186	190.5	262.2
August	295	1	28	92	280	1,157	222.4	307.6
September	232	6	39	111	310	1,123	226.8	289.9
October	282	14	28	92	294	1,089	219.7	268.6
November	252	12	28	58	284	1,062	195.0	270.1
December	225	1	21	56	266	1,034	197.4	292.7
2020								
January	222	3	28	134	338	1,000	228.1	263.7
February	265	14	28	133	351	967	257.2	285.3

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	247	6	28	112	357	943	246.0	289.3
April	179	1	56	151	283	912	216.2	216.5
May	170	3	28	102	232	883	200.7	248.2
June	202	1	30	154	315	852	227.2	248.8
July	295	8	42	120	252	822	199.0	219.6
August	268	5	42	121	279	788	210.4	235.6
September	274	1	28	105	234	760	183.8	204.8
October	304	10	43	93	257	729	189.4	204.0
November	271	14	28	111	313	696	197.0	209.3
December	263	1	25	70	271	669	171.9	203.0
2021								
January	235	14	28	94	284	636	180.6	185.5
February	229	14	28	140	322	607	212.2	201.7
March	267	14	45	124	303	579	196.1	189.4
April	246	9	28	117	257	548	174.3	164.5
May	243	5	28	101	230	515	172.3	168.2
June	237	2	28	123	227	485	165.1	152.2
July	270	14	28	99	210	456	147.5	134.7
August	327	12	28	98	256	425	156.0	142.7
September	265	11	28	91	301	395	152.2	139.6
October	278	14	42	88	224	362	139.6	121.0
November	281	10	28	75	266	334	133.3	118.7
December	276	1	28	84	275	304	128.6	111.2
2022								
January	264	1	28	99	250	273	132.5	100.6
February	263	13	56	146	221	242	136.2	83.3
March	269	1	28	116	194	214	117.9	75.9
April	312	1	28	140	166	183	109.5	63.5
May	272	6	29	117	138	152	93.8	50.7
June	283	8	45	95	107	122	78.7	35.8
July	334	14	34	68	81	92	60.7	24.3

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	397	6	30	39	51	61	39.9	13.6
September	342	1	8	14	22	30	14.5	8.4
<i>Chronic</i>								
<i>Rhinosinusitis</i>	7,627	1	28	93	224	1,977	172.8	210.8
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	5	48	204	251	613	867	396.6	334.6
May	14	14	42	164	516	1,977	431.3	674.1
June	16	1	54	124	245	682	183.2	184.2
July	11	14	28	49	174	1,914	259.0	562.9
August	24	9	36	88	158	1,880	218.5	394.0
September	9	14	31	98	266	1,510	272.2	475.4
October	9	14	62	93	126	357	117.9	107.8
November	11	14	14	85	322	1,330	287.8	420.5
December	13	13	14	28	42	611	98.6	175.6
2018								
January	14	14	28	50	154	721	124.9	188.8
February	15	14	14	105	290	322	134.4	126.5
March	13	56	76	118	302	855	261.0	280.0
April	16	14	30	121	241	512	156.3	132.5
May	18	12	56	97	164	285	112.3	84.6
June	11	14	14	57	362	523	145.1	191.8
July	24	14	42	85	148	778	152.9	193.0
August	26	14	84	148	213	496	175.2	144.2
September	22	14	28	100	154	858	152.8	192.6
October	18	14	28	56	133	446	108.6	130.1
November	33	14	14	42	251	1,240	189.2	306.4
December	50	1	21	85	355	1,397	268.0	359.8
2019								

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	59	14	28	154	335	1,351	246.1	302.6
February	49	14	14	163	322	1,331	232.9	292.6
March	59	14	28	133	280	1,305	222.3	280.4
April	83	14	28	146	398	1,278	331.7	418.2
May	76	1	28	112	391	1,235	259.9	337.7
June	82	14	28	88	195	1,205	187.3	251.8
July	104	14	28	99	250	1,186	211.5	297.6
August	159	10	28	100	339	1,153	230.5	309.4
September	162	6	30	111	275	1,123	219.7	285.9
October	184	14	28	90	338	1,089	220.7	254.9
November	189	14	28	58	284	1,058	187.3	253.5
December	166	1	27	44	250	1,034	181.5	268.8
2020								
January	152	1	28	115	339	989	206.7	229.3
February	172	4	32	139	331	964	240.1	250.5
March	176	14	28	147	404	942	262.9	288.3
April	126	14	56	156	262	912	218.5	220.4
May	115	5	28	99	217	879	194.2	240.6
June	138	8	49	157	336	852	233.7	248.9
July	187	8	56	155	336	822	226.5	228.8
August	166	5	45	126	316	789	223.9	249.8
September	178	1	28	113	264	760	190.4	202.4
October	195	9	56	101	299	730	210.5	220.5
November	175	12	28	84	257	696	170.3	190.3
December	185	1	28	84	305	668	182.2	208.9
2021								
January	154	14	30	142	308	634	198.0	186.9
February	160	14	70	189	348	607	239.2	195.3
March	154	14	56	141	364	578	218.1	197.8
April	158	9	28	116	269	548	184.7	176.3
May	165	14	28	127	338	516	191.6	170.1

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	161	14	28	150	280	487	182.4	161.2
July	171	14	28	119	260	457	172.9	151.2
August	209	14	28	136	252	424	164.0	139.2
September	165	14	28	98	271	395	155.8	135.4
October	191	14	28	114	239	362	149.5	121.6
November	169	10	28	58	305	334	135.2	124.7
December	212	9	28	89	272	304	129.4	107.9
2022								
January	182	1	45	129	250	271	142.8	96.6
February	191	14	56	140	221	242	135.2	81.3
March	210	7	28	140	197	214	122.6	75.5
April	208	1	28	141	166	183	108.4	63.4
May	215	1	42	123	140	152	97.4	50.0
June	212	14	53	99	110	122	81.5	35.9
July	181	14	34	67	79	92	61.0	22.5
August	247	6	30	40	53	61	41.3	12.8
September	203	1	5	12	19	30	13.3	8.3
<i>Eosinophilic Esophagitis</i>	2,155	1	28	62	169	1,477	137.6	190.3
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	30	30	300	613	613	314.3	291.8
May	6	14	14	14	90	1,324	245.0	529.5
June	5	105	158	159	182	209	162.6	38.3
July	8	14	29	248	821	1,477	460.6	545.2
August	8	28	35	57	88	418	100.6	130.6
September	6	42	83	98	314	690	220.7	249.1
October	1	146	146	146	146	146	146.0	NaN
November	6	42	42	63	98	103	68.5	29.7

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December 2018	9	6	14	30	128	611	110.0	193.8
January	5	14	28	56	70	728	179.2	307.6
February	10	14	42	59	185	281	102.1	94.0
March	11	14	70	183	336	528	219.8	173.2
April	5	14	42	42	100	269	93.4	103.0
May	9	28	28	56	131	595	137.8	180.9
June	13	14	28	56	205	1,295	240.1	372.5
July	15	14	58	100	229	1,044	221.1	298.0
August	10	14	30	161	283	473	182.5	166.6
September	9	14	84	90	103	197	99.1	63.0
October	17	14	28	140	378	1,178	243.9	294.3
November	15	14	42	144	771	1,402	366.0	468.5
December 2019	22	5	14	38	203	843	181.0	250.3
January	18	14	28	111	344	1,342	261.4	382.1
February	16	14	28	179	566	1,331	380.5	461.2
March	23	14	28	59	222	1,254	182.3	286.6
April	24	14	21	47	157	1,268	157.3	278.1
May	24	14	86	147	223	1,248	207.7	249.8
June	20	14	14	59	162	938	140.5	222.7
July	35	14	28	63	164	1,186	156.1	243.7
August	40	14	28	84	157	757	132.4	158.5
September	32	6	36	87	177	788	163.8	196.3
October	40	14	28	85	273	1,067	202.6	266.1
November	38	14	28	84	407	1,058	284.9	363.5
December 2020	34	13	28	58	259	665	143.1	166.8
January	36	14	28	84	417	977	229.3	271.9
February	48	14	28	68	226	950	171.3	225.6
March	41	14	28	99	196	943	179.0	227.1

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	19	14	56	157	254	638	200.4	197.2
May	21	14	28	87	269	878	205.9	253.3
June	29	13	28	84	185	841	124.7	158.4
July	30	14	30	112	287	801	198.2	210.7
August	29	14	84	151	364	786	252.3	235.4
September	25	14	38	84	130	751	140.2	194.3
October	25	14	28	89	233	560	151.6	146.0
November	42	14	28	57	185	696	160.6	203.4
December	45	3	14	31	171	619	119.1	152.3
2021								
January	47	14	28	84	251	634	166.3	183.9
February	30	14	65	166	402	603	238.4	208.9
March	36	14	56	102	253	569	166.2	157.3
April	30	14	28	84	196	449	117.9	108.1
May	44	14	28	88	169	506	120.8	111.1
June	37	14	28	86	192	485	138.6	143.3
July	41	14	28	91	205	442	129.9	121.3
August	46	14	28	95	172	415	132.6	124.1
September	38	14	28	59	228	383	136.1	136.1
October	53	14	56	177	338	362	179.5	130.5
November	63	14	28	84	210	333	125.1	109.6
December	62	9	28	84	276	296	129.6	111.9
2022								
January	47	14	28	112	254	270	136.1	101.6
February	36	14	48	116	220	241	123.1	82.2
March	51	14	28	98	193	213	111.7	76.9
April	51	14	28	143	166	180	107.9	61.9
May	51	1	28	84	135	150	82.4	50.2
June	62	14	28	95	109	122	79.7	35.6
July	93	14	51	66	78	92	61.0	22.3
August	164	14	31	44	53	61	41.8	12.2

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	146	1	5	11	22	30	13.0	8.8
<i>Prurigo Nodularis</i>	767	1	28	86	218	1,754	164.1	214.8
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	42	42	59	855	855	318.7	464.6
May	2	43	43	44	45	45	44.0	1.4
June	3	14	14	185	218	218	139.0	109.5
July	5	14	14	30	503	686	249.4	321.7
August	6	14	45	98	243	309	134.5	116.1
September	2	28	28	46	64	64	46.0	25.5
October	5	14	31	69	267	378	151.8	161.9
November	4	14	22	36	595	1,148	308.3	559.9
December	3	24	24	131	1,754	1,754	636.3	969.4
2018								
January	4	14	14	103	399	606	206.5	279.2
February	7	14	42	146	241	1,038	253.0	354.3
March	2	98	98	887	1,675	1,675	886.5	1,115.1
April	6	14	14	32	113	393	99.5	148.5
May	5	14	28	42	84	133	60.2	48.4
June	4	14	29	260	547	618	287.8	305.1
July	3	89	89	168	1,252	1,252	503.0	649.9
August	5	14	56	270	699	714	350.6	339.1
September	7	14	28	126	143	497	147.9	162.0
October	6	14	14	86	134	266	100.0	94.8
November	12	14	14	34	250	398	124.1	151.9
December	4	111	113	141	283	398	197.8	136.0
2019								
January	5	14	28	28	83	178	66.2	67.9
February	9	14	126	131	194	675	200.7	199.4

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	10	14	14	49	103	302	83.7	94.6
April	10	14	14	63	162	472	118.3	149.1
May	12	14	14	197	397	602	231.2	228.5
June	13	14	84	203	378	1,199	350.4	399.8
July	14	14	14	35	131	420	89.6	114.2
August	11	28	28	374	747	1,131	448.9	426.5
September	14	14	42	92	294	1,123	274.4	377.6
October	14	28	71	135	267	1,090	272.4	331.5
November	14	1	15	92	169	626	159.6	205.4
December	14	14	14	39	252	619	158.5	193.3
2020								
January	19	14	42	126	252	983	187.1	222.1
February	10	14	28	77	218	946	190.6	290.0
March	9	14	14	28	267	385	122.2	148.7
April	3	14	14	14	434	434	154.0	242.5
May	7	14	33	44	210	357	114.0	125.9
June	6	14	56	133	240	417	165.5	147.2
July	14	14	28	127	280	808	215.4	268.1
August	16	14	49	111	289	535	181.4	174.5
September	11	14	48	252	350	740	254.3	208.0
October	11	14	28	87	308	406	154.6	143.2
November	29	14	42	140	294	682	191.3	188.5
December	12	11	17	182	274	454	175.6	152.6
2021								
January	13	14	56	126	476	623	255.2	243.3
February	13	14	14	98	126	490	112.0	125.3
March	20	14	49	130	317	576	203.0	207.4
April	9	14	28	56	252	536	141.4	178.1
May	13	14	42	147	253	508	198.8	184.6
June	18	14	84	168	465	485	230.1	185.6
July	17	10	56	158	294	457	181.2	162.0

Table 5d. Continuous Summary of First Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	14	14	14	56	91	423	76.1	105.5
September	22	14	56	104	362	393	191.9	151.0
October	9	14	42	82	201	362	130.8	113.7
November	17	14	28	45	115	305	83.7	88.3
December	20	3	14	170	293	303	160.4	131.2
2022								
January	25	14	56	148	254	261	147.6	96.6
February	23	14	28	146	221	240	138.7	88.0
March	14	28	87	137	199	214	139.4	62.5
April	17	6	56	88	157	177	99.2	61.7
May	21	1	60	129	145	151	105.4	51.7
June	24	14	28	93	103	120	72.8	37.3
July	21	14	35	65	78	92	56.1	26.5
August	27	14	16	38	51	60	36.3	16.3
September	25	2	10	17	24	30	17.1	8.6

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6a. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	124,254	1	28	28	84	1,886	79.2	114.8
<i>Any Indication</i>	115,728	1	28	28	84	1,886	78.9	114.7
<i>Atopic Dermatitis</i>	92,468	1	28	28	84	1,886	78.2	115.6
<i>Asthma</i>	42,825	1	28	28	84	1,820	78.4	112.5
<i>Chronic Rhinosinusitis</i>	23,261	1	28	28	84	1,796	78.7	110.3
<i>Eosinophilic Esophagitis</i>	6,807	1	28	28	84	1,584	72.9	106.1
<i>Prurigo Nodularis</i>	2,445	1	28	30	84	1,486	82.9	113.5
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	61,363	1	28	58	140	1,920	112.8	148.3
<i>Any Indication</i>	56,801	1	28	58	140	1,920	112.5	148.0
<i>Atopic Dermatitis</i>	45,816	1	28	57	128	1,920	110.5	147.2
<i>Asthma</i>	20,552	1	28	57	139	1,833	112.0	146.7
<i>Chronic Rhinosinusitis</i>	10,769	1	28	59	140	1,732	113.9	147.0
<i>Eosinophilic Esophagitis</i>	3,114	1	28	56	116	1,801	102.4	134.6
<i>Prurigo Nodularis</i>	1,111	1	28	62	146	1,387	122.7	149.1

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	124,254	1	28	28	84	1,886	79.2	114.8
Female	69,246	1	28	28	84	1,886	78.8	114.3
Male	55,008	1	28	28	84	1,852	79.6	115.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	115,728	1	28	28	84	1,886	78.9	114.7
Female	64,576	1	28	28	84	1,886	78.7	114.1
Male	51,152	1	28	28	84	1,852	79.3	115.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	92,468	1	28	28	84	1,886	78.2	115.6
Female	51,288	1	28	28	84	1,886	77.8	114.4
Male	41,180	1	28	28	84	1,852	78.7	117.1
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	42,825	1	28	28	84	1,820	78.4	112.5
Female	24,564	1	28	28	84	1,712	79.0	114.2
Male	18,261	1	28	28	84	1,820	77.6	110.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	23,261	1	28	28	84	1,796	78.7	110.3
Female	13,021	1	28	28	84	1,653	78.5	111.2
Male	10,240	1	28	28	84	1,796	79.0	109.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	6,807	1	28	28	84	1,584	72.9	106.1
Female	3,969	1	28	28	84	1,428	73.2	105.1
Male	2,838	1	28	28	84	1,584	72.5	107.4
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	2,445	1	28	30	84	1,486	82.9	113.5
Female	1,486	1	28	40	84	1,180	81.9	110.3
Male	959	1	28	28	84	1,486	84.5	118.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	61,363	1	28	58	140	1,920	112.8	148.3

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	34,478	1	28	58	138	1,900	111.8	146.0
Male	26,885	1	28	58	140	1,920	114.1	151.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	56,801	1	28	58	140	1,920	112.5	148.0
Female	31,976	1	28	58	137	1,833	111.7	145.7
Male	24,825	1	28	58	140	1,920	113.5	150.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	45,816	1	28	57	128	1,920	110.5	147.2
Female	25,671	1	28	57	126	1,833	109.6	144.0
Male	20,145	1	28	57	129	1,920	111.7	151.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	20,552	1	28	57	139	1,833	112.0	146.7
Female	11,918	1	28	57	135	1,833	112.0	147.1
Male	8,634	1	28	57	140	1,820	112.0	146.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	10,769	1	28	59	140	1,732	113.9	147.0
Female	6,073	1	28	58	138	1,732	113.4	148.5
Male	4,696	1	28	60	141	1,663	114.6	145.1
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	3,114	1	28	56	116	1,801	102.4	134.6
Female	1,841	1	28	56	113	1,174	100.0	131.5
Male	1,273	1	28	56	134	1,801	105.9	139.0
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	1,111	1	28	62	146	1,387	122.7	149.1
Female	676	1	28	63	146	1,387	122.5	149.6
Male	435	3	28	58	144	842	122.9	148.4
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6c. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	124,254	1	28	28	84	1,886	79.2	114.8
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	383	1	28	30	56	675	47.9	66.6
6-11 years	4,246	1	28	30	62	1,033	67.5	85.7
12-17 years	13,103	1	28	28	84	1,313	74.8	103.2
18-79 years	105,794	1	28	28	84	1,886	80.3	117.4
≥ 80 years	728	1	28	56	84	753	79.2	91.3
<i>Any Indication</i>	115,728	1	28	28	84	1,886	78.9	114.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	366	1	28	30	56	675	47.0	64.9
6-11 years	4,110	1	28	30	62	1,033	67.7	86.1
12-17 years	12,486	1	28	28	84	1,313	75.0	103.6
18-79 years	98,150	1	28	28	84	1,886	80.0	117.2
≥ 80 years	616	2	28	54	84	753	79.2	91.9
<i>Atopic Dermatitis</i>	92,468	1	28	28	84	1,886	78.2	115.6
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	358	1	28	30	56	675	45.9	63.3
6-11 years	3,971	1	28	30	62	1,033	68.2	86.9
12-17 years	11,595	1	28	28	84	1,313	75.3	104.1
18-79 years	76,059	1	28	28	84	1,886	79.4	118.8
≥ 80 years	485	2	28	56	84	753	80.5	90.4
<i>Asthma</i>	42,825	1	28	28	84	1,820	78.4	112.5
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	69	3	28	30	36	476	45.6	61.8
6-11 years	1,579	1	28	30	60	952	65.4	81.9
12-17 years	4,931	1	28	28	84	1,160	73.8	103.9
18-79 years	36,095	1	28	28	84	1,820	79.7	114.9
≥ 80 years	151	2	28	56	88	618	77.0	91.1
<i>Chronic Rhinosinusitis</i>	23,261	1	28	28	84	1,796	78.7	110.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6c. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
6-71 months	21	8	28	30	38	476	54.9	98.7
6-11 years	203	3	28	30	56	711	64.2	97.1
12-17 years	1,079	1	28	28	84	1,120	69.4	98.5
18-79 years	21,847	1	28	28	84	1,796	79.4	111.1
≥ 80 years	111	3	28	28	84	364	67.2	73.7
<i>Eosinophilic Esophagitis</i>	6,807	1	28	28	84	1,584	72.9	106.1
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	17	4	28	40	140	476	103.0	133.2
6-11 years	211	1	28	30	56	728	56.1	79.2
12-17 years	535	2	28	28	84	1,160	80.5	120.7
18-79 years	5,983	1	28	28	84	1,584	72.7	105.5
≥ 80 years	61	2	28	28	70	497	72.1	93.3
<i>Prurigo Nodularis</i>	2,445	1	28	30	84	1,486	82.9	113.5
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-11 years	7	28	28	84	223	369	131.7	123.8
12-17 years	110	9	28	33	84	952	82.1	114.2
18-79 years	2,273	1	28	28	84	1,486	83.2	114.0
≥ 80 years	55	9	28	30	84	537	68.8	85.8
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	61,363	1	28	58	140	1,920	112.8	148.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	263	1	28	30	34	647	52.3	77.4
6-11 years	2,516	1	28	34	90	1,548	85.7	111.8
12-17 years	6,657	1	28	57	123	1,269	107.4	135.5
18-79 years	51,594	1	28	59	140	1,920	115.1	151.7
≥ 80 years	333	1	28	60	141	981	111.9	124.8
<i>Any Indication</i>	56,801	1	28	58	140	1,920	112.5	148.0
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	255	1	28	30	31	647	51.5	77.5
6-11 years	2,438	1	28	34	90	1,548	85.7	111.7

Table 6c. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
12-17 years	6,300	1	28	57	124	1,269	107.8	136.4
18-79 years	47,524	1	28	59	140	1,920	114.8	151.3
≥ 80 years	284	2	28	60	140	753	109.4	118.3
<i>Atopic Dermatitis</i>	<i>45,816</i>	<i>1</i>	<i>28</i>	<i>57</i>	<i>128</i>	<i>1,920</i>	<i>110.5</i>	<i>147.2</i>
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	250	1	28	30	31	647	48.4	72.2
6-11 years	2,361	1	28	34	90	1,548	86.1	112.6
12-17 years	5,836	1	28	57	124	1,269	107.7	136.3
18-79 years	37,154	1	28	58	136	1,920	112.9	151.1
≥ 80 years	215	8	28	61	142	753	113.7	118.8
<i>Asthma</i>	<i>20,552</i>	<i>1</i>	<i>28</i>	<i>57</i>	<i>139</i>	<i>1,833</i>	<i>112.0</i>	<i>146.7</i>
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	42	5	28	30	61	403	52.2	71.9
6-11 years	928	1	28	38	91	1,548	86.2	117.2
12-17 years	2,436	1	28	56	119	1,269	105.9	138.6
18-79 years	17,077	1	28	58	140	1,833	114.5	149.4
≥ 80 years	69	2	28	57	116	606	92.8	97.9
<i>Chronic Rhinosinusitis</i>	<i>10,769</i>	<i>1</i>	<i>28</i>	<i>59</i>	<i>140</i>	<i>1,732</i>	<i>113.9</i>	<i>147.0</i>
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	10	8	9	30	38	121	37.4	34.5
6-11 years	126	3	28	32	73	561	70.5	92.0
12-17 years	578	2	28	56	112	1,269	98.0	136.0
18-79 years	10,004	1	28	60	140	1,732	115.5	148.2
≥ 80 years	51	5	28	60	141	534	107.9	114.4
<i>Eosinophilic Esophagitis</i>	<i>3,114</i>	<i>1</i>	<i>28</i>	<i>56</i>	<i>116</i>	<i>1,801</i>	<i>102.4</i>	<i>134.6</i>
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	7	4	8	117	149	336	114.1	115.0
6-11 years	123	1	28	31	63	764	63.4	92.8
12-17 years	271	3	28	56	115	1,088	104.4	140.2
18-79 years	2,694	1	28	56	119	1,801	104.2	135.8
≥ 80 years	19	9	28	56	109	221	70.3	58.2

Table 6c. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Prurigo Nodularis</i>	1,111	1	28	62	146	1,387	122.7	149.1
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-11 years	2	74	74	95	115	115	94.5	29.0
12-17 years	44	9	28	84	144	397	120.1	113.3
18-79 years	1,035	1	28	62	148	1,387	124.8	152.1
≥ 80 years	30	9	28	30	88	176	55.3	42.6

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	124,254	1	28	28	84	1,886	79.2	114.8
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	17	28	28	28	28	140	41.1	33.0
April	613	1	28	56	112	1,820	103.2	160.3
May	1,531	1	28	56	84	1,852	101.4	174.4
June	1,582	1	28	28	84	1,758	90.0	155.7
July	1,583	1	28	30	84	1,886	89.8	157.7
August	1,754	2	28	28	84	1,568	86.9	141.0
September	1,361	2	28	30	84	1,736	93.2	150.5
October	1,622	1	28	28	84	1,683	84.9	150.3
November	1,504	1	28	28	84	1,597	86.8	136.7
December	1,014	3	28	28	84	1,663	91.4	151.3
2018								
January	1,024	1	28	28	84	1,632	87.2	132.9
February	1,188	1	28	28	84	1,676	91.3	155.3
March	1,456	2	28	56	84	1,633	96.2	156.8
April	1,252	1	28	28	84	1,372	84.3	129.9
May	1,202	1	28	28	84	1,397	86.5	142.7
June	1,071	1	28	28	84	1,526	89.1	147.9
July	1,875	1	28	28	84	1,299	77.7	118.5
August	1,909	1	28	28	84	1,459	81.7	134.6
September	1,405	1	28	28	84	1,446	88.7	149.7
October	1,792	1	28	30	84	1,313	88.0	127.9
November	1,759	1	28	28	84	1,404	89.4	144.9
December	1,440	1	28	40	84	1,328	97.2	147.4
2019								
January	2,022	1	28	28	84	1,335	93.4	140.5
February	2,258	1	28	28	84	1,313	84.0	131.5

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	2,180	1	28	28	84	1,150	83.6	125.2
April	2,748	1	28	28	84	1,230	89.3	138.1
May	2,636	1	28	28	84	1,216	80.5	123.4
June	2,282	1	28	28	84	1,176	88.7	128.2
July	3,324	1	28	28	84	1,163	79.2	116.2
August	3,280	1	28	28	84	1,130	87.1	135.7
September	2,599	1	28	28	84	1,103	83.7	123.8
October	3,188	1	28	28	84	1,074	81.6	112.7
November	2,878	1	28	28	84	1,044	83.6	112.6
December	2,648	1	28	28	84	1,005	88.1	124.8
2020								
January	2,586	1	28	28	84	984	82.0	112.7
February	2,369	1	28	30	84	946	88.9	124.9
March	2,521	1	28	28	84	911	76.5	102.2
April	1,796	1	28	28	84	892	79.9	108.4
May	1,674	1	28	28	84	845	79.6	107.9
June	2,089	1	28	28	84	823	77.6	103.4
July	4,143	1	28	28	84	792	72.9	98.3
August	3,077	1	28	28	84	774	71.7	92.3
September	3,078	1	28	28	84	729	74.2	93.3
October	2,680	1	28	28	84	708	76.4	100.0
November	2,421	1	28	29	84	679	75.8	92.5
December	2,342	1	28	30	84	649	78.1	92.4
2021								
January	2,225	1	28	28	84	619	74.2	87.8
February	2,080	1	28	28	84	590	79.0	95.3
March	2,282	1	28	30	84	563	78.6	93.5
April	2,114	1	28	28	84	526	74.5	82.7
May	1,863	1	28	28	84	500	72.7	81.6
June	1,745	1	28	30	84	464	75.2	79.5
July	2,679	1	28	28	80	436	65.6	71.6

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	2,604	1	28	28	84	403	68.6	72.1
September	1,820	1	28	28	84	373	70.2	72.5
October	1,932	1	28	28	84	345	65.7	64.6
November	1,655	1	28	28	84	319	60.4	59.6
December	1,389	1	28	30	84	285	67.1	62.1
2022								
January	1,273	1	28	28	84	254	61.7	54.0
February	1,027	1	28	28	79	227	57.4	48.5
March	1,146	1	28	28	66	198	53.1	42.8
April	984	1	28	28	73	168	51.9	39.1
May	819	1	28	28	56	136	45.4	31.4
June	704	1	25	28	54	103	36.6	22.5
July	660	1	18	28	39	73	29.1	16.3
August	446	1	8	17	25	45	16.9	10.7
September	34	1	3	5	9	16	5.7	3.9
<i>Any Indication</i>	<i>115,728</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>84</i>	<i>1,886</i>	<i>78.9</i>	<i>114.7</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	17	28	28	28	28	140	41.1	33.0
April	556	1	28	56	112	1,820	106.1	165.6
May	1,254	1	28	56	84	1,852	102.2	176.3
June	1,381	1	28	28	84	1,758	87.8	153.8
July	1,493	1	28	28	84	1,886	88.6	157.1
August	1,641	2	28	28	84	1,568	88.5	142.8
September	1,295	2	28	28	84	1,736	91.1	150.1
October	1,443	1	28	28	84	1,683	87.4	154.9
November	1,346	1	28	28	84	1,597	84.2	136.8
December	907	3	28	28	84	1,663	91.5	153.7
2018								
January	1,043	2	28	28	84	969	81.9	115.4

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
February	1,051	1	28	28	84	1,676	91.9	158.3
March	1,230	2	28	56	112	1,633	102.5	166.5
April	1,182	1	28	28	84	1,372	83.6	126.8
May	1,064	1	28	30	84	1,397	88.3	144.3
June	954	1	28	28	84	1,526	89.1	149.4
July	1,751	1	28	28	84	1,299	77.9	118.9
August	1,732	1	28	28	84	1,459	80.7	133.8
September	1,339	1	28	28	84	1,446	85.9	148.7
October	1,743	1	28	28	84	1,313	85.7	128.8
November	1,641	1	28	28	84	1,404	88.8	141.8
December	1,346	1	28	40	86	1,328	96.5	144.6
2019								
January	1,918	1	28	28	84	1,335	92.3	142.2
February	2,121	1	28	28	84	1,313	84.2	134.5
March	2,104	1	28	28	84	1,150	82.4	123.0
April	2,563	1	28	28	84	1,230	89.9	139.9
May	2,525	1	28	28	84	1,216	81.3	124.9
June	2,067	1	28	30	84	1,176	89.8	129.5
July	3,083	1	28	28	84	1,163	79.7	116.8
August	3,166	1	28	28	84	1,130	87.0	135.6
September	2,508	1	28	28	84	1,103	84.2	125.0
October	3,013	1	28	28	84	1,074	80.6	110.6
November	2,729	1	28	28	84	1,044	83.0	112.5
December	2,514	1	28	28	84	1,005	86.0	122.7
2020								
January	2,491	1	28	28	84	984	81.7	112.3
February	2,215	1	28	30	84	946	90.2	127.0
March	2,341	1	28	28	84	911	75.6	100.0
April	1,740	1	28	28	84	892	79.6	108.1
May	1,562	1	28	28	84	845	80.1	105.7
June	2,040	1	28	28	84	821	74.6	98.9

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	3,651	1	28	28	84	792	75.0	100.7
August	2,727	1	28	28	84	774	72.1	92.4
September	2,831	1	28	28	84	729	74.7	95.3
October	2,514	1	28	28	84	708	74.5	98.1
November	2,247	1	28	28	84	669	75.6	92.5
December	2,080	1	28	30	84	649	78.5	92.3
2021								
January	2,101	1	28	28	84	619	74.3	87.9
February	2,056	1	28	28	84	590	77.0	93.2
March	2,158	1	28	30	84	563	78.1	92.4
April	2,032	1	28	28	84	526	72.7	80.9
May	1,849	1	28	28	84	500	70.8	79.3
June	1,693	1	28	30	84	464	72.1	76.7
July	2,244	1	28	28	84	436	67.7	73.6
August	2,357	1	28	28	84	403	68.7	72.1
September	1,723	1	28	28	84	373	71.2	74.1
October	1,768	1	28	28	84	345	65.6	65.0
November	1,511	1	28	28	84	319	60.8	59.6
December	1,371	1	28	30	84	283	66.0	61.6
2022								
January	1,202	1	28	28	84	254	60.5	52.6
February	984	1	28	28	78	227	56.7	48.0
March	1,106	1	28	28	64	198	52.5	42.0
April	943	1	28	28	78	168	52.1	39.1
May	769	1	28	28	56	136	45.3	31.3
June	673	1	25	28	52	103	35.9	21.6
July	589	1	18	28	40	73	29.4	16.6
August	407	1	8	17	25	45	16.9	10.8
September	33	1	3	5	9	16	5.8	3.9
<i>Atopic Dermatitis</i>	<i>92,468</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>84</i>	<i>1,886</i>	<i>78.2</i>	<i>115.6</i>
2017								

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	17	28	28	28	28	140	41.1	33.0
April	536	1	28	56	112	1,820	106.0	165.7
May	1,243	1	28	56	84	1,852	101.2	175.9
June	1,383	1	28	28	84	1,758	88.0	154.0
July	1,404	1	28	28	84	1,886	88.6	152.2
August	1,531	2	28	28	84	1,568	87.9	140.9
September	1,276	2	28	28	84	1,736	89.8	147.6
October	1,417	1	28	28	84	1,683	88.1	160.6
November	1,335	1	28	28	84	1,597	83.8	136.7
December	892	3	28	28	84	1,663	90.2	151.7
2018								
January	1,037	2	28	28	84	1,362	85.0	126.1
February	1,028	1	28	28	84	1,676	92.4	159.7
March	1,191	2	28	56	112	1,633	102.8	168.0
April	1,077	1	28	28	84	1,372	86.1	131.8
May	1,009	1	28	45	84	1,397	89.8	146.4
June	940	1	28	28	84	1,526	89.4	148.7
July	1,717	1	28	28	84	1,299	78.1	119.5
August	1,669	1	28	28	84	1,459	81.9	135.8
September	1,300	1	28	28	84	1,446	87.3	150.7
October	1,696	1	28	28	84	1,313	85.2	128.6
November	1,498	2	28	28	84	1,404	86.3	134.1
December	1,125	1	28	30	84	1,328	96.3	148.4
2019								
January	1,596	1	28	28	84	1,331	89.5	139.5
February	1,676	1	28	28	84	1,313	83.9	138.2
March	1,609	1	28	28	84	1,150	82.1	126.8
April	2,103	1	28	28	84	1,221	87.7	135.5
May	2,125	1	28	28	84	1,216	77.4	119.9

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	1,749	2	28	28	84	1,176	84.6	122.1
July	2,478	1	28	28	84	1,163	80.3	119.9
August	2,405	1	28	28	84	1,130	82.7	128.0
September	1,783	1	28	28	84	1,089	82.3	120.0
October	2,103	1	28	28	84	1,074	78.9	108.8
November	1,889	1	28	28	84	1,044	80.1	109.8
December	1,844	1	28	28	84	1,005	80.9	113.7
2020								
January	1,948	1	28	28	84	984	74.7	102.3
February	1,522	1	28	28	84	942	86.5	123.5
March	1,561	1	28	28	84	911	73.4	96.7
April	1,078	1	28	28	84	892	78.5	112.7
May	1,071	1	28	28	84	845	80.0	105.0
June	1,428	1	28	28	84	795	75.4	98.7
July	2,737	1	28	28	84	792	71.9	96.4
August	2,001	1	28	28	84	774	69.8	88.3
September	2,086	1	28	28	84	729	71.2	90.1
October	1,803	1	28	28	84	708	72.9	94.5
November	1,660	1	28	30	84	669	74.8	90.8
December	1,548	1	28	30	84	649	78.3	92.8
2021								
January	1,521	1	28	28	84	604	77.2	90.0
February	1,519	1	28	28	84	590	73.8	87.6
March	1,588	1	28	28	84	557	78.0	93.0
April	1,558	1	28	28	84	513	69.8	76.4
May	1,356	1	28	30	84	500	69.5	75.1
June	1,292	1	28	30	84	464	70.5	73.8
July	1,779	1	28	28	84	436	66.7	72.7
August	1,790	1	28	28	84	400	66.6	69.7
September	1,366	1	28	28	84	373	69.3	74.2
October	1,295	1	28	29	84	345	66.2	66.4

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	1,152	1	28	28	69	309	59.7	59.4
December	1,051	1	28	30	84	283	64.4	59.9
2022								
January	966	1	28	28	66	254	58.6	51.7
February	743	1	28	28	81	227	57.2	48.7
March	830	1	28	28	67	198	53.5	42.0
April	734	1	28	28	70	168	51.5	38.5
May	579	1	28	28	56	136	44.5	30.9
June	475	1	28	28	53	103	36.4	21.7
July	436	1	18	28	43	73	29.7	17.1
August	290	1	8	17	25	44	17.4	11.1
September	24	1	3	5	9	13	5.2	3.5
<i>Asthma</i>	42,825	1	28	28	84	1,820	78.4	112.5
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	17	28	28	28	28	140	41.1	33.0
April	142	2	28	45	92	1,820	101.2	181.4
May	318	4	28	28	84	1,712	102.8	200.1
June	273	6	28	28	84	1,360	87.4	167.6
July	371	5	28	28	84	1,559	85.5	156.7
August	444	1	28	30	84	1,362	81.5	118.4
September	315	3	28	28	84	986	100.7	163.3
October	403	4	28	28	84	1,338	83.4	125.6
November	270	4	28	28	84	1,597	87.3	145.3
December	311	5	28	28	84	1,080	75.9	110.7
2018								
January	284	2	28	49	84	1,179	96.1	147.6
February	281	2	28	30	108	1,663	98.7	190.8
March	320	5	28	56	112	1,633	106.5	167.0
April	324	3	28	55	84	840	84.7	110.7

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	407	1	28	28	84	1,397	77.5	127.5
June	178	1	28	56	112	1,276	113.0	171.0
July	470	3	28	28	84	1,092	67.6	95.4
August	463	5	28	28	72	1,366	77.4	131.4
September	308	1	28	28	84	1,397	82.8	134.7
October	380	5	28	28	84	1,288	88.8	145.5
November	548	1	28	28	84	1,216	79.4	136.0
December	558	1	28	32	84	1,328	94.4	144.7
2019								
January	903	2	28	34	84	1,335	94.1	139.6
February	835	1	28	28	84	1,199	81.6	130.7
March	874	1	28	28	84	1,008	76.0	105.2
April	1,095	1	28	28	84	1,230	92.1	149.9
May	995	1	28	28	84	1,216	81.5	123.6
June	756	1	28	56	94	1,174	96.9	137.0
July	1,151	1	28	28	84	1,092	77.2	108.1
August	1,366	1	28	28	84	1,123	90.2	141.7
September	1,024	2	28	28	84	1,082	85.5	121.7
October	1,369	1	28	28	84	1,010	83.0	110.9
November	1,219	1	28	28	84	1,041	84.2	116.0
December	847	2	28	28	84	998	92.7	139.1
2020								
January	920	1	28	28	84	956	91.0	126.9
February	1,008	2	28	30	98	946	93.1	130.9
March	1,107	1	28	28	84	857	78.9	107.9
April	867	1	28	28	84	812	73.6	92.8
May	676	2	28	28	84	784	76.2	100.0
June	909	1	28	28	84	821	71.9	95.5
July	1,368	1	28	28	84	792	77.6	104.1
August	1,138	1	28	28	71	732	69.8	90.7
September	1,172	1	28	28	84	710	73.9	95.3

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
October	1,023	1	28	28	84	699	75.2	97.0
November	904	2	28	28	84	669	74.5	90.7
December	816	1	28	28	84	588	72.8	86.2
2021								
January	924	1	28	28	84	619	67.0	79.8
February	763	1	28	30	84	590	81.1	97.9
March	868	1	28	30	84	563	75.2	85.7
April	792	1	28	30	84	526	73.2	83.8
May	782	1	28	28	84	491	70.1	79.9
June	652	2	28	28	84	451	68.9	73.5
July	773	1	28	28	84	416	68.3	73.4
August	886	1	28	29	84	403	68.7	71.9
September	578	1	28	30	84	373	74.4	76.4
October	660	1	28	28	84	345	62.4	62.1
November	529	1	28	30	84	319	65.2	62.1
December	480	1	28	30	84	280	66.1	61.5
2022								
January	431	1	28	30	84	249	63.6	55.1
February	388	2	28	28	60	220	55.1	46.3
March	349	2	28	28	57	191	50.4	41.5
April	341	1	28	28	68	166	49.5	38.2
May	286	1	28	28	56	128	44.4	30.5
June	235	1	23	28	44	100	33.9	22.3
July	225	1	17	28	35	68	28.3	16.3
August	143	1	5	16	24	45	15.9	10.6
September	13	1	2	4	8	12	5.3	3.6
<i>Chronic Rhinosinusitis</i>	<i>23,261</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>84</i>	<i>1,796</i>	<i>78.7</i>	<i>110.3</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	52	14	28	51	112	539	93.7	110.3
May	91	4	28	56	84	672	86.7	110.3
June	124	6	28	28	84	588	81.8	106.6
July	63	14	28	30	56	1,796	73.1	223.4
August	160	2	28	28	73	1,362	82.6	149.2
September	68	10	28	56	154	986	117.3	162.7
October	73	14	28	28	84	448	70.6	86.2
November	61	3	28	56	112	1,092	111.1	177.5
December	49	14	28	28	91	989	124.7	198.5
2018								
January	124	3	28	28	56	545	67.3	92.1
February	95	14	28	28	84	1,663	118.9	265.8
March	106	12	28	56	103	775	105.8	148.5
April	139	14	28	28	56	392	57.6	57.1
May	123	9	28	28	56	1,386	65.4	136.2
June	52	28	28	28	83	932	90.5	153.3
July	142	3	28	28	84	532	76.3	88.3
August	169	2	28	28	84	1,275	89.7	162.2
September	118	15	28	56	84	1,372	88.6	145.6
October	103	3	28	56	140	1,120	117.5	165.9
November	192	3	28	28	84	1,216	86.9	157.9
December	224	3	28	56	125	1,316	113.2	159.9
2019								
January	270	2	28	56	112	1,335	111.1	157.7
February	360	2	28	28	84	1,033	85.8	132.3
March	320	3	28	41	84	840	79.5	105.4
April	500	1	28	28	84	1,230	91.6	143.9
May	362	3	28	28	84	1,208	89.6	135.3
June	324	9	28	56	112	1,174	112.1	164.4
July	555	1	28	28	84	1,107	80.7	123.7
August	738	1	28	28	84	1,122	92.5	143.8

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	751	3	28	28	84	1,039	79.3	122.7
October	739	1	28	30	84	960	86.5	111.3
November	791	3	28	28	84	1,041	90.0	123.2
December	699	2	28	28	84	962	90.1	133.3
2020								
January	631	1	28	56	112	956	94.5	126.0
February	640	1	28	28	84	946	87.5	121.3
March	692	1	28	28	84	857	77.4	105.6
April	564	1	28	46	84	812	80.0	95.8
May	419	2	28	28	84	828	83.4	117.5
June	615	1	28	28	84	821	73.9	103.2
July	774	1	28	28	84	760	81.4	109.5
August	683	1	28	28	83	752	70.6	91.8
September	584	1	28	28	84	710	84.1	108.1
October	567	1	28	28	84	683	73.1	93.5
November	538	1	28	28	84	654	77.7	94.0
December	544	1	28	32	84	572	76.3	85.5
2021								
January	594	1	28	28	58	589	63.7	74.7
February	565	1	28	28	84	582	81.6	97.2
March	486	2	28	30	84	544	77.1	88.7
April	486	1	28	28	84	526	73.1	86.3
May	519	2	28	28	84	478	66.8	74.6
June	437	2	28	28	84	451	71.4	80.2
July	505	1	28	28	84	416	68.8	78.6
August	485	1	28	28	84	403	72.3	76.3
September	413	1	28	30	84	362	69.3	66.7
October	477	1	28	28	84	339	63.6	63.5
November	347	1	28	28	84	309	60.9	60.0
December	343	3	28	30	84	268	64.3	56.4
2022								

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	300	1	28	43	84	233	63.6	52.3
February	248	3	28	28	65	220	54.9	45.8
March	269	2	28	28	56	186	49.4	41.0
April	234	1	28	28	56	159	48.7	37.5
May	207	2	28	28	56	128	43.2	29.5
June	165	1	22	28	50	92	34.5	21.9
July	104	1	20	28	32	68	27.6	14.6
August	81	1	9	17	24	45	17.0	10.4
September	8	1	2	4	10	16	5.8	5.5
<i>Eosinophilic Esophagitis</i>	<i>6,807</i>	<i>1</i>	<i>28</i>	<i>28</i>	<i>84</i>	<i>1,584</i>	<i>72.9</i>	<i>106.1</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	13	28	46	112	336	616	223.8	216.9
May	12	5	28	42	84	1,161	140.8	322.8
June	10	6	28	28	87	142	54.3	50.1
July	56	9	28	56	112	1,584	144.0	292.4
August	42	28	28	28	84	672	96.4	140.9
September	47	12	28	56	112	644	97.8	125.3
October	1	56	56	56	56	56	56.0	NaN
November	45	28	28	56	84	866	106.1	164.5
December	56	28	28	56	100	392	79.7	78.1
2018								
January	42	20	28	28	70	976	78.7	155.0
February	60	16	28	28	56	266	55.9	48.7
March	57	16	28	56	84	814	95.9	138.7
April	49	14	28	28	56	252	43.4	35.4
May	43	12	28	28	56	580	66.1	100.2
June	83	14	28	28	84	422	61.3	65.4
July	91	6	28	28	84	1,014	89.8	150.0

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	80	14	28	28	56	1,006	74.3	131.7
September	47	28	28	45	56	252	57.7	51.2
October	72	2	28	28	84	420	73.9	96.4
November	91	14	28	28	56	868	70.5	136.1
December	145	14	28	30	112	1,263	96.9	138.2
2019								
January	94	10	28	42	84	896	87.3	125.0
February	43	5	28	56	112	1,285	148.5	247.6
March	104	12	28	28	84	1,064	81.3	129.0
April	114	9	28	28	84	1,160	93.1	160.1
May	179	5	28	28	84	560	76.5	88.6
June	83	5	28	32	84	1,174	97.6	161.6
July	229	5	28	28	84	670	74.0	101.7
August	159	17	28	30	112	947	98.3	148.1
September	219	2	28	28	84	560	71.1	83.0
October	218	1	28	28	56	1,010	68.8	107.9
November	164	1	28	28	112	1,041	104.5	169.5
December	156	1	28	28	84	840	78.9	109.7
2020								
January	155	5	28	56	137	756	103.6	135.0
February	261	2	28	28	56	809	67.2	102.2
March	171	5	28	28	79	336	67.7	72.3
April	121	14	28	51	84	504	79.2	87.6
May	86	12	28	56	84	784	83.5	112.3
June	96	18	28	28	74	786	70.5	100.2
July	125	3	28	28	84	588	82.8	110.0
August	138	1	28	28	68	432	63.0	77.4
September	127	2	28	28	56	557	61.4	81.0
October	133	10	28	28	56	586	51.3	70.0
November	140	1	28	28	84	654	72.3	86.0
December	115	8	28	28	88	476	80.3	92.6

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2021								
January	157	2	28	28	56	586	67.0	89.2
February	114	4	28	28	84	572	77.7	105.8
March	159	1	28	28	56	392	56.0	58.2
April	125	13	28	30	84	486	71.3	77.6
May	158	3	28	28	84	430	67.1	68.9
June	110	4	28	55	84	362	69.6	63.0
July	128	11	28	28	57	401	63.0	64.2
August	138	12	28	28	84	376	75.1	82.9
September	134	3	28	28	84	322	59.2	55.0
October	154	2	28	28	64	327	59.4	61.0
November	170	1	28	28	56	290	56.9	57.0
December	140	1	28	28	84	267	59.2	56.7
2022								
January	92	2	28	28	56	232	50.8	46.3
February	78	4	28	28	40	208	42.8	38.4
March	80	1	28	28	58	163	48.0	34.4
April	63	11	28	28	67	134	46.7	32.5
May	60	2	23	29	56	109	40.0	27.9
June	57	5	25	28	36	92	32.9	18.4
July	68	1	16	28	30	71	26.8	16.4
August	49	1	5	15	23	33	14.9	8.9
September	1	9	9	9	9	9	9.0	NaN
<i>Prurigo Nodularis</i>	2,445	1	28	30	84	1,486	82.9	113.5
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	31	28	28	56	140	1,023	118.2	184.9
May	6	28	28	28	28	55	32.5	11.0
June	4	15	36	71	98	112	67.0	41.3

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	75	28	28	56	84	448	66.7	65.4
August	27	14	28	112	252	483	160.0	136.2
September	1	56	56	56	56	56	56.0	NaN
October	20	13	28	28	126	387	96.7	120.1
November	12	28	42	84	181	584	153.5	175.5
December	6	28	28	112	243	1,486	334.8	571.9
2018								
January	34	14	28	28	84	504	70.6	87.5
February	25	16	28	56	112	364	80.9	79.0
March	4	84	84	84	126	168	105.0	42.0
April	27	14	56	112	224	476	150.1	120.4
May	19	28	28	28	56	308	57.3	66.2
June	47	2	28	56	84	364	72.9	72.4
July	31	28	28	50	56	532	66.3	92.3
August	25	14	28	28	56	842	97.2	178.2
September	44	28	28	28	84	448	81.0	101.5
October	59	14	28	28	56	532	57.6	83.4
November	40	9	28	41	154	1,124	129.4	203.6
December	34	12	28	29	56	840	79.7	149.0
2019								
January	53	14	28	28	56	420	69.2	84.7
February	42	14	28	42	84	1,180	118.5	218.6
March	26	28	28	56	84	308	78.8	69.4
April	32	28	28	48	102	280	71.1	58.3
May	47	5	28	28	112	616	90.9	114.7
June	86	5	28	56	112	952	103.2	131.3
July	85	3	28	28	84	308	58.4	52.8
August	60	8	28	56	141	606	111.1	142.0
September	38	2	28	56	168	1,103	144.1	229.8
October	59	23	28	56	112	674	107.5	142.3
November	74	16	28	28	84	224	61.1	53.3

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December	57	14	28	56	112	588	105.8	134.9
2020								
January	37	8	28	56	140	786	109.0	142.6
February	46	1	28	28	84	786	86.7	155.3
March	24	2	28	28	84	364	79.8	101.4
April	30	12	28	55	84	280	68.1	60.8
May	40	16	28	28	70	448	71.2	88.0
June	31	15	28	56	112	369	77.7	75.5
July	56	3	28	56	112	537	93.2	111.6
August	68	15	28	48	84	588	92.3	112.6
September	58	10	28	28	84	683	72.4	98.6
October	38	4	28	28	56	504	70.1	101.4
November	74	3	28	36	84	476	81.0	94.7
December	58	1	28	28	57	336	60.8	66.6
2021								
January	47	23	28	28	84	593	87.9	122.0
February	73	24	28	28	84	338	63.4	59.1
March	55	1	28	56	112	556	102.8	126.7
April	28	14	28	28	56	364	66.8	83.4
May	25	28	28	84	168	334	106.5	88.5
June	37	28	28	56	112	368	88.2	96.0
July	44	11	28	28	56	382	72.9	96.8
August	35	5	28	56	79	168	55.0	34.9
September	52	2	28	30	84	317	65.1	67.4
October	28	5	28	28	56	318	58.3	63.0
November	37	9	28	28	56	175	47.1	38.2
December	26	14	28	56	112	252	85.2	74.2
2022								
January	43	3	28	56	95	242	68.0	54.1
February	25	19	28	28	84	185	65.4	50.4
March	15	16	28	28	84	185	60.7	55.8

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	23	18	28	39	56	142	52.6	34.6
May	26	2	28	33	86	120	54.0	38.4
June	20	1	28	28	50	95	38.3	24.4
July	10	5	16	26	28	46	24.3	13.9
August	5	10	12	17	19	36	18.8	10.3
September	1	15	15	15	15	15	15.0	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>								
	61,363	1	28	58	140	1,920	112.8	148.3
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	9	28	28	55	118	241	80.9	73.1
April	291	1	28	84	198	1,820	160.9	208.3
May	766	1	28	84	168	1,920	153.4	231.3
June	836	2	28	57	145	1,833	142.0	226.5
July	737	1	28	59	143	1,801	125.9	185.4
August	836	3	28	61	168	1,830	141.9	212.7
September	692	5	28	63	168	1,429	139.8	193.1
October	823	1	28	57	119	1,797	121.9	199.9
November	796	1	28	62	147	1,597	128.2	178.6
December	516	3	28	62	159	1,692	139.8	216.0
2018								
January	524	2	28	59	143	1,632	125.9	182.8
February	597	1	28	59	155	1,663	145.7	230.2
March	720	4	28	84	174	1,515	149.1	195.0
April	608	3	28	63	168	1,547	140.8	197.9
May	604	2	28	60	148	1,534	127.5	181.4
June	561	4	28	60	134	1,494	119.1	165.4
July	775	1	28	57	117	1,362	115.1	166.7
August	928	3	28	56	117	1,395	116.9	179.2

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	773	3	28	58	133	1,457	120.6	174.1
October	936	2	28	62	145	1,313	122.2	155.6
November	937	1	28	57	146	1,407	131.8	192.6
December	692	1	28	67	174	1,278	147.2	192.4
2019								
January	1,062	1	28	63	162	1,331	129.2	164.0
February	1,169	1	28	61	142	1,311	124.1	164.9
March	1,126	1	28	62	140	1,270	120.1	158.2
April	1,382	1	28	59	140	1,234	119.9	161.0
May	1,344	1	28	60	127	1,216	113.3	150.3
June	1,169	2	28	61	149	1,176	127.1	163.9
July	1,650	1	28	60	140	1,149	118.2	153.6
August	1,710	1	28	58	140	1,114	122.3	169.8
September	1,306	1	28	61	149	1,076	124.7	157.8
October	1,624	1	28	61	146	1,034	122.5	150.4
November	1,452	1	28	61	168	1,026	126.8	153.8
December	1,398	1	28	62	148	992	125.2	155.0
2020								
January	1,339	1	28	61	146	956	122.4	150.7
February	1,135	1	28	61	168	939	124.4	148.3
March	1,321	1	28	57	130	911	107.4	128.6
April	899	1	28	58	141	882	111.5	134.0
May	796	1	28	62	146	843	115.0	133.0
June	1,048	1	28	59	138	822	109.7	129.5
July	1,752	1	28	56	116	792	98.9	121.8
August	1,504	1	28	56	113	730	95.2	105.5
September	1,518	1	28	56	126	722	103.7	118.7
October	1,333	1	28	57	122	699	102.0	112.9
November	1,296	1	28	58	140	663	102.7	109.6
December	1,299	1	28	60	140	641	107.2	114.8
2021								

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	1,090	1	28	57	140	609	105.8	113.6
February	1,003	1	28	60	141	590	108.6	115.5
March	1,088	1	28	61	143	549	108.7	111.8
April	1,065	1	28	60	144	516	104.7	105.1
May	964	2	28	56	118	481	96.4	98.1
June	873	1	28	56	130	457	96.3	93.0
July	1,186	1	28	56	113	432	86.7	88.2
August	1,194	1	28	56	114	403	87.8	86.3
September	931	1	28	56	116	369	87.5	82.8
October	918	1	28	56	129	341	89.6	80.2
November	776	1	28	56	114	309	81.0	71.6
December	648	1	28	57	120	278	84.1	68.5
2022								
January	582	1	28	56	112	246	74.9	61.7
February	458	1	28	56	90	220	66.6	51.8
March	516	1	28	44	84	184	60.5	46.9
April	450	1	28	52	87	159	59.7	41.4
May	342	1	25	38	77	128	49.2	33.9
June	295	1	22	31	58	100	39.9	24.7
July	243	1	15	28	39	67	27.6	16.3
August	148	1	6	12	20	38	14.2	9.5
September	4	1	2	4	11	16	6.0	6.9
Any Indication	56,801	1	28	58	140	1,920	112.5	148.0
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	9	28	28	55	118	241	80.9	73.1
April	254	1	44	84	199	1,820	169.7	217.4
May	625	1	28	84	168	1,920	152.1	225.8
June	718	2	28	56	141	1,833	141.2	232.6
July	693	1	28	59	142	1,801	125.2	183.2

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	768	3	28	63	170	1,830	144.0	210.4
September	657	5	28	62	143	1,429	131.7	184.8
October	722	1	28	56	118	1,797	123.1	206.3
November	702	1	28	59	141	1,597	123.9	177.4
December	450	3	28	61	168	1,692	138.9	211.2
2018								
January	514	2	28	57	140	1,354	115.5	158.4
February	550	12	28	57	140	1,663	140.4	228.5
March	589	4	28	84	196	1,515	161.9	205.1
April	593	3	28	62	168	1,547	137.9	191.3
May	530	2	28	62	165	1,534	132.0	185.6
June	494	4	28	62	140	1,494	120.9	164.4
July	724	1	28	57	115	1,362	115.7	171.5
August	782	3	28	57	118	1,395	119.3	183.8
September	762	3	28	56	119	1,457	115.1	173.6
October	924	2	28	61	146	1,313	122.2	156.6
November	855	1	28	58	147	1,407	133.1	194.6
December	642	1	28	64	176	1,278	145.5	189.0
2019								
January	1,002	1	28	63	153	1,331	127.5	163.0
February	1,071	1	28	63	143	1,311	124.8	165.7
March	1,062	1	28	60	140	1,270	120.0	159.8
April	1,308	1	28	58	140	1,234	119.0	159.9
May	1,292	1	28	60	123	1,216	113.6	152.3
June	1,055	2	28	62	153	1,176	127.1	159.3
July	1,502	1	28	59	140	1,149	119.9	158.0
August	1,618	1	28	58	140	1,114	124.4	171.2
September	1,269	1	28	61	146	1,076	123.8	157.8
October	1,538	1	28	62	146	1,034	121.8	148.0
November	1,411	1	28	60	168	1,026	125.1	152.8
December	1,309	1	28	60	145	992	124.3	156.3

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2020								
January	1,283	1	28	60	144	956	120.4	150.4
February	1,050	1	28	61	168	939	127.6	153.9
March	1,216	1	28	57	140	911	108.3	128.9
April	877	1	28	59	140	882	110.3	131.3
May	745	1	28	63	149	843	116.4	134.1
June	991	1	28	58	128	814	107.4	127.1
July	1,566	1	28	56	118	792	101.6	124.5
August	1,355	1	28	56	113	730	95.2	106.3
September	1,369	1	28	56	122	722	104.0	118.9
October	1,217	1	28	58	119	699	102.0	113.6
November	1,188	1	28	57	140	663	101.6	110.5
December	1,151	1	28	60	140	641	106.2	114.2
2021								
January	1,045	1	28	57	140	609	105.5	114.2
February	979	1	28	60	140	590	106.4	113.6
March	1,023	1	28	60	143	549	108.0	110.6
April	1,022	1	28	59	140	516	102.4	104.3
May	920	1	28	56	118	481	94.3	95.3
June	826	1	28	56	122	457	93.8	89.4
July	1,004	1	28	56	121	432	91.7	92.3
August	1,102	1	28	56	114	403	87.9	86.3
September	863	1	28	56	117	369	88.2	83.4
October	841	1	28	56	119	341	86.9	78.7
November	702	1	28	56	116	309	82.0	72.0
December	617	1	28	56	117	278	81.7	68.2
2022								
January	552	1	28	56	107	246	74.1	61.7
February	421	1	28	56	90	220	66.7	52.1
March	508	1	28	44	84	184	60.3	46.4
April	425	1	28	47	86	159	58.5	40.6

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	314	1	26	38	77	127	49.5	33.9
June	281	1	23	30	57	100	39.6	24.1
July	208	1	15	28	39	65	27.1	16.3
August	142	1	5	11	20	38	14.1	9.7
September	4	1	2	4	11	16	6.0	6.9
<i>Atopic Dermatitis</i>	45,816	1	28	57	128	1,920	110.5	147.2
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	9	28	28	55	118	241	80.9	73.1
April	246	1	45	84	199	1,820	166.9	216.2
May	620	1	28	84	160	1,920	149.2	220.1
June	714	2	28	56	141	1,833	140.7	232.4
July	649	1	28	59	144	1,402	121.6	164.9
August	714	3	28	63	170	1,830	142.7	202.8
September	644	5	28	62	142	1,429	128.8	179.8
October	699	1	28	56	117	1,797	121.4	205.7
November	687	1	28	59	140	1,597	123.5	178.3
December	442	3	28	61	154	1,692	136.7	207.2
2018								
January	514	2	28	56	140	1,354	116.6	159.7
February	541	12	28	57	140	1,663	140.9	229.7
March	571	4	28	84	196	1,515	160.7	205.0
April	530	3	28	62	173	1,547	142.8	200.0
May	495	2	28	61	165	1,534	132.2	185.8
June	479	4	28	62	140	1,494	122.5	166.3
July	703	1	28	57	115	1,362	115.8	172.5
August	764	3	28	58	120	1,395	120.7	184.3
September	723	3	28	57	122	1,457	118.3	175.8
October	894	2	28	61	146	1,313	122.6	158.0
November	770	2	28	59	146	1,407	129.0	179.8

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December 2019	521	1	28	62	169	1,278	145.3	194.1
January	835	1	28	62	143	1,331	122.7	160.2
February	866	1	28	68	141	1,180	122.9	159.8
March	802	1	28	60	140	1,270	117.9	163.4
April	1,098	2	28	58	140	1,174	115.3	149.0
May	1,109	1	28	58	116	1,216	106.8	144.8
June	890	2	28	61	143	1,122	118.1	141.6
July	1,196	1	28	60	140	1,149	120.5	159.9
August	1,218	1	28	58	130	1,102	117.8	158.5
September	921	1	28	61	141	1,076	119.4	152.5
October	1,081	2	28	61	142	982	120.3	145.3
November	951	1	28	58	145	1,025	117.6	143.0
December 2020	1,002	2	28	58	124	969	110.5	137.3
January	1,014	1	28	58	140	956	113.6	142.6
February	749	1	28	56	140	927	115.6	148.6
March	857	1	28	58	118	911	103.3	117.8
April	558	2	28	56	116	882	99.7	118.6
May	541	1	28	60	146	843	112.3	128.4
June	686	1	28	58	140	814	108.0	126.2
July	1,192	1	28	56	114	792	96.1	118.0
August	1,031	1	28	56	112	730	91.8	103.9
September	1,053	1	28	56	113	722	97.8	114.6
October	905	1	28	56	113	696	97.3	109.9
November	894	1	28	56	137	663	99.3	106.4
December 2021	860	1	28	60	140	641	107.9	117.0
January	744	1	28	59	144	609	108.4	114.0
February	759	1	28	56	127	590	100.0	108.5
March	749	1	28	62	144	549	109.8	111.8

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	801	1	28	56	135	516	98.2	101.8
May	671	1	28	56	123	481	92.6	91.7
June	659	1	28	56	116	457	88.8	86.0
July	802	1	28	56	115	432	88.9	89.0
August	856	1	28	56	112	397	85.7	84.8
September	699	1	28	56	112	366	83.9	81.4
October	631	1	28	56	119	341	88.1	80.7
November	548	1	28	56	110	309	78.3	70.7
December	482	1	28	56	117	278	80.0	67.8
2022								
January	444	1	28	56	94	246	69.4	59.1
February	309	1	28	56	90	220	67.6	53.6
March	382	1	28	43	84	184	59.0	44.3
April	338	2	28	46	85	157	57.9	40.3
May	241	1	28	33	73	122	49.3	33.3
June	205	1	24	31	59	98	40.6	23.9
July	156	1	15	28	39	64	26.8	16.4
August	100	1	8	12	23	38	15.2	9.9
September	2	1	1	3	5	5	3.0	2.8
<i>Asthma</i>	20,552	1	28	57	139	1,833	112.0	146.7
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	9	28	28	55	118	241	80.9	73.1
April	57	2	45	84	199	1,820	175.5	271.6
May	154	4	28	63	172	1,440	155.6	230.4
June	158	6	28	56	146	1,833	138.1	238.3
July	160	8	28	56	136	1,491	114.9	169.7
August	241	1	28	60	148	1,732	129.6	192.7
September	140	14	28	56	137	981	125.4	179.4
October	192	4	28	57	141	1,370	129.6	191.2

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	166	5	28	56	126	1,597	118.3	183.1
December	165	5	28	56	141	1,548	117.6	188.6
2018								
January	159	2	28	56	120	1,402	120.5	197.9
February	122	12	28	68	168	1,663	164.1	282.3
March	161	5	28	63	170	1,122	165.1	220.8
April	120	3	28	74	164	1,100	131.7	167.8
May	172	2	28	84	169	1,534	141.2	185.0
June	108	14	28	84	160	1,494	125.7	173.9
July	206	6	28	57	115	1,235	97.4	129.6
August	201	8	28	56	87	1,395	109.4	198.2
September	166	8	28	59	118	1,111	116.8	165.1
October	188	5	28	61	123	1,269	124.6	170.4
November	292	1	28	56	132	1,387	123.6	204.0
December	304	1	28	59	168	1,232	125.9	159.0
2019								
January	480	2	28	76	150	930	126.9	150.5
February	390	1	28	60	140	1,311	127.3	184.3
March	450	1	28	60	131	1,239	112.9	141.8
April	552	1	28	57	132	1,234	118.1	170.0
May	480	1	28	62	145	1,216	120.9	152.8
June	415	3	28	62	168	1,176	139.7	181.9
July	569	1	28	58	140	1,144	116.7	152.4
August	696	1	28	57	140	1,114	128.2	184.3
September	512	4	28	63	149	1,030	129.4	161.3
October	685	1	28	67	157	1,034	126.1	153.7
November	606	1	28	61	168	1,010	126.6	151.2
December	423	1	28	60	168	992	133.7	175.3
2020								
January	451	1	28	61	147	956	127.9	165.6
February	463	2	28	84	187	939	136.0	153.8

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	488	3	28	56	142	911	111.6	140.6
April	422	1	28	61	124	873	111.1	135.0
May	311	2	28	59	113	835	108.2	133.6
June	421	1	28	57	118	791	104.1	126.8
July	576	1	28	58	128	792	110.2	135.7
August	569	1	28	56	114	730	94.2	102.6
September	549	1	28	57	138	656	103.3	112.3
October	457	1	28	59	120	699	105.1	117.6
November	406	2	28	61	146	654	110.3	120.0
December	456	2	28	56	112	614	92.2	95.8
2021								
January	455	1	28	56	119	604	98.3	110.5
February	344	2	28	62	129	585	109.1	116.1
March	401	2	28	57	140	547	103.4	105.7
April	407	1	28	57	140	509	99.7	104.6
May	378	2	28	56	114	474	93.7	94.9
June	321	4	28	58	134	451	97.5	92.3
July	328	1	28	60	130	417	96.9	95.8
August	395	4	28	56	114	403	88.9	84.4
September	288	1	28	57	116	369	90.6	86.1
October	306	1	28	56	115	339	81.5	73.2
November	247	2	28	56	125	304	85.6	73.3
December	212	1	28	56	118	271	82.4	67.7
2022								
January	191	1	28	56	123	243	81.8	64.8
February	161	2	28	45	87	212	65.4	51.8
March	171	2	28	28	84	176	57.7	48.7
April	144	1	28	30	84	159	55.3	41.4
May	125	1	26	30	63	127	45.0	32.3
June	97	1	18	28	56	100	36.4	25.2
July	66	1	17	28	40	65	29.3	16.7

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	45	1	5	12	19	32	13.5	9.2
September	2	1	1	2	2	2	1.5	0.7
<i>Chronic</i>								
<i>Rhinosinusitis</i>	10,769	1	28	59	140	1,732	113.9	147.0
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	23	14	28	91	232	872	164.9	201.2
May	42	4	28	84	147	1,440	169.9	277.6
June	52	6	28	72	196	826	166.0	213.3
July	42	14	28	30	30	160	42.1	33.6
August	62	14	28	59	169	1,732	159.4	266.0
September	25	10	28	203	392	855	255.7	234.0
October	16	28	42	84	288	448	153.4	148.5
November	27	3	28	79	238	1,261	209.7	328.8
December	25	28	28	59	123	1,159	150.0	266.0
2018								
January	56	18	28	28	62	1,008	83.1	149.4
February	42	28	28	59	198	1,663	222.9	419.4
March	45	28	28	56	91	775	118.5	172.7
April	64	20	28	63	134	710	108.4	116.4
May	69	9	28	56	84	1,534	92.6	195.6
June	27	28	28	57	91	1,494	133.1	281.4
July	79	14	28	56	131	863	109.8	140.8
August	77	14	28	58	151	1,311	148.7	247.0
September	82	8	28	56	118	1,457	114.0	187.2
October	68	14	28	84	168	1,269	149.4	200.6
November	87	3	28	62	127	1,363	132.8	222.7
December	99	5	28	84	175	709	143.2	148.4
2019								

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	131	2	28	59	168	713	135.6	166.9
February	160	8	28	84	173	1,095	139.4	186.7
March	143	3	28	84	140	902	116.8	136.8
April	222	2	28	57	119	1,230	117.3	178.8
May	189	16	28	61	149	871	117.6	149.7
June	170	11	28	85	193	1,176	165.2	211.6
July	275	1	28	58	135	1,144	115.1	157.7
August	381	1	28	60	141	1,113	131.8	185.3
September	349	4	28	63	147	1,039	129.4	168.6
October	379	1	28	84	168	1,034	133.4	160.5
November	411	8	28	60	178	1,026	135.3	162.7
December	315	4	28	70	179	992	140.3	175.5
2020								
January	314	1	28	65	168	956	137.8	181.1
February	302	3	28	84	172	906	135.1	154.3
March	304	3	28	58	140	911	109.8	139.6
April	259	1	28	61	156	856	120.6	138.7
May	206	14	28	63	147	829	118.8	136.7
June	271	1	28	57	122	764	105.9	121.1
July	316	3	28	62	140	769	110.6	132.8
August	283	1	28	58	116	625	98.7	108.8
September	280	4	28	64	169	675	121.7	129.1
October	256	1	28	60	139	504	99.8	97.9
November	253	3	28	60	145	654	114.4	127.8
December	279	1	28	58	119	611	100.5	103.7
2021								
January	266	3	28	56	140	589	107.4	122.7
February	226	2	28	84	145	582	120.7	124.8
March	238	4	28	58	140	529	100.0	103.9
April	220	3	28	62	141	499	103.1	100.9
May	258	2	28	56	102	478	87.3	93.1

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	204	7	28	58	140	451	95.9	90.6
July	198	4	28	61	141	416	102.5	100.7
August	231	3	28	56	140	403	93.1	89.0
September	194	1	28	59	121	367	88.8	77.7
October	212	2	28	56	112	339	76.5	67.2
November	143	1	28	75	140	309	91.3	73.5
December	170	7	28	59	112	267	80.5	62.2
2022								
January	119	2	28	56	130	243	81.1	61.0
February	120	4	28	56	97	211	67.6	48.0
March	118	2	28	31	84	176	63.0	51.2
April	96	4	28	48	85	159	57.4	39.2
May	75	2	16	28	60	122	43.0	31.6
June	65	1	18	28	54	89	35.6	22.5
July	34	1	12	28	36	64	28.4	17.6
August	23	2	6	11	20	32	13.1	8.4
September	2	2	2	9	16	16	9.0	9.9
<i>Eosinophilic Esophagitis</i>	3,114	1	28	56	116	1,801	102.4	134.6
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	8	28	28	51	605	872	283.5	350.0
May	5	20	28	28	116	213	81.0	83.6
June	1	6	6	6	6	6	6.0	NaN
July	28	9	28	61	141	1,801	153.4	333.2
August	26	28	28	61	168	847	146.2	199.9
September	16	28	28	56	198	891	145.4	217.6
October	1	56	56	56	56	56	56.0	NaN
November	22	28	84	84	164	1,019	167.3	223.4

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December 2018	18	28	28	107	172	421	128.3	112.9
January	18	20	28	28	57	976	94.4	221.8
February	25	28	28	56	118	266	73.4	57.7
March	23	16	28	85	314	814	188.1	219.8
April	24	28	28	28	86	211	59.5	49.9
May	27	12	28	62	148	358	100.6	93.1
June	42	28	28	84	88	367	79.9	71.0
July	37	6	28	83	168	434	117.7	117.9
August	24	14	28	56	135	1,006	141.2	227.1
September	35	28	28	62	211	826	139.6	163.9
October	35	9	28	56	112	599	99.4	129.2
November	36	14	28	39	84	229	66.7	57.8
December 2019	69	14	28	84	197	1,134	163.1	196.3
January	52	28	28	66	154	930	117.8	151.8
February	35	5	28	30	71	521	72.0	98.0
March	38	12	57	87	196	778	143.6	142.6
April	42	15	28	56	161	721	133.7	185.9
May	70	5	28	58	140	411	104.6	106.3
June	43	9	28	56	116	1,176	164.1	277.0
July	95	8	28	84	154	681	130.9	151.0
August	80	21	28	86	191	1,088	170.4	220.0
September	86	10	28	56	123	764	110.9	133.3
October	112	1	28	56	113	364	82.9	76.3
November	83	1	28	56	140	961	125.6	179.4
December 2020	83	12	28	84	184	840	135.6	152.1
January	76	9	28	78	175	787	142.5	168.7
February	139	3	28	51	88	724	90.9	124.7
March	104	4	28	62	123	485	96.6	93.0

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	58	19	31	62	140	695	115.0	144.0
May	35	26	28	62	140	813	114.2	153.2
June	55	26	28	56	112	625	94.8	115.2
July	42	3	28	56	112	634	90.5	113.4
August	59	1	28	56	84	572	76.1	91.6
September	63	3	28	50	100	364	78.5	77.0
October	51	1	28	60	140	618	100.3	117.5
November	71	9	28	56	113	654	92.6	111.0
December	48	8	28	71	135	631	122.5	146.1
2021								
January	84	8	28	56	84	586	81.7	104.3
February	39	19	28	59	140	515	99.6	111.5
March	73	1	28	57	112	449	84.9	83.4
April	72	19	28	56	88	486	83.5	84.6
May	74	7	28	60	148	461	101.7	97.0
June	49	3	28	90	168	278	101.6	71.7
July	42	11	28	69	141	401	101.8	90.3
August	67	12	28	56	88	376	83.9	90.6
September	45	3	28	58	140	322	86.0	74.0
October	65	2	28	30	91	242	67.6	58.5
November	68	1	28	56	132	283	82.0	65.9
December	61	1	28	38	84	263	72.0	70.1
2022								
January	37	2	28	28	63	150	50.5	38.4
February	33	8	28	28	56	186	46.6	42.8
March	44	3	28	30	84	173	57.7	45.1
April	37	4	28	28	63	118	43.2	29.8
May	31	4	28	30	56	114	44.7	30.2
June	17	14	23	28	44	89	35.3	20.4
July	21	3	15	23	29	65	26.3	17.8
August	15	1	4	12	18	33	11.9	9.8

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	1,111	1	28	62	146	1,387	122.7	149.1
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	14	28	56	104	476	1,023	262.6	310.9
May	3	28	28	55	57	57	46.7	16.2
June	2	15	15	36	57	57	36.0	29.7
July	15	28	84	126	321	766	236.0	256.9
August	14	28	168	227	377	706	275.1	185.0
September	1	56	56	56	56	56	56.0	NaN
October	6	13	28	213	424	682	262.2	261.6
November	7	28	28	56	112	140	72.0	42.3
December	1	243	243	243	243	243	243.0	NaN
2018								
January	20	28	28	74	143	521	109.1	115.3
February	13	18	28	56	140	454	115.0	126.1
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	10	14	56	174	424	609	234.7	211.4
May	12	28	28	58	114	308	84.6	83.4
June	27	9	56	112	235	367	150.5	114.9
July	22	28	28	56	84	194	64.9	37.1
August	15	14	28	56	97	842	113.5	207.1
September	24	28	36	58	154	535	123.5	136.3
October	26	17	28	57	168	610	126.0	161.6
November	20	18	36	104	368	1,387	241.1	319.4
December	8	12	29	163	398	840	253.6	300.6
2019								
January	26	14	28	56	140	790	136.2	180.7
February	18	17	28	120	168	1,180	203.1	284.4

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	11	28	57	85	171	537	150.0	154.2
April	17	28	28	86	150	308	105.0	80.0
May	14	14	42	76	159	397	113.6	103.5
June	37	9	56	92	176	650	142.2	139.4
July	42	3	28	84	126	568	114.9	120.1
August	13	8	28	86	174	495	131.2	149.2
September	18	24	56	89	205	718	170.3	183.1
October	27	23	28	84	168	594	136.9	154.7
November	31	28	51	84	170	422	121.5	104.5
December	24	28	42	85	299	588	169.6	181.3
2020								
January	22	8	28	145	287	786	195.4	204.7
February	36	12	28	28	156	756	112.6	145.5
March	21	2	28	28	154	308	99.3	100.6
April	3	54	54	56	267	267	125.7	122.4
May	15	16	28	56	140	456	119.0	143.7
June	12	15	33	70	98	207	79.9	58.4
July	11	14	28	112	385	620	187.1	206.7
August	31	15	40	87	257	597	157.2	159.7
September	18	10	28	60	91	361	103.8	118.8
October	15	15	28	56	202	504	124.1	145.8
November	46	8	28	62	144	562	102.5	110.9
December	34	22	28	28	89	317	68.0	60.5
2021								
January	19	28	28	65	135	448	105.0	102.3
February	37	25	28	63	127	481	108.1	113.5
March	28	1	28	84	172	348	116.5	102.7
April	19	14	28	52	85	368	84.4	107.6
May	24	28	28	58	85	341	88.4	88.9
June	11	28	28	130	368	438	169.3	163.7
July	16	14	28	28	164	243	82.4	80.6

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	21	5	36	56	88	253	72.0	53.6
September	33	11	28	28	56	178	47.4	36.3
October	11	24	28	38	101	318	80.9	91.1
November	15	28	28	58	96	175	70.4	46.1
December	9	28	28	43	86	196	68.7	60.1
2022								
January	19	3	28	51	107	187	65.9	52.1
February	9	21	28	62	78	187	68.9	50.2
March	5	28	28	49	58	102	53.0	30.4
April	9	24	28	56	62	142	61.2	41.3
May	7	17	23	28	99	100	53.9	37.9
June	9	18	28	28	64	95	43.7	26.9
July	4	5	11	30	45	46	27.8	20.4
August	4	10	14	18	28	36	20.5	11.0
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	124,254	1	3	8	19	1,716	22.5	61.5
<i>Any Indication</i>	115,728	1	3	8	19	1,716	22.5	61.5
<i>Atopic Dermatitis</i>	92,468	1	3	8	20	1,716	23.3	64.4
<i>Asthma</i>	42,825	1	3	8	19	1,669	21.1	56.1
<i>Chronic Rhinosinusitis</i>	23,261	1	3	7	18	1,401	20.3	51.8
<i>Eosinophilic Esophagitis</i>	6,807	1	3	8	19	1,154	20.7	48.7
<i>Prurigo Nodularis</i>	2,445	1	3	7	18	1,110	24.2	71.3
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	61,363	8	12	19	36	1,716	41.1	82.1
<i>Any Indication</i>	56,801	8	12	19	36	1,716	41.1	82.4
<i>Atopic Dermatitis</i>	45,816	8	12	19	36	1,716	42.1	85.8
<i>Asthma</i>	20,552	8	12	19	35	1,669	38.6	74.8
<i>Chronic Rhinosinusitis</i>	10,769	8	12	18	35	1,401	37.9	70.2
<i>Eosinophilic Esophagitis</i>	3,114	8	12	19	36	1,154	37.4	65.0
<i>Prurigo Nodularis</i>	1,111	8	12	19	37	1,028	46.4	94.9

Table 7b. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	124,254	1	3	8	19	1,716	22.5	61.5
Female	69,246	1	3	8	19	1,716	22.6	61.2
Male	55,008	1	3	8	19	1,669	22.4	61.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	115,728	1	3	8	19	1,716	22.5	61.5
Female	64,576	1	3	8	19	1,716	22.6	61.2
Male	51,152	1	3	8	19	1,669	22.4	61.9
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	92,468	1	3	8	20	1,716	23.3	64.4
Female	51,288	1	3	8	20	1,716	23.5	64.2
Male	41,180	1	3	8	20	1,669	23.1	64.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	42,825	1	3	8	19	1,669	21.1	56.1
Female	24,564	1	3	8	19	1,130	21.4	56.4
Male	18,261	1	3	7	19	1,669	20.8	55.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	23,261	1	3	7	18	1,401	20.3	51.8
Female	13,021	1	3	8	18	1,099	20.3	50.2
Male	10,240	1	3	7	17	1,401	20.3	53.7
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	6,807	1	3	8	19	1,154	20.7	48.7
Female	3,969	1	3	8	19	880	21.1	48.7
Male	2,838	1	3	8	18	1,154	20.1	48.7
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	2,445	1	3	7	18	1,110	24.2	71.3
Female	1,486	1	3	7	18	1,110	23.6	67.4
Male	959	1	3	7	18	964	25.2	76.9
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	61,363	8	12	19	36	1,716	41.1	82.1

Table 7b. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	34,478	8	12	19	36	1,716	40.9	81.1
Male	26,885	8	12	19	36	1,669	41.3	83.4
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	56,801	8	12	19	36	1,716	41.1	82.4
Female	31,976	8	12	19	36	1,716	40.9	81.3
Male	24,825	8	12	19	36	1,669	41.3	83.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	45,816	8	12	19	36	1,716	42.1	85.8
Female	25,671	8	12	19	36	1,716	42.1	84.9
Male	20,145	8	12	19	37	1,669	42.2	86.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	20,552	8	12	19	35	1,669	38.6	74.8
Female	11,918	8	12	18	35	1,130	38.7	74.4
Male	8,634	8	12	19	35	1,669	38.4	75.4
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	10,769	8	12	18	35	1,401	37.9	70.2
Female	6,073	8	12	18	35	1,099	37.5	67.4
Male	4,696	8	12	18	34	1,401	38.4	73.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	3,114	8	12	19	36	1,154	37.4	65.0
Female	1,841	8	12	19	38	880	38.0	64.6
Male	1,273	8	12	18	34	1,154	36.4	65.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	1,111	8	12	19	37	1,028	46.4	94.9
Female	676	8	12	19	39	1,028	44.0	85.0
Male	435	8	12	19	35	964	50.0	108.4
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7c. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	124,254	1	3	8	19	1,716	22.5	61.5
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	383	1	6	16	32	277	24.4	30.3
6-11 years	4,246	1	4	11	25	1,018	22.6	45.2
12-17 years	13,103	1	3	8	20	1,229	22.1	54.6
18-79 years	105,794	1	3	8	19	1,716	22.6	62.9
≥ 80 years	728	1	3	7	17	753	20.9	55.1
<i>Any Indication</i>	115,728	1	3	8	19	1,716	22.5	61.5
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	366	1	6	17	33	277	24.8	30.4
6-11 years	4,110	1	4	11	25	1,018	22.7	45.4
12-17 years	12,486	1	3	8	20	1,229	22.0	54.8
18-79 years	98,150	1	3	8	19	1,716	22.5	63.0
≥ 80 years	616	1	3	7	17	735	19.9	47.5
<i>Atopic Dermatitis</i>	92,468	1	3	8	20	1,716	23.3	64.4
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	358	1	6	17	33	277	25.2	30.6
6-11 years	3,971	1	4	11	25	1,018	22.7	45.5
12-17 years	11,595	1	3	8	20	1,229	22.2	55.2
18-79 years	76,059	1	3	8	19	1,716	23.5	66.7
≥ 80 years	485	1	3	7	17	735	20.5	50.9
<i>Asthma</i>	42,825	1	3	8	19	1,669	21.1	56.1
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	69	1	6	21	30	79	21.0	18.1
6-11 years	1,579	1	4	12	24	1,018	23.5	54.1
12-17 years	4,931	1	3	8	20	1,014	21.2	51.2
18-79 years	36,095	1	3	7	18	1,669	21.1	56.9
≥ 80 years	151	1	3	7	14	234	15.7	30.1
<i>Chronic Rhinosinusitis</i>	23,261	1	3	7	18	1,401	20.3	51.8
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 7c. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
6-71 months	21	1	2	7	27	79	18.9	21.8
6-11 years	203	1	5	14	25	860	22.7	62.9
12-17 years	1,079	1	4	9	20	902	20.4	43.2
18-79 years	21,847	1	3	7	18	1,401	20.3	52.1
≥ 80 years	111	1	3	7	16	253	16.5	34.2
<i>Eosinophilic Esophagitis</i>	6,807	1	3	8	19	1,154	20.7	48.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	17	1	2	4	10	44	9.9	12.8
6-11 years	211	1	5	12	25	393	21.8	38.1
12-17 years	535	1	3	8	20	756	20.5	54.5
18-79 years	5,983	1	3	8	19	1,154	20.8	48.7
≥ 80 years	61	1	2	6	13	234	13.0	30.5
<i>Prurigo Nodularis</i>	2,445	1	3	7	18	1,110	24.2	71.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-11 years	7	1	3	5	11	201	33.0	74.2
12-17 years	110	1	3	7	14	155	14.9	24.2
18-79 years	2,273	1	3	7	18	1,110	24.8	73.5
≥ 80 years	55	1	4	11	24	99	18.4	24.0
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	61,363	8	12	19	36	1,716	41.1	82.1
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	263	8	16	26	39	277	33.9	32.3
6-11 years	2,516	8	13	21	37	1,018	35.4	55.0
12-17 years	6,657	8	12	19	37	1,229	39.4	71.7
18-79 years	51,594	8	12	19	36	1,716	41.6	84.6
≥ 80 years	333	8	12	17	34	753	40.5	76.8
<i>Any Indication</i>	56,801	8	12	19	36	1,716	41.1	82.4
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	255	8	16	26	40	277	33.9	32.4
6-11 years	2,438	8	13	21	37	1,018	35.4	55.2

Table 7c. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
12-17 years	6,300	8	12	19	36	1,229	39.3	72.3
18-79 years	47,524	8	12	19	36	1,716	41.7	85.0
≥ 80 years	284	8	12	18	34	735	37.7	65.3
<i>Atopic Dermatitis</i>	45,816	8	12	19	36	1,716	42.1	85.8
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	250	8	16	26	40	277	34.3	32.6
6-11 years	2,361	8	13	21	37	1,018	35.4	55.3
12-17 years	5,836	8	12	19	36	1,229	39.6	72.8
18-79 years	37,154	8	12	19	36	1,716	43.0	89.5
≥ 80 years	215	8	12	18	35	735	40.3	71.4
<i>Asthma</i>	20,552	8	12	19	35	1,669	38.6	74.8
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	42	10	22	27	38	79	32.0	14.8
6-11 years	928	8	14	21	37	1,018	37.1	67.2
12-17 years	2,436	8	12	19	35	1,014	37.8	67.5
18-79 years	17,077	8	12	18	35	1,669	38.8	76.4
≥ 80 years	69	8	12	15	30	234	29.7	40.3
<i>Chronic Rhinosinusitis</i>	10,769	8	12	18	35	1,401	37.9	70.2
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	10	14	20	27	50	79	36.1	20.6
6-11 years	126	8	15	20	31	860	33.8	77.8
12-17 years	578	8	12	18	34	902	34.2	55.2
18-79 years	10,004	8	12	18	35	1,401	38.2	71.0
≥ 80 years	51	8	12	16	24	253	31.3	46.4
<i>Eosinophilic Esophagitis</i>	3,114	8	12	19	36	1,154	37.4	65.0
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	7	8	9	13	35	44	20.6	14.4
6-11 years	123	8	14	22	36	393	34.1	46.0
12-17 years	271	8	12	19	34	756	36.3	73.2
18-79 years	2,694	8	12	19	36	1,154	37.8	65.1
≥ 80 years	19	9	11	16	23	47	19.9	11.7

Table 7c. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Prurigo Nodularis</i>	1,111	8	12	19	37	1,028	46.4	94.9
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-11 years	2	11	11	106	201	201	106.0	134.4
12-17 years	44	8	13	20	38	155	31.3	31.8
18-79 years	1,035	8	12	19	38	1,028	47.3	97.7
≥ 80 years	30	8	12	23	36	99	30.5	27.1

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	124,254	1	3	8	19	1,716	22.5	61.5
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	17	1	3	10	16	742	55.2	177.3
April	613	1	3	7	16	850	23.2	75.4
May	1,531	1	4	8	18	1,106	24.9	78.7
June	1,582	1	4	8	21	1,169	26.1	79.7
July	1,583	1	3	7	18	1,094	24.8	76.3
August	1,754	1	3	7	18	1,505	30.9	109.7
September	1,361	1	3	8	19	1,087	28.0	86.9
October	1,622	1	3	8	21	1,529	34.1	109.0
November	1,504	1	4	8	20	1,669	28.2	91.6
December	1,014	1	3	8	17	1,716	28.1	101.7
2018								
January	1,024	1	3	8	20	1,354	30.7	100.5
February	1,188	1	3	8	18	1,401	27.9	93.2
March	1,456	1	3	7	18	1,495	28.2	95.0
April	1,252	1	3	8	18	1,160	25.4	81.1
May	1,202	1	3	8	21	1,107	26.2	77.2
June	1,071	1	4	8	24	1,167	31.8	89.9
July	1,875	1	3	8	20	1,494	27.7	86.4
August	1,909	1	4	9	23	1,364	33.5	101.7
September	1,405	1	4	9	21	1,118	30.6	89.0
October	1,792	1	3	8	20	1,175	27.5	78.6
November	1,759	1	4	9	21	1,229	26.3	77.1
December	1,440	1	3	7	18	1,154	24.0	72.7
2019								
January	2,022	1	3	8	20	1,047	25.9	75.8
February	2,258	1	3	8	18	1,057	22.0	57.1

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	2,180	1	4	8	20	980	25.4	69.5
April	2,748	1	3	8	20	902	25.0	65.8
May	2,636	1	3	8	19	1,003	22.1	57.5
June	2,282	1	3	8	20	913	26.1	69.8
July	3,324	1	4	8	20	967	24.0	63.8
August	3,280	1	4	8	21	948	25.2	63.3
September	2,599	1	3	8	20	1,018	25.6	64.3
October	3,188	1	3	8	20	1,017	23.5	61.3
November	2,878	1	3	7	20	1,000	23.9	63.0
December	2,648	1	3	8	20	905	23.6	57.6
2020								
January	2,586	1	3	8	18	725	20.6	46.5
February	2,369	1	3	7	19	836	21.9	53.9
March	2,521	1	3	8	20	726	22.3	51.7
April	1,796	1	4	8	20	849	23.3	56.3
May	1,674	1	3	7	19	653	22.4	51.4
June	2,089	1	3	7	18	665	21.2	50.6
July	4,143	1	3	8	20	714	20.9	43.8
August	3,077	1	3	8	20	735	20.6	43.8
September	3,078	1	3	8	21	508	21.3	42.6
October	2,680	1	3	7	19	691	22.3	52.2
November	2,421	1	3	8	21	596	22.6	48.5
December	2,342	1	3	8	21	571	20.5	40.6
2021								
January	2,225	1	3	7	18	501	18.0	36.5
February	2,080	1	3	7	18	540	18.6	38.5
March	2,282	1	3	7	19	473	18.0	34.2
April	2,114	1	3	7	18	376	18.2	33.8
May	1,863	1	3	8	19	437	19.0	36.5
June	1,745	1	3	8	20	340	18.6	31.0
July	2,679	1	3	8	19	382	17.9	30.5

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	2,604	1	3	8	19	317	17.1	27.6
September	1,820	1	3	8	19	303	17.6	29.3
October	1,932	1	3	7	17	293	15.8	24.9
November	1,655	1	3	7	17	293	15.4	24.7
December	1,389	1	3	7	17	258	15.0	24.6
2022								
January	1,273	1	3	7	15	238	14.3	23.9
February	1,027	1	3	6	14	175	13.1	19.6
March	1,146	1	3	7	15	162	12.9	18.2
April	984	1	3	7	15	145	12.2	17.2
May	819	1	3	6	13	112	11.1	14.6
June	704	1	3	6	13	97	10.5	12.9
July	660	1	3	6	13	71	9.7	10.5
August	446	1	2	6	10	36	7.4	6.7
September	34	1	2	4	6	12	4.2	3.1
<i>Any Indication</i>	<i>115,728</i>	<i>1</i>	<i>3</i>	<i>8</i>	<i>19</i>	<i>1,716</i>	<i>22.5</i>	<i>61.5</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	17	1	3	10	16	742	55.2	177.3
April	556	1	3	7	15	850	22.8	78.5
May	1,254	1	4	7	18	1,099	23.4	71.1
June	1,381	1	3	8	21	1,067	26.8	79.2
July	1,493	1	3	7	19	1,169	25.2	80.5
August	1,641	1	3	7	18	1,505	31.6	112.4
September	1,295	1	4	8	20	1,087	28.5	88.2
October	1,443	1	3	8	22	1,529	34.6	111.5
November	1,346	1	4	8	20	1,669	27.3	91.5
December	907	1	3	8	17	1,716	28.9	105.1
2018								
January	1,043	1	4	8	20	1,354	29.5	96.8

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
February	1,051	1	4	8	19	1,401	27.7	92.4
March	1,230	1	3	7	18	1,495	29.4	101.3
April	1,182	1	3	8	18	1,160	26.3	83.2
May	1,064	1	3	8	20	1,107	25.5	76.9
June	954	1	4	8	24	1,167	32.0	93.9
July	1,751	1	3	8	20	1,494	28.4	87.8
August	1,732	1	4	8	22	1,364	33.8	106.8
September	1,339	1	4	10	24	1,118	31.0	85.3
October	1,743	1	3	8	20	951	26.2	70.2
November	1,641	1	4	9	21	1,229	26.9	78.7
December	1,346	1	3	8	19	1,154	24.1	73.2
2019								
January	1,918	1	4	8	20	1,047	25.6	75.9
February	2,121	1	3	7	18	1,057	21.6	57.3
March	2,104	1	4	8	20	980	25.7	70.4
April	2,563	1	3	8	20	902	24.6	64.4
May	2,525	1	3	8	19	1,003	21.6	57.3
June	2,067	1	3	8	20	913	25.2	65.7
July	3,083	1	3	8	19	967	23.1	61.6
August	3,166	1	4	8	20	948	24.5	61.7
September	2,508	1	3	8	20	1,018	25.9	65.3
October	3,013	1	3	8	20	1,017	23.6	62.1
November	2,729	1	3	8	20	1,000	24.3	63.8
December	2,514	1	3	8	20	905	23.1	56.3
2020								
January	2,491	1	3	8	18	725	21.1	48.7
February	2,215	1	3	7	18	836	22.2	54.6
March	2,341	1	3	8	20	726	22.9	52.8
April	1,740	1	4	8	20	849	23.7	57.8
May	1,562	1	3	7	18	653	22.2	50.4
June	2,040	1	3	7	18	665	19.9	47.1

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	3,651	1	3	8	19	714	20.5	44.1
August	2,727	1	3	8	20	735	20.9	44.1
September	2,831	1	3	8	21	508	20.7	42.1
October	2,514	1	3	7	19	691	22.2	51.7
November	2,247	1	3	8	21	596	22.4	47.2
December	2,080	1	3	8	20	571	20.9	43.1
2021								
January	2,101	1	3	7	18	501	18.7	38.4
February	2,056	1	3	7	18	540	18.7	38.2
March	2,158	1	3	7	19	473	18.2	34.9
April	2,032	1	3	8	19	376	18.7	34.7
May	1,849	1	3	8	19	437	18.9	36.3
June	1,693	1	3	8	20	340	18.5	30.9
July	2,244	1	3	8	19	382	17.7	30.2
August	2,357	1	3	8	19	364	17.1	28.3
September	1,723	1	3	7	18	303	17.1	29.0
October	1,768	1	3	7	18	293	16.1	25.3
November	1,511	1	3	7	17	293	15.2	24.7
December	1,371	1	3	7	17	258	14.9	24.2
2022								
January	1,202	1	3	7	15	238	14.7	24.7
February	984	1	3	6	14	193	13.3	20.6
March	1,106	1	3	7	15	162	12.9	18.2
April	943	1	3	7	15	137	12.1	16.8
May	769	1	3	6	13	117	11.1	14.3
June	673	1	3	6	13	97	10.5	12.9
July	589	1	3	6	12	71	9.3	10.4
August	407	1	2	6	11	36	7.6	6.8
September	33	1	2	3	6	12	4.2	3.1
<i>Atopic Dermatitis</i>	<i>92,468</i>	<i>1</i>	<i>3</i>	<i>8</i>	<i>20</i>	<i>1,716</i>	<i>23.3</i>	<i>64.4</i>
2017								

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	17	1	3	10	16	742	55.2	177.3
April	536	1	3	7	15	850	23.3	79.9
May	1,243	1	4	7	18	1,099	23.5	71.4
June	1,383	1	3	8	21	1,067	26.1	76.6
July	1,404	1	3	7	19	1,169	25.1	79.8
August	1,531	1	3	7	18	1,505	32.4	115.4
September	1,276	1	3	8	20	1,087	27.7	85.6
October	1,417	1	3	8	22	1,529	35.2	114.0
November	1,335	1	4	8	20	1,669	27.3	90.1
December	892	1	3	8	17	1,716	29.0	105.7
2018								
January	1,037	1	4	9	20	1,354	29.6	97.0
February	1,028	1	3	8	18	1,401	27.5	93.2
March	1,191	1	3	7	19	1,495	28.4	97.3
April	1,077	1	3	8	18	1,160	25.9	82.5
May	1,009	1	3	8	20	1,107	25.5	77.0
June	940	1	4	8	22	1,167	33.7	102.3
July	1,717	1	3	8	20	1,494	28.4	88.5
August	1,669	1	4	8	22	1,364	34.6	109.8
September	1,300	1	4	9	23	1,118	30.9	86.2
October	1,696	1	3	8	20	951	25.4	68.2
November	1,498	1	4	9	21	1,229	26.5	76.3
December	1,125	1	3	7	18	1,110	23.0	68.6
2019								
January	1,596	1	3	8	21	1,047	27.1	81.1
February	1,676	1	3	8	19	916	21.4	48.0
March	1,609	1	4	8	20	980	27.0	73.3
April	2,103	1	3	8	20	902	25.2	65.8
May	2,125	1	4	8	19	902	21.6	56.1

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	1,749	1	3	8	21	861	25.2	65.3
July	2,478	1	4	8	19	967	23.7	63.0
August	2,405	1	4	8	21	948	24.7	61.7
September	1,783	1	3	8	21	1,018	27.4	68.7
October	2,103	1	3	8	21	1,017	25.3	65.2
November	1,889	1	3	8	20	1,000	24.9	68.9
December	1,844	1	3	9	20	756	23.6	55.5
2020								
January	1,948	1	3	8	19	725	22.1	51.7
February	1,522	1	3	8	21	836	25.3	61.2
March	1,561	1	3	8	22	726	24.8	54.6
April	1,078	1	4	8	21	849	23.3	52.2
May	1,071	1	3	8	20	653	23.5	52.8
June	1,428	1	3	7	18	665	19.4	45.1
July	2,737	1	3	8	20	714	21.0	44.4
August	2,001	1	4	9	22	735	22.2	47.4
September	2,086	1	3	8	22	448	21.4	41.6
October	1,803	1	3	8	20	553	21.7	46.8
November	1,660	1	4	9	22	596	23.5	48.7
December	1,548	1	3	8	21	510	21.9	43.9
2021								
January	1,521	1	3	7	18	501	18.9	41.2
February	1,519	1	4	8	20	540	20.5	41.8
March	1,588	1	3	7	19	473	18.9	36.3
April	1,558	1	3	8	20	376	19.2	33.3
May	1,356	1	3	8	20	437	20.0	39.0
June	1,292	1	3	8	22	340	19.6	30.9
July	1,779	1	3	8	19	382	17.6	30.5
August	1,790	1	3	8	20	364	17.3	27.8
September	1,366	1	3	7	19	294	17.5	29.3
October	1,295	1	3	8	19	293	16.9	26.1

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	1,152	1	3	7	18	293	15.8	25.6
December	1,051	1	3	7	17	258	15.6	25.2
2022								
January	966	1	3	7	15	238	14.5	24.1
February	743	1	3	6	14	161	12.5	18.8
March	830	1	3	7	16	162	13.0	18.2
April	734	1	3	7	15	137	12.2	16.2
May	579	1	3	7	13	117	11.2	14.7
June	475	1	3	6	13	97	10.3	12.4
July	436	1	3	6	13	71	9.5	10.7
August	290	1	2	6	11	36	7.4	6.3
September	24	1	1	3	6	11	4.0	2.9
<i>Asthma</i>	42,825	1	3	8	19	1,669	21.1	56.1
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	17	1	3	10	16	742	55.2	177.3
April	142	1	3	6	13	393	16.9	48.4
May	318	1	4	7	17	1,099	24.1	90.2
June	273	1	5	10	29	1,067	35.5	89.7
July	371	1	3	7	17	1,070	26.0	92.4
August	444	1	4	9	24	1,130	37.9	116.9
September	315	1	4	9	24	818	31.1	87.8
October	403	1	3	8	22	720	26.2	69.2
November	270	1	4	10	28	1,669	41.2	149.7
December	311	1	4	9	22	892	27.3	75.2
2018								
January	284	1	4	11	22	576	25.8	57.4
February	281	1	3	7	17	1,401	27.3	104.9
March	320	1	4	7	22	987	32.6	96.7
April	324	1	3	7	17	833	25.8	84.8

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	407	1	4	7	17	769	23.7	72.3
June	178	1	3	10	27	736	32.6	82.4
July	470	1	3	8	18	848	21.0	59.4
August	463	1	4	10	24	940	31.6	94.8
September	308	1	4	9	21	782	29.5	78.0
October	380	1	3	8	18	872	22.2	69.4
November	548	1	5	10	24	1,067	32.4	93.1
December	558	1	3	9	22	1,154	29.3	86.8
2019								
January	903	1	4	8	20	1,001	26.0	78.0
February	835	1	3	7	16	1,057	20.7	66.2
March	874	1	4	8	19	927	22.3	63.0
April	1,095	1	4	8	22	601	24.5	54.4
May	995	1	3	8	18	1,003	20.4	49.3
June	756	1	3	8	18	913	22.3	59.7
July	1,151	1	4	8	20	886	23.6	62.5
August	1,366	1	4	8	18	918	23.7	61.8
September	1,024	1	3	8	19	1,018	23.6	61.9
October	1,369	1	3	7	18	755	20.0	46.9
November	1,219	1	3	8	20	620	23.0	53.5
December	847	1	4	8	21	905	24.5	63.6
2020								
January	920	1	3	7	17	469	17.7	35.6
February	1,008	1	3	7	16	475	17.0	35.5
March	1,107	1	3	7	17	726	19.6	49.2
April	867	1	3	8	17	666	21.1	50.7
May	676	1	3	7	16	675	20.5	50.4
June	909	1	3	7	18	641	19.8	43.9
July	1,368	1	3	8	19	482	20.3	43.1
August	1,138	1	3	8	19	459	18.0	33.6
September	1,172	1	3	8	20	410	19.3	38.2

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
October	1,023	1	3	7	19	691	22.0	56.4
November	904	1	3	7	18	596	19.6	42.2
December	816	1	3	8	21	571	19.5	40.7
2021								
January	924	1	3	8	18	419	17.2	31.3
February	763	1	3	7	17	340	16.4	30.3
March	868	1	3	8	20	354	17.6	30.6
April	792	1	3	8	18	343	19.2	36.7
May	782	1	3	8	19	386	18.0	31.6
June	652	1	3	7	17	335	17.4	30.6
July	773	1	3	7	18	212	16.6	26.6
August	886	1	3	7	18	317	16.8	28.4
September	578	1	3	8	19	303	18.1	33.4
October	660	1	3	7	17	189	15.0	22.4
November	529	1	3	7	16	256	14.5	23.0
December	480	1	3	6	18	186	14.3	22.2
2022								
January	431	1	3	7	14	220	15.3	26.7
February	388	1	3	6	16	193	13.3	19.0
March	349	1	3	7	16	152	13.3	17.7
April	341	1	3	6	14	123	12.2	17.5
May	286	1	3	7	16	93	12.0	14.3
June	235	1	2	6	13	90	10.8	14.8
July	225	1	3	6	10	58	8.7	10.1
August	143	1	2	5	11	34	7.4	6.7
September	13	1	1	3	7	9	3.8	3.1
<i>Chronic Rhinosinusitis</i>	<i>23,261</i>	<i>1</i>	<i>3</i>	<i>7</i>	<i>18</i>	<i>1,401</i>	<i>20.3</i>	<i>51.8</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	52	1	3	7	16	393	23.2	60.7
May	91	1	3	7	17	1,099	34.2	139.9
June	124	1	3	6	16	766	28.5	97.5
July	63	1	7	21	33	372	27.9	47.5
August	160	1	2	7	21	766	30.7	97.2
September	68	1	3	5	12	642	17.9	77.4
October	73	1	3	8	14	154	14.9	25.1
November	61	1	5	9	17	354	30.0	69.0
December	49	1	4	10	21	391	22.9	56.1
2018								
January	124	1	5	12	28	892	37.2	105.7
February	95	1	3	7	26	1,401	44.7	154.6
March	106	1	6	12	35	244	26.9	40.2
April	139	1	3	14	31	392	29.8	51.8
May	123	1	5	12	27	548	27.9	57.7
June	52	1	3	8	24	149	21.6	33.7
July	142	1	4	8	24	833	25.8	78.2
August	169	1	5	10	27	940	40.1	112.6
September	118	1	5	13	36	212	28.1	37.2
October	103	1	4	9	24	370	28.1	59.7
November	192	1	4	8	18	968	27.8	94.2
December	224	1	3	7	21	1,154	29.5	101.7
2019								
January	270	1	4	8	21	720	22.1	58.5
February	360	1	3	7	16	1,057	19.1	66.4
March	320	1	4	7	18	784	24.0	66.6
April	500	1	3	8	19	902	24.6	71.0
May	362	1	3	8	21	316	21.2	39.1
June	324	1	4	8	18	913	22.5	64.2
July	555	1	4	10	21	352	20.6	36.3
August	738	1	4	8	19	918	24.1	58.9

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	751	1	3	7	18	669	21.8	52.4
October	739	1	3	7	17	767	21.0	62.8
November	791	1	3	8	20	860	24.0	58.3
December	699	1	3	7	18	905	22.1	60.2
2020								
January	631	1	3	8	17	380	20.5	41.3
February	640	1	3	7	15	620	18.5	47.4
March	692	1	2	6	17	713	23.0	63.5
April	564	1	3	7	18	666	25.2	70.7
May	419	1	3	7	16	520	18.6	41.2
June	615	1	3	8	20	592	19.2	41.1
July	774	1	3	7	19	467	19.2	35.8
August	683	1	3	6	15	304	18.3	37.1
September	584	1	3	7	18	508	20.1	45.6
October	567	1	4	8	20	637	22.9	55.1
November	538	1	3	7	17	528	19.2	45.8
December	544	1	3	7	18	403	17.3	33.9
2021								
January	594	1	3	7	16	302	17.8	33.1
February	565	1	3	7	16	485	16.2	34.6
March	486	1	3	8	19	332	17.5	31.7
April	486	1	3	7	17	343	19.3	41.4
May	519	1	3	8	18	386	15.8	26.0
June	437	1	3	7	16	279	17.2	30.6
July	505	1	4	7	16	212	16.2	23.7
August	485	1	4	8	19	317	18.0	32.3
September	413	1	3	7	16	303	16.4	32.1
October	477	1	3	7	16	189	15.3	24.1
November	347	1	2	7	17	196	14.1	20.8
December	343	1	3	7	17	209	15.2	23.2
2022								

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	300	1	2	7	16	203	14.8	23.2
February	248	1	3	7	13	175	13.2	20.5
March	269	1	3	7	14	129	12.9	18.1
April	234	1	3	6	14	113	11.4	15.1
May	207	1	3	5	12	65	10.1	12.5
June	165	1	2	6	14	75	10.6	13.2
July	104	1	2	5	10	47	7.9	8.6
August	81	1	2	5	9	32	7.2	7.7
September	8	1	1	2	7	12	4.0	4.2
<i>Eosinophilic Esophagitis</i>	<i>6,807</i>	<i>1</i>	<i>3</i>	<i>8</i>	<i>19</i>	<i>1,154</i>	<i>20.7</i>	<i>48.7</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	13	1	6	12	16	393	41.6	106.3
May	12	1	3	7	13	30	8.8	8.4
June	10	1	2	4	7	25	6.2	6.9
July	56	1	3	8	23	480	26.8	67.7
August	42	1	4	10	24	552	35.7	90.2
September	47	1	1	4	14	245	26.1	55.8
October	1	14	14	14	14	14	14.0	NaN
November	45	1	3	8	23	382	24.9	59.1
December	56	1	3	6	12	506	17.9	67.4
2018								
January	42	1	3	9	19	410	25.3	66.3
February	60	1	3	8	16	172	15.3	30.0
March	57	1	2	5	11	629	21.3	83.3
April	49	1	4	9	39	880	59.8	159.9
May	43	1	5	12	29	235	24.5	39.5
June	83	1	3	10	32	155	24.1	35.2
July	91	1	2	6	13	250	14.2	29.2

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	80	1	4	7	14	589	22.9	76.6
September	47	1	5	8	16	398	26.5	66.5
October	72	1	4	10	19	507	27.4	72.5
November	91	1	7	12	32	403	31.8	61.5
December	145	1	3	11	28	1,154	33.9	107.7
2019								
January	94	1	5	10	19	212	17.2	25.8
February	43	1	3	8	18	324	29.3	64.0
March	104	1	3	6	12	204	15.0	29.7
April	114	1	4	8	23	633	33.9	86.5
May	179	1	4	8	21	651	27.0	75.0
June	83	1	3	7	12	435	16.9	50.3
July	229	1	3	7	17	175	16.5	26.8
August	159	1	4	7	22	522	26.1	62.1
September	219	1	4	7	17	389	21.5	45.1
October	218	1	4	10	25	363	25.8	43.8
November	164	1	3	9	18	371	21.3	44.7
December	156	1	5	10	21	160	18.7	24.7
2020								
January	155	1	3	7	15	226	15.3	28.3
February	261	1	4	11	21	756	20.6	53.0
March	171	1	4	11	20	310	21.3	36.4
April	121	1	4	8	24	554	25.0	59.5
May	86	1	3	7	31	130	22.6	31.2
June	96	1	3	8	25	641	31.6	76.4
July	125	1	3	7	21	329	22.0	45.0
August	138	1	3	8	20	292	22.8	43.1
September	127	1	4	13	26	260	24.9	42.6
October	133	1	4	8	18	206	18.2	34.8
November	140	1	3	8	21	141	15.8	22.1
December	115	1	3	7	18	227	15.6	26.1

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2021								
January	157	1	4	11	31	202	23.5	33.8
February	114	1	4	7	16	256	17.1	34.8
March	159	1	3	7	16	473	17.8	42.5
April	125	1	4	12	22	312	19.6	32.8
May	158	1	3	7	18	235	18.4	32.2
June	110	1	3	6	14	244	16.2	33.2
July	128	1	3	7	14	306	17.6	38.8
August	138	1	4	9	24	306	21.5	37.7
September	134	1	3	6	15	85	12.1	15.6
October	154	1	4	7	15	161	13.4	19.3
November	170	1	2	7	19	157	16.8	27.3
December	140	1	4	8	19	100	13.8	16.7
2022								
January	92	1	3	6	11	143	13.6	23.4
February	78	1	3	9	21	113	16.4	21.7
March	80	1	3	10	19	84	15.2	18.0
April	63	1	3	8	16	134	14.7	21.4
May	60	1	3	7	18	58	11.5	11.7
June	57	1	2	5	12	69	10.0	14.4
July	68	1	3	5	13	34	8.9	8.9
August	49	1	4	6	9	21	6.5	4.8
September	1	2	2	2	2	2	2.0	NaN
<i>Prurigo Nodularis</i>	2,445	1	3	7	18	1,110	24.2	71.3
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	31	1	2	6	18	457	24.1	80.9
May	6	1	1	6	12	25	8.3	9.2
June	4	4	4	8	15	17	9.3	6.4

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	75	1	2	4	9	849	30.2	105.9
August	27	1	4	10	28	1,028	97.1	250.5
September	1	12	12	12	12	12	12.0	NaN
October	20	1	2	5	8	815	64.9	194.6
November	12	1	6	15	57	731	92.1	206.0
December	6	1	1	5	7	9	4.7	3.3
2018								
January	34	1	4	9	28	184	22.7	34.8
February	25	1	5	8	19	167	33.8	51.3
March	4	34	36	50	69	76	52.3	20.2
April	27	1	3	8	29	394	29.8	75.5
May	19	1	2	12	26	964	65.4	218.2
June	47	1	3	8	15	119	13.9	19.8
July	31	1	2	12	22	105	19.5	25.0
August	25	1	6	9	27	369	36.8	75.8
September	44	1	3	9	19	934	41.8	142.1
October	59	1	2	6	15	532	28.6	81.8
November	40	1	4	8	16	735	30.4	115.4
December	34	1	2	6	12	1,110	58.0	200.7
2019								
January	53	1	3	7	15	218	30.5	53.6
February	42	1	3	6	13	307	19.6	54.1
March	26	1	3	7	25	751	47.2	146.9
April	32	1	4	10	20	457	36.1	90.6
May	47	1	2	6	11	353	16.1	51.2
June	86	1	3	7	14	73	11.3	13.6
July	85	1	3	9	30	171	23.3	34.1
August	60	1	2	4	13	311	17.3	44.6
September	38	1	3	7	34	162	27.8	41.9
October	59	1	3	7	18	174	20.0	35.5
November	74	1	3	6	19	322	23.6	51.9

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December	57	1	5	8	20	85	18.1	20.6
2020								
January	37	1	5	9	20	389	43.7	95.0
February	46	1	5	13	24	231	28.1	50.5
March	24	1	7	10	34	327	34.0	67.3
April	30	1	3	9	17	131	17.8	28.7
May	40	1	3	8	21	183	21.8	37.8
June	31	1	4	8	16	165	19.0	33.2
July	56	1	4	6	23	229	24.8	50.6
August	68	1	3	6	17	295	23.0	52.2
September	58	1	3	7	15	400	20.6	54.9
October	38	1	4	9	12	51	12.3	13.6
November	74	1	3	8	17	99	15.1	20.5
December	58	1	3	8	17	129	17.6	27.9
2021								
January	47	1	3	8	19	94	16.6	21.1
February	73	1	4	7	19	168	17.2	26.1
March	55	1	3	8	19	473	29.9	73.2
April	28	1	4	12	42	243	35.7	56.7
May	25	1	3	10	14	59	13.0	13.4
June	37	1	1	3	13	47	9.2	11.6
July	44	2	5	10	23	179	17.2	27.6
August	35	1	4	14	40	141	32.2	39.6
September	52	1	3	8	20	231	18.4	35.2
October	28	1	5	11	17	38	12.6	11.0
November	37	1	3	6	17	95	16.1	23.2
December	26	1	2	3	12	155	13.6	31.0
2022								
January	43	1	2	6	17	64	10.6	12.3
February	25	1	4	6	13	139	16.2	29.3
March	15	1	2	5	17	40	9.9	11.2

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	23	1	3	6	13	44	9.1	9.6
May	26	1	3	6	14	31	9.4	9.4
June	20	1	3	6	15	30	9.1	8.5
July	10	2	5	8	14	17	8.6	5.0
August	5	6	8	9	10	17	10.0	4.2
September	1	1	1	1	1	1	1.0	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>								
	61,363	8	12	19	36	1,716	41.1	82.1
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	9	10	14	16	34	742	101.1	240.6
April	291	8	12	17	30	850	45.2	105.2
May	766	8	12	18	33	1,106	46.0	107.1
June	836	8	12	20	37	1,169	46.2	105.7
July	737	8	12	19	34	1,094	45.3	100.7
August	836	8	12	19	37	1,505	60.5	153.5
September	692	8	12	18	36	1,087	51.2	119.6
October	823	8	12	20	42	1,529	61.2	144.2
November	796	8	12	19	39	1,669	50.5	122.3
December	516	8	12	17	30	1,716	50.5	132.9
2018								
January	524	8	12	19	40	1,354	56.2	135.1
February	597	8	12	18	38	1,401	50.7	126.5
March	720	8	12	19	40	1,495	55.7	134.8
April	608	8	11	17	36	1,160	48.1	112.5
May	604	8	12	21	36	1,107	44.9	99.6
June	561	8	13	22	49	1,167	56.5	118.5
July	775	8	12	20	42	1,494	53.2	120.1
August	928	8	12	21	46	1,364	56.7	129.5

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	773	8	13	19	40	1,118	50.9	109.3
October	936	8	12	20	43	1,175	51.8	108.0
November	937	8	12	19	36	1,229	45.0	94.3
December	692	8	12	19	35	1,154	44.3	93.6
2019								
January	1,062	8	12	19	36	1,047	46.2	100.3
February	1,169	8	12	18	37	1,057	42.2	82.0
March	1,126	8	12	19	37	980	44.9	91.4
April	1,382	8	12	19	38	902	45.4	87.5
May	1,344	8	12	18	36	1,003	39.2	76.6
June	1,169	8	13	20	41	913	47.8	92.5
July	1,650	8	12	18	36	967	41.4	84.7
August	1,710	8	12	20	40	948	43.3	80.8
September	1,306	8	12	20	42	1,018	47.3	84.2
October	1,624	8	12	20	39	1,017	42.8	82.5
November	1,452	8	12	20	37	1,000	43.7	82.8
December	1,398	8	12	19	37	905	41.8	74.8
2020								
January	1,339	8	12	18	33	725	37.1	60.6
February	1,135	8	12	19	37	836	41.5	73.0
March	1,321	8	12	19	37	726	39.6	66.0
April	899	8	12	19	39	849	41.9	74.8
May	796	8	12	19	41	653	43.0	69.2
June	1,048	8	12	19	36	665	39.9	69.1
July	1,752	8	12	20	39	714	38.4	58.6
August	1,504	8	12	20	37	735	36.8	55.0
September	1,518	8	12	20	36	508	36.6	52.8
October	1,333	8	12	20	39	691	41.8	68.5
November	1,296	8	12	20	38	596	40.2	61.2
December	1,299	8	12	20	36	571	34.7	48.5
2021								

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	1,090	8	12	19	33	501	33.2	47.2
February	1,003	8	12	18	32	540	34.0	50.5
March	1,088	8	12	19	35	473	33.6	44.5
April	1,065	8	12	19	35	376	33.5	43.1
May	964	8	12	19	35	437	33.7	47.3
June	873	8	13	20	37	340	33.0	37.8
July	1,186	8	12	18	34	382	32.3	38.7
August	1,194	8	13	20	35	346	31.2	34.9
September	931	8	12	19	33	303	30.9	35.4
October	918	8	12	18	32	293	29.0	31.2
November	776	8	12	18	31	293	28.2	30.5
December	648	8	12	20	32	258	29.7	31.8
2022								
January	582	8	11	17	30	238	27.5	30.8
February	458	8	11	17	28	175	25.0	24.0
March	516	8	11	16	27	162	23.7	20.7
April	450	8	11	16	25	145	22.7	21.3
May	342	8	10	15	25	112	21.6	18.1
June	295	8	10	15	25	97	20.6	15.4
July	243	8	10	15	24	71	18.9	11.5
August	148	8	10	13	18	36	14.6	6.0
September	4	9	9	10	12	12	10.3	1.5
<i>Any Indication</i>	<i>56,801</i>	<i>8</i>	<i>12</i>	<i>19</i>	<i>36</i>	<i>1,716</i>	<i>41.1</i>	<i>82.4</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	9	10	14	16	34	742	101.1	240.6
April	254	8	12	16	27	850	46.1	111.8
May	625	8	12	18	32	1,099	43.2	96.8
June	718	8	12	21	38	1,067	47.8	105.2
July	693	8	12	19	34	1,169	47.0	110.3

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	768	8	12	19	38	1,505	62.4	157.8
September	657	8	12	19	37	1,087	52.2	119.1
October	722	8	13	21	41	1,529	62.0	147.7
November	702	8	12	19	38	1,669	49.7	124.8
December	450	8	12	17	30	1,716	53.6	140.5
2018								
January	514	8	13	20	37	1,354	53.4	131.3
February	550	8	12	18	38	1,401	49.2	123.2
March	589	8	13	20	40	1,495	58.9	145.8
April	593	8	11	17	38	1,160	48.7	113.6
May	530	8	12	20	35	1,107	45.4	100.3
June	494	8	13	21	48	1,167	57.6	125.0
July	724	8	12	20	44	1,494	55.2	124.3
August	782	8	12	21	42	1,364	58.7	139.0
September	762	8	13	19	40	1,118	48.7	102.5
October	924	8	12	20	42	951	47.7	93.1
November	855	8	12	19	37	1,229	46.4	98.0
December	642	8	12	19	35	1,154	45.0	98.2
2019								
January	1,002	8	12	20	36	1,047	46.5	101.6
February	1,071	8	12	18	36	1,057	41.6	82.5
March	1,062	8	12	18	35	980	45.0	93.5
April	1,308	8	12	19	38	902	44.3	85.1
May	1,292	8	12	18	36	1,003	39.2	77.1
June	1,055	8	12	20	41	913	46.5	87.3
July	1,502	8	11	18	36	967	41.0	83.9
August	1,618	8	12	19	39	948	42.2	79.0
September	1,269	8	12	20	42	1,018	47.7	84.8
October	1,538	8	12	19	39	1,017	43.0	83.7
November	1,411	8	12	20	36	1,000	43.3	83.3
December	1,309	8	12	19	36	905	41.4	73.6

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2020								
January	1,283	8	12	18	34	725	38.4	63.6
February	1,050	8	12	19	37	836	41.9	74.0
March	1,216	8	12	19	38	726	41.0	69.3
April	877	8	12	19	39	849	41.9	75.0
May	745	8	12	19	39	653	42.1	67.4
June	991	8	12	18	35	665	37.0	63.0
July	1,566	8	12	20	40	714	38.6	59.4
August	1,355	8	12	20	37	735	36.9	55.6
September	1,369	8	12	20	36	508	36.3	53.0
October	1,217	8	12	20	39	691	41.3	67.6
November	1,188	8	12	21	39	596	39.9	60.5
December	1,151	8	12	20	36	571	35.7	52.1
2021								
January	1,045	8	12	19	34	501	33.9	49.2
February	979	8	12	18	33	540	34.3	50.3
March	1,023	8	12	20	34	473	33.5	44.8
April	1,022	8	12	19	35	376	34.2	44.2
May	920	8	12	19	35	437	33.2	46.3
June	826	8	13	20	38	340	33.4	38.5
July	1,004	8	12	19	35	382	32.8	39.4
August	1,102	8	13	20	36	364	31.3	34.9
September	863	8	12	19	33	303	30.9	35.7
October	841	8	12	18	32	293	28.8	31.0
November	702	8	11	17	31	293	28.1	31.1
December	617	8	11	19	31	258	29.0	31.1
2022								
January	552	8	11	16	31	238	28.2	32.3
February	421	8	11	17	29	193	25.6	25.7
March	508	8	11	16	27	162	23.6	21.0
April	425	8	11	16	26	137	22.9	21.2

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	314	8	11	15	26	117	21.9	18.0
June	281	8	10	15	24	97	20.1	14.9
July	208	8	10	16	24	71	19.1	11.8
August	142	8	10	13	19	36	14.8	6.0
September	4	9	9	10	12	12	10.3	1.5
<i>Atopic Dermatitis</i>	45,816	8	12	19	36	1,716	42.1	85.8
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	9	10	14	16	34	742	101.1	240.6
April	246	8	12	16	27	850	47.0	113.5
May	620	8	12	18	32	1,099	43.4	97.2
June	714	8	12	21	37	1,067	46.7	102.0
July	649	8	12	19	34	1,169	46.8	109.3
August	714	8	12	19	39	1,505	64.2	162.3
September	644	8	12	19	37	1,087	50.7	115.8
October	699	8	12	21	41	1,529	62.0	149.4
November	687	8	12	19	39	1,669	49.4	123.1
December	442	8	12	17	30	1,716	53.3	141.3
2018								
January	514	8	13	20	38	1,354	55.0	135.0
February	541	8	12	18	38	1,401	49.8	124.5
March	571	8	13	20	41	1,495	56.9	140.4
April	530	8	11	17	38	1,160	48.6	113.7
May	495	8	12	20	34	1,107	45.3	101.1
June	479	8	13	21	47	1,167	57.2	125.3
July	703	8	12	20	43	1,494	55.5	126.0
August	764	8	12	21	45	1,364	59.0	139.6
September	723	8	13	19	40	1,118	50.9	109.1
October	894	8	12	20	42	951	46.4	90.8
November	770	8	12	19	37	1,229	47.0	101.0

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December	521	8	12	18	35	852	43.5	92.2
2019								
January	835	8	12	20	38	1,047	49.3	108.6
February	866	8	12	19	39	916	41.0	71.1
March	802	8	12	19	37	980	47.5	97.6
April	1,098	8	12	19	37	902	44.4	86.1
May	1,109	8	12	18	35	902	38.4	75.0
June	890	8	13	21	42	861	47.0	87.1
July	1,196	8	12	19	37	967	42.9	86.9
August	1,218	8	12	20	40	948	42.0	78.1
September	921	8	13	20	47	1,018	49.6	87.1
October	1,081	8	12	20	41	1,017	45.7	87.9
November	951	8	12	19	36	1,000	45.0	91.3
December	1,002	8	12	19	36	756	41.4	72.0
2020								
January	1,014	8	12	18	33	725	39.4	67.3
February	749	8	12	21	41	836	46.3	81.5
March	857	8	12	20	43	726	42.8	70.0
April	558	8	12	20	41	849	39.8	65.3
May	541	8	13	20	38	653	42.8	68.9
June	686	8	12	18	36	665	36.8	60.4
July	1,192	8	13	20	40	714	38.3	58.6
August	1,031	8	13	20	37	735	37.9	59.5
September	1,053	8	13	21	37	448	36.0	50.1
October	905	8	13	20	39	553	39.3	59.1
November	894	8	12	21	38	596	41.0	62.2
December	860	8	12	20	38	510	36.1	50.8
2021								
January	744	8	11	19	33	501	34.9	53.5
February	759	8	12	19	35	540	35.9	53.5
March	749	8	12	20	35	473	34.8	46.0

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	801	8	13	20	39	376	34.2	41.4
May	671	8	12	19	36	437	35.1	50.1
June	659	8	13	21	40	340	34.5	37.5
July	802	8	12	19	34	382	31.9	39.5
August	856	8	13	20	35	364	30.8	34.4
September	699	8	12	19	34	294	31.2	35.6
October	631	8	12	19	34	293	30.0	32.0
November	548	8	11	17	32	293	28.2	31.8
December	482	8	11	19	31	258	29.6	32.1
2022								
January	444	8	11	16	30	238	27.8	31.8
February	309	8	11	16	27	161	24.9	24.6
March	382	8	12	17	28	162	24.0	21.6
April	338	8	11	16	24	137	22.1	19.9
May	241	8	11	15	26	117	22.0	18.4
June	205	8	10	14	22	97	18.9	13.8
July	156	8	11	16	26	71	19.7	12.0
August	100	8	10	13	17	36	14.0	5.2
September	2	9	9	10	11	11	10.0	1.4
<i>Asthma</i>	20,552	8	12	19	35	1,669	38.6	74.8
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	9	10	14	16	34	742	101.1	240.6
April	57	8	10	15	23	393	36.9	72.1
May	154	8	12	17	31	1,099	45.8	126.2
June	158	8	13	27	54	1,067	58.5	112.5
July	160	8	11	17	28	1,070	52.3	135.0
August	241	8	12	23	42	1,130	66.6	153.0
September	140	8	14	23	46	818	60.3	125.2
October	192	8	12	20	34	720	41.7	81.3

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	166	8	13	22	43	1,669	66.3	181.4
December	165	8	12	20	36	892	44.8	94.9
2018								
January	159	8	13	18	35	576	39.8	69.5
February	122	8	12	19	34	1,401	56.1	154.5
March	161	8	13	24	44	987	63.2	128.7
April	120	8	11	19	34	807	44.3	102.3
May	172	8	12	18	33	769	47.9	104.3
June	108	8	14	24	52	736	54.1	101.1
July	206	8	11	18	34	848	38.6	81.6
August	201	8	13	22	38	940	51.7	111.5
September	166	8	12	18	45	782	50.5	94.1
October	188	8	11	17	33	872	46.4	113.8
November	292	8	13	21	39	968	49.6	106.0
December	304	8	13	21	37	1,154	48.2	108.9
2019								
January	480	8	11	19	36	1,001	46.1	102.9
February	390	8	12	16	29	1,057	40.6	99.9
March	450	8	13	18	32	927	38.2	82.4
April	552	8	12	20	41	601	42.7	70.2
May	480	8	11	18	36	1,003	36.9	66.6
June	415	8	12	18	34	913	40.7	78.2
July	569	8	12	17	37	886	40.4	82.4
August	696	8	11	17	38	918	42.0	80.7
September	512	8	12	19	39	1,018	43.2	82.3
October	685	8	12	18	36	755	36.3	61.8
November	606	8	13	20	38	620	42.0	70.4
December	423	8	13	20	38	905	44.4	84.5
2020								
January	451	8	12	17	32	380	31.0	41.1
February	463	8	12	18	32	475	32.7	47.4

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	488	8	11	18	33	726	38.6	69.1
April	422	8	11	17	34	666	37.3	65.7
May	311	8	12	18	34	675	39.4	69.4
June	421	8	12	18	39	641	37.4	59.2
July	576	8	12	19	36	482	36.4	56.2
August	569	8	12	19	35	459	32.3	42.9
September	549	8	12	19	34	410	33.7	47.2
October	457	8	12	19	37	691	42.1	78.0
November	406	8	12	20	42	596	37.9	56.6
December	456	8	12	20	36	571	33.8	51.0
2021								
January	455	8	11	18	33	419	30.9	40.3
February	344	8	12	20	32	340	30.1	39.5
March	401	8	13	21	35	354	32.8	39.3
April	407	8	12	18	31	343	33.7	46.5
May	378	8	12	18	36	386	31.4	39.8
June	321	8	13	18	35	335	31.3	37.5
July	328	8	11	18	35	212	31.9	34.3
August	395	8	13	20	36	317	32.1	35.4
September	288	8	12	18	30	303	31.1	40.8
October	306	8	12	17	30	207	27.5	29.0
November	247	8	11	18	31	256	27.7	29.3
December	212	8	13	20	31	186	27.7	26.7
2022								
January	191	8	11	16	35	220	31.0	35.6
February	161	8	10	17	28	193	23.9	21.9
March	171	8	11	16	28	152	23.5	20.6
April	144	8	12	15	29	123	24.5	21.6
May	125	8	11	17	26	93	22.3	16.2
June	97	8	11	15	24	90	21.3	17.1
July	66	8	10	15	22	58	19.3	13.3

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	45	8	11	12	16	34	14.6	6.4
September	2	9	9	9	9	9	9.0	0.0
<i>Chronic</i>								
<i>Rhinosinusitis</i>	10,769	8	12	18	35	1,401	37.9	70.2
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	23	11	13	17	31	393	47.1	86.4
May	42	8	13	18	31	1,099	70.1	201.2
June	52	8	12	21	34	766	62.7	144.5
July	42	8	18	26	39	372	37.2	55.4
August	62	8	12	22	47	766	67.9	147.7
September	25	8	11	15	25	642	42.8	125.3
October	16	8	12	15	28	154	30.7	38.7
November	27	8	12	17	33	354	58.6	96.8
December	25	8	11	15	32	391	38.4	75.6
2018								
January	56	8	13	22	48	892	69.8	151.9
February	42	8	14	29	63	1,401	90.3	222.8
March	45	8	10	23	41	209	33.9	37.7
April	64	8	14	21	45	255	42.6	52.8
May	69	8	14	21	40	548	43.1	72.8
June	27	8	14	24	36	149	34.9	36.2
July	79	8	13	26	49	392	41.5	61.8
August	77	8	14	27	56	940	80.5	155.8
September	82	8	14	24	47	212	38.1	38.1
October	68	8	13	19	43	833	55.7	118.4
November	87	8	10	17	33	968	45.0	117.9
December	99	8	13	23	42	1,154	58.0	146.6
2019								

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	131	8	12	21	42	372	36.3	53.5
February	160	8	12	17	30	1,057	37.7	96.7
March	143	8	11	17	36	784	43.5	90.2
April	222	8	12	18	39	902	47.1	100.3
May	189	8	12	21	46	316	38.1	48.3
June	170	8	12	17	30	913	39.6	85.9
July	275	8	12	18	33	280	31.7	37.6
August	381	8	11	17	38	918	41.1	74.7
September	349	8	12	19	33	669	40.3	70.2
October	379	8	11	17	32	767	37.4	81.7
November	411	8	13	20	40	860	43.7	76.4
December	315	8	12	19	34	905	43.1	84.8
2020								
January	314	8	12	17	34	380	35.1	49.6
February	302	8	11	15	29	620	35.2	64.9
March	304	8	11	18	36	713	46.9	90.1
April	259	8	11	19	37	666	49.6	98.5
May	206	8	12	17	34	520	36.3	55.6
June	271	8	13	19	36	592	35.5	56.6
July	316	8	12	20	41	467	37.0	48.4
August	283	8	11	19	37	304	36.6	48.4
September	280	8	12	18	32	508	35.9	57.5
October	256	8	12	20	39	637	44.9	77.1
November	253	8	12	19	36	528	38.5	62.9
December	279	8	13	20	34	403	32.3	41.7
2021								
January	266	8	11	17	32	302	33.1	43.6
February	226	8	11	17	31	485	32.4	49.3
March	238	8	12	18	33	332	31.4	41.9
April	220	8	12	17	29	343	37.4	55.4
May	258	8	12	17	32	386	27.9	33.3

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	204	8	12	19	36	279	31.9	38.8
July	198	8	11	18	37	212	31.2	31.5
August	231	8	13	19	38	317	32.7	39.8
September	194	8	11	17	31	303	30.8	42.8
October	212	8	11	16	32	189	28.2	30.8
November	143	8	12	19	30	196	27.1	26.2
December	170	8	12	18	32	209	27.8	27.1
2022								
January	119	8	12	18	33	203	29.5	29.9
February	120	8	10	14	24	175	23.2	24.4
March	118	8	11	15	26	100	22.8	19.8
April	96	8	12	17	28	113	23.9	19.3
May	75	8	10	15	35	65	22.3	15.3
June	65	8	11	17	28	75	22.3	15.3
July	34	8	9	13	21	47	16.8	9.7
August	23	8	10	14	24	32	17.2	7.7
September	2	9	9	11	12	12	10.5	2.1
<i>Eosinophilic Esophagitis</i>	3,114	8	12	19	36	1,154	37.4	65.0
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	8	8	12	14	34	393	65.1	133.1
May	5	9	10	15	17	30	16.2	8.4
June	1	25	25	25	25	25	25.0	NaN
July	28	8	12	21	38	480	48.8	91.0
August	26	8	11	22	42	552	55.6	110.8
September	16	9	11	22	99	208	55.8	65.7
October	1	14	14	14	14	14	14.0	NaN
November	22	8	9	22	43	115	30.5	26.9

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December 2018	18	8	10	14	20	506	42.3	115.9
January	18	8	10	17	24	168	26.2	36.4
February	25	8	11	15	22	172	28.4	43.0
March	23	8	9	17	39	629	48.8	127.8
April	24	9	13	41	85	880	118.0	215.5
May	27	8	13	22	40	235	37.4	45.3
June	42	8	11	31	55	155	42.9	41.3
July	37	8	10	15	42	250	29.4	41.3
August	24	8	12	20	40	369	38.1	72.2
September	35	8	9	12	19	398	33.8	75.1
October	35	8	12	19	37	507	49.5	99.6
November	36	8	13	21	55	225	41.5	51.1
December 2019	69	8	15	24	44	1,154	68.0	163.9
January	52	8	12	17	31	212	25.3	30.3
February	35	8	12	19	62	324	43.7	57.9
March	38	8	11	19	42	204	34.4	42.8
April	42	8	12	21	49	633	73.7	132.7
May	70	8	12	22	41	651	45.2	93.9
June	43	8	11	14	35	435	35.3	68.1
July	95	8	11	16	27	485	34.7	64.3
August	80	8	11	19	36	522	45.1	82.1
September	86	8	13	21	47	389	44.8	64.0
October	112	8	12	23	45	363	42.3	52.0
November	83	8	13	21	36	371	39.6	57.5
December 2020	83	8	13	18	38	160	31.6	31.2
January	76	8	11	16	27	226	26.8	33.0
February	139	8	12	20	35	756	31.9	65.7
March	104	8	12	17	26	310	30.1	40.9

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	58	8	13	21	37	554	44.2	80.6
May	35	8	13	33	70	130	42.8	33.0
June	55	8	12	21	62	641	55.8	96.4
July	42	8	15	23	44	329	38.5	54.2
August	59	8	14	26	55	292	44.6	51.4
September	63	8	14	23	32	229	34.1	39.0
October	51	8	10	13	25	204	29.5	40.6
November	71	8	12	20	33	244	31.9	37.3
December	48	8	11	17	26	81	22.8	17.3
2021								
January	84	8	14	26	47	202	39.0	39.6
February	39	8	14	20	49	227	44.6	56.6
March	73	8	12	16	29	473	32.8	59.0
April	72	8	13	20	32	312	30.2	38.6
May	74	8	11	18	36	256	35.3	45.9
June	49	8	13	17	38	244	35.3	44.9
July	42	8	10	16	48	306	38.6	59.4
August	67	8	11	21	43	306	36.7	48.5
September	45	8	14	21	31	85	26.6	19.6
October	65	8	10	14	21	98	21.4	18.3
November	68	8	12	20	31	157	32.4	35.3
December	61	8	11	17	29	103	24.8	21.6
2022								
January	37	8	11	18	42	161	34.4	37.5
February	33	8	13	18	27	113	30.0	28.6
March	44	8	11	16	28	84	24.1	19.3
April	37	8	13	16	24	134	24.9	24.4
May	31	8	10	18	23	58	20.0	11.3
June	17	8	12	15	24	69	23.9	19.9
July	21	8	12	19	27	34	19.7	8.4
August	15	8	9	12	15	21	12.3	3.5

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	1,111	8	12	19	37	1,028	46.4	94.9
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	14	10	15	18	25	457	50.3	117.3
May	3	8	8	12	25	25	15.0	8.9
June	2	12	12	15	17	17	14.5	3.5
July	15	8	10	35	168	849	120.7	215.3
August	14	10	13	26	56	1,028	184.2	329.4
September	1	12	12	12	12	12	12.0	NaN
October	6	8	8	24	371	815	208.3	329.6
November	7	11	19	51	157	731	154.3	258.8
December	1	9	9	9	9	9	9.0	NaN
2018								
January	20	8	12	27	45	184	36.4	40.3
February	13	8	15	19	101	167	60.9	60.0
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	10	8	13	18	30	394	56.4	119.0
May	12	8	13	19	38	964	102.2	271.9
June	27	8	11	17	32	119	27.6	26.9
July	22	8	14	22	49	105	34.1	27.5
August	15	8	11	27	79	369	58.3	92.8
September	24	8	12	17	48	934	73.8	188.1
October	26	8	11	17	36	532	61.0	116.6
November	20	8	11	16	23	735	57.1	160.7
December	8	8	11	18	178	329	93.6	141.6
2019								
January	26	8	11	18	110	218	58.5	66.1
February	18	8	9	13	28	307	41.3	78.7

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	11	10	14	25	99	751	106.5	217.4
April	17	9	15	19	24	457	64.9	118.5
May	14	8	10	15	27	353	41.7	90.2
June	37	8	12	16	23	73	21.6	15.6
July	42	8	10	29	53	171	41.1	40.9
August	13	11	14	25	46	311	49.0	80.2
September	18	8	16	35	88	162	54.6	48.7
October	27	8	12	19	46	174	39.3	45.7
November	31	8	15	23	61	322	51.2	72.1
December	24	8	12	28	54	85	34.0	23.4
2020								
January	22	8	11	17	68	389	71.3	116.2
February	36	8	13	19	33	231	39.7	55.7
March	21	8	11	17	47	327	42.6	69.8
April	3	44	44	99	131	131	91.3	44.0
May	15	9	14	22	54	183	46.9	52.9
June	12	8	13	21	38	165	39.1	47.3
July	11	14	16	23	36	215	55.8	75.7
August	31	8	11	17	29	295	37.4	57.7
September	18	8	13	26	36	400	51.8	92.2
October	15	8	10	12	42	51	22.1	16.6
November	46	8	13	18	31	99	26.6	22.8
December	34	8	10	14	36	129	29.2	32.5
2021								
January	19	8	11	19	35	94	25.7	22.4
February	37	9	13	18	38	168	31.6	31.5
March	28	8	13	17	46	473	52.5	97.0
April	19	8	11	22	79	243	51.4	63.4
May	24	8	12	14	27	72	22.9	18.5
June	11	10	13	17	33	47	22.8	12.1
July	16	8	10	18	26	179	30.3	42.1

Table 7d. Continuous Summary of All Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	21	9	14	29	74	141	46.6	42.0
September	33	8	12	20	28	231	30.8	40.5
October	11	8	9	15	35	38	20.1	11.9
November	15	8	11	25	56	95	34.5	27.7
December	9	12	15	20	32	155	36.9	45.9
2022								
January	19	8	11	18	28	64	20.2	13.2
February	9	11	12	13	15	139	27.4	41.9
March	5	8	15	17	22	40	20.4	12.1
April	9	8	9	15	19	44	17.1	11.2
May	7	10	14	19	27	31	20.3	8.1
June	9	8	12	17	18	30	16.9	7.0
July	4	8	9	12	16	17	12.3	4.0
August	4	8	9	10	14	17	11.0	4.1
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8a. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	28,800	1	3	7	17	1,716	23.3	72.0
<i>Any Indication</i>	26,691	1	3	7	17	1,716	23.3	72.7
<i>Atopic Dermatitis</i>	20,628	1	3	7	17	1,716	23.9	75.7
<i>Asthma</i>	9,665	1	3	7	17	1,669	23.0	68.9
<i>Chronic Rhinosinusitis</i>	5,685	1	3	7	16	1,099	22.4	66.3
<i>Eosinophilic Esophagitis</i>	1,636	1	3	7	17	651	20.1	47.6
<i>Prurigo Nodularis</i>	600	1	3	8	19	815	26.1	73.1
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	21,315	8	11	17	33	1,716	43.1	95.9
<i>Any Indication</i>	19,667	8	11	17	33	1,716	43.0	96.5
<i>Atopic Dermatitis</i>	15,307	8	11	17	33	1,716	44.2	101.1
<i>Asthma</i>	6,962	8	11	17	33	1,669	41.1	88.7
<i>Chronic Rhinosinusitis</i>	4,022	8	11	17	33	1,099	41.2	83.0
<i>Eosinophilic Esophagitis</i>	1,112	8	12	18	36	651	37.3	64.5
<i>Prurigo Nodularis</i>	427	8	11	19	36	1,028	48.8	105.0

Table 8b. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	28,800	1	3	7	17	1,716	23.3	72.0
Female	16,180	1	3	7	17	1,716	23.7	73.1
Male	12,620	1	3	7	17	1,669	22.8	70.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	26,691	1	3	7	17	1,716	23.3	72.7
Female	14,997	1	3	7	17	1,716	23.7	73.9
Male	11,694	1	3	7	17	1,669	22.9	71.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	20,628	1	3	7	17	1,716	23.9	75.7
Female	11,591	1	3	7	17	1,716	24.2	76.2
Male	9,037	1	3	7	17	1,669	23.4	75.1
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	9,665	1	3	7	17	1,669	23.0	68.9
Female	5,640	1	3	7	17	1,108	24.0	72.9
Male	4,025	1	3	7	17	1,669	21.6	62.8
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	5,685	1	3	7	16	1,099	22.4	66.3
Female	3,114	1	3	7	16	1,099	22.7	69.0
Male	2,571	1	3	7	17	902	22.0	62.9
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	1,636	1	3	7	17	651	20.1	47.6
Female	952	1	3	8	18	651	20.1	45.6
Male	684	1	3	7	16	633	20.2	50.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	600	1	3	8	19	815	26.1	73.1
Female	358	1	3	8	19	735	24.3	66.5
Male	242	1	3	7	19	815	28.9	81.9
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	21,315	8	11	17	33	1,716	43.1	95.9

Table 8b. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	12,028	8	11	17	33	1,716	43.1	95.3
Male	9,287	8	11	17	33	1,669	43.1	96.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	19,667	8	11	17	33	1,716	43.0	96.5
Female	11,109	8	11	17	33	1,716	43.1	95.9
Male	8,558	8	11	17	33	1,669	43.0	97.4
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	15,307	8	11	17	33	1,716	44.2	101.1
Female	8,651	8	11	17	32	1,716	44.3	100.3
Male	6,656	8	11	17	33	1,669	44.0	102.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	6,962	8	11	17	33	1,669	41.1	88.7
Female	4,093	8	11	17	33	1,108	41.5	88.2
Male	2,869	8	11	17	32	1,669	40.6	89.4
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	4,022	8	11	17	33	1,099	41.2	83.0
Female	2,196	8	11	17	34	1,099	40.7	83.4
Male	1,826	8	11	17	32	902	41.7	82.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	1,112	8	12	18	36	651	37.3	64.5
Female	646	8	11	17	38	651	37.5	65.8
Male	466	8	12	18	33	633	37.1	62.7
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	427	8	11	19	36	1,028	48.8	105.0
Female	259	8	11	19	39	1,028	49.5	110.5
Male	168	8	12	19	31	815	47.6	96.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8c. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	28,800	1	3	7	17	1,716	23.3	72.0
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	137	1	6	14	26	114	19.8	22.1
6-11 years	1,085	1	4	9	21	1,018	22.5	58.3
12-17 years	2,834	1	3	7	17	1,014	23.1	66.2
18-79 years	24,504	1	3	7	16	1,716	23.4	73.4
≥ 80 years	240	1	3	7	17	753	22.1	63.6
<i>Any Indication</i>	26,691	1	3	7	17	1,716	23.3	72.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	132	1	6	14	26	114	20.3	22.4
6-11 years	1,044	1	4	9	21	1,018	22.4	59.1
12-17 years	2,699	1	3	7	16	1,169	23.3	69.8
18-79 years	22,609	1	3	7	16	1,716	23.4	74.0
≥ 80 years	207	1	3	7	19	373	20.3	44.3
<i>Atopic Dermatitis</i>	20,628	1	3	7	17	1,716	23.9	75.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	128	1	7	14	28	114	21.0	22.6
6-11 years	999	1	4	10	21	1,018	22.8	60.3
12-17 years	2,490	1	3	8	17	1,169	23.8	69.4
18-79 years	16,848	1	3	7	16	1,716	24.0	77.9
≥ 80 years	163	1	3	8	19	373	20.6	46.1
<i>Asthma</i>	9,665	1	3	7	17	1,669	23.0	68.9
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	22	1	4	12	26	79	18.2	19.3
6-11 years	389	1	4	10	22	1,018	26.0	74.4
12-17 years	982	1	3	7	16	1,014	23.3	75.3
18-79 years	8,218	1	3	7	17	1,669	22.9	68.1
≥ 80 years	54	1	3	6	13	216	16.7	34.0
<i>Chronic Rhinosinusitis</i>	5,685	1	3	7	16	1,099	22.4	66.3
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 8c. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
6-71 months	10	2	3	7	49	79	21.9	27.3
6-11 years	59	1	3	9	21	860	30.7	113.3
12-17 years	234	1	4	8	20	902	23.4	71.6
18-79 years	5,347	1	3	7	16	1,099	22.3	65.5
≥ 80 years	35	1	3	6	15	216	18.8	39.7
<i>Eosinophilic Esophagitis</i>	<i>1,636</i>	<i>1</i>	<i>3</i>	<i>7</i>	<i>17</i>	<i>651</i>	<i>20.1</i>	<i>47.6</i>
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	9	1	3	4	8	44	8.7	13.5
6-11 years	52	1	4	9	21	393	22.6	55.4
12-17 years	128	1	3	7	16	651	17.9	58.7
18-79 years	1,424	1	3	7	18	633	20.5	46.7
≥ 80 years	23	1	1	6	8	27	7.2	7.0
<i>Prurigo Nodularis</i>	<i>600</i>	<i>1</i>	<i>3</i>	<i>8</i>	<i>19</i>	<i>815</i>	<i>26.1</i>	<i>73.1</i>
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-11 years	5	3	5	7	11	201	45.4	87.0
12-17 years	26	1	3	6	10	155	13.2	29.7
18-79 years	556	1	3	8	19	815	26.9	75.2
≥ 80 years	13	1	4	7	24	47	13.5	13.9
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	<i>21,315</i>	<i>8</i>	<i>11</i>	<i>17</i>	<i>33</i>	<i>1,716</i>	<i>43.1</i>	<i>95.9</i>
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	106	8	14	21	34	114	28.2	22.2
6-11 years	869	8	12	19	31	1,018	36.7	72.1
12-17 years	2,207	8	11	17	33	1,014	40.1	81.4
18-79 years	17,970	8	11	17	33	1,716	43.9	98.9
≥ 80 years	163	8	12	17	28	753	38.4	77.8
<i>Any Indication</i>	<i>19,667</i>	<i>8</i>	<i>11</i>	<i>17</i>	<i>33</i>	<i>1,716</i>	<i>43.0</i>	<i>96.5</i>
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	101	8	14	21	35	114	28.5	22.7
6-11 years	836	8	12	19	31	1,018	37.0	73.3

Table 8c. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
12-17 years	2,094	8	11	16	31	1,169	40.3	85.3
18-79 years	16,500	8	11	17	33	1,716	43.9	99.4
≥ 80 years	136	8	12	18	30	373	35.1	55.0
<i>Atopic Dermatitis</i>	15,307	8	11	17	33	1,716	44.2	101.1
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	98	8	14	21	35	114	28.8	22.9
6-11 years	806	8	12	19	31	1,018	37.3	74.5
12-17 years	1,936	8	11	16	32	1,169	40.7	84.8
18-79 years	12,361	8	11	17	33	1,716	45.4	105.5
≥ 80 years	106	8	12	17	29	373	33.9	54.5
<i>Asthma</i>	6,962	8	11	17	33	1,669	41.1	88.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	17	10	21	26	38	79	31.2	17.3
6-11 years	304	8	13	20	33	1,018	40.8	87.6
12-17 years	724	8	11	17	30	1,014	40.5	91.4
18-79 years	5,887	8	11	17	33	1,669	41.3	88.7
≥ 80 years	30	8	10	20	36	234	40.7	57.1
<i>Chronic Rhinosinusitis</i>	4,022	8	11	17	33	1,099	41.2	83.0
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	6	14	25	50	52	79	44.8	22.8
6-11 years	45	8	14	19	28	860	45.6	127.7
12-17 years	180	8	11	17	30	902	38.1	83.0
18-79 years	3,770	8	11	17	34	1,099	41.3	82.6
≥ 80 years	21	8	10	19	34	216	36.7	50.3
<i>Eosinophilic Esophagitis</i>	1,112	8	12	18	36	651	37.3	64.5
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	4	8	9	17	35	44	21.5	16.9
6-11 years	35	8	15	23	39	393	38.0	64.3
12-17 years	95	8	11	19	39	651	36.4	74.7
18-79 years	967	8	11	17	36	641	37.7	63.9
≥ 80 years	11	9	11	16	23	47	19.2	10.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Prurigo Nodularis</i>	427	8	11	19	36	1,028	48.8	105.0
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-11 years	2	11	11	106	201	201	106.0	134.4
12-17 years	18	8	11	16	31	155	35.7	45.0
18-79 years	396	8	11	19	36	1,028	49.6	108.2
≥ 80 years	11	8	14	23	28	95	28.7	24.3

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	28,800	1	3	7	17	1,716	23.3	72.0
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	80	1	4	7	15	441	17.9	51.0
May	213	1	4	7	15	1,106	28.1	112.3
June	202	1	3	7	19	1,067	37.1	131.2
July	210	1	3	7	17	603	26.8	76.1
August	245	1	2	7	19	1,505	40.5	159.2
September	202	1	3	7	13	1,087	28.4	105.4
October	237	1	2	7	15	856	25.2	96.2
November	212	1	3	7	15	1,669	37.0	148.2
December	155	1	3	8	15	1,716	32.9	149.7
2018								
January	155	1	3	8	15	576	27.5	78.2
February	178	1	3	7	14	1,382	35.5	124.0
March	222	1	3	7	16	1,491	36.8	140.7
April	161	1	3	7	14	1,060	31.8	120.3
May	169	1	2	6	15	1,107	27.1	104.7
June	164	1	3	7	13	1,167	32.0	117.1
July	303	1	3	7	15	1,494	36.4	144.7
August	312	1	3	7	16	1,060	37.4	120.4
September	251	1	3	7	16	935	26.3	90.1
October	300	1	3	6	14	936	28.5	100.2
November	297	1	3	8	19	1,067	38.0	113.6
December	257	1	3	8	19	509	26.9	67.0
2019								
January	344	1	3	6	13	860	19.3	65.3
February	348	1	3	7	15	1,057	23.9	88.6

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	345	1	3	7	15	980	25.4	95.7
April	473	1	3	6	15	902	25.9	89.8
May	413	1	3	7	15	902	21.6	66.7
June	425	1	4	8	21	913	27.5	87.0
July	579	1	3	8	19	967	28.5	90.6
August	612	1	4	8	17	948	31.8	102.0
September	521	1	4	8	20	1,018	32.4	95.2
October	573	1	3	7	18	1,017	27.7	91.3
November	529	1	4	8	18	1,000	33.8	101.4
December	510	1	4	8	23	905	31.6	83.4
2020								
January	478	1	3	8	17	464	23.0	54.9
February	497	1	3	7	16	777	23.9	66.5
March	507	1	4	8	22	726	28.0	70.0
April	370	1	3	7	17	849	30.6	91.3
May	379	1	3	7	17	606	23.3	59.2
June	458	1	3	7	15	665	22.3	62.6
July	880	1	3	7	16	627	21.3	55.6
August	668	1	3	7	16	735	24.2	62.9
September	657	1	4	8	18	508	24.7	56.6
October	683	1	3	7	18	691	24.2	63.4
November	605	1	3	8	19	596	28.7	70.8
December	573	1	3	8	20	571	24.7	57.6
2021								
January	551	1	3	7	15	501	18.9	47.4
February	552	1	4	8	17	540	21.8	53.0
March	616	1	3	8	20	473	21.2	45.9
April	597	1	3	8	17	347	19.4	40.1
May	550	1	4	8	19	437	23.2	50.4
June	551	1	3	8	19	335	19.8	37.7
July	801	1	3	8	18	382	19.2	37.6

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	845	1	3	8	19	317	18.3	32.9
September	654	1	4	8	21	303	20.6	36.1
October	703	1	3	7	18	293	16.7	27.3
November	627	1	3	8	18	293	17.4	30.3
December	591	1	3	7	16	258	16.2	28.5
2022								
January	564	1	3	7	15	238	15.5	29.2
February	491	1	3	6	15	175	13.9	22.0
March	582	1	3	7	15	162	13.9	20.2
April	545	1	3	8	16	145	14.2	20.7
May	507	1	3	7	14	112	12.3	16.6
June	485	1	3	7	15	97	12.1	14.4
July	563	1	3	7	14	71	10.4	11.1
August	438	1	2	6	11	36	7.5	6.7
September	34	1	2	4	6	12	4.2	3.1
<i>Any Indication</i>	<i>26,691</i>	<i>1</i>	<i>3</i>	<i>7</i>	<i>17</i>	<i>1,716</i>	<i>23.3</i>	<i>72.7</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	71	1	3	6	15	441	18.1	53.9
May	182	1	3	7	14	1,099	24.0	90.4
June	179	1	3	7	19	1,067	38.9	138.6
July	192	1	2	7	17	1,169	33.7	114.3
August	230	1	2	7	19	1,505	42.6	164.1
September	187	1	3	7	14	1,087	30.6	110.8
October	218	1	2	7	14	856	24.9	99.7
November	191	1	3	6	15	1,669	33.5	145.0
December	139	1	3	7	15	1,716	35.4	158.7
2018								
January	144	1	2	7	16	576	28.5	81.0

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
February	156	1	3	7	15	1,382	35.6	126.8
March	194	1	3	7	16	1,491	37.2	147.2
April	152	1	3	7	15	1,060	33.9	123.8
May	150	1	2	6	16	1,107	30.0	111.8
June	150	1	3	7	14	1,167	29.2	116.0
July	268	1	3	7	16	1,494	40.3	153.6
August	278	1	4	7	16	1,060	39.1	125.5
September	238	1	3	7	16	750	23.5	71.2
October	269	1	3	6	14	936	28.7	101.2
November	282	1	3	8	19	1,067	38.9	116.4
December	237	1	3	8	18	509	25.8	67.0
2019								
January	320	1	2	6	13	860	19.4	67.5
February	323	1	3	7	14	1,057	25.1	92.9
March	332	1	3	7	15	980	24.4	93.7
April	440	1	3	6	15	902	27.4	94.2
May	394	1	3	7	15	902	20.8	67.2
June	396	1	4	8	20	913	24.7	75.4
July	535	1	3	8	18	967	27.1	88.4
August	588	1	4	8	16	948	29.4	95.9
September	489	1	3	8	20	1,018	32.9	97.9
October	530	1	3	7	18	1,017	27.7	93.4
November	499	1	4	8	18	1,000	34.7	103.8
December	471	1	3	8	21	905	31.3	84.3
2020								
January	453	1	3	8	17	464	23.6	56.3
February	474	1	3	7	16	777	24.6	66.0
March	475	1	4	8	22	726	28.5	71.9
April	352	1	3	7	17	849	32.1	94.3
May	353	1	3	7	17	606	23.8	60.2
June	424	1	3	7	14	665	18.9	54.0

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	788	1	3	7	16	627	21.4	56.9
August	593	1	3	7	17	735	24.8	64.0
September	602	1	4	7	19	508	24.4	57.1
October	626	1	3	7	18	691	24.7	64.5
November	560	1	3	8	19	596	27.6	68.0
December	522	1	3	8	19	571	24.6	59.4
2021								
January	515	1	3	7	15	501	20.0	51.8
February	528	1	4	8	18	540	21.5	51.6
March	583	1	3	7	20	473	21.7	47.7
April	557	1	3	8	17	347	19.8	41.2
May	529	1	4	8	20	437	23.3	49.8
June	516	1	3	7	19	335	20.1	38.7
July	681	1	3	8	18	382	18.7	36.7
August	772	1	3	8	18	364	18.2	34.9
September	621	1	3	7	20	303	20.3	36.7
October	650	1	3	7	19	293	16.6	26.5
November	576	1	3	8	18	293	17.4	30.9
December	575	1	3	7	16	258	15.9	27.7
2022								
January	527	1	3	7	14	238	16.3	30.3
February	465	1	3	7	15	193	14.7	23.8
March	555	1	3	7	16	162	14.4	20.9
April	521	1	3	7	16	137	14.1	20.1
May	478	1	3	7	14	117	12.3	16.3
June	460	1	3	7	15	97	12.0	14.5
July	502	1	3	6	13	71	10.0	10.9
August	400	1	2	6	11	36	7.7	6.8
September	33	1	2	3	6	12	4.2	3.1
<i>Atopic Dermatitis</i>	<i>20,628</i>	<i>1</i>	<i>3</i>	<i>7</i>	<i>17</i>	<i>1,716</i>	<i>23.9</i>	<i>75.7</i>
2017								

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	67	1	3	6	15	441	18.8	55.4
May	179	1	3	7	14	1,099	24.3	91.1
June	177	1	3	7	17	1,067	39.1	139.3
July	182	1	2	6	17	1,169	34.3	117.3
August	217	1	2	7	19	1,505	44.4	168.8
September	180	1	3	7	14	1,087	30.2	111.8
October	213	1	2	6	14	856	25.4	100.9
November	189	1	3	7	15	1,669	29.9	135.9
December	135	1	2	7	15	1,716	34.4	159.9
2018								
January	144	1	2	6	16	576	28.3	81.1
February	151	1	3	7	15	1,382	35.6	128.4
March	188	1	3	7	16	1,491	37.9	149.5
April	143	1	3	8	15	1,060	35.8	127.4
May	146	1	2	6	16	1,107	30.2	113.3
June	150	1	3	7	14	1,167	37.0	140.5
July	261	1	3	7	15	1,494	40.8	155.6
August	270	1	4	7	16	1,060	38.0	124.8
September	233	1	3	7	16	750	23.6	71.9
October	257	1	3	6	14	936	26.5	98.0
November	254	1	3	8	16	949	35.6	101.7
December	198	1	3	7	16	509	22.4	59.8
2019								
January	264	1	2	6	13	860	22.1	74.5
February	250	1	3	7	14	317	18.5	44.3
March	260	1	3	7	15	980	24.7	93.8
April	356	1	3	7	15	902	25.0	91.0
May	314	1	3	7	15	902	21.7	73.7

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	314	1	4	7	18	861	23.7	67.3
July	433	1	3	7	16	967	28.2	95.2
August	427	1	4	7	17	948	28.2	93.1
September	351	1	3	7	19	1,018	30.0	96.3
October	368	1	3	7	18	1,017	31.7	107.2
November	348	1	4	8	17	1,000	35.2	112.9
December	333	1	3	8	21	701	30.2	75.7
2020								
January	327	1	3	9	18	464	26.4	63.0
February	321	1	3	7	18	777	27.4	75.1
March	331	1	4	9	23	726	31.8	76.7
April	227	1	4	7	16	849	26.5	82.0
May	241	1	3	7	15	606	22.8	57.3
June	307	1	3	7	14	665	19.9	58.1
July	578	1	4	7	17	627	21.6	57.4
August	435	1	3	7	18	735	26.0	69.1
September	427	1	4	8	21	448	26.1	58.2
October	428	1	3	7	19	464	23.1	52.0
November	412	1	3	8	21	596	28.5	67.7
December	388	1	3	9	21	459	23.9	54.2
2021								
January	384	1	3	7	16	501	21.9	57.8
February	387	1	4	8	20	540	24.2	57.5
March	428	1	3	8	22	473	22.7	47.1
April	407	1	3	8	18	347	19.8	39.1
May	388	1	4	9	21	437	26.4	56.2
June	383	1	3	8	21	264	20.6	37.1
July	530	1	3	8	18	382	18.8	38.4
August	566	1	4	8	18	364	18.2	35.4
September	485	1	3	7	20	294	20.2	37.2
October	483	1	3	8	18	293	16.7	26.3

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	436	1	3	8	18	293	18.2	32.8
December	447	1	4	7	17	258	16.8	28.6
2022								
January	408	1	3	7	14	238	15.6	29.8
February	346	1	3	7	15	158	13.7	20.5
March	414	1	3	7	16	162	14.4	21.2
April	399	1	3	8	16	137	14.1	19.6
May	353	1	3	7	14	117	12.7	17.0
June	323	1	3	7	15	97	11.7	13.9
July	378	1	3	6	13	71	10.1	11.2
August	284	1	3	6	11	36	7.5	6.3
September	24	1	1	3	6	11	4.0	2.9
<i>Asthma</i>	<i>9,665</i>	<i>1</i>	<i>3</i>	<i>7</i>	<i>17</i>	<i>1,669</i>	<i>23.0</i>	<i>68.9</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	17	1	3	7	8	15	6.0	3.6
May	38	1	3	7	18	1,099	47.4	178.4
June	34	1	3	10	34	1,067	68.0	197.3
July	52	1	1	6	12	480	27.6	88.7
August	62	1	4	10	21	1,108	45.0	155.6
September	41	1	3	8	19	630	39.9	105.6
October	58	1	2	6	10	63	8.8	10.6
November	43	1	4	9	22	1,669	73.6	275.1
December	35	1	5	11	27	252	24.1	44.8
2018								
January	40	1	4	9	23	576	42.8	110.6
February	41	1	2	7	12	386	29.4	81.0
March	46	1	3	7	13	435	21.6	64.9
April	38	1	2	5	15	583	40.0	116.0

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	38	1	2	6	17	160	14.2	26.2
June	30	1	3	7	19	573	32.3	103.9
July	69	1	4	7	16	848	36.5	121.6
August	70	1	4	8	24	877	57.1	159.6
September	48	1	4	7	14	399	21.3	59.0
October	51	1	4	7	16	842	35.3	120.6
November	76	1	6	12	23	1,067	46.2	139.3
December	93	1	3	8	26	511	47.1	106.3
2019								
January	143	1	3	6	13	420	16.3	44.2
February	127	1	3	7	15	1,057	34.2	135.1
March	125	1	3	6	14	784	20.5	78.9
April	178	1	3	7	19	523	22.1	61.4
May	151	1	3	6	14	195	16.4	28.0
June	152	1	4	10	22	913	28.3	91.2
July	190	1	4	10	21	886	30.2	88.6
August	255	1	4	8	14	918	31.1	101.7
September	195	1	4	8	26	1,018	39.3	111.1
October	237	1	4	7	18	523	21.4	53.1
November	209	1	4	9	19	590	32.0	82.6
December	172	1	4	9	22	905	32.9	97.6
2020								
January	187	1	3	7	17	295	20.4	40.5
February	209	1	3	7	14	320	17.3	34.6
March	207	1	3	7	20	726	28.8	79.4
April	157	1	3	8	15	666	28.0	81.9
May	147	1	3	7	18	675	25.2	76.2
June	173	1	2	6	14	411	16.9	38.9
July	292	1	3	7	15	482	21.2	58.5
August	227	1	3	7	15	303	19.4	39.3
September	236	1	3	7	18	388	21.3	47.2

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
October	260	1	4	7	16	691	28.3	83.8
November	213	1	3	8	17	596	23.5	63.4
December	191	1	2	7	20	571	27.1	70.4
2021								
January	195	1	3	8	18	419	20.1	45.9
February	204	1	3	8	18	205	14.9	25.1
March	226	1	3	6	20	354	18.9	40.1
April	221	1	4	8	17	343	19.8	41.2
May	212	1	3	8	18	363	18.6	37.4
June	185	1	3	7	20	335	22.7	45.8
July	236	1	3	8	18	185	17.6	28.6
August	287	1	3	8	20	317	19.6	35.4
September	215	1	3	7	22	303	22.9	45.6
October	228	1	4	8	22	189	16.5	23.5
November	210	1	3	8	19	256	17.8	29.8
December	189	1	3	6	17	186	15.0	25.7
2022								
January	191	1	3	7	16	220	18.7	33.0
February	177	1	2	7	17	193	14.3	22.9
March	173	1	3	8	19	152	14.8	20.0
April	189	1	3	7	15	123	14.5	20.7
May	180	1	3	7	16	93	13.3	16.0
June	156	1	3	7	14	90	12.5	17.0
July	183	1	3	6	11	58	9.5	10.9
August	141	1	2	5	11	34	7.4	6.7
September	13	1	1	3	7	9	3.8	3.1
<i>Chronic Rhinosinusitis</i>	5,685	1	3	7	16	1,099	22.4	66.3
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	4	1	3	5	6	6	4.0	2.2
May	9	2	6	9	29	1,099	134.2	362.0
June	15	1	3	6	25	73	15.9	20.9
July	9	3	6	11	17	46	14.7	13.7
August	22	1	2	7	19	766	44.1	161.5
September	9	5	6	11	15	51	16.0	15.4
October	11	1	2	5	8	11	4.9	3.4
November	9	1	6	13	33	207	36.7	65.1
December	10	2	5	10	21	28	12.6	9.7
2018								
January	14	1	1	6	9	892	74.6	236.4
February	16	1	2	9	17	386	52.5	112.6
March	15	1	1	3	6	42	5.7	10.3
April	16	1	2	4	13	80	11.9	19.9
May	14	1	1	6	12	40	9.3	11.1
June	9	1	3	8	24	48	14.7	16.2
July	19	1	3	8	18	70	17.7	21.1
August	26	1	2	8	19	378	40.8	96.9
September	18	1	4	8	16	94	15.8	23.9
October	19	1	3	7	14	68	12.3	15.4
November	30	1	3	10	17	116	15.4	22.2
December	42	1	3	7	21	419	34.6	89.2
2019								
January	56	1	3	5	11	720	24.6	98.0
February	48	1	3	6	16	1,057	42.4	159.3
March	49	1	3	6	10	784	32.2	122.4
April	80	1	3	8	22	902	48.5	149.6
May	60	1	4	8	16	222	18.2	32.1
June	73	1	4	8	13	913	29.8	111.9
July	88	1	3	13	22	190	21.2	31.5
August	137	1	3	8	16	918	32.9	100.6

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	134	1	4	7	18	669	32.5	88.9
October	137	1	3	7	18	747	27.1	81.9
November	142	1	4	10	23	860	38.4	103.9
December	133	1	3	8	18	905	33.5	104.2
2020								
January	126	1	3	8	14	219	17.1	33.9
February	135	1	3	7	14	457	23.1	56.8
March	139	1	2	7	23	606	31.9	85.8
April	107	1	3	5	21	666	45.2	127.4
May	97	1	3	7	17	520	24.4	65.3
June	119	1	3	6	14	411	15.8	41.8
July	173	1	2	6	15	467	19.6	44.8
August	143	1	2	5	14	303	23.6	51.5
September	140	1	3	7	17	508	24.5	64.1
October	150	1	4	7	14	637	25.7	75.8
November	132	1	3	8	22	528	32.5	80.9
December	130	1	2	7	16	263	18.6	37.5
2021								
January	130	1	3	8	17	302	21.2	42.7
February	145	1	3	6	14	273	14.9	30.5
March	123	1	2	7	16	332	21.7	50.6
April	142	1	4	8	16	343	22.1	50.4
May	137	1	3	9	19	152	15.8	23.4
June	132	1	3	7	17	279	19.5	39.8
July	148	1	4	8	14	111	15.3	21.4
August	165	1	3	7	19	317	19.1	38.8
September	138	1	3	7	18	303	20.2	45.6
October	163	1	3	7	20	189	16.9	28.8
November	131	1	3	9	18	196	16.0	23.6
December	141	1	3	7	18	209	14.3	22.9
2022								

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	133	1	3	7	18	203	16.2	27.1
February	122	1	2	7	12	175	13.8	23.8
March	132	1	3	8	15	129	14.5	20.2
April	123	1	3	7	14	113	12.3	15.9
May	130	1	3	5	13	65	10.3	12.5
June	113	1	2	6	16	75	12.2	14.9
July	85	1	2	5	11	47	8.5	9.1
August	80	1	2	5	9	32	7.3	7.8
September	8	1	1	2	7	12	4.0	4.2
<i>Eosinophilic Esophagitis</i>	1,636	1	3	7	17	651	20.1	47.6
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	4	4	6	12	12	7.3	4.2
May	4	6	8	10	20	30	13.8	11.0
June	5	1	2	4	6	25	7.6	9.9
July	9	1	1	12	46	480	68.7	155.6
August	8	1	1	8	42	139	30.3	49.5
September	8	1	4	5	7	12	5.3	3.3
October	1	14	14	14	14	14	14.0	NaN
November	6	4	5	15	23	64	20.8	22.6
December	7	3	3	9	17	19	9.4	6.5
2018								
January	5	3	8	11	16	34	14.4	11.9
February	9	1	3	7	8	16	6.9	4.7
March	9	1	3	7	8	18	7.1	5.5
April	4	3	4	26	49	51	26.3	25.8
May	6	1	5	19	28	40	18.7	14.6
June	13	1	10	18	39	155	32.1	40.9
July	15	1	2	3	8	50	8.1	12.3

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	12	1	5	9	17	66	16.0	20.1
September	8	1	4	7	12	19	8.0	6.4
October	13	1	6	14	15	181	26.2	48.1
November	11	1	2	9	26	403	46.4	118.7
December	21	1	5	19	58	419	68.0	122.9
2019								
January	14	1	3	6	9	20	6.8	5.0
February	12	2	3	4	10	324	34.8	92.0
March	18	1	4	6	15	72	11.9	16.5
April	25	1	4	9	23	633	70.0	161.2
May	26	1	1	7	28	651	42.5	126.6
June	15	1	5	10	24	49	14.7	14.4
July	33	2	7	14	26	154	29.4	37.6
August	34	1	4	8	28	101	18.5	23.4
September	33	1	2	5	17	389	24.6	68.5
October	36	1	5	8	21	125	20.4	29.3
November	34	1	4	8	15	371	24.1	63.7
December	25	1	6	11	21	108	18.6	22.7
2020								
January	34	1	3	7	14	73	12.9	16.7
February	44	1	4	10	16	97	16.5	22.3
March	32	1	3	12	19	310	26.8	57.8
April	23	1	4	8	27	197	30.9	53.8
May	21	1	3	7	36	125	22.2	31.7
June	21	1	4	9	15	86	16.6	22.0
July	30	1	3	7	18	329	26.2	61.4
August	30	1	3	6	16	138	19.3	32.5
September	27	1	4	6	17	210	21.7	42.7
October	23	1	4	9	21	153	18.5	31.0
November	34	1	2	6	12	77	9.7	13.5
December	31	1	2	7	15	41	10.1	10.3

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2021								
January	42	1	2	7	24	194	21.7	37.8
February	29	1	2	5	13	205	16.9	38.5
March	34	1	3	8	19	473	27.1	81.1
April	32	1	4	9	31	105	21.6	28.5
May	38	1	2	7	22	137	20.4	31.1
June	30	1	4	8	18	244	26.0	53.2
July	40	1	2	6	17	233	17.9	39.6
August	44	1	5	12	25	306	24.3	47.1
September	42	1	3	7	15	85	14.2	18.8
October	47	1	3	7	14	92	13.8	18.4
November	56	1	2	8	23	157	18.9	28.7
December	52	1	5	8	22	53	14.1	13.8
2022								
January	34	1	3	6	10	100	14.9	23.1
February	31	1	3	7	24	113	18.8	26.1
March	36	1	3	10	20	84	15.5	20.0
April	34	1	3	8	17	134	17.3	26.6
May	37	1	3	7	18	58	12.9	13.3
June	41	1	3	7	12	69	11.9	16.2
July	56	1	3	5	14	34	9.5	9.4
August	48	1	4	6	9	21	6.6	4.8
September	1	2	2	2	2	2	2.0	NaN
<i>Prurigo Nodularis</i>	600	1	3	8	19	815	26.1	73.1
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	1	1	21	34	34	18.7	16.6
May	2	1	1	2	3	3	2.0	1.4
June	2	4	4	11	17	17	10.5	9.2

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	6	2	3	9	44	202	44.8	78.6
August	5	1	3	5	24	30	12.6	13.4
September	1	12	12	12	12	12	12.0	NaN
October	4	2	4	7	412	815	207.8	404.8
November	3	4	4	8	731	731	247.7	418.6
December	2	1	1	4	7	7	4.0	4.2
2018								
January	4	4	4	7	15	20	9.5	7.5
February	6	3	4	6	16	154	31.5	60.2
March	1	34	34	34	34	34	34.0	NaN
April	6	3	7	8	13	29	11.3	9.2
May	4	6	9	13	30	47	19.5	18.6
June	4	1	2	7	38	64	19.5	30.0
July	2	4	4	5	5	5	4.5	0.7
August	4	3	4	8	13	15	8.5	5.5
September	7	1	3	9	16	18	9.0	6.5
October	6	1	3	8	30	532	96.8	213.4
November	9	1	8	10	14	735	90.2	241.9
December	5	1	2	2	3	15	4.6	5.9
2019								
January	5	5	6	8	11	52	16.4	20.0
February	8	1	2	5	15	192	29.4	66.0
March	6	5	6	15	61	131	38.8	49.8
April	6	1	2	17	20	457	85.7	182.1
May	13	1	2	6	13	28	9.8	9.9
June	14	1	3	5	9	57	9.3	14.1
July	11	4	10	26	42	171	43.3	55.2
August	11	1	2	6	22	114	18.1	33.0
September	14	1	4	8	36	148	33.7	49.2
October	11	1	3	3	9	36	7.6	10.0
November	13	1	2	4	19	91	15.3	24.6

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December 2020	13	3	6	19	43	73	26.4	22.7
January	14	2	5	11	20	119	19.4	29.6
February	9	2	5	12	22	123	24.8	37.8
March	7	7	8	8	11	22	10.6	5.2
April	5	5	9	19	44	131	41.6	52.2
May	7	2	3	7	103	183	45.4	70.6
June	9	1	5	8	16	102	21.1	32.0
July	12	1	5	16	33	201	39.8	62.9
August	15	1	3	8	106	295	65.1	99.5
September	11	1	4	9	26	400	51.9	117.9
October	11	2	3	9	33	51	15.7	17.6
November	19	1	3	6	19	67	14.5	17.4
December 2021	12	1	2	7	14	30	9.3	10.0
January	11	2	3	11	21	38	14.4	13.0
February	13	1	6	16	35	168	29.3	44.2
March	18	1	5	6	15	473	47.0	120.6
April	8	4	6	9	42	79	24.6	27.4
May	9	1	3	10	14	59	14.2	17.7
June	13	1	6	13	27	47	16.2	14.8
July	14	2	5	6	13	59	12.7	15.4
August	12	1	5	17	53	106	30.6	35.0
September	17	1	4	9	27	231	33.7	57.5
October	11	1	4	6	16	24	9.5	7.6
November	13	2	3	6	11	56	12.5	15.8
December 2022	15	1	1	2	15	155	19.1	40.1
January	20	1	2	4	11	28	7.4	8.3
February	15	3	5	8	15	139	21.8	36.7
March	10	1	3	5	22	40	11.9	13.0

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	12	1	2	6	12	44	9.6	12.2
May	18	1	3	6	14	27	9.2	9.0
June	15	1	2	7	13	24	8.5	7.2
July	8	2	4	7	9	14	6.9	3.9
August	5	6	8	9	10	17	10.0	4.2
September	1	1	1	1	1	1	1.0	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>								
	21,315	8	11	17	33	1,716	43.1	95.9
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	68	8	12	17	28	441	42.8	81.8
May	169	8	10	15	29	1,106	54.4	151.7
June	172	8	11	16	33	1,067	54.4	145.3
July	164	8	11	16	33	777	57.9	125.6
August	192	8	10	17	30	1,505	78.8	220.7
September	162	8	11	14	26	1,087	56.1	150.8
October	190	8	11	17	31	1,528	62.1	173.0
November	175	8	11	16	33	1,669	76.4	210.2
December	129	8	11	15	26	1,716	56.7	177.0
2018								
January	121	8	11	15	26	576	48.5	94.7
February	147	8	11	16	38	1,382	65.6	160.1
March	177	8	13	21	44	1,495	79.0	205.4
April	140	8	11	15	31	1,060	47.3	127.9
May	136	8	11	17	28	1,107	43.3	111.1
June	123	8	11	17	45	1,167	84.7	202.5
July	197	8	12	17	34	1,494	68.5	181.3
August	239	8	10	17	47	1,364	72.9	173.6

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	198	8	12	16	34	935	56.3	126.1
October	235	8	11	16	33	951	60.3	144.2
November	248	8	12	18	41	735	52.4	100.3
December	197	8	11	17	32	509	45.4	84.0
2019								
January	270	8	11	16	30	1,001	48.1	113.5
February	301	8	11	15	30	1,057	43.0	107.0
March	290	8	11	16	35	980	48.9	118.0
April	372	8	11	18	35	902	61.7	134.1
May	322	8	11	15	34	902	40.2	88.4
June	360	8	12	19	36	913	51.4	114.4
July	433	8	10	16	30	967	44.9	107.0
August	485	8	11	16	32	948	49.8	116.0
September	414	8	12	19	40	1,018	57.0	117.4
October	470	8	11	18	36	1,017	53.7	120.3
November	424	8	11	18	36	1,000	56.1	120.0
December	433	8	12	18	35	905	49.1	96.6
2020								
January	402	8	11	15	28	469	37.0	65.3
February	387	8	11	19	38	836	48.1	92.2
March	423	8	11	18	37	726	45.3	84.8
April	297	8	11	19	41	849	52.5	106.2
May	286	8	11	19	36	606	40.5	67.3
June	360	8	11	17	35	665	45.8	90.0
July	575	8	11	17	37	627	39.9	70.1
August	492	8	11	17	34	735	40.2	73.7
September	510	8	12	18	33	508	38.9	64.0
October	506	8	12	19	37	691	46.7	84.7
November	478	8	11	18	38	596	46.1	81.2
December	482	8	12	18	35	571	37.6	61.9
2021								

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	437	8	11	17	30	501	34.3	58.1
February	427	8	11	17	33	540	39.9	67.1
March	472	8	12	19	34	473	37.7	56.2
April	467	8	11	18	34	347	35.1	50.0
May	436	8	12	18	33	437	37.2	60.1
June	414	8	11	18	34	335	33.3	42.6
July	541	8	11	17	34	382	34.5	46.5
August	596	8	12	20	34	346	32.1	40.4
September	474	8	12	20	36	303	33.7	41.0
October	522	8	12	18	33	293	30.6	34.4
November	445	8	11	18	32	293	29.9	35.0
December	408	8	11	19	31	258	30.1	34.7
2022								
January	375	8	11	16	29	238	29.0	35.4
February	314	8	10	17	29	175	26.2	26.8
March	358	8	11	15	27	162	23.6	21.8
April	339	8	11	16	26	145	23.5	23.1
May	285	8	10	15	26	112	22.3	19.0
June	262	8	10	16	26	97	21.4	16.1
July	239	8	10	15	24	71	19.0	11.6
August	148	8	10	13	18	36	14.6	6.0
September	4	9	9	10	12	12	10.3	1.5
<i>Any Indication</i>	<i>19,667</i>	<i>8</i>	<i>11</i>	<i>17</i>	<i>33</i>	<i>1,716</i>	<i>43.0</i>	<i>96.5</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	61	8	11	16	28	441	44.6	86.0
May	143	8	10	15	27	1,099	42.6	108.2
June	149	8	10	16	33	1,067	57.4	155.1
July	150	8	11	17	34	1,169	68.8	159.0

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	175	8	11	16	34	1,505	84.5	230.4
September	149	8	11	14	26	1,087	58.4	156.5
October	173	8	11	15	31	1,528	59.9	178.2
November	156	8	11	16	33	1,669	73.7	213.8
December	112	8	11	15	28	1,716	61.8	186.1
2018								
January	111	8	11	15	27	576	48.9	97.2
February	127	8	11	16	38	1,382	61.8	155.6
March	151	8	12	21	43	1,495	81.2	219.4
April	131	8	10	14	32	1,060	48.1	131.6
May	120	8	11	18	28	1,107	46.0	117.4
June	112	8	11	17	35	1,167	87.5	212.2
July	177	8	12	17	34	1,494	73.7	190.9
August	203	8	10	17	42	1,364	76.8	185.9
September	188	8	12	16	34	742	49.1	103.2
October	219	8	11	16	30	951	56.1	135.7
November	233	8	12	18	40	735	53.7	103.2
December	184	8	11	16	28	509	42.5	80.5
2019								
January	252	8	11	16	30	1,001	49.0	117.0
February	271	8	11	16	31	1,057	47.5	114.7
March	274	8	11	16	32	980	47.3	117.7
April	347	8	11	18	35	902	60.1	130.5
May	305	8	11	15	34	902	41.0	90.9
June	326	8	12	19	37	913	48.1	101.1
July	400	8	10	16	29	967	44.3	106.6
August	465	8	11	16	31	948	46.7	110.0
September	386	8	12	19	39	1,018	58.2	120.6
October	440	8	11	18	36	1,017	54.4	123.0
November	404	8	11	17	36	1,000	55.7	121.8
December	401	8	12	18	32	905	48.0	95.6

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2020								
January	383	8	11	15	28	591	38.4	71.2
February	365	8	11	18	38	836	48.5	92.7
March	391	8	11	19	38	726	47.9	89.4
April	282	8	11	18	41	849	53.0	108.4
May	268	8	11	19	36	606	40.5	67.9
June	326	8	11	16	34	665	41.4	80.3
July	523	8	11	17	36	627	39.7	71.1
August	439	8	11	17	33	735	40.2	74.6
September	462	8	12	18	33	508	38.3	64.1
October	461	8	12	19	38	691	47.2	85.5
November	436	8	11	18	38	596	45.8	80.8
December	438	8	12	19	36	571	38.3	63.4
2021								
January	410	8	11	17	30	501	35.8	62.6
February	402	8	11	17	33	540	39.3	66.4
March	446	8	12	19	34	473	37.9	57.6
April	435	8	11	18	34	347	35.6	51.5
May	413	8	12	18	34	437	37.4	59.0
June	392	8	11	18	35	335	33.4	42.7
July	474	8	11	17	34	382	35.1	47.9
August	553	8	12	19	33	364	31.5	40.5
September	445	8	12	20	37	303	34.2	41.8
October	473	8	12	19	32	293	29.7	33.3
November	403	8	11	17	31	293	29.5	36.0
December	380	8	11	18	30	258	29.1	33.9
2022								
January	359	8	11	16	31	238	29.7	36.2
February	290	8	11	16	30	193	27.0	29.0
March	347	8	11	16	27	162	24.0	22.6
April	316	8	11	16	27	137	23.9	23.1

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	260	8	11	15	27	117	22.5	18.8
June	249	8	11	15	25	97	20.9	15.5
July	204	8	10	15	24	71	19.2	11.9
August	142	8	10	13	19	36	14.8	6.0
September	4	9	9	10	12	12	10.3	1.5
<i>Atopic Dermatitis</i>	<i>15,307</i>	<i>8</i>	<i>11</i>	<i>17</i>	<i>33</i>	<i>1,716</i>	<i>44.2</i>	<i>101.1</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	57	8	11	16	28	441	46.5	88.7
May	140	8	10	15	27	1,099	43.1	109.3
June	147	8	10	15	33	1,067	57.6	156.1
July	141	8	11	17	33	1,169	71.5	163.5
August	163	8	11	16	35	1,505	89.2	238.1
September	143	8	11	14	26	1,087	58.8	158.9
October	165	8	11	15	31	1,528	61.3	182.1
November	153	8	11	16	32	1,669	70.0	208.6
December	108	8	11	15	28	1,716	61.5	188.5
2018								
January	111	8	11	16	29	576	49.5	97.2
February	123	8	11	16	37	1,382	61.4	157.6
March	146	8	12	21	43	1,495	76.7	209.8
April	121	8	10	15	32	1,060	50.2	136.6
May	115	8	11	18	28	1,107	47.2	119.8
June	110	8	11	18	36	1,167	86.3	210.5
July	171	8	12	18	34	1,494	75.2	194.0
August	199	8	10	17	40	1,364	75.6	185.8
September	183	8	12	16	34	742	51.7	107.3
October	209	8	11	15	28	951	50.9	130.4
November	208	8	11	18	42	735	55.3	106.3

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December 2019	151	8	11	15	28	509	40.0	75.8
January	207	8	11	17	33	1,001	55.5	128.0
February	212	8	11	16	31	739	40.2	75.3
March	215	8	12	15	31	980	45.8	117.1
April	285	8	11	17	34	902	59.1	132.0
May	247	8	11	15	30	902	42.1	98.1
June	260	8	12	19	37	861	48.1	96.4
July	323	8	10	15	30	967	49.0	117.8
August	334	8	11	16	30	948	44.9	107.4
September	281	8	12	19	36	1,018	58.4	124.5
October	307	8	11	19	39	1,017	59.3	131.9
November	276	8	11	17	33	1,000	58.7	133.8
December 2020	291	8	12	18	32	701	47.4	89.5
January	283	8	11	16	27	591	42.7	81.7
February	246	8	11	20	43	836	53.5	103.4
March	284	8	13	19	44	726	51.5	92.2
April	172	8	11	18	39	849	44.5	92.9
May	187	8	11	19	36	606	39.4	64.1
June	236	8	11	16	34	665	40.4	76.6
July	387	8	11	18	35	627	39.1	71.9
August	330	8	11	18	34	735	42.5	81.4
September	340	8	12	20	36	448	38.4	62.8
October	322	8	12	20	36	553	43.9	73.4
November	320	8	11	18	41	596	48.6	82.4
December 2021	323	8	12	19	36	403	36.6	56.7
January	297	8	11	17	32	501	38.9	70.1
February	305	8	11	17	35	540	41.8	70.9
March	331	8	12	20	34	473	38.7	57.3

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	327	8	12	18	34	347	32.8	43.3
May	302	8	12	18	35	437	41.8	66.8
June	298	8	11	20	36	264	33.8	39.9
July	368	8	11	17	33	382	34.1	49.1
August	413	8	11	19	31	364	30.5	40.3
September	349	8	12	20	37	294	33.7	41.2
October	361	8	12	18	32	293	30.4	34.8
November	307	8	11	17	32	293	30.5	37.9
December	299	8	11	18	30	258	29.9	35.2
2022								
January	274	8	11	16	30	238	29.2	36.0
February	211	8	11	16	29	161	26.6	28.0
March	255	8	12	16	28	162	24.5	23.6
April	246	8	11	16	26	137	23.3	22.1
May	198	8	11	15	26	117	22.4	19.4
June	179	8	10	15	22	97	19.7	14.5
July	152	8	11	16	26	71	19.8	12.1
August	100	8	10	13	17	36	14.0	5.2
September	2	9	9	10	11	11	10.0	1.4
<i>Asthma</i>	<i>6,962</i>	<i>8</i>	<i>11</i>	<i>17</i>	<i>33</i>	<i>1,669</i>	<i>41.1</i>	<i>88.7</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	1	14	14	14	14	14	14.0	NaN
April	16	8	9	15	29	393	64.7	113.3
May	31	9	10	16	44	1,099	76.0	202.9
June	29	8	10	25	49	1,067	84.8	210.7
July	38	8	12	15	26	777	87.1	192.2
August	49	8	10	15	27	1,108	65.0	176.8
September	30	8	12	17	40	630	54.9	119.6
October	41	8	10	14	24	139	24.3	26.3

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	34	8	13	19	34	1,669	144.5	360.9
December	29	8	12	15	42	252	35.3	48.2
2018								
January	29	8	13	17	29	576	63.9	126.2
February	31	8	11	15	36	834	79.8	170.1
March	36	8	13	22	37	987	77.2	187.2
April	26	8	11	15	31	583	64.6	135.3
May	32	8	12	19	28	409	48.5	96.7
June	23	8	13	24	55	573	78.1	147.8
July	45	8	11	16	29	848	62.0	151.7
August	49	8	13	23	47	600	72.2	137.6
September	36	8	11	15	39	399	46.8	90.5
October	46	8	11	15	25	842	44.3	124.1
November	64	8	13	17	31	366	44.1	79.0
December	75	8	11	17	35	509	51.0	97.8
2019								
January	114	8	10	15	28	1,001	45.8	124.9
February	102	8	11	15	29	1,057	59.7	168.4
March	102	8	11	17	27	784	40.4	95.4
April	135	8	11	19	35	601	52.5	100.9
May	117	8	11	15	34	472	34.2	57.2
June	126	8	12	19	35	913	52.3	118.8
July	144	8	12	17	29	886	40.8	96.7
August	202	8	10	14	29	918	48.3	115.1
September	149	8	13	20	39	1,018	55.0	121.7
October	192	8	11	18	34	755	46.1	97.8
November	165	8	12	17	38	590	52.7	98.0
December	133	8	11	18	36	905	51.0	113.6
2020								
January	146	8	11	15	30	295	31.9	44.3
February	162	8	12	17	33	475	36.6	61.2

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	151	8	11	17	36	726	45.4	93.1
April	128	8	10	15	36	666	49.6	102.3
May	105	8	11	18	33	675	44.0	89.7
June	124	8	11	17	36	641	45.4	87.1
July	187	8	11	17	36	482	40.2	73.1
August	167	8	11	17	31	411	35.7	54.7
September	173	8	11	18	32	286	33.0	45.1
October	184	8	11	19	36	691	51.5	103.9
November	163	8	11	16	33	596	36.1	71.0
December	154	8	11	17	34	571	41.0	76.6
2021								
January	168	8	11	16	29	419	30.3	48.3
February	141	8	11	19	33	340	32.7	48.1
March	167	8	13	21	35	354	34.0	45.9
April	166	8	11	17	34	343	39.1	59.1
May	158	8	11	16	31	363	28.5	39.5
June	147	8	12	16	33	335	32.9	47.3
July	159	8	11	18	36	212	35.3	40.2
August	200	8	13	21	38	317	34.0	39.4
September	150	8	12	20	37	303	37.4	50.6
October	156	8	13	21	33	207	29.2	29.9
November	145	8	11	17	31	256	28.8	33.6
December	122	8	12	18	28	186	26.9	28.8
2022								
January	134	8	11	17	35	220	33.7	39.9
February	110	8	10	16	28	193	24.4	24.3
March	117	8	11	16	28	152	24.4	22.1
April	110	8	12	15	31	123	26.1	23.7
May	101	8	11	17	29	93	23.0	17.3
June	83	8	10	16	27	90	22.3	18.1
July	66	8	10	15	22	58	19.3	13.3

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	45	8	11	12	16	34	14.6	6.4
September	2	9	9	9	9	9	9.0	0.0
<i>Chronic</i>								
<i>Rhinosinusitis</i>	4,022	8	11	17	33	1,099	41.2	83.0
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	4	13	14	109	298	393	155.8	181.7
May	8	9	13	18	35	1,099	154.8	381.7
June	12	8	11	20	42	73	27.2	21.5
July	5	8	11	17	25	26	17.4	8.1
August	16	8	10	17	29	766	65.5	187.1
September	8	8	10	13	23	51	18.9	14.8
October	7	8	11	12	34	154	35.0	53.2
November	8	8	11	21	34	207	43.0	67.1
December	8	8	10	13	21	28	15.4	7.9
2018								
January	9	8	12	20	90	892	132.2	287.4
February	10	8	9	14	254	386	105.9	143.9
March	8	8	8	10	14	65	17.0	19.7
April	13	11	12	14	25	80	23.8	20.2
May	12	8	9	18	26	96	24.2	24.6
June	7	9	14	16	31	48	22.3	13.5
July	17	8	9	14	18	70	22.8	20.4
August	19	8	13	27	56	600	89.4	156.0
September	15	8	9	17	58	94	32.2	28.1
October	13	8	13	16	40	370	56.5	99.6
November	25	9	12	16	29	116	23.4	22.3
December	30	8	9	20	43	419	59.8	108.1
2019								

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	38	8	11	13	32	316	37.8	60.6
February	42	8	12	16	34	1,057	59.7	168.3
March	34	8	10	15	37	784	65.0	152.5
April	56	8	12	23	67	902	86.7	178.6
May	45	8	13	21	43	316	37.8	54.8
June	58	8	12	16	33	913	55.9	134.1
July	60	8	14	20	32	280	35.7	46.9
August	108	8	10	15	33	918	50.3	114.5
September	104	8	12	19	34	669	50.7	99.2
October	117	8	10	15	28	755	50.7	118.1
November	118	8	11	16	44	860	54.3	113.9
December	99	8	12	18	32	905	59.2	129.3
2020								
January	106	8	11	13	28	219	27.5	38.1
February	107	8	10	14	30	475	40.5	75.4
March	101	8	12	19	38	606	57.1	108.6
April	87	8	11	21	66	666	76.1	143.5
May	74	8	12	18	32	520	39.3	72.8
June	81	8	12	19	32	411	40.1	66.6
July	115	8	12	20	47	467	39.4	54.8
August	99	8	11	16	32	303	38.0	56.9
September	104	8	11	18	33	508	39.4	68.8
October	103	8	12	19	44	637	55.6	103.2
November	103	8	12	20	36	528	48.6	89.4
December	104	8	12	18	38	403	37.8	55.3
2021								
January	106	8	11	14	29	302	32.9	48.9
February	98	8	11	17	31	485	37.3	66.8
March	94	8	13	20	37	332	40.1	59.4
April	102	8	11	17	43	343	48.2	74.0
May	112	8	12	17	30	152	25.8	26.3

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	97	8	11	16	33	279	33.2	46.2
July	95	8	11	14	42	212	32.1	36.7
August	121	8	13	20	40	317	35.7	47.2
September	94	8	10	19	32	303	37.4	56.5
October	106	8	13	20	34	189	30.8	32.7
November	84	8	12	17	30	196	27.3	28.7
December	101	8	12	18	31	209	26.4	26.5
2022								
January	81	8	12	18	33	203	32.4	34.2
February	85	8	10	13	24	175	22.8	25.7
March	82	8	11	14	26	100	22.5	20.1
April	71	8	11	16	31	113	24.2	19.7
May	62	8	10	16	35	65	22.8	15.5
June	55	8	11	19	29	75	23.5	16.2
July	34	8	9	13	21	47	16.8	9.7
August	23	8	10	14	24	32	17.2	7.7
September	2	9	9	11	12	12	10.5	2.1
<i>Eosinophilic Esophagitis</i>	1,112	8	12	18	36	651	37.3	64.5
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	8	8	12	393	393	137.7	221.1
May	3	9	9	10	30	30	16.3	11.8
June	1	25	25	25	25	25	25.0	NaN
July	7	8	12	17	105	480	99.4	171.4
August	6	9	15	17	69	139	44.2	51.4
September	3	9	9	9	12	12	10.0	1.7
October	1	14	14	14	14	14	14.0	NaN
November	5	8	9	20	23	64	24.8	22.9

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December	5	8	9	10	17	19	12.6	5.0
2018								
January	3	8	8	16	34	34	19.3	13.3
February	4	11	12	14	27	37	19.0	12.2
March	7	8	8	13	18	40	16.0	11.4
April	3	46	46	51	84	84	60.3	20.6
May	6	12	12	19	28	40	21.7	10.9
June	10	10	11	25	48	155	39.1	43.6
July	11	8	10	14	42	50	23.7	16.0
August	8	8	12	20	47	66	28.9	21.5
September	9	8	10	14	19	398	78.8	138.9
October	9	8	14	14	30	507	88.3	166.4
November	8	9	11	17	30	54	22.1	15.6
December	18	8	16	23	71	419	81.8	128.3
2019								
January	12	8	10	14	21	43	17.0	10.1
February	8	8	11	16	33	324	56.3	108.9
March	13	8	11	15	28	72	24.5	20.4
April	17	8	12	15	34	633	100.9	189.0
May	17	8	15	37	45	651	72.4	151.2
June	13	8	11	14	32	59	23.3	16.4
July	27	8	11	16	38	347	43.8	70.3
August	28	8	11	15	48	383	45.2	74.8
September	25	12	17	30	51	389	53.2	75.5
October	27	9	11	17	55	125	35.3	35.4
November	25	8	12	22	41	371	44.2	72.9
December	23	8	13	19	32	138	32.4	35.0
2020								
January	29	8	11	14	23	73	20.0	15.7
February	34	8	12	18	36	97	28.1	25.4
March	27	8	12	16	32	310	33.1	57.9

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	16	8	11	27	46	197	47.9	59.3
May	12	9	12	36	64	90	40.5	27.7
June	17	9	12	19	62	641	70.1	151.0
July	17	9	17	21	50	329	54.4	81.8
August	19	8	12	16	37	138	32.6	36.4
September	15	9	13	17	31	210	38.3	52.4
October	15	8	11	19	23	137	27.7	33.3
November	23	8	11	15	33	244	35.5	54.2
December	22	8	10	16	25	64	19.4	13.6
2021								
January	33	8	11	24	44	194	39.6	42.3
February	16	8	13	18	47	205	44.8	57.4
March	26	8	13	16	26	473	39.2	90.4
April	23	9	13	21	47	312	44.7	63.7
May	28	8	11	18	45	235	38.1	48.7
June	27	8	13	17	38	244	38.5	53.9
July	27	8	10	16	45	233	32.8	45.0
August	28	9	13	22	42	306	38.4	56.1
September	24	8	12	16	32	85	25.8	20.7
October	33	8	10	14	23	92	22.1	19.9
November	39	8	12	22	45	157	35.2	37.9
December	29	8	11	17	30	100	23.4	19.0
2022								
January	20	8	10	16	56	143	36.0	38.4
February	18	8	15	24	49	113	35.8	30.8
March	27	8	10	15	27	84	24.4	21.1
April	26	8	14	18	33	134	28.5	28.1
May	25	8	12	18	23	58	20.4	12.1
June	16	8	12	15	30	69	24.0	20.6
July	21	8	12	19	27	34	19.7	8.4
August	15	8	9	12	15	21	12.3	3.5

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	427	8	11	19	36	1,028	48.8	105.0
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	3	21	21	25	34	34	26.7	6.7
May	1	12	12	12	12	12	12.0	NaN
June	2	12	12	15	17	17	14.5	3.5
July	5	8	9	10	44	202	54.6	83.8
August	4	13	19	27	529	1,028	273.8	502.9
September	1	12	12	12	12	12	12.0	NaN
October	3	8	8	39	815	815	287.3	457.2
November	1	731	731	731	731	731	731.0	NaN
December	1	9	9	9	9	9	9.0	NaN
2018								
January	4	8	9	15	54	88	31.5	38.0
February	6	8	12	16	134	154	56.5	68.1
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	5	8	13	22	29	30	20.4	9.7
May	4	12	13	21	38	47	25.3	16.5
June	4	9	20	34	50	64	35.0	22.6
July	3	21	21	38	62	62	40.3	20.6
August	4	9	10	13	21	27	15.5	8.1
September	5	9	11	15	16	18	13.8	3.7
October	6	8	10	21	193	532	130.8	209.2
November	9	8	10	14	24	735	102.1	238.7
December	4	8	10	14	172	329	91.0	158.7
2019								
January	5	8	8	11	14	52	18.6	18.8
February	4	13	15	23	110	192	62.5	86.6

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	6	10	20	80	131	751	178.7	284.1
April	4	17	17	19	239	457	127.8	219.5
May	6	8	10	17	27	28	17.7	9.0
June	9	9	12	15	23	57	21.4	15.5
July	11	8	10	27	42	171	45.7	54.1
August	5	11	13	13	19	28	16.8	6.9
September	9	8	11	30	88	148	53.7	52.9
October	8	8	11	16	53	132	37.3	43.6
November	13	10	19	27	89	322	74.5	102.9
December	11	8	19	24	51	73	32.5	20.8
2020								
January	12	9	11	17	24	119	26.2	30.5
February	9	8	12	16	28	123	39.0	46.1
March	7	8	8	11	22	47	17.6	14.0
April	2	44	44	88	131	131	87.5	61.5
May	6	13	14	15	103	183	57.0	71.3
June	5	8	14	35	40	102	39.8	37.3
July	6	15	16	21	35	201	51.5	73.6
August	13	8	10	20	75	295	62.1	83.9
September	6	9	11	27	85	400	93.2	152.8
October	8	9	10	11	38	51	22.1	17.2
November	15	8	13	19	32	67	24.1	15.4
December	9	8	14	25	38	122	35.4	34.5
2021								
January	7	11	19	35	38	94	36.1	27.4
February	13	9	13	17	45	168	38.3	42.7
March	13	10	15	19	93	473	90.5	134.2
April	8	8	9	30	64	243	56.9	79.1
May	9	8	10	14	26	59	21.4	16.5
June	8	13	14	22	34	47	25.0	12.6
July	7	8	10	13	25	59	21.4	18.0

Table 8d. Continuous Summary of First Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	10	14	19	29	74	106	41.6	32.0
September	11	8	9	21	80	231	51.2	66.0
October	6	8	8	14	18	35	16.0	10.1
November	8	9	10	26	46	95	33.4	29.9
December	5	15	20	32	50	155	54.4	57.8
2022								
January	14	9	12	19	23	29	18.6	6.9
February	9	11	12	13	15	139	27.4	41.9
March	5	8	15	17	22	40	20.4	12.1
April	7	8	8	13	19	44	16.6	12.8
May	6	10	14	21	27	31	20.5	8.8
June	9	8	12	17	18	30	16.9	7.0
July	4	8	9	12	16	17	12.3	4.0
August	4	8	9	10	14	17	11.0	4.1
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 9a. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	95,454	1	3	8	20	1,529	22.3	57.9
<i>Any Indication</i>	89,037	1	3	8	20	1,529	22.2	57.7
<i>Atopic Dermatitis</i>	71,840	1	3	8	20	1,529	23.1	60.7
<i>Asthma</i>	33,160	1	3	8	19	1,401	20.6	51.7
<i>Chronic Rhinosinusitis</i>	17,576	1	3	8	18	1,401	19.6	46.1
<i>Eosinophilic Esophagitis</i>	5,171	1	3	8	19	1,154	20.8	49.1
<i>Prurigo Nodularis</i>	1,845	1	3	7	17	1,110	23.6	70.7
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	40,048	8	12	20	38	1,529	40.0	73.7
<i>Any Indication</i>	37,134	8	12	20	38	1,529	40.0	73.8
<i>Atopic Dermatitis</i>	30,509	8	13	20	39	1,529	41.1	76.9
<i>Asthma</i>	13,590	8	12	19	36	1,401	37.3	66.6
<i>Chronic Rhinosinusitis</i>	6,747	8	12	19	35	1,401	35.9	61.2
<i>Eosinophilic Esophagitis</i>	2,002	8	12	20	36	1,154	37.4	65.2
<i>Prurigo Nodularis</i>	684	8	12	19	38	964	44.9	88.0

Table 9b. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	95,454	1	3	8	20	1,529	22.3	57.9
Female	53,066	1	3	8	20	1,529	22.3	57.0
Male	42,388	1	3	8	20	1,528	22.3	59.0
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	89,037	1	3	8	20	1,529	22.2	57.7
Female	49,579	1	3	8	20	1,529	22.2	56.7
Male	39,458	1	3	8	20	1,528	22.2	58.9
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	71,840	1	3	8	20	1,529	23.1	60.7
Female	39,697	1	3	8	20	1,529	23.2	60.3
Male	32,143	1	3	8	20	1,528	23.0	61.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	33,160	1	3	8	19	1,401	20.6	51.7
Female	18,924	1	3	8	19	1,130	20.6	50.4
Male	14,236	1	3	8	19	1,401	20.5	53.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	17,576	1	3	8	18	1,401	19.6	46.1
Female	9,907	1	3	8	19	968	19.6	42.6
Male	7,669	1	3	7	18	1,401	19.7	50.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	5,171	1	3	8	19	1,154	20.8	49.1
Female	3,017	1	3	8	20	880	21.4	49.7
Male	2,154	1	3	8	19	1,154	20.0	48.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	1,845	1	3	7	17	1,110	23.6	70.7
Female	1,128	1	3	7	17	1,110	23.4	67.7
Male	717	1	3	7	17	964	24.0	75.2
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	40,048	8	12	20	38	1,529	40.0	73.7

Table 9b. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	22,450	8	12	20	38	1,529	39.8	72.3
Male	17,598	8	12	20	38	1,401	40.4	75.5
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	<i>37,134</i>	<i>8</i>	<i>12</i>	<i>20</i>	<i>38</i>	<i>1,529</i>	<i>40.0</i>	<i>73.8</i>
Female	20,867	8	12	20	38	1,529	39.7	72.4
Male	16,267	8	12	20	38	1,401	40.4	75.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	<i>30,509</i>	<i>8</i>	<i>13</i>	<i>20</i>	<i>39</i>	<i>1,529</i>	<i>41.1</i>	<i>76.9</i>
Female	17,020	8	13	20	39	1,529	40.9	76.0
Male	13,489	8	13	20	38	1,401	41.3	78.1
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	<i>13,590</i>	<i>8</i>	<i>12</i>	<i>19</i>	<i>36</i>	<i>1,401</i>	<i>37.3</i>	<i>66.6</i>
Female	7,825	8	12	19	36	1,130	37.2	66.0
Male	5,765	8	12	20	37	1,401	37.3	67.4
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	<i>6,747</i>	<i>8</i>	<i>12</i>	<i>19</i>	<i>35</i>	<i>1,401</i>	<i>35.9</i>	<i>61.2</i>
Female	3,877	8	12	19	35	968	35.7	56.3
Male	2,870	8	12	19	35	1,401	36.2	67.3
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	<i>2,002</i>	<i>8</i>	<i>12</i>	<i>20</i>	<i>36</i>	<i>1,154</i>	<i>37.4</i>	<i>65.2</i>
Female	1,195	8	12	20	37	880	38.3	64.0
Male	807	8	12	19	35	1,154	36.0	67.1
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	<i>684</i>	<i>8</i>	<i>12</i>	<i>19</i>	<i>38</i>	<i>964</i>	<i>44.9</i>	<i>88.0</i>
Female	417	8	12	19	40	613	40.6	64.2
Male	267	8	12	20	37	964	51.5	115.6
Other	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 9c. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	95,454	1	3	8	20	1,529	22.3	57.9
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	246	1	6	19	34	277	27.0	33.7
6-11 years	3,161	1	4	12	27	959	22.7	39.7
12-17 years	10,269	1	3	8	20	1,229	21.8	50.9
18-79 years	81,290	1	3	8	19	1,529	22.3	59.4
≥ 80 years	488	1	3	7	16	735	20.3	50.5
<i>Any Indication</i>	89,037	1	3	8	20	1,529	22.2	57.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	234	1	6	20	34	277	27.3	33.9
6-11 years	3,066	1	4	12	27	959	22.7	39.7
12-17 years	9,787	1	3	8	20	1,229	21.7	49.9
18-79 years	75,541	1	3	8	19	1,529	22.3	59.3
≥ 80 years	409	1	3	7	17	735	19.7	49.1
<i>Atopic Dermatitis</i>	71,840	1	3	8	20	1,529	23.1	60.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	230	1	6	20	34	277	27.5	34.1
6-11 years	2,972	1	4	12	27	959	22.6	39.2
12-17 years	9,105	1	3	8	20	1,229	21.7	50.6
18-79 years	59,211	1	3	8	20	1,529	23.4	63.1
≥ 80 years	322	1	3	7	16	735	20.5	53.2
<i>Asthma</i>	33,160	1	3	8	19	1,401	20.6	51.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	47	1	6	25	31	65	22.3	17.5
6-11 years	1,190	1	4	12	25	959	22.7	45.5
12-17 years	3,949	1	3	8	20	756	20.7	43.2
18-79 years	27,877	1	3	8	18	1,401	20.5	53.2
≥ 80 years	97	1	4	7	15	234	15.1	27.9
<i>Chronic Rhinosinusitis</i>	17,576	1	3	8	18	1,401	19.6	46.1
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 9c. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
6-71 months	11	1	1	18	27	52	16.2	16.3
6-11 years	144	1	6	15	27	109	19.4	18.8
12-17 years	845	1	4	9	21	280	19.6	31.1
18-79 years	16,500	1	3	7	18	1,401	19.6	47.0
≥ 80 years	76	1	3	7	16	253	15.4	31.7
<i>Eosinophilic Esophagitis</i>	5,171	1	3	8	19	1,154	20.8	49.1
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	8	1	1	8	19	35	11.4	12.6
6-11 years	159	1	5	14	26	253	21.5	30.6
12-17 years	407	1	4	8	21	756	21.3	53.2
18-79 years	4,559	1	3	8	19	1,154	20.8	49.3
≥ 80 years	38	1	2	6	16	234	16.5	38.1
<i>Prurigo Nodularis</i>	1,845	1	3	7	17	1,110	23.6	70.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-11 years	2	1	1	2	3	3	2.0	1.4
12-17 years	84	1	3	7	19	122	15.4	22.4
18-79 years	1,717	1	3	7	17	1,110	24.1	73.0
≥ 80 years	42	1	4	12	23	99	20.0	26.3
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>	40,048	8	12	20	38	1,529	40.0	73.7
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	157	8	18	27	42	277	37.7	37.2
6-11 years	1,647	8	14	23	39	959	34.7	43.3
12-17 years	4,450	8	12	20	39	1,229	39.0	66.3
18-79 years	33,624	8	12	20	37	1,529	40.4	75.9
≥ 80 years	170	8	12	18	39	735	42.6	76.0
<i>Any Indication</i>	37,134	8	12	20	38	1,529	40.0	73.8
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	154	8	18	27	42	277	37.5	37.0
6-11 years	1,602	8	14	23	39	959	34.6	42.9

Table 9c. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
12-17 years	4,206	8	12	20	39	1,229	38.8	64.8
18-79 years	31,024	8	12	20	37	1,529	40.5	76.3
≥ 80 years	148	8	12	18	39	735	40.1	73.5
<i>Atopic Dermatitis</i>	30,509	8	13	20	39	1,529	41.1	76.9
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	152	8	18	27	42	277	37.8	37.2
6-11 years	1,555	8	14	23	39	959	34.3	41.9
12-17 years	3,900	8	12	20	39	1,229	39.0	66.0
18-79 years	24,793	8	12	20	38	1,529	41.9	80.2
≥ 80 years	109	8	12	21	40	735	46.6	84.4
<i>Asthma</i>	13,590	8	12	19	36	1,401	37.3	66.6
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	25	16	26	27	37	65	32.5	13.2
6-11 years	624	8	14	22	40	959	35.3	54.6
12-17 years	1,712	8	13	20	37	756	36.7	54.2
18-79 years	11,190	8	12	19	36	1,401	37.5	69.0
≥ 80 years	39	8	12	15	23	76	21.3	15.9
<i>Chronic Rhinosinusitis</i>	6,747	8	12	19	35	1,401	35.9	61.2
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	4	18	19	24	27	27	23.0	4.7
6-11 years	81	8	15	20	32	109	27.2	19.2
12-17 years	398	8	12	19	36	272	32.4	36.1
18-79 years	6,234	8	12	19	35	1,401	36.3	62.9
≥ 80 years	30	8	12	16	23	253	27.5	44.0
<i>Eosinophilic Esophagitis</i>	2,002	8	12	20	36	1,154	37.4	65.2
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	3	10	10	13	35	35	19.3	13.7
6-11 years	88	8	14	22	35	253	32.6	36.6
12-17 years	176	8	12	19	33	756	36.3	72.5
18-79 years	1,727	8	12	19	37	1,154	37.8	65.8
≥ 80 years	8	10	11	16	29	47	20.9	13.5

Table 9c. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Prurigo Nodularis</i>	684	8	12	19	38	964	44.9	88.0
0-6 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-71 months	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
6-11 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
12-17 years	26	8	13	24	45	73	28.3	18.4
18-79 years	639	8	12	19	38	964	45.9	90.7
≥ 80 years	19	9	12	16	37	99	31.5	29.2

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Dupilumab Use with a 0-day Treatment Gap								
<i>No Indication Requirement</i>	95,454	1	3	8	20	1,529	22.3	57.9
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	16	1	3	9	22	742	57.8	182.8
April	533	1	3	7	16	850	24.0	78.4
May	1,318	1	4	8	18	1,037	24.3	71.8
June	1,380	1	4	8	21	1,169	24.5	69.0
July	1,373	1	3	7	19	1,094	24.5	76.3
August	1,509	1	3	7	18	1,310	29.4	99.3
September	1,159	1	4	8	21	1,065	27.9	83.3
October	1,385	1	4	9	22	1,529	35.6	111.1
November	1,292	1	4	8	21	1,154	26.8	78.5
December	859	1	3	8	17	1,094	27.2	90.5
2018								
January	869	1	4	8	21	1,354	31.3	103.9
February	1,010	1	4	8	19	1,401	26.5	86.6
March	1,234	1	3	7	19	1,495	26.7	84.2
April	1,091	1	3	8	18	1,160	24.5	73.6
May	1,033	1	4	8	21	980	26.1	71.7
June	907	1	4	9	25	1,006	31.7	84.1
July	1,572	1	3	8	21	988	26.0	69.7
August	1,597	1	4	9	25	1,364	32.8	97.6
September	1,154	1	4	9	23	1,118	31.6	88.7
October	1,492	1	3	8	21	1,175	27.3	73.6
November	1,462	1	4	9	21	1,229	23.9	67.1
December	1,183	1	3	7	18	1,154	23.3	73.9
2019								
January	1,678	1	4	8	21	1,047	27.3	77.7
February	1,910	1	4	8	19	916	21.6	49.3

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	1,835	1	4	8	20	759	25.5	63.4
April	2,275	1	4	8	21	837	24.9	59.6
May	2,223	1	4	8	20	1,003	22.2	55.6
June	1,857	1	3	8	20	748	25.8	65.3
July	2,745	1	4	8	20	882	23.1	56.6
August	2,668	1	4	9	21	675	23.7	50.3
September	2,078	1	3	8	20	673	23.9	53.7
October	2,615	1	3	8	20	769	22.6	52.4
November	2,349	1	3	7	20	755	21.7	50.3
December	2,138	1	3	8	19	756	21.6	49.4
2020								
January	2,108	1	3	8	19	725	20.0	44.4
February	1,872	1	3	7	19	836	21.4	50.0
March	2,014	1	3	8	20	713	20.8	45.9
April	1,426	1	4	8	20	554	21.4	42.7
May	1,295	1	3	7	19	653	22.1	48.9
June	1,631	1	3	8	19	641	20.8	46.7
July	3,263	1	3	8	21	714	20.7	40.1
August	2,409	1	3	8	21	454	19.6	36.8
September	2,421	1	3	8	21	410	20.4	37.9
October	1,997	1	3	8	20	553	21.6	47.8
November	1,816	1	3	8	21	391	20.6	38.1
December	1,769	1	3	8	21	416	19.2	33.2
2021								
January	1,674	1	3	7	19	421	17.7	32.1
February	1,528	1	3	7	18	340	17.4	31.6
March	1,666	1	3	7	18	329	16.8	28.6
April	1,517	1	3	7	19	376	17.7	31.0
May	1,313	1	3	8	19	386	17.2	28.7
June	1,194	1	3	8	20	340	18.1	27.4
July	1,878	1	3	8	19	286	17.3	26.9

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	1,759	1	3	7	19	246	16.5	24.6
September	1,166	1	3	7	17	212	15.9	24.5
October	1,229	1	3	7	17	259	15.3	23.5
November	1,028	1	3	7	16	152	14.2	20.4
December	798	1	3	6	17	201	14.2	21.3
2022								
January	709	1	3	7	15	144	13.4	18.6
February	536	1	3	6	14	161	12.3	17.2
March	564	1	2	6	15	109	11.8	15.7
April	439	1	2	6	13	92	9.7	11.2
May	312	1	3	5	13	77	9.1	10.1
June	219	1	2	4	10	45	7.1	7.5
July	97	1	2	4	7	21	5.8	4.8
August	8	1	1	2	2	4	1.8	1.0
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	89,037	1	3	8	20	1,529	22.2	57.7
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	16	1	3	9	22	742	57.8	182.8
April	485	1	3	7	15	850	23.5	81.5
May	1,072	1	4	8	18	1,027	23.3	67.4
June	1,202	1	4	8	21	981	25.0	65.9
July	1,301	1	3	7	19	1,094	23.9	74.2
August	1,411	1	3	7	18	1,310	29.8	101.4
September	1,108	1	4	8	21	1,065	28.2	83.8
October	1,225	1	4	9	23	1,529	36.3	113.4
November	1,155	1	4	9	21	1,154	26.3	79.3
December	768	1	3	8	17	1,094	27.7	92.2
2018								
January	899	1	4	9	21	1,354	29.6	99.1

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
February	895	1	4	8	19	1,401	26.3	85.0
March	1,036	1	3	7	19	1,495	27.9	90.2
April	1,030	1	4	8	19	1,160	25.2	75.4
May	914	1	3	8	21	980	24.8	69.5
June	804	1	4	9	25	1,006	32.6	89.3
July	1,483	1	3	8	21	988	26.2	69.4
August	1,454	1	4	9	23	1,364	32.7	102.9
September	1,101	1	4	11	26	1,118	32.6	88.0
October	1,474	1	4	8	21	951	25.7	62.9
November	1,359	1	4	9	21	1,229	24.5	68.1
December	1,109	1	3	8	19	1,154	23.8	74.5
2019								
January	1,598	1	4	8	21	1,047	26.9	77.5
February	1,798	1	4	8	19	916	21.0	48.2
March	1,772	1	4	9	20	759	25.9	65.1
April	2,123	1	4	8	21	742	24.0	56.2
May	2,131	1	4	8	20	1,003	21.8	55.3
June	1,671	1	3	8	20	748	25.3	63.2
July	2,548	1	4	8	20	882	22.2	54.4
August	2,578	1	4	9	21	675	23.4	50.7
September	2,019	1	3	8	20	673	24.2	54.5
October	2,483	1	3	8	20	769	22.7	53.0
November	2,230	1	3	8	20	755	21.9	50.5
December	2,043	1	3	8	20	756	21.2	47.5
2020								
January	2,038	1	3	8	19	725	20.6	46.8
February	1,741	1	3	7	19	836	21.6	51.1
March	1,866	1	3	8	20	713	21.5	46.7
April	1,388	1	4	8	20	554	21.6	43.8
May	1,209	1	3	7	19	653	21.8	47.1
June	1,616	1	3	8	19	641	20.1	45.2

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	2,863	1	3	8	20	714	20.3	39.9
August	2,134	1	3	8	21	454	19.8	36.7
September	2,229	1	3	8	21	410	19.8	36.9
October	1,888	1	3	8	20	553	21.4	46.7
November	1,687	1	3	8	21	399	20.7	37.7
December	1,558	1	3	8	21	510	19.7	36.0
2021								
January	1,586	1	3	8	19	421	18.3	32.9
February	1,528	1	3	7	18	340	17.7	32.3
March	1,575	1	3	7	19	329	16.9	28.7
April	1,475	1	3	8	19	376	18.3	31.9
May	1,320	1	3	8	19	386	17.1	29.0
June	1,177	1	3	8	20	340	17.8	26.8
July	1,563	1	3	8	19	286	17.2	26.9
August	1,585	1	3	7	20	233	16.6	24.5
September	1,102	1	3	7	17	212	15.4	23.4
October	1,118	1	3	7	17	259	15.8	24.5
November	935	1	3	7	16	152	13.8	19.9
December	796	1	3	7	17	201	14.3	21.3
2022								
January	675	1	3	7	15	144	13.5	19.3
February	519	1	3	6	14	161	12.1	17.0
March	551	1	2	6	15	96	11.5	14.8
April	422	1	2	6	13	92	9.7	11.1
May	291	1	2	5	13	77	9.0	9.9
June	213	1	2	4	10	45	7.1	7.4
July	87	1	2	4	7	21	5.6	4.9
August	7	1	1	2	2	4	1.9	1.1
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	<i>71,840</i>	<i>1</i>	<i>3</i>	<i>8</i>	<i>20</i>	<i>1,529</i>	<i>23.1</i>	<i>60.7</i>
2017								

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	16	1	3	9	22	742	57.8	182.8
April	469	1	3	7	15	850	23.9	82.8
May	1,064	1	4	8	18	1,027	23.4	67.6
June	1,206	1	3	8	21	981	24.2	62.2
July	1,222	1	3	7	19	1,094	23.7	72.6
August	1,314	1	3	7	18	1,310	30.4	104.0
September	1,096	1	4	8	21	1,065	27.3	80.5
October	1,204	1	4	9	24	1,529	37.0	116.1
November	1,146	1	4	9	21	1,154	26.9	80.1
December	757	1	3	8	17	1,094	28.0	92.8
2018								
January	893	1	4	9	21	1,354	29.8	99.4
February	877	1	4	8	19	1,401	26.1	85.7
March	1,003	1	3	7	20	1,495	26.6	83.9
April	934	1	3	8	18	1,160	24.4	73.2
May	863	1	3	8	20	980	24.6	69.1
June	790	1	4	9	24	1,006	33.0	93.4
July	1,456	1	3	8	21	988	26.2	69.9
August	1,399	1	4	8	24	1,364	34.0	106.7
September	1,067	1	4	10	25	1,118	32.5	89.0
October	1,439	1	4	8	21	951	25.1	61.4
November	1,244	1	4	9	21	1,229	24.6	69.8
December	927	1	3	7	18	1,110	23.1	70.3
2019								
January	1,332	1	4	8	22	1,047	28.1	82.4
February	1,426	1	4	8	20	916	21.9	48.7
March	1,349	1	4	9	21	759	27.4	68.6
April	1,747	1	4	8	21	742	25.2	59.4
May	1,811	1	4	9	20	870	21.6	52.5

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	1,435	1	3	8	21	748	25.5	64.8
July	2,045	1	4	8	20	798	22.8	53.8
August	1,978	1	4	8	21	675	23.9	52.5
September	1,432	1	3	8	22	673	26.8	60.1
October	1,735	1	3	8	21	769	23.9	52.1
November	1,541	1	3	8	21	755	22.6	54.0
December	1,511	1	3	9	20	756	22.2	49.9
2020								
January	1,621	1	3	8	19	725	21.2	49.1
February	1,201	1	3	8	22	836	24.7	57.0
March	1,230	1	3	8	22	713	23.0	46.8
April	851	1	4	9	22	432	22.4	40.8
May	830	1	3	8	21	653	23.7	51.5
June	1,121	1	3	7	19	530	19.3	40.9
July	2,159	1	3	8	21	714	20.9	40.3
August	1,566	1	4	9	23	454	21.1	39.3
September	1,659	1	3	9	22	402	20.2	36.1
October	1,375	1	3	8	20	553	21.2	45.1
November	1,248	1	4	9	23	399	21.8	40.5
December	1,160	1	3	8	22	510	21.2	39.8
2021								
January	1,137	1	3	7	19	421	18.0	33.8
February	1,132	1	4	8	20	337	19.2	34.7
March	1,160	1	3	7	18	329	17.6	31.3
April	1,151	1	3	8	21	376	18.9	31.0
May	968	1	3	8	20	327	17.4	29.1
June	909	1	4	9	23	340	19.2	28.0
July	1,249	1	3	8	19	286	17.1	26.4
August	1,224	1	3	8	20	205	16.8	23.6
September	881	1	3	7	18	179	15.9	23.9
October	812	1	3	7	20	259	17.0	26.0

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	716	1	3	7	18	152	14.4	20.0
December	604	1	3	7	18	201	14.7	22.3
2022								
January	558	1	3	7	15	144	13.7	18.9
February	397	1	3	6	13	161	11.5	17.2
March	416	1	3	6	15	96	11.7	14.6
April	335	1	3	7	14	67	9.9	10.3
May	226	1	3	5	13	77	8.9	9.7
June	152	1	2	5	10	45	7.2	7.3
July	58	1	2	4	6	21	5.8	5.2
August	6	1	1	2	2	4	1.8	1.2
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	<i>33,160</i>	<i>1</i>	<i>3</i>	<i>8</i>	<i>19</i>	<i>1,401</i>	<i>20.6</i>	<i>51.7</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	16	1	3	9	22	742	57.8	182.8
April	125	1	3	6	14	393	18.3	51.4
May	280	1	4	7	17	1,027	20.9	70.3
June	239	1	5	10	29	547	30.8	60.2
July	319	1	3	7	17	1,070	25.7	93.2
August	382	1	4	9	24	1,130	36.7	109.6
September	274	1	4	9	24	818	29.8	85.0
October	345	1	4	10	23	720	29.1	74.2
November	227	1	4	11	29	1,154	35.1	111.2
December	276	1	4	9	22	892	27.7	78.3
2018								
January	244	1	5	11	22	382	23.0	42.6
February	240	1	3	8	19	1,401	26.9	108.6
March	274	1	4	8	22	987	34.4	101.0
April	286	1	3	7	17	833	24.0	79.8

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	369	1	4	7	17	769	24.7	75.4
June	148	1	4	12	29	736	32.7	77.8
July	401	1	3	8	18	486	18.4	39.7
August	393	1	4	10	23	940	27.0	77.3
September	260	1	3	10	25	782	31.1	81.0
October	329	1	3	8	18	872	20.2	57.6
November	472	1	4	9	25	968	30.2	83.4
December	465	1	3	9	21	1,154	25.7	82.1
2019								
January	760	1	4	8	21	1,001	27.8	82.7
February	708	1	3	8	17	484	18.3	43.3
March	749	1	4	9	20	927	22.6	60.0
April	917	1	4	8	23	601	25.0	52.9
May	844	1	4	8	20	1,003	21.1	52.2
June	604	1	3	8	17	534	20.8	48.7
July	961	1	4	8	19	882	22.3	55.9
August	1,111	1	4	8	18	664	22.0	48.1
September	829	1	3	7	19	392	19.9	42.0
October	1,132	1	3	7	18	755	19.7	45.5
November	1,010	1	3	8	20	620	21.2	45.1
December	675	1	3	8	21	756	22.3	51.4
2020								
January	733	1	3	7	17	469	17.0	34.2
February	799	1	3	7	17	475	16.9	35.7
March	900	1	3	7	16	471	17.5	38.9
April	710	1	3	8	18	446	19.6	40.6
May	529	1	4	7	16	421	19.1	40.4
June	736	1	3	8	19	641	20.5	45.0
July	1,076	1	4	8	20	439	20.0	37.8
August	911	1	4	8	19	459	17.6	32.0
September	936	1	3	8	20	410	18.7	35.6

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
October	763	1	3	8	20	499	19.9	43.1
November	691	1	3	7	18	313	18.3	33.0
December	625	1	3	8	21	250	17.2	25.1
2021								
January	729	1	3	8	18	232	16.4	26.1
February	559	1	3	7	17	340	16.9	32.0
March	642	1	3	8	20	268	17.2	26.5
April	571	1	3	8	19	312	18.9	34.8
May	570	1	3	9	19	386	17.8	29.2
June	467	1	3	7	16	144	15.4	21.6
July	537	1	3	7	18	212	16.2	25.7
August	599	1	3	7	17	212	15.4	24.4
September	363	1	3	8	17	191	15.3	23.0
October	432	1	3	7	15	160	14.2	21.8
November	319	1	3	6	15	125	12.4	16.7
December	291	1	2	7	18	135	13.9	19.6
2022								
January	240	1	2	6	13	143	12.7	20.0
February	211	1	3	6	16	96	12.4	15.0
March	176	1	3	6	14	86	11.9	15.0
April	152	1	2	6	13	92	9.4	11.7
May	106	1	2	6	14	47	9.8	10.3
June	79	1	2	5	11	42	7.4	7.9
July	42	1	3	4	7	21	5.2	4.0
August	2	1	1	2	2	2	1.5	0.7
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic Rhinosinusitis</i>	<i>17,576</i>	<i>1</i>	<i>3</i>	<i>8</i>	<i>18</i>	<i>1,401</i>	<i>19.6</i>	<i>46.1</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	48	1	3	7	17	393	24.8	63.0
May	82	1	3	6	17	769	23.2	86.9
June	109	1	3	6	16	766	30.2	103.7
July	54	1	7	23	35	372	30.1	50.8
August	138	1	3	7	21	666	28.6	83.3
September	59	1	3	4	11	642	18.2	83.0
October	62	1	4	10	15	154	16.6	26.9
November	52	1	5	9	17	354	28.8	70.2
December	39	1	4	10	23	391	25.5	62.6
2018								
January	110	1	5	13	29	713	32.4	75.7
February	79	1	3	7	27	1,401	43.1	162.3
March	91	1	7	14	37	244	30.3	42.3
April	123	1	4	14	35	392	32.1	54.2
May	109	1	5	15	28	548	30.3	60.8
June	43	1	3	8	24	149	23.0	36.3
July	123	1	4	8	24	833	27.0	83.6
August	143	1	5	11	27	940	40.0	115.6
September	100	1	6	16	41	212	30.4	38.9
October	84	1	5	9	26	370	31.7	65.3
November	162	1	5	8	18	968	30.1	102.0
December	182	1	2	7	21	1,154	28.3	104.6
2019								
January	214	1	5	10	23	372	21.4	42.9
February	312	1	4	8	17	364	15.5	34.0
March	271	1	4	8	20	453	22.5	50.6
April	420	1	3	8	18	406	20.0	40.7
May	302	1	3	8	21	316	21.9	40.4
June	251	1	4	8	20	337	20.3	41.2
July	467	1	4	9	21	352	20.5	37.1
August	601	1	4	8	20	438	22.1	44.1

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	617	1	3	8	17	392	19.4	40.1
October	602	1	3	7	17	767	19.6	57.6
November	649	1	3	7	20	416	20.9	41.7
December	566	1	3	7	18	461	19.4	43.7
2020								
January	505	1	3	8	19	380	21.4	43.0
February	505	1	3	7	15	620	17.3	44.6
March	553	1	3	6	16	713	20.7	56.4
April	457	1	4	8	18	554	20.5	47.8
May	322	1	3	7	15	233	16.9	30.3
June	496	1	3	9	20	592	20.0	40.9
July	601	1	3	8	20	295	19.1	32.9
August	540	1	3	7	15	304	16.9	32.2
September	444	1	3	8	18	407	18.7	37.9
October	417	1	4	8	21	397	21.9	45.5
November	406	1	3	7	16	239	14.8	24.1
December	414	1	3	7	19	403	16.9	32.7
2021								
January	464	1	3	7	16	232	16.9	29.8
February	420	1	3	7	16	485	16.6	35.9
March	363	1	3	8	20	138	16.0	21.7
April	344	1	3	7	17	312	18.2	37.1
May	382	1	3	8	18	386	15.9	26.9
June	305	1	3	7	16	201	16.3	25.7
July	357	1	4	7	18	212	16.6	24.6
August	320	1	4	8	19	233	17.4	28.4
September	275	1	3	8	15	212	14.5	22.4
October	314	1	3	7	15	160	14.5	21.2
November	216	1	2	6	17	136	13.0	18.9
December	202	1	3	7	17	124	15.8	23.5
2022								

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	167	1	2	7	15	124	13.7	19.5
February	126	1	3	6	16	96	12.7	16.7
March	137	1	3	6	14	93	11.3	15.7
April	111	1	3	6	12	92	10.4	14.2
May	77	1	2	5	11	54	9.8	12.5
June	52	1	2	5	9	30	7.2	7.4
July	19	1	2	4	7	21	5.5	5.3
August	1	2	2	2	2	2	2.0	NaN
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	<i>5,171</i>	<i>1</i>	<i>3</i>	<i>8</i>	<i>19</i>	<i>1,154</i>	<i>20.8</i>	<i>49.1</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	10	1	6	12	18	393	51.9	120.6
May	8	1	2	4	11	17	6.4	6.2
June	5	2	4	4	7	7	4.8	2.2
July	47	1	4	8	21	140	18.8	29.4
August	34	1	4	11	24	552	37.0	97.9
September	39	1	1	3	21	245	30.4	60.4
October	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
November	39	1	2	7	27	382	25.6	63.1
December	49	1	3	6	11	506	19.1	72.0
2018								
January	37	1	3	8	19	410	26.8	70.5
February	51	1	2	10	17	172	16.7	32.3
March	48	1	2	5	14	629	24.0	90.6
April	45	1	4	9	21	880	62.8	166.6
May	37	1	5	12	29	235	25.4	42.2
June	70	1	3	9	30	150	22.6	34.1
July	76	1	3	6	14	250	15.4	31.4

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	68	1	4	7	13	589	24.1	82.7
September	39	1	5	10	16	398	30.3	72.5
October	59	1	3	8	20	507	27.6	77.2
November	80	1	7	12	32	305	29.8	49.8
December	124	1	3	11	28	1,154	28.1	104.4
2019								
January	80	1	5	12	21	212	19.0	27.5
February	31	1	4	10	19	253	27.2	51.2
March	86	1	3	6	11	204	15.7	31.8
April	89	1	4	8	22	268	23.8	45.3
May	153	1	4	9	20	485	24.3	62.4
June	68	1	3	6	11	435	17.4	55.3
July	196	1	3	7	16	175	14.4	23.9
August	125	1	4	7	20	522	28.2	68.9
September	186	1	4	7	17	308	20.9	39.8
October	182	1	4	10	26	363	26.9	46.1
November	130	1	3	9	20	286	20.5	38.5
December	131	1	4	10	20	160	18.7	25.1
2020								
January	121	1	3	7	15	226	16.0	30.8
February	217	1	4	11	22	756	21.4	57.2
March	139	1	5	11	21	183	20.0	29.5
April	98	1	4	8	22	554	23.6	61.0
May	65	1	3	7	31	130	22.7	31.3
June	75	1	3	7	27	641	35.7	85.3
July	95	1	3	7	23	237	20.6	38.7
August	108	1	3	8	21	292	23.8	45.7
September	100	1	5	14	26	260	25.7	42.7
October	110	1	3	7	14	206	18.2	35.7
November	106	1	3	10	25	141	17.7	23.9
December	84	1	3	7	20	227	17.7	29.7

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2021								
January	115	1	5	14	35	202	24.2	32.3
February	85	1	4	8	16	256	17.2	33.7
March	125	1	4	7	16	165	15.2	22.9
April	93	1	4	12	21	312	18.9	34.3
May	120	1	4	6	18	235	17.8	32.7
June	80	1	3	6	13	145	12.5	20.9
July	88	1	3	7	13	306	17.5	38.7
August	94	1	3	8	21	239	20.1	32.7
September	92	1	3	6	15	85	11.1	13.8
October	107	1	4	8	16	161	13.3	19.8
November	114	1	2	7	18	152	15.7	26.7
December	88	1	3	7	18	100	13.6	18.3
2022								
January	58	1	2	6	11	143	12.9	23.8
February	47	1	3	10	20	106	14.8	18.3
March	44	1	4	9	18	59	14.9	16.3
April	29	1	2	7	15	64	11.6	12.9
May	23	1	2	7	14	28	9.3	8.6
June	16	1	1	3	8	23	5.2	6.2
July	12	1	2	4	8	21	6.2	6.2
August	1	4	4	4	4	4	4.0	NaN
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	<i>1,845</i>	<i>1</i>	<i>3</i>	<i>7</i>	<i>17</i>	<i>1,110</i>	<i>23.6</i>	<i>70.7</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	28	1	2	5	16	457	24.7	85.1
May	4	1	5	10	19	25	11.5	10.1
June	2	4	4	8	12	12	8.0	5.7

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
July	69	1	2	4	7	849	28.9	108.3
August	22	1	4	11	28	1,028	116.3	274.9
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
October	16	1	2	4	8	371	29.1	91.6
November	9	1	7	19	51	157	40.2	49.4
December	4	1	3	5	8	9	5.0	3.4
2018								
January	30	1	4	9	28	184	24.5	36.6
February	19	1	5	10	53	167	34.5	50.0
March	3	37	37	62	76	76	58.3	19.8
April	21	1	3	8	30	394	35.0	85.2
May	15	1	2	12	26	964	77.7	245.8
June	43	1	3	8	15	119	13.3	19.1
July	29	1	2	12	22	105	20.5	25.6
August	21	1	6	9	29	369	42.2	81.9
September	37	1	3	8	23	934	48.0	154.4
October	53	1	2	6	14	260	20.9	49.9
November	31	1	4	7	16	90	13.1	18.0
December	29	1	4	6	12	1,110	67.2	216.5
2019								
January	48	1	3	7	18	218	32.0	55.9
February	34	1	3	6	13	307	17.4	51.8
March	20	1	3	6	20	751	49.7	166.5
April	26	1	4	8	19	227	24.7	53.2
May	34	1	2	6	10	353	18.5	60.0
June	72	1	3	7	16	73	11.7	13.6
July	74	1	3	8	27	164	20.3	29.2
August	49	1	2	3	13	311	17.1	47.1
September	24	1	3	7	32	162	24.3	37.6
October	48	1	3	8	20	174	22.8	38.6
November	61	1	3	7	18	322	25.4	56.1

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December 2020	44	1	5	7	14	85	15.6	19.6
January	23	1	5	8	39	389	58.5	116.8
February	37	1	7	13	24	231	28.9	53.5
March	17	1	6	13	47	327	43.7	78.5
April	25	1	3	7	15	99	13.1	20.0
May	33	1	3	9	19	139	16.7	25.7
June	22	1	4	8	15	165	18.1	34.3
July	44	1	3	6	18	229	20.8	46.7
August	53	1	3	6	12	69	11.0	13.7
September	47	1	3	7	15	129	13.2	20.4
October	27	1	4	8	12	51	10.9	11.7
November	55	1	2	9	15	99	15.3	21.7
December 2021	46	1	3	9	17	129	19.8	30.6
January	36	1	4	8	17	94	17.3	23.1
February	60	1	3	7	19	105	14.6	19.8
March	37	1	3	10	21	137	21.6	30.8
April	20	1	3	12	43	243	40.1	65.0
May	16	1	4	12	18	35	12.3	10.8
June	24	1	1	2	8	29	5.4	7.2
July	30	3	6	10	23	179	19.3	31.8
August	23	1	4	14	40	141	33.0	42.6
September	35	1	3	6	13	47	11.0	11.5
October	17	1	5	12	20	38	14.7	12.6
November	24	1	2	6	23	95	18.0	26.5
December 2022	11	1	2	4	8	20	6.0	5.6
January	23	1	2	8	19	64	13.3	14.6
February	10	1	2	5	12	25	7.8	7.6
March	5	2	2	5	6	15	6.0	5.3

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	11	3	4	6	13	22	8.5	6.0
May	8	1	1	6	17	31	9.8	10.8
June	5	1	3	3	17	30	10.8	12.5
July	2	14	14	16	17	17	15.5	2.1
August	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Dupilumab Use with a 7-day Treatment Gap								
<i>No Indication Requirement</i>								
	40,048	8	12	20	38	1,529	40.0	73.7
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	8	10	14	22	37	742	112.0	254.8
April	223	8	12	17	30	850	46.0	111.5
May	597	8	12	18	35	1,027	43.7	90.6
June	664	8	12	21	38	1,169	44.1	92.8
July	573	8	12	20	34	1,094	41.7	92.2
August	644	8	12	20	38	1,130	55.1	126.5
September	530	8	13	20	37	1,065	49.7	108.4
October	633	8	13	21	48	1,529	61.0	134.6
November	621	8	12	20	39	833	43.2	80.9
December	387	8	12	18	32	1,094	48.4	114.7
2018								
January	403	8	13	21	41	1,354	58.6	145.1
February	450	8	12	18	38	1,401	45.9	113.2
March	543	8	12	18	37	1,157	48.1	100.8
April	468	8	12	18	38	1,160	48.4	107.6
May	468	8	13	21	38	980	45.3	96.1
June	438	8	14	23	50	736	48.6	79.0
July	578	8	12	21	44	988	48.0	89.9
August	689	8	13	22	45	1,358	51.0	109.7

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	575	8	13	20	41	1,118	49.0	103.0
October	701	8	12	21	45	1,175	48.9	92.8
November	689	8	12	19	35	1,229	42.4	92.0
December	495	8	12	20	36	1,154	43.8	97.2
2019								
January	792	8	12	20	38	1,047	45.5	95.4
February	868	8	12	20	40	916	42.0	71.4
March	836	8	13	20	38	759	43.5	80.2
April	1,010	8	12	20	39	742	39.3	61.1
May	1,022	8	12	19	36	1,003	38.8	72.6
June	809	8	13	21	42	748	46.1	80.9
July	1,217	8	12	19	39	882	40.1	75.2
August	1,225	8	12	20	43	675	40.7	61.5
September	892	8	12	20	42	475	42.8	62.7
October	1,154	8	12	20	40	769	38.4	60.2
November	1,028	8	13	20	37	755	38.6	60.6
December	965	8	12	19	37	756	38.6	62.3
2020								
January	937	8	12	19	35	725	37.1	58.5
February	748	8	12	19	37	733	38.1	60.5
March	898	8	12	20	37	713	36.9	54.8
April	602	8	12	19	36	554	36.7	52.2
May	510	8	13	20	42	653	44.4	70.3
June	688	8	12	20	38	592	36.8	54.8
July	1,177	8	13	21	40	714	37.7	52.1
August	1,012	8	13	21	38	410	35.2	43.1
September	1,008	8	13	21	38	410	35.4	46.1
October	827	8	13	21	40	499	38.8	56.1
November	818	8	13	22	39	391	36.8	45.4
December	817	8	13	20	36	416	33.0	38.4
2021								

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	653	8	12	19	35	299	32.5	38.3
February	576	8	13	19	32	337	29.7	32.6
March	616	8	12	19	35	268	30.5	32.6
April	598	8	13	20	36	376	32.4	36.8
May	528	8	12	20	37	386	30.7	33.0
June	459	8	13	21	39	340	32.7	33.0
July	645	8	13	19	34	212	30.5	30.6
August	598	8	13	20	37	205	30.4	28.4
September	457	8	12	17	30	193	28.0	28.2
October	396	8	12	17	32	160	26.9	26.3
November	331	8	12	18	30	140	26.0	23.1
December	240	8	12	20	33	145	29.0	26.3
2022								
January	207	8	12	17	30	128	24.7	19.7
February	144	8	11	17	27	83	22.4	15.9
March	158	8	12	18	28	96	23.8	17.8
April	111	8	12	16	22	86	20.1	14.1
May	57	8	11	13	21	77	17.7	11.9
June	33	8	10	13	16	28	14.3	5.6
July	4	9	13	17	18	18	15.3	4.3
August	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Any Indication</i>	<i>37,134</i>	<i>8</i>	<i>12</i>	<i>20</i>	<i>38</i>	<i>1,529</i>	<i>40.0</i>	<i>73.8</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	8	10	14	22	37	742	112.0	254.8
April	193	8	12	16	26	850	46.6	119.0
May	482	8	12	19	35	1,027	43.3	93.3
June	569	8	13	21	39	981	45.2	87.6
July	543	8	13	20	34	1,094	41.0	91.8

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	593	8	12	20	39	1,130	55.9	128.3
September	508	8	13	21	40	1,065	50.3	105.7
October	549	8	14	22	48	1,529	62.7	136.9
November	546	8	12	20	39	833	42.8	82.5
December	338	8	12	17	30	1,094	50.8	121.9
2018								
January	403	8	13	21	40	1,354	54.6	139.4
February	423	8	12	19	38	1,401	45.4	111.6
March	438	8	13	20	39	1,157	51.3	108.8
April	462	8	11	18	40	1,160	48.9	108.1
May	410	8	13	21	36	980	45.2	94.9
June	382	8	13	24	50	736	48.9	82.2
July	547	8	12	21	45	988	49.3	92.6
August	579	8	13	22	42	1,358	52.4	117.8
September	574	8	13	20	41	1,118	48.5	102.3
October	705	8	12	21	44	872	45.2	75.0
November	622	8	12	20	37	1,229	43.7	95.9
December	458	8	12	20	38	1,154	46.0	104.5
2019								
January	750	8	13	21	40	1,047	45.7	96.0
February	800	8	12	20	39	916	39.7	68.2
March	788	8	12	19	37	759	44.2	83.5
April	961	8	12	20	38	742	38.6	60.0
May	987	8	12	19	37	1,003	38.7	72.4
June	729	8	13	21	42	748	45.8	80.4
July	1,102	8	12	19	39	882	39.8	74.0
August	1,153	8	12	20	42	675	40.3	62.2
September	883	8	13	20	43	475	43.1	62.5
October	1,098	8	12	20	40	769	38.5	60.7
November	1,007	8	13	20	37	755	38.3	60.7
December	908	8	12	19	38	756	38.5	61.3

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
2020								
January	900	8	12	20	36	725	38.5	60.1
February	685	8	12	20	36	733	38.4	61.6
March	825	8	12	20	38	713	37.7	57.1
April	595	8	12	20	38	554	36.6	51.4
May	477	8	13	20	41	653	43.0	67.1
June	665	8	12	19	36	592	34.9	52.5
July	1,043	8	13	21	40	714	38.1	52.6
August	916	8	13	21	38	410	35.4	43.7
September	907	8	13	21	38	410	35.2	46.3
October	756	8	13	20	39	499	37.6	53.6
November	752	8	13	22	40	399	36.5	44.5
December	713	8	13	20	37	510	34.2	43.8
2021								
January	635	8	12	20	35	299	32.7	38.1
February	577	8	13	19	33	337	30.8	34.7
March	577	8	12	20	34	268	30.2	31.2
April	587	8	13	19	37	376	33.1	38.0
May	507	8	12	20	35	386	29.8	32.2
June	434	8	13	21	40	340	33.5	34.3
July	530	8	13	20	35	212	30.7	29.8
August	549	8	14	21	39	205	31.1	28.4
September	418	8	12	17	29	179	27.5	27.4
October	368	8	12	18	32	167	27.8	27.7
November	299	8	12	18	30	136	26.2	22.8
December	237	8	12	20	33	145	28.8	26.1
2022								
January	193	8	12	17	30	163	25.5	23.2
February	131	8	11	17	26	83	22.3	15.8
March	161	8	12	18	25	96	22.7	17.2
April	109	8	12	16	22	86	19.9	14.0

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
May	54	8	11	13	22	77	19.1	13.1
June	32	8	10	13	16	28	14.3	5.7
July	4	9	13	17	18	18	15.3	4.3
August	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Atopic Dermatitis</i>	<i>30,509</i>	<i>8</i>	<i>13</i>	<i>20</i>	<i>39</i>	<i>1,529</i>	<i>41.1</i>	<i>76.9</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	8	10	14	22	37	742	112.0	254.8
April	189	8	12	16	26	850	47.2	120.2
May	480	8	12	20	35	1,027	43.5	93.5
June	567	8	13	21	39	981	43.9	82.3
July	508	8	13	20	34	1,094	39.9	87.5
August	551	8	12	20	39	1,130	56.9	131.2
September	501	8	13	21	39	1,065	48.5	100.3
October	534	8	14	22	48	1,529	62.2	137.9
November	534	8	12	20	40	833	43.5	83.3
December	334	8	12	17	30	1,094	50.7	122.5
2018								
January	403	8	13	21	40	1,354	56.5	143.8
February	418	8	12	19	38	1,401	46.4	112.9
March	425	8	13	20	40	1,157	50.1	106.2
April	409	8	11	18	39	1,160	48.2	106.2
May	380	8	13	21	36	980	44.8	94.9
June	369	8	13	22	49	736	48.5	83.3
July	532	8	12	21	45	988	49.2	93.7
August	565	8	13	22	46	1,358	53.1	118.7
September	540	8	13	20	40	1,118	50.6	109.8
October	685	8	12	21	45	872	45.0	74.7
November	562	8	12	20	37	1,229	44.0	98.8

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December	370	8	12	19	37	852	45.0	98.1
2019								
January	628	8	13	21	41	1,047	47.3	101.4
February	654	8	12	20	42	916	41.2	69.8
March	587	8	13	20	41	759	48.2	89.5
April	813	8	12	20	38	742	39.2	61.9
May	862	8	12	19	36	870	37.4	66.9
June	630	8	13	22	44	748	46.6	83.0
July	873	8	12	20	40	798	40.6	72.1
August	884	8	12	21	43	675	40.9	63.6
September	640	8	13	21	48	475	45.7	63.9
October	774	8	12	21	41	769	40.3	61.7
November	675	8	12	20	37	755	39.4	65.8
December	711	8	13	19	37	756	38.9	63.4
2020								
January	731	8	12	19	35	725	38.1	60.9
February	503	8	13	21	41	733	42.8	68.1
March	573	8	12	21	41	713	38.5	55.4
April	386	8	13	21	42	432	37.8	48.3
May	354	8	13	20	42	653	44.6	71.4
June	450	8	12	20	37	530	34.9	49.8
July	805	8	13	21	41	714	37.9	51.1
August	701	8	14	21	38	410	35.8	45.6
September	713	8	13	21	38	392	34.8	42.7
October	583	8	13	20	40	469	36.8	49.4
November	574	8	13	22	38	399	36.7	46.9
December	537	8	13	20	39	510	35.8	46.9
2021								
January	447	8	12	19	34	299	32.3	38.6
February	454	8	13	19	35	337	31.9	37.1
March	418	8	12	20	36	268	31.7	34.3

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	474	8	13	20	40	376	35.1	40.0
May	369	8	12	20	36	256	29.7	29.1
June	361	8	14	24	42	340	35.1	35.4
July	434	8	13	20	34	212	30.1	28.9
August	443	8	14	21	38	205	31.1	27.8
September	350	8	12	19	30	179	28.7	28.9
October	270	8	13	19	36	167	29.4	27.8
November	241	8	12	16	31	128	25.3	21.3
December	183	8	12	20	33	145	29.1	26.5
2022								
January	170	8	12	18	30	163	25.4	23.3
February	98	8	11	17	25	83	21.4	14.4
March	127	8	12	18	27	96	23.0	16.9
April	92	8	12	15	22	67	19.0	12.2
May	43	8	11	16	26	77	20.1	13.5
June	26	8	9	12	15	28	13.5	5.7
July	4	9	13	17	18	18	15.3	4.3
August	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Asthma</i>	<i>13,590</i>	<i>8</i>	<i>12</i>	<i>19</i>	<i>36</i>	<i>1,401</i>	<i>37.3</i>	<i>66.6</i>
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	8	10	14	22	37	742	112.0	254.8
April	41	8	11	15	22	290	26.0	45.1
May	123	8	12	17	31	1,027	38.2	97.8
June	129	8	15	27	56	547	52.5	75.0
July	122	8	11	17	28	1,070	41.4	110.3
August	192	8	14	24	49	1,130	67.0	146.8
September	110	8	14	24	50	818	61.7	127.2
October	151	8	13	20	34	720	46.4	90.1

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
November	132	8	13	23	44	540	46.2	81.5
December	136	8	13	20	34	892	46.8	102.1
2018								
January	130	8	13	20	35	382	34.4	48.0
February	91	8	12	20	34	1,401	48.0	149.0
March	125	8	13	25	47	629	59.1	106.8
April	94	8	11	20	35	807	38.6	91.2
May	140	8	11	18	34	769	47.8	106.3
June	85	8	14	24	50	736	47.6	84.2
July	161	8	11	18	35	393	32.0	44.9
August	152	8	13	22	36	940	45.0	101.3
September	130	8	13	19	45	782	51.5	95.5
October	142	8	11	18	35	872	47.1	110.8
November	228	8	13	21	40	968	51.1	112.5
December	229	8	14	22	37	1,154	47.2	112.5
2019								
January	366	8	12	20	38	959	46.2	95.2
February	288	8	12	17	29	484	33.9	58.0
March	348	8	13	19	33	927	37.5	78.4
April	417	8	12	20	41	594	39.6	56.6
May	363	8	12	19	38	1,003	37.7	69.4
June	289	8	12	18	33	352	35.7	50.8
July	425	8	12	18	40	882	40.2	77.2
August	494	8	12	18	40	664	39.4	61.3
September	363	8	12	19	38	392	38.4	58.6
October	493	8	12	18	36	321	32.5	39.2
November	441	8	13	20	38	620	38.0	56.4
December	290	8	13	21	40	756	41.4	67.1
2020								
January	305	8	12	19	33	380	30.6	39.6
February	301	8	12	18	32	366	30.6	37.8

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	337	8	11	19	31	471	35.6	55.0
April	294	8	12	18	31	324	31.9	39.8
May	206	8	13	18	34	421	37.0	56.5
June	297	8	12	19	39	371	34.0	42.2
July	389	8	13	20	36	439	34.6	45.9
August	402	8	12	19	35	459	30.9	36.9
September	376	8	13	19	35	410	34.0	48.1
October	273	8	13	20	37	499	35.7	53.1
November	243	8	13	24	49	313	39.1	44.5
December	302	8	13	21	36	250	30.1	30.2
2021								
January	287	8	12	20	36	232	31.2	34.9
February	203	8	13	20	30	337	28.4	32.1
March	234	8	12	21	34	268	32.0	34.0
April	241	8	13	18	29	287	30.0	35.1
May	220	8	13	20	40	386	33.5	40.0
June	174	8	13	20	37	188	29.8	26.6
July	169	8	12	18	33	168	28.7	27.5
August	195	8	13	19	35	204	30.0	30.7
September	138	8	12	15	27	179	24.3	24.7
October	150	8	11	15	28	160	25.8	27.9
November	102	8	11	19	30	125	26.1	21.9
December	90	8	14	20	37	135	28.8	23.6
2022								
January	57	8	10	14	32	106	24.6	21.6
February	51	8	10	18	29	72	22.7	15.6
March	54	8	10	16	24	84	21.6	16.7
April	34	8	12	15	23	75	19.1	12.0
May	24	8	11	17	24	47	19.2	10.5
June	14	9	12	14	18	26	15.4	5.5
July	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Chronic</i>								
<i>Rhinosinusitis</i>	6,747	8	12	19	35	1,401	35.9	61.2
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	19	11	13	17	25	101	24.3	21.1
May	34	8	13	18	31	769	50.2	131.3
June	40	8	12	21	31	766	73.3	163.3
July	37	8	20	27	40	372	39.9	58.5
August	46	8	13	23	54	666	68.8	133.9
September	17	8	12	15	25	642	54.1	151.7
October	9	12	14	16	21	89	27.3	25.5
November	19	8	12	17	32	354	65.2	107.9
December	17	8	13	23	42	391	49.2	90.4
2018								
January	47	8	13	22	45	713	57.9	110.9
February	32	8	15	31	54	1,401	85.5	244.0
March	37	8	14	26	41	209	37.5	39.8
April	51	8	14	21	48	255	47.4	57.4
May	57	8	15	21	48	548	47.1	78.9
June	20	8	14	24	43	149	39.3	40.7
July	62	8	18	27	49	392	46.6	68.2
August	58	8	14	27	57	940	77.6	157.0
September	67	8	15	25	46	212	39.4	40.0
October	55	8	12	20	46	833	55.5	123.3
November	62	8	10	18	33	968	53.8	138.3
December	69	8	13	24	38	1,154	57.3	161.2
2019								

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
January	93	8	12	22	42	372	35.7	50.6
February	118	8	11	18	28	364	29.8	50.4
March	109	8	11	18	34	453	36.8	58.4
April	166	8	12	17	36	406	33.7	46.2
May	144	8	11	21	47	286	38.2	46.4
June	112	8	12	17	29	273	31.2	42.5
July	215	8	12	18	34	219	30.6	34.7
August	273	8	12	18	40	438	37.4	50.9
September	245	8	12	19	33	392	35.8	53.0
October	262	8	12	18	33	767	31.5	58.0
November	293	8	13	21	38	416	39.4	54.0
December	216	8	12	19	34	380	35.8	52.1
2020								
January	208	8	13	20	37	380	38.9	54.2
February	195	8	11	16	28	620	32.2	58.3
March	203	8	11	18	35	713	41.8	79.2
April	172	8	12	18	34	554	36.3	61.2
May	132	8	12	17	35	233	34.7	43.3
June	190	8	13	19	37	592	33.6	51.9
July	201	8	12	20	36	295	35.6	44.3
August	184	8	13	21	40	304	35.9	43.4
September	176	8	12	17	32	407	33.8	49.7
October	153	8	12	21	37	393	37.6	51.8
November	150	8	12	19	37	239	31.6	33.1
December	175	8	13	21	33	250	29.1	30.8
2021								
January	160	8	12	18	36	232	33.3	40.0
February	128	8	12	17	29	161	28.6	29.4
March	144	8	11	16	32	138	25.8	23.2
April	118	8	13	17	27	177	28.1	29.0
May	146	8	12	18	33	386	29.5	37.8

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
June	107	8	13	19	36	201	30.7	30.8
July	103	8	12	21	37	146	30.3	25.9
August	110	8	13	18	36	161	29.5	29.5
September	100	8	12	16	30	162	24.6	22.3
October	106	8	9	15	28	160	25.6	28.6
November	59	8	13	21	30	136	26.8	22.3
December	69	8	13	18	33	124	29.8	28.1
2022								
January	38	8	11	17	32	74	23.4	16.3
February	35	8	10	16	27	86	24.0	21.1
March	36	8	11	17	24	84	23.4	19.5
April	25	8	15	18	25	86	23.0	18.5
May	13	9	10	13	25	51	20.0	14.6
June	10	8	12	14	23	24	15.8	5.6
July	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
August	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Eosinophilic Esophagitis</i>	2,002	8	12	20	36	1,154	37.4	65.2
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	5	12	12	16	18	50	21.6	16.1
May	2	15	15	16	17	17	16.0	1.4
June	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
July	21	8	12	21	29	140	31.9	34.2
August	20	8	11	23	39	552	59.0	124.1
September	13	9	21	26	110	208	66.4	68.9
October	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
November	17	8	10	27	43	115	32.1	28.3

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
December 2018	13	8	11	15	20	506	53.8	136.0
January	15	8	10	18	24	168	27.5	39.7
February	21	8	11	15	22	172	30.1	46.7
March	16	8	11	19	40	629	63.1	152.2
April	21	9	13	21	85	880	126.3	229.7
May	21	8	14	29	42	235	42.0	50.4
June	32	8	12	32	58	150	44.0	41.1
July	26	8	9	15	43	250	31.8	48.3
August	16	8	12	20	34	369	42.8	87.8
September	26	8	9	12	15	121	18.2	22.6
October	26	8	11	20	37	327	36.1	62.5
November	28	8	15	23	61	225	47.0	56.4
December 2019	51	8	14	24	42	1,154	63.1	175.7
January 2019	40	8	13	17	33	212	27.8	33.8
February	27	8	13	23	69	132	40.0	33.5
March	25	8	11	22	42	204	39.6	50.3
April	25	8	14	23	49	268	55.2	73.3
May	53	8	12	20	31	457	36.5	66.0
June	30	8	10	14	35	435	40.5	80.7
July	68	8	11	16	25	485	31.2	61.9
August	52	8	11	20	31	522	45.1	86.5
September	61	8	11	15	45	308	41.4	59.0
October	85	8	12	24	45	363	44.5	56.3
November	58	8	13	21	35	286	37.6	50.1
December 2020	60	8	13	18	40	160	31.2	29.9
January 2020	47	8	12	17	31	226	31.0	39.7
February	105	8	12	21	34	756	33.1	74.3
March	77	8	12	17	24	183	29.1	33.4

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
April	42	8	13	19	35	554	42.8	87.9
May	23	8	14	31	79	130	44.0	36.0
June	38	8	14	22	51	245	49.5	59.7
July	25	8	15	24	38	71	27.8	16.2
August	40	8	19	26	67	292	50.2	56.7
September	48	8	16	24	34	229	32.8	34.3
October	36	8	10	13	27	204	30.2	43.6
November	48	8	12	21	35	107	30.1	26.2
December	26	8	11	19	28	81	25.7	19.8
2021								
January	51	8	16	27	49	202	38.6	38.2
February	23	11	14	23	49	227	44.4	57.3
March	47	8	12	16	34	165	29.2	31.2
April	49	8	13	19	29	67	23.4	14.0
May	46	8	12	18	34	256	33.7	44.5
June	22	10	14	19	41	145	31.3	31.3
July	15	8	10	13	56	306	49.1	80.0
August	39	8	11	19	45	239	35.4	43.0
September	21	8	16	21	30	85	27.5	18.7
October	32	9	11	17	20	98	20.7	16.8
November	29	9	12	19	28	148	28.6	31.6
December	32	8	11	18	28	103	26.1	23.9
2022								
January	17	8	11	21	37	161	32.5	37.4
February	15	9	11	15	20	106	23.0	24.9
March	17	8	12	16	29	59	23.6	16.7
April	11	8	10	14	23	33	16.5	8.1
May	6	8	9	22	24	28	18.7	8.2
June	1	23	23	23	23	23	23.0	NaN
July	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
August	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Prurigo Nodularis</i>	684	8	12	19	38	964	44.9	88.0
2017								
January	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	11	10	12	16	22	457	56.7	132.9
May	2	8	8	17	25	25	16.5	12.0
June	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
July	10	9	16	49	168	849	153.7	255.6
August	10	10	12	26	56	666	148.4	259.7
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
October	3	8	8	9	371	371	129.3	209.3
November	6	11	19	50	62	157	58.2	52.3
December	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2018								
January	16	8	17	28	45	184	37.6	41.9
February	7	10	17	53	101	167	64.7	57.3
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	5	8	13	14	33	394	92.4	168.9
May	8	8	13	19	45	964	140.6	333.2
June	23	8	11	15	30	119	26.3	27.9
July	19	8	12	21	49	105	33.1	28.8
August	11	8	11	29	86	369	73.9	105.1
September	19	8	12	23	88	934	89.6	209.6
October	20	10	12	17	29	260	40.0	66.0
November	11	10	11	16	21	55	20.2	12.8
December	4	10	15	30	178	316	96.3	147.0
2019								
January	21	8	12	23	113	218	68.0	70.0
February	14	8	8	13	18	307	35.2	78.6

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
March	5	10	14	25	25	25	19.8	7.3
April	13	9	13	19	24	227	45.5	70.4
May	8	8	9	15	35	353	59.8	119.2
June	28	8	12	17	25	73	21.6	15.9
July	31	8	14	30	61	164	39.4	36.0
August	8	14	21	41	53	311	69.1	98.9
September	9	9	26	38	64	162	55.4	47.3
October	19	8	14	21	46	174	40.2	47.6
November	18	8	13	20	49	127	34.4	31.7
December	13	8	12	33	58	85	35.4	26.1
2020								
January	10	8	14	42	265	389	125.4	156.2
February	27	8	13	19	37	231	39.9	59.3
March	14	9	12	28	51	327	55.1	83.0
April	1	99	99	99	99	99	99.0	NaN
May	9	9	19	24	45	139	40.2	39.9
June	7	9	11	14	30	165	38.6	56.3
July	5	14	17	23	36	215	61.0	86.5
August	18	9	11	17	29	42	19.5	9.7
September	12	8	14	22	32	129	31.2	33.4
October	7	8	10	15	43	51	22.1	17.4
November	31	9	13	15	31	99	27.8	25.8
December	25	8	9	12	19	129	27.0	32.1
2021								
January	12	8	8	13	22	63	19.7	17.4
February	24	9	14	19	31	105	28.0	23.7
March	15	8	10	15	27	65	19.6	14.4
April	11	9	12	16	85	168	47.4	53.0
May	15	10	12	14	27	72	23.8	20.1
June	3	10	10	12	29	29	17.0	10.4
July	9	9	10	22	27	179	37.1	54.4

Table 9d. Continuous Summary of Second and Subsequent Treatment Episode Gaps for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022, by Year and Month

Distribution of Treatment Episode Durations Excluding First Treatment Episode Gap, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
August	11	9	11	29	109	141	51.2	50.7
September	22	9	12	20	27	47	20.6	10.1
October	5	9	14	28	36	38	25.0	13.0
November	7	8	14	25	58	84	35.9	27.3
December	4	12	12	14	18	20	15.0	3.8
2022								
January	5	8	8	11	33	64	24.8	24.3
February	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
March	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
April	2	16	16	19	22	22	19.0	4.2
May	1	19	19	19	19	19	19.0	NaN
June	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
July	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
August	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
September	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 10. Summary of Reasons First Treatment Episodes Ended for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022¹

	Censoring Reason										
	Total Number of Patients	End of Exposure Episode ²		Evidence of Death ³		Disenrollment ⁴		End of Data ⁵		End of Study Period ⁶	
			Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients
Dupilumab Use with a 0-day Treatment Gap											
<i>No Indication Requirement</i>	39,944	39,944	100.0%	0	0.0%	6,946	17.4%	4,201	10.5%	4,201	10.5%
<i>Any Indication</i>	36,986	36,986	100.0%	0	0.0%	6,498	17.6%	3,940	10.7%	3,940	10.7%
<i>Atopic Dermatitis</i>	28,055	28,055	100.0%	0	0.0%	4,595	16.4%	2,688	9.6%	2,688	9.6%
<i>Asthma</i>	13,372	13,372	100.0%	0	0.0%	2,474	18.5%	1,510	11.3%	1,510	11.3%
<i>Chronic Rhinosinusitis</i>	8,142	8,142	100.0%	0	0.0%	1,627	20.0%	1,002	12.3%	1,002	12.3%
<i>Eosinophilic Esophagitis</i>	2,453	2,453	100.0%	0	0.0%	564	23.0%	414	16.9%	414	16.9%
<i>Prurigo Nodularis</i>	828	828	100.0%	0	0.0%	159	19.2%	94	11.4%	94	11.4%
Dupilumab Use with a 7-day Treatment Gap											
<i>No Indication Requirement</i>	38,506	38,506	100.0%	0	0.0%	11,165	29.0%	6,647	17.3%	6,647	17.3%
<i>Any Indication</i>	35,371	35,371	100.0%	0	0.0%	10,307	29.1%	6,178	17.5%	6,178	17.5%
<i>Atopic Dermatitis</i>	26,674	26,674	100.0%	0	0.0%	7,290	27.3%	4,261	16.0%	4,261	16.0%
<i>Asthma</i>	12,473	12,473	100.0%	0	0.0%	3,818	30.6%	2,301	18.4%	2,301	18.4%
<i>Chronic Rhinosinusitis</i>	7,627	7,627	100.0%	0	0.0%	2,498	32.8%	1,531	20.1%	1,531	20.1%
<i>Eosinophilic Esophagitis</i>	2,155	2,155	100.0%	0	0.0%	725	33.6%	524	24.3%	524	24.3%
<i>Prurigo Nodularis</i>	767	767	100.0%	0	0.0%	243	31.7%	152	19.8%	152	19.8%

¹A patient's episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of patients.

²Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

³Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

⁴Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁵Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

⁶Represents episodes censored due to user-specified study end date.

Table 11. Summary of Reasons Treatment Episodes Ended for Dupilumab Use by Indication in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022¹

Censoring Reason											
	End of Exposure Episode ²			Evidence of Death ³		Disenrollment ⁴		End of Data ⁵		End of Study Period ⁶	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Dupilumab Use with a 0-day Treatment Gap											
<i>No Indication Requirement</i>	164,198	164,198	100.0%	0	0.0%	25,456	15.5%	15,771	9.6%	15,771	9.6%
<i>Any Indication</i>	152,714	152,714	100.0%	0	0.0%	23,731	15.5%	14,763	9.7%	14,763	9.7%
<i>Atopic Dermatitis</i>	120,523	120,523	100.0%	0	0.0%	17,653	14.6%	10,675	8.9%	10,675	8.9%
<i>Asthma</i>	56,197	56,197	100.0%	0	0.0%	9,020	16.1%	5,712	10.2%	5,712	10.2%
<i>Chronic Rhinosinusitis</i>	31,403	31,403	100.0%	0	0.0%	5,510	17.5%	3,646	11.6%	3,646	11.6%
<i>Eosinophilic Esophagitis</i>	9,260	9,260	100.0%	0	0.0%	1,625	17.5%	1,129	12.2%	1,129	12.2%
<i>Prurigo Nodularis</i>	3,273	3,273	100.0%	0	0.0%	543	16.6%	353	10.8%	353	10.8%
Dupilumab Use with a 7-day Treatment Gap											
<i>No Indication Requirement</i>	99,869	99,869	100.0%	0	0.0%	24,321	24.4%	15,097	15.1%	15,097	15.1%
<i>Any Indication</i>	92,172	92,172	100.0%	0	0.0%	22,488	24.4%	14,028	15.2%	14,028	15.2%
<i>Atopic Dermatitis</i>	72,490	72,490	100.0%	0	0.0%	16,587	22.9%	10,084	13.9%	10,084	13.9%
<i>Asthma</i>	33,025	33,025	100.0%	0	0.0%	8,326	25.2%	5,277	16.0%	5,277	16.0%
<i>Chronic Rhinosinusitis</i>	18,396	18,396	100.0%	0	0.0%	5,125	27.9%	3,385	18.4%	3,385	18.4%
<i>Eosinophilic Esophagitis</i>	5,269	5,269	100.0%	0	0.0%	1,420	27.0%	991	18.8%	991	18.8%
<i>Prurigo Nodularis</i>	1,878	1,878	100.0%	0	0.0%	497	26.5%	324	17.3%	324	17.3%

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

²Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

³Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

⁴Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁵Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

⁶Represents episodes censored due to user-specified study end date.

Table 12. Summary of Patient-Level Cohort Attrition in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Dupilumab Use with a 0-day Treatment Gap								
	No Indication Requirement		Any Indication		Atopic Dermatitis		Asthma	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	57,254,556	N/A	57,254,556	N/A	57,254,556	N/A	57,254,556	N/A
Had required coverage type (medical and/or drug coverage)	54,318,914	2,935,642	54,318,914	2,935,642	54,318,914	2,935,642	54,318,914	2,935,642
Enrolled during specified age range	54,318,854	60	54,318,854	60	54,318,854	60	54,318,854	60
Had requestable medical charts	54,318,854	0	54,318,854	0	54,318,854	0	54,318,854	0
Met demographic requirements (sex, race, and Hispanic origin)	54,318,854	0	54,318,854	0	54,318,854	0	54,318,854	0
Members with a valid index event								
Had any cohort-defining claim during the query period	45,839	54,273,015	45,839	54,273,015	45,839	54,273,015	45,839	54,273,015
Claim recorded during specified age range	45,839	0	45,839	0	45,839	0	45,839	0
Episode defining index claim recorded during the query period	45,839	0	45,839	0	45,839	0	45,839	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	39,944	5,895	39,944	5,895	39,944	5,895	39,944	5,895
Met inclusion and exclusion criteria ¹	39,944	0	36,986	2,958	28,055	11,889	13,372	26,572
<i>No evidence of any_indication</i>	N/A	N/A	N/A	2,958	N/A	N/A	N/A	N/A
<i>No evidence of asthma</i>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	26,572
<i>No evidence of atopic_dermatitis</i>	N/A	N/A	N/A	N/A	N/A	11,889	N/A	N/A
<i>No evidence of chronic_rhinosinusitis</i>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of eoe</i>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of prurigo_nodularis</i>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	39,944	0	36,986	0	28,055	0	13,372	0
Final cohort								
Number of members	39,944	N/A	36,986	N/A	28,055	N/A	13,372	N/A

Table 12. Summary of Patient-Level Cohort Attrition in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Dupilumab Use with a 0-day Treatment Gap								
	Chronic Rhinosinusitis		Eosinophilic Esophagitis		Prurigo Nodularis		No Indication Requirement	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	57,254,556	N/A	57,254,556	N/A	57,254,556	N/A	57,254,556	N/A
Had required coverage type (medical and/or drug coverage)	54,318,914	2,935,642	54,318,914	2,935,642	54,318,914	2,935,642	54,318,914	2,935,642
Enrolled during specified age range	54,318,854	60	54,318,854	60	54,318,854	60	54,318,854	60
Had requestable medical charts	54,318,854	0	54,318,854	0	54,318,854	0	54,318,854	0
Met demographic requirements (sex, race, and Hispanic origin)	54,318,854	0	54,318,854	0	54,318,854	0	54,318,854	0
Members with a valid index event								
Had any cohort-defining claim during the query period	45,839	54,273,015	45,839	54,273,015	45,839	54,273,015	45,839	54,273,015
Claim recorded during specified age range	45,839	0	45,839	0	45,839	0	45,839	0
Episode defining index claim recorded during the query period	45,839	0	45,839	0	45,839	0	45,839	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	39,944	5,895	39,944	5,895	39,944	5,895	38,506	7,333
Met inclusion and exclusion criteria ¹	8,142	31,802	2,453	37,491	828	39,116	38,506	0
<i>No evidence of any_indication</i>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of asthma</i>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of atopic_dermatitis</i>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of chronic_rhinosinusitis</i>	N/A	31,802	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of eoe</i>	N/A	N/A	N/A	37,491	N/A	N/A	N/A	N/A
<i>No evidence of prurigo_nodularis</i>	N/A	N/A	N/A	N/A	N/A	39,116	N/A	N/A
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	8,142	0	2,453	0	828	0	38,506	0
Final cohort								
Number of members	8,142	N/A	2,453	N/A	828	N/A	38,506	N/A

Table 12. Summary of Patient-Level Cohort Attrition in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

Dupilumab Use with a 7-day Treatment Gap								
	Any Indication		Atopic Dermatitis		Asthma		Chronic Rhinosinusitis	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	57,254,556	N/A	57,254,556	N/A	57,254,556	N/A	57,254,556	N/A
Had required coverage type (medical and/or drug coverage)	54,318,914	2,935,642	54,318,914	2,935,642	54,318,914	2,935,642	54,318,914	2,935,642
Enrolled during specified age range	54,318,854	60	54,318,854	60	54,318,854	60	54,318,854	60
Had requestable medical charts	54,318,854	0	54,318,854	0	54,318,854	0	54,318,854	0
Met demographic requirements (sex, race, and Hispanic origin)	54,318,854	0	54,318,854	0	54,318,854	0	54,318,854	0
Members with a valid index event								
Had any cohort-defining claim during the query period	45,839	54,273,015	45,839	54,273,015	45,839	54,273,015	45,839	54,273,015
Claim recorded during specified age range	45,839	0	45,839	0	45,839	0	45,839	0
Episode defining index claim recorded during the query period	45,839	0	45,839	0	45,839	0	45,839	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	38,506	7,333	38,506	7,333	38,506	7,333	38,506	7,333
Met inclusion and exclusion criteria ¹	35,371	3,135	26,674	11,832	12,473	26,033	7,627	30,879
<i>No evidence of any_indication</i>	N/A	3,135	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of asthma</i>	N/A	N/A	N/A	N/A	N/A	26,033	N/A	N/A
<i>No evidence of atopic_dermatitis</i>	N/A	N/A	N/A	11,832	N/A	N/A	N/A	N/A
<i>No evidence of chronic_rhinosinusitis</i>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	30,879
<i>No evidence of eoe</i>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of prurigo_nodularis</i>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	35,371	0	26,674	0	12,473	0	7,627	0
Final cohort								
Number of members	35,371	N/A	26,674	N/A	12,473	N/A	7,627	N/A

Table 12. Summary of Patient-Level Cohort Attrition in the Merative MarketScan Research Databases from January 1, 2017 to September 30, 2022

	Dupilumab Use with a 7-day Treatment Gap			
	Eosinophilic Esophagitis		Prurigo Nodularis	
	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements				
Enrolled at any point during the query period	57,254,556	N/A	57,254,556	N/A
Had required coverage type (medical and/or drug coverage)	54,318,914	2,935,642	54,318,914	2,935,642
Enrolled during specified age range	54,318,854	60	54,318,854	60
Had requestable medical charts	54,318,854	0	54,318,854	0
Met demographic requirements (sex, race, and Hispanic origin)	54,318,854	0	54,318,854	0
Members with a valid index event				
Had any cohort-defining claim during the query period	45,839	54,273,015	45,839	54,273,015
Claim recorded during specified age range	45,839	0	45,839	0
Episode defining index claim recorded during the query period	45,839	0	45,839	0
Members with required pre-index history				
Had sufficient pre-index continuous enrollment	38,506	7,333	38,506	7,333
Met inclusion and exclusion criteria ¹	2,155	36,351	767	37,739
<i>No evidence of any_indication</i>	N/A	N/A	N/A	N/A
<i>No evidence of asthma</i>	N/A	N/A	N/A	N/A
<i>No evidence of atopic_dermatitis</i>	N/A	N/A	N/A	N/A
<i>No evidence of chronic_rhinosinusitis</i>	N/A	N/A	N/A	N/A
<i>No evidence of eoe</i>	N/A	36,351	N/A	N/A
<i>No evidence of prurigo_nodularis</i>	N/A	N/A	N/A	37,739
Members with required post-index follow-up				
Had sufficient post-index continuous enrollment	2,155	0	767	0
Final cohort				
Number of members	2,155	N/A	767	N/A

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date

Masked DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2010	09/30/2022

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
Dupilumab	
dupilumab	Dupixent Pen
dupilumab	Dupixent Syringe

Appendix C. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
Atopic Dermatitis			
L20	Atopic dermatitis	Diagnosis	ICD-10-CM
L20.0	Besnier's prurigo	Diagnosis	ICD-10-CM
L20.8	Other atopic dermatitis	Diagnosis	ICD-10-CM
L20.81	Atopic neurodermatitis	Diagnosis	ICD-10-CM
L20.82	Flexural eczema	Diagnosis	ICD-10-CM
L20.83	Infantile (acute) (chronic) eczema	Diagnosis	ICD-10-CM
L20.84	Intrinsic (allergic) eczema	Diagnosis	ICD-10-CM
L20.89	Other atopic dermatitis	Diagnosis	ICD-10-CM
L20.9	Atopic dermatitis, unspecified	Diagnosis	ICD-10-CM
Asthma			
J45	Asthma	Diagnosis	ICD-10-CM
J45.2	Mild intermittent asthma	Diagnosis	ICD-10-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.3	Mild persistent asthma	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.4	Moderate persistent asthma	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.5	Severe persistent asthma	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.9	Other and unspecified asthma	Diagnosis	ICD-10-CM
J45.90	Unspecified asthma	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.99	Other asthma	Diagnosis	ICD-10-CM
Chronic Rhinosinusitis			
J31	Chronic rhinitis, nasopharyngitis and pharyngitis	Diagnosis	ICD-10-CM
J31.0	Chronic rhinitis	Diagnosis	ICD-10-CM
J31.1	Chronic nasopharyngitis	Diagnosis	ICD-10-CM
J31.2	Chronic pharyngitis	Diagnosis	ICD-10-CM
J32	Chronic sinusitis	Diagnosis	ICD-10-CM
J32.0	Chronic maxillary sinusitis	Diagnosis	ICD-10-CM
J32.1	Chronic frontal sinusitis	Diagnosis	ICD-10-CM
J32.2	Chronic ethmoidal sinusitis	Diagnosis	ICD-10-CM
J32.3	Chronic sphenoidal sinusitis	Diagnosis	ICD-10-CM
J32.4	Chronic pansinusitis	Diagnosis	ICD-10-CM
J32.8	Other chronic sinusitis	Diagnosis	ICD-10-CM
J32.9	Chronic sinusitis, unspecified	Diagnosis	ICD-10-CM

Appendix C. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
J33	Nasal polyp	Diagnosis	ICD-10-CM
J33.0	Polyp of nasal cavity	Diagnosis	ICD-10-CM
J33.1	Polypoid sinus degeneration	Diagnosis	ICD-10-CM
J33.8	Other polyp of sinus	Diagnosis	ICD-10-CM
J33.9	Nasal polyp, unspecified	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
Eosinophilic Esophagitis			
K20	Esophagitis	Diagnosis	ICD-10-CM
K20.0	Eosinophilic esophagitis	Diagnosis	ICD-10-CM
K20.8	Other esophagitis	Diagnosis	ICD-10-CM
K20.80	Other esophagitis without bleeding	Diagnosis	ICD-10-CM
K20.81	Other esophagitis with bleeding	Diagnosis	ICD-10-CM
K20.9	Esophagitis, unspecified	Diagnosis	ICD-10-CM
K29.0	Acute gastritis	Diagnosis	ICD-10-CM
K29.00	Acute gastritis without bleeding	Diagnosis	ICD-10-CM
K29.01	Acute gastritis with bleeding	Diagnosis	ICD-10-CM
K29.3	Chronic superficial gastritis	Diagnosis	ICD-10-CM
K29.30	Chronic superficial gastritis without bleeding	Diagnosis	ICD-10-CM
K29.31	Chronic superficial gastritis with bleeding	Diagnosis	ICD-10-CM
K29.4	Chronic atrophic gastritis	Diagnosis	ICD-10-CM
K29.40	Chronic atrophic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.41	Chronic atrophic gastritis with bleeding	Diagnosis	ICD-10-CM
K29.5	Unspecified chronic gastritis	Diagnosis	ICD-10-CM
K29.50	Unspecified chronic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.51	Unspecified chronic gastritis with bleeding	Diagnosis	ICD-10-CM
K29.6	Other gastritis	Diagnosis	ICD-10-CM
K29.60	Other gastritis without bleeding	Diagnosis	ICD-10-CM
K29.61	Other gastritis with bleeding	Diagnosis	ICD-10-CM
K29.7	Gastritis, unspecified	Diagnosis	ICD-10-CM
K29.70	Gastritis, unspecified, without bleeding	Diagnosis	ICD-10-CM
K29.71	Gastritis, unspecified, with bleeding	Diagnosis	ICD-10-CM
K52.2	Allergic and dietetic gastroenteritis and colitis	Diagnosis	ICD-10-CM
K52.21	Food protein-induced enterocolitis syndrome	Diagnosis	ICD-10-CM
K52.22	Food protein-induced enteropathy	Diagnosis	ICD-10-CM
K52.29	Other allergic and dietetic gastroenteritis and colitis	Diagnosis	ICD-10-CM
K52.8	Other specified noninfective gastroenteritis and colitis	Diagnosis	ICD-10-CM
K52.81	Eosinophilic gastritis or gastroenteritis	Diagnosis	ICD-10-CM
K52.89	Other specified noninfective gastroenteritis and colitis	Diagnosis	ICD-10-CM
K52.9	Noninfective gastroenteritis and colitis, unspecified	Diagnosis	ICD-10-CM
Prurigo Nodularis			
L28.1	Prurigo nodularis	Diagnosis	ICD-10-CM

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
Topical Glucocorticoids	
HYDROCORTISONE	First-Hydrocortisone
alclometasone dipropionate	alclometasone
amcinonide	amcinonide
benzoyl peroxide/hydrocortisone	Vanoxide-HC
betamethasone dipropionate	Sernivo
betamethasone dipropionate	betamethasone dipropionate
betamethasone dipropionate	betamethasone, augmented
betamethasone dipropionate/propylene glycol	Diprolene (augmented)
betamethasone dipropionate/propylene glycol	Diprolene AF
betamethasone dipropionate/propylene glycol	betamethasone, augmented
betamethasone valerate	Luxiq
betamethasone valerate	betamethasone valerate
clobetasol propionate	Clobex
clobetasol propionate	Clodan
clobetasol propionate	Cormax
clobetasol propionate	Impeklo
clobetasol propionate	Impoyz
clobetasol propionate	Olux
clobetasol propionate	Temovate
clobetasol propionate	clobetasol
clobetasol propionate/emollient base	Olux-E
clobetasol propionate/emollient base	Tovet Emollient
clobetasol propionate/emollient base	clobetasol-emollient
clobetasol propionate/emollient combination no.65	Tovet Kit
clobetasol propionate/gauze bandage/silicone, adhesive	Tasoprol
clobetasol propionate/hydrocolloid dressing	Clobetavix
clobetasol propionate/niacinamide	Chlooxia
clobetasol propionate/niacinamide	Oxiachlo
clobetasol propionate/niacinamide	clobetasol-niacinamide
clobetasol propionate/skin cleanser combination no.28	Clodan Kit
clocortolone pivalate	Cloderm
clocortolone pivalate	clocortolone pivalate
desonide	DesOwen
desonide	DesRx
desonide	Desonate
desonide	Tridesilon
desonide	Verdeso
desonide	desonide
desoximetasone	Topicort
desoximetasone	desoximetasone
desoximetasone/niacinamide	Fluoxia
desoximetasone/niacinamide	desoximetasone-niacinamide
diflorasone diacetate	Psorcon
diflorasone diacetate	diflorasone
diflorasone diacetate/emollient base	ApexiCon E
fluocinolone acetone	Capex
fluocinolone acetone	Derma-Smoothe/FS Body Oil

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
fluocinolone acetonide	Synalar
fluocinolone acetonide	fluocinolone
fluocinolone acetonide/emollient combination no.65	Synalar Cream Kit
fluocinolone acetonide/emollient combination no.65	Synalar Ointment Kit
fluocinolone acetonide/niacinamide	Tetoxia
fluocinolone acetonide/niacinamide	fluocinolone-niacinamide
fluocinolone acetonide/shower cap	Derma-Smoothe/FS Scalp Oil
fluocinolone acetonide/shower cap	fluocinolone and shower cap
fluocinolone acetonide/skin cleanser comb no.28	Synalar TS
fluocinolone acetonide/skin cleanser no.10/silicone, tape	Xilapak
fluocinolone acetonide/urea/silicone, adhesive	Noxipak
fluocinonide	Vanos
fluocinonide	fluocinonide
fluocinonide/dimethicone	Fluopar
fluocinonide/emollient base	Fluocinonide-E
fluocinonide/emollient base	fluocinonide-emollient
fluocinonide/silicone, adhesive	Fluovix
fluocinonide/silicone, adhesive	Fluovix Plus
flurandrenolide	Cordran
flurandrenolide	Cordran Tape Large Roll
flurandrenolide	Cordran Tape Small Roll
flurandrenolide	Nolix
flurandrenolide	flurandrenolide
fluticasone propionate	Beser
fluticasone propionate	Cutivate
fluticasone propionate	fluticasone propionate
fluticasone propionate/emollient combination no.65	Beser Kit
halcinonide	Halog
halcinonide	halcinonide
halobetasol propionate	Bryhali
halobetasol propionate	Lexette
halobetasol propionate	Ultravate
halobetasol propionate	halobetasol propionate
halobetasol propionate/lactic acid	Ultravate X
hydrocortisone	Advanced Allergy Collect Kit
hydrocortisone	Ala-Cort
hydrocortisone	Ala-Scalp
hydrocortisone	Anusol-HC
hydrocortisone	Procto-Med HC
hydrocortisone	Procto-Pak
hydrocortisone	Proctocort
hydrocortisone	Proctosol HC
hydrocortisone	Proctozone-HC
hydrocortisone	Scalacort
hydrocortisone	Texacort
hydrocortisone	hydrocortisone
hydrocortisone acetate	MiCort-HC
hydrocortisone acetate/aloe vera	Nucort

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
hydrocortisone acetate/iodoquinol/aloe polysaccharides no.2	Alcortin A
hydrocortisone acetate/iodoquinol/aloe polysaccharides no.2	hydrocortisone-iodoquinol-aloe2
hydrocortisone acetate/iodoquinol/aloe vera	Vytone
hydrocortisone acetate/iodoquinol/aloe vera	hydrocortisone-iodoquinol-aloe
hydrocortisone acetate/pramoxine HCl	Analpram-HC
hydrocortisone acetate/pramoxine HCl	Epifoam
hydrocortisone acetate/pramoxine HCl	Mezparox-HC
hydrocortisone acetate/pramoxine HCl	Novacort
hydrocortisone acetate/pramoxine HCl	Pramosone
hydrocortisone acetate/pramoxine HCl	hydrocortisone-pramoxine
hydrocortisone acetate/pramoxine HCl/emollient base	Pramosone E
hydrocortisone acetate/urea	U-Cort
hydrocortisone butyrate	Locoid
hydrocortisone butyrate	hydrocortisone butyrate
hydrocortisone butyrate/emollient base	Locoid Lipocream
hydrocortisone butyrate/emollient base	hydrocortisone butyr-emollient
hydrocortisone probutate	Pandel
hydrocortisone valerate	hydrocortisone valerate
hydrocortisone/emollient combination no.45	Pediaderm HC
hydrocortisone/iodoquinol	Corti-Sav
hydrocortisone/iodoquinol	Dermazene
hydrocortisone/iodoquinol	hydrocortisone-iodoquinol
hydrocortisone/mineral oil/petrolatum,white	hydrocortisone-min oil-wht pet
hydrocortisone/pramoxine HCl/chloroxylenol	Cortane-B
hydrocortisone/salicylic acid/sulfur/shampoo no. 1	Scalacort DK
hydrocortisone/skin cleanser combination no.25	Aqua Glycolic HC
hydrocortisone/skin cleanser combination no.35	Dermasorb HC Complete Kit
lidocaine HCl/hydrocortisone acetate	Lidocort
lidocaine HCl/hydrocortisone acetate	lidocaine HCl-hydrocortison ac
mometasone furoate	Elocon
mometasone furoate	mometasone
mometasone furoate/ammonium lactate	Quinosone
mometasone furoate/dimethicone	Quinixil
prednicarbate	Dermatop
prednicarbate	prednicarbate
triamcinolone acetonide	Kenalog
triamcinolone acetonide	Trianex
triamcinolone acetonide	Triderm
triamcinolone acetonide	Tritocin
triamcinolone acetonide	triamcinolone acetonide
triamcinolone acetonide/dimethicone	Ellzia Pak
triamcinolone acetonide/dimethicone/silicone, adhesive	DermaWerx SDS
triamcinolone acetonide/dimethicone/silicone, adhesive	DermacinRx SilaPak
triamcinolone acetonide/dimethicone/silicone, adhesive	NuTriRx
triamcinolone acetonide/dimethicone/silicone, adhesive	SanaDermRx
triamcinolone acetonide/dimethicone/silicone, adhesive	Sure Result Tac Pak
triamcinolone acetonide/dimethicone/silicone, adhesive	Tri-Sila
triamcinolone acetonide/dimethicone/silicone, adhesive	TriHeal-80

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
triamcinolone acetonide/dimethicone/silicone, adhesive	TriaDime
triamcinolone acetonide/dimethicone/silicone, adhesive	TriaDime-80
triamcinolone acetonide/dimethicone/silicone, adhesive	Trivix
triamcinolone acetonide/dimethicone/silicone, adhesive	Whytederm TDPak
triamcinolone acetonide/dimethicone/silicone, adhesive	Whytederm Trilasil Pak
triamcinolone acetonide/emollient combination no.45	Pediaderm TA
triamcinolone acetonide/emollient combination no.86	Dermasorb TA Complete Kit
triamcinolone acetonide/gauze bandage/silicone, adhesive	Sila III
triamcinolone acetonide/gauze bandage/silicone, adhesive	Triasil
triamcinolone acetonide/niacinamide	triamcinolone-niacinamide
triamcinolone acetonide/silicones	DermacinRx SilaZone
triamcinolone acetonide/silicones	Dermazone
triamcinolone acetonide/silicones	SilaLite Pak
triamcinolone acetonide/silicones	Silazone-II
Topical Calcineurin Inhibitors	
pimecrolimus	Elidel
pimecrolimus	pimecrolimus
tacrolimus	Nuju
tacrolimus	Protopic
tacrolimus	tacrolimus
tacrolimus in vehicle base no.238	Nuju
tacrolimus in vehicle base no.238	tacrolimus-vehicle base no.238
tacrolimus/hyaluronate sodium/niacinamide	Oxianujo (with hyaluronate)
tacrolimus/hyaluronate sodium/niacinamide	tacrolimus-hyaluronate-niacin
tacrolimus/niacinamide	Oxianuji
tacrolimus/niacinamide	Oxianujo
tacrolimus/niacinamide	tacrolimus-niacinamide
Other Topical Prescription Therapies	
ruxolitinib phosphate	Opzelura
Systemic Therapies for Atopic Dermatitis	
abrocitinib	Cibinqo
azathioprine	Azasan
azathioprine	Imuran
azathioprine	azathioprine
azathioprine sodium	azathioprine sodium
cyclosporine	Sandimmune
cyclosporine	cyclosporine
cyclosporine, modified	Gengraf
cyclosporine, modified	Neoral
cyclosporine, modified	cyclosporine modified
methotrexate	Xatmep
methotrexate sodium	Rheumatrex
methotrexate sodium	Trexall
methotrexate sodium	methotrexate sodium
methotrexate sodium/PF	methotrexate sodium (PF)
methotrexate/PF	Otrexup (PF)
methotrexate/PF	Rasuvo (PF)
methotrexate/PF	RediTrex (PF)

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
mycophenolate mofetil	CellCept
mycophenolate mofetil	mycophenolate mofetil
mycophenolate mofetil HCl	CellCept Intravenous
mycophenolate mofetil HCl	mycophenolate mofetil (HCl)
ruxolitinib phosphate	Jakafi
tralokinumab-ldrm	Adbry
upadacitinib	Rinvoq
Asthma Biologics	
benralizumab	Fasenra
benralizumab	Fasenra Pen
mepolizumab	Nucala
omalizumab	Xolair
reslizumab	Cinqair
tezepelumab-ekko	Tezspire
Oral Azithromycin	
azithromycin	Zithromax
azithromycin	Zithromax TRI-PAK
azithromycin	Zithromax Z-Pak
azithromycin	Zmax
azithromycin	azithromycin
Exacerbation Asthma Inhalers (SABA or SAMA)	
albuterol sulfate	ProAir HFA
albuterol sulfate	ProAir RespiClick
albuterol sulfate	Proair Digihaler
albuterol sulfate	Proventil HFA
albuterol sulfate	Ventolin HFA
albuterol sulfate	albuterol sulfate
ipratropium bromide	Atrovent HFA
ipratropium bromide	ipratropium bromide
levalbuterol HCl	Xopenex
levalbuterol HCl	Xopenex Concentrate
levalbuterol HCl	levalbuterol HCl
levalbuterol tartrate	Xopenex HFA
levalbuterol tartrate	levalbuterol tartrate
Oral Glucocorticoids	
cortisone acetate	cortisone
dexamethasone	Decadron
dexamethasone	DexPak 10 day
dexamethasone	DexPak 13 Day
dexamethasone	DexPak 6 Day
dexamethasone	Dexabliss
dexamethasone	Dexamethasone IntensoI
dexamethasone	Dxevo
dexamethasone	Hemady
dexamethasone	HiDex
dexamethasone	LoCort
dexamethasone	TaperDex
dexamethasone	ZCort

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dexamethasone	ZoDex
dexamethasone	ZonaCort
dexamethasone	dexamethasone
hydrocortisone	Alkindi Sprinkle
hydrocortisone	Cortef
hydrocortisone	hydrocortisone
methylprednisolone	Medrol
methylprednisolone	Medrol (Pak)
methylprednisolone	Methylpred DP
methylprednisolone	methylprednisolone
prednisolone	Millipred
prednisolone	Millipred DP
prednisolone	prednisolone
prednisolone acetate	Flo-Pred
prednisolone sodium phosphate	Millipred
prednisolone sodium phosphate	Orapred ODT
prednisolone sodium phosphate	Pediapred
prednisolone sodium phosphate	Veripred 20
prednisolone sodium phosphate	prednisolone sodium phosphate
prednisone	Deltasone
prednisone	Prednisone Intensol
prednisone	Rayos
prednisone	prednisone
Zileuton	
zileuton	Zyflo
zileuton	Zyflo CR
zileuton	zileuton
Montelukast	
montelukast sodium	Singulair
montelukast sodium	montelukast
Maintenance Asthma Inhalers (ICS or LABA or LAMA)	
beclomethasone dipropionate	Qvar
beclomethasone dipropionate	Qvar RediHaler
budesonide	Pulmicort
budesonide	Pulmicort Flexhaler
budesonide	budesonide
budesonide/formoterol fumarate	Symbicort
budesonide/formoterol fumarate	budesonide-formoterol
ciclesonide	Alvesco
flunisolide	Aerospan
fluticasone furoate	Arnuity Ellipta
fluticasone furoate/umeclidinium bromide/vilanterol trifenate	Trelegy Ellipta
fluticasone furoate/vilanterol trifenate	Breo Ellipta
fluticasone furoate/vilanterol trifenate	fluticasone furoate-vilanterol
fluticasone propionate	ArmonAir Digihaler
fluticasone propionate	ArmonAir RespiClick
fluticasone propionate	Flovent Diskus
fluticasone propionate	Flovent HFA

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
fluticasone propionate	fluticasone propionate
fluticasone propionate/salmeterol xinafoate	Advair Diskus
fluticasone propionate/salmeterol xinafoate	Advair HFA
fluticasone propionate/salmeterol xinafoate	AirDuo Digihaler
fluticasone propionate/salmeterol xinafoate	AirDuo RespiClick
fluticasone propionate/salmeterol xinafoate	Wixela Inhub
fluticasone propionate/salmeterol xinafoate	fluticasone propion-salmeterol
formoterol fumarate	Foradil Aerolizer
formoterol fumarate	Perforomist
formoterol fumarate	formoterol fumarate
ipratropium bromide/albuterol sulfate	Combivent Respimat
ipratropium bromide/albuterol sulfate	ipratropium-albuterol
mometasone furoate	Asmanex HFA
mometasone furoate	Asmanex Twisthaler
mometasone furoate/formoterol fumarate	Dulera
salmeterol xinafoate	Serevent Diskus
tiotropium bromide	Spiriva Respimat
tiotropium bromide	Spiriva with HandiHaler
Proton Pump Inhibitors	
LANSOPRAZOLE	FIRST-Lansoprazole
OMEPRAZOLE	FIRST-Omeprazole
OMEPRAZOLE	Omeprazole+SyrSpend SF Alka
dexlansoprazole	Dexilant
dexlansoprazole	dexlansoprazole
esomeprazole magnesium	Heartburn Treatment
esomeprazole magnesium	Nexium
esomeprazole magnesium	Nexium 24HR
esomeprazole magnesium	Nexium Packet
esomeprazole magnesium	esomeprazole magnesium
esomeprazole sodium	Nexium IV
esomeprazole sodium	esomeprazole sodium
esomeprazole strontium	esomeprazole strontium
lansoprazole	Heartburn Treatment 24 Hour
lansoprazole	Prevacid
lansoprazole	Prevacid 24Hr
lansoprazole	Prevacid SoluTab
lansoprazole	lansoprazole
lansoprazole	lansoprazole (bulk)
naproxen/esomeprazole magnesium	Vimovo
naproxen/esomeprazole magnesium	naproxen-esomeprazole
omeprazole	omeprazole
omeprazole	omeprazole (bulk)
omeprazole magnesium	Acid Reducer (omeprazole)
omeprazole magnesium	Prilosec
omeprazole magnesium	Prilosec OTC
omeprazole magnesium	omeprazole magnesium
omeprazole/sodium bicarbonate	Konvomep
omeprazole/sodium bicarbonate	OmePPI

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
omeprazole/sodium bicarbonate	Zegerid
omeprazole/sodium bicarbonate	Zegerid OTC
omeprazole/sodium bicarbonate	omeprazole-sodium bicarbonate
pantoprazole sodium	Protonix
pantoprazole sodium	pantoprazole
rabeprazole sodium	AcipHex
rabeprazole sodium	AcipHex Sprinkle
rabeprazole sodium	rabeprazole
IL-5 mAbs	
benralizumab	Fasenra
benralizumab	Fasenra Pen
mepolizumab	Nucala
reslizumab	Cinqair
Purine Analogues	
azathioprine	Azasan
azathioprine	Imuran
azathioprine	azathioprine
azathioprine sodium	azathioprine sodium
IL-13 mAbs	
tralokinumab-ldrm	Adbry
Systemic Non-Oral or Injectable Glucocorticoids	
betamethasone acetate and sodium phos in sterile water/PF	betameth ac,sod phos(PF)-water
betamethasone acetate/betamethasone sodium phosphate	BSP-0820
betamethasone acetate/betamethasone sodium phosphate	Beta-1
betamethasone acetate/betamethasone sodium phosphate	Celestone Soluspan
betamethasone acetate/betamethasone sodium phosphate	Pod-Care 100C
betamethasone acetate/betamethasone sodium phosphate	ReadySharp Betamethasone
betamethasone acetate/betamethasone sodium phosphate	betamethasone acet,sod phos
betamethasone acetate/betamethasone sodium phosphate/water	betamethasone ace,sod phos-wtr
betamethasone sodium phosph in sterile water for injection	betamethasone sod phosph-water
dexamethasone acetate and sodium phosphate in sterile water	dexamethasone ac, sod ph-water
dexamethasone acetate in sodium chloride, iso-osmotic	dexamethasone ace-NaCl,iso-osm
dexamethasone sodium phosphate	ReadySharp dexamethasone
dexamethasone sodium phosphate	dexamethasone sodium phosphate
dexamethasone sodium phosphate in 0.9 % sodium chloride	dexamethasone-0.9 % sod. chlor
dexamethasone sodium phosphate/PF	Active Injection Kit D (PF)
dexamethasone sodium phosphate/PF	DoubleDex (PF)
dexamethasone sodium phosphate/PF	MAS Care-Pak (PF)
dexamethasone sodium phosphate/PF	dexamethasone sodium phos (PF)
dexamethasone sodium phosphate/lidocaine HCl	Lidocidex-I
hydrocortisone sodium succinate	A-Hydrocort
hydrocortisone sodium succinate	Solu-Cortef
hydrocortisone sodium succinate/PF	Solu-Cortef Act-O-Vial (PF)
methylprednisolone acetate	Depo-Medrol
methylprednisolone acetate	P-Care D40
methylprednisolone acetate	P-Care D80
methylprednisolone acetate	ReadySharp Methylprednisolone

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
methylprednisolone acetate	methylprednisolone acetate
methylprednisolone acetate in sodium chloride,iso-osmotic/PF	methylpred ac(PF)-NaCl,iso-osm
methylprednisolone acetate in sterile water for injection	methylprednisolone acet-water
methylprednisolone sodium succinate	Solu-Medrol
methylprednisolone sodium succinate	methylprednisolone sodium succ
methylprednisolone sodium succinate/PF	Solu-Medrol (PF)
triamcinolone acetonide	Arze-Ject-A
triamcinolone acetonide	Kenalog
triamcinolone acetonide	Kenalog-80
triamcinolone acetonide	P-Care K40
triamcinolone acetonide	P-Care K80
triamcinolone acetonide	Pod-Care 100K
triamcinolone acetonide	Pro-C-Dure 5
triamcinolone acetonide	Pro-C-Dure 6
triamcinolone acetonide	ReadySharp Triamcinolone
triamcinolone acetonide	triamcinolone acetonide
triamcinolone acetonide in 0.9 % sodium chloride	triamcinolone aceton-0.9% NaCl
triamcinolone acetonide/0.9% sodium chloride/PF	triamcinol ac (PF) in 0.9%NaCl
triamcinolone diacetate in 0.9 % sodium chloride	triamcinolone diacet-0.9% NaCl
triamcinolone diacetate in 0.9 % sodium chloride/PF	triamcinolone dia(PF)-0.9%NaCl
triamcinolone hexacetonide	Aristospan Intra-Articular
triamcinolone hexacetonide	Aristospan Intralesional
triamcinolone hexacetonide	Hexatrione
Topical Capsaicin	
capsaicin/skin cleanser	Qutenza
diclofenac sodium/capsaicin	CapsFenac Pak
diclofenac sodium/capsaicin	Dicloheal-60
diclofenac sodium/capsaicin	Diclopak
diclofenac sodium/capsaicin	NuDiclo SoluPAK
diclofenac sodium/capsaicin	Pennaicain
diclofenac sodium/capsaicin	Ziclocin
lidocaine HCl/benzocaine/methyl salicylate/capsaicin	Adazin
Topical Vitamin D Analogues	
calcipotriene	Calcitrene
calcipotriene	Dovonex
calcipotriene	Sorilux
calcipotriene	calcipotriene
calcipotriene/betamethasone dipropionate	Enstilar
calcipotriene/betamethasone dipropionate	Taclonex
calcipotriene/betamethasone dipropionate	Wynzora
calcipotriene/betamethasone dipropionate	calcipotriene-betamethasone
calcipotriene/dimethicone	NuDermRxPAK
calcipotriene/niacinamide	Diooxia
calcipotriene/transparent dressing	Trionex
Systemic Therapies for Prurigo Nodularis	
GABAPENTIN	Fanatrex
aprepitant	Aponvie
aprepitant	Cinvanti

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
aprepitant	Emend
aprepitant	aprepitant
cetirizine HCl	24Hour Allergy
cetirizine HCl	All Day Allergy (cetirizine)
cetirizine HCl	All Day Allergy Relief(cetir)
cetirizine HCl	Aller-Tec
cetirizine HCl	Allergy Relief (cetirizine)
cetirizine HCl	Child Allergy Relf(cetirizine)
cetirizine HCl	Child's All Day Allergy(cetir)
cetirizine HCl	Children's Aller-Tec
cetirizine HCl	Children's Allergy Complete
cetirizine HCl	Children's Allergy(cetirizine)
cetirizine HCl	Children's Cetirizine
cetirizine HCl	Children's Wal-Zyr
cetirizine HCl	Children's Zyrtec Allergy
cetirizine HCl	Quzyttir
cetirizine HCl	Wal-Zyr (cetirizine)
cetirizine HCl	Zyrtec
cetirizine HCl	cetirizine
cyclosporine	Sandimmune
cyclosporine	cyclosporine
cyclosporine, modified	Gengraf
cyclosporine, modified	Neoral
cyclosporine, modified	cyclosporine modified
desloratadine	Clarinx
desloratadine	desloratadine
fexofenadine HCl	Allegra Allergy
fexofenadine HCl	Allegra Hives
fexofenadine HCl	Aller-Ease
fexofenadine HCl	Aller-Fex
fexofenadine HCl	Aller-ease
fexofenadine HCl	Allergy Relief (fexofenadine)
fexofenadine HCl	Children's Allegra Allergy
fexofenadine HCl	Children's Allergy Relief(fex)
fexofenadine HCl	Children's Wal-Fex
fexofenadine HCl	Wal-Fex Allergy
fexofenadine HCl	fexofenadine
fexofenadine HCl/pseudoephedrine HCl	24HR Allergy-Congestion Relief
fexofenadine HCl/pseudoephedrine HCl	Allegra-D 12 Hour
fexofenadine HCl/pseudoephedrine HCl	Allegra-D 24 Hour
fexofenadine HCl/pseudoephedrine HCl	Allergy Relief-D(fexofenadine)
fexofenadine HCl/pseudoephedrine HCl	Allergy-Congest Relief-D(fexo)
fexofenadine HCl/pseudoephedrine HCl	Wal-Fex D 12 Hour
fexofenadine HCl/pseudoephedrine HCl	Wal-Fex D 24 Hour
fexofenadine HCl/pseudoephedrine HCl	fexofenadine-pseudoephedrine
gabapentin	Gralise
gabapentin	Gralise 30-Day Starter Pack
gabapentin	Neuraptine

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
gabapentin	Neurontin
gabapentin	gabapentin
gabapentin enacarbil	Horizant
lenalidomide	Revlimid
lenalidomide	lenalidomide
levocetirizine dihydrochloride	24HR Allergy Relief
levocetirizine dihydrochloride	Allergy Relief (levocetirizin)
levocetirizine dihydrochloride	Xyzal
levocetirizine dihydrochloride	levocetirizine
loratadine	Alavert
loratadine	Allerclear
loratadine	Allergy Relief (loratadine)
loratadine	Children's Allergy Relief(lor)
loratadine	Children's Claritin
loratadine	Children's Loratadine
loratadine	Claritin
loratadine	Claritin Liqui-Gel
loratadine	Claritin RediTabs
loratadine	Loradamed
loratadine	Non-Drowsy Allergy
loratadine	Vicks QlearQuil Allergy
loratadine	Wal-itin
loratadine	loratadine
methotrexate	Xatmep
methotrexate sodium	Rheumatrex
methotrexate sodium	Trexall
methotrexate sodium	methotrexate sodium
methotrexate sodium/PF	methotrexate sodium (PF)
methotrexate/PF	Otrexup (PF)
methotrexate/PF	Rasuvo (PF)
methotrexate/PF	RediTrex (PF)
montelukast sodium	Singulair
montelukast sodium	montelukast
naltrexone HCl	Naltrex
naltrexone HCl	naltrexone
naltrexone microspheres	Vivitrol
pregabalin	Lyrica
pregabalin	Lyrica CR
pregabalin	pregabalin
thalidomide	Thalomid
Local Nasal Glucocorticoids	
beclomethasone dipropionate	Beconase AQ
beclomethasone dipropionate	QNASL
budesonide	Rhinocort Allergy
budesonide	Rhinocort Aqua
budesonide	budesonide
ciclesonide	Omnaris
ciclesonide	Zetonna

Appendix D. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
flunisolide	flunisolide
fluticasone furoate	Children's Flonase Sensimist
fluticasone furoate	Flonase Sensimist
fluticasone furoate	Veramyst
fluticasone propionate	24 Hour Allergy Relief
fluticasone propionate	Aller-Flo
fluticasone propionate	Allergy Relief (fluticasone)
fluticasone propionate	Children's Flonase Allergy Rf
fluticasone propionate	Childrens 24 Hr Allergy Relief
fluticasone propionate	ClariSpray
fluticasone propionate	Flonase Allergy Relief
fluticasone propionate	Xhance
fluticasone propionate	fluticasone propionate
fluticasone propionate/sodium chloride/sodium bicarbonate	Ticanase
fluticasone propionate/sodium chloride/sodium bicarbonate	Ticaspray
mometasone furoate	Nasonex
mometasone furoate	Nasonex 24hr Allergy
mometasone furoate	Sinuva
mometasone furoate	mometasone
triamcinolone acetonide	24 Hour Nasal Allergy
triamcinolone acetonide	Aller-Cort
triamcinolone acetonide	Children's Nasacort
triamcinolone acetonide	Nasacort
triamcinolone acetonide	Nasacort Allergy
triamcinolone acetonide	Nasal Allergy
triamcinolone acetonide	triamcinolone acetonide

Appendix E. List of Healthcare Common Procedure Coding System, Level II (HCPCS and ICD-10) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
Atopic Dermatitis			
L20	Atopic dermatitis	Diagnosis	ICD-10-CM
L20.0	Besnier's prurigo	Diagnosis	ICD-10-CM
L20.8	Other atopic dermatitis	Diagnosis	ICD-10-CM
L20.81	Atopic neurodermatitis	Diagnosis	ICD-10-CM
L20.82	Flexural eczema	Diagnosis	ICD-10-CM
L20.83	Infantile (acute) (chronic) eczema	Diagnosis	ICD-10-CM
L20.84	Intrinsic (allergic) eczema	Diagnosis	ICD-10-CM
L20.89	Other atopic dermatitis	Diagnosis	ICD-10-CM
L20.9	Atopic dermatitis, unspecified	Diagnosis	ICD-10-CM
Asthma			
J45	Asthma	Diagnosis	ICD-10-CM
J45.2	Mild intermittent asthma	Diagnosis	ICD-10-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.3	Mild persistent asthma	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.4	Moderate persistent asthma	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.5	Severe persistent asthma	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.9	Other and unspecified asthma	Diagnosis	ICD-10-CM
J45.90	Unspecified asthma	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.99	Other asthma	Diagnosis	ICD-10-CM
Chronic Rhinosinusitis			
J31	Chronic rhinitis, nasopharyngitis and pharyngitis	Diagnosis	ICD-10-CM
J31.0	Chronic rhinitis	Diagnosis	ICD-10-CM
J31.1	Chronic nasopharyngitis	Diagnosis	ICD-10-CM
J31.2	Chronic pharyngitis	Diagnosis	ICD-10-CM
J32	Chronic sinusitis	Diagnosis	ICD-10-CM
J32.0	Chronic maxillary sinusitis	Diagnosis	ICD-10-CM
J32.1	Chronic frontal sinusitis	Diagnosis	ICD-10-CM
J32.2	Chronic ethmoidal sinusitis	Diagnosis	ICD-10-CM
J32.3	Chronic sphenoidal sinusitis	Diagnosis	ICD-10-CM
J32.4	Chronic pansinusitis	Diagnosis	ICD-10-CM
J32.8	Other chronic sinusitis	Diagnosis	ICD-10-CM
J32.9	Chronic sinusitis, unspecified	Diagnosis	ICD-10-CM

Appendix E. List of Healthcare Common Procedure Coding System, Level II (HCPCS and ICD-10) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
J33	Nasal polyp	Diagnosis	ICD-10-CM
J33.0	Polyp of nasal cavity	Diagnosis	ICD-10-CM
J33.1	Polypoid sinus degeneration	Diagnosis	ICD-10-CM
J33.8	Other polyp of sinus	Diagnosis	ICD-10-CM
J33.9	Nasal polyp, unspecified	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
Eosinophilic Esophagitis			
K20	Esophagitis	Diagnosis	ICD-10-CM
K20.0	Eosinophilic esophagitis	Diagnosis	ICD-10-CM
K20.8	Other esophagitis	Diagnosis	ICD-10-CM
K20.80	Other esophagitis without bleeding	Diagnosis	ICD-10-CM
K20.81	Other esophagitis with bleeding	Diagnosis	ICD-10-CM
K20.9	Esophagitis, unspecified	Diagnosis	ICD-10-CM
K29.0	Acute gastritis	Diagnosis	ICD-10-CM
K29.00	Acute gastritis without bleeding	Diagnosis	ICD-10-CM
K29.01	Acute gastritis with bleeding	Diagnosis	ICD-10-CM
K29.3	Chronic superficial gastritis	Diagnosis	ICD-10-CM
K29.30	Chronic superficial gastritis without bleeding	Diagnosis	ICD-10-CM
K29.31	Chronic superficial gastritis with bleeding	Diagnosis	ICD-10-CM
K29.4	Chronic atrophic gastritis	Diagnosis	ICD-10-CM
K29.40	Chronic atrophic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.41	Chronic atrophic gastritis with bleeding	Diagnosis	ICD-10-CM
K29.5	Unspecified chronic gastritis	Diagnosis	ICD-10-CM
K29.50	Unspecified chronic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.51	Unspecified chronic gastritis with bleeding	Diagnosis	ICD-10-CM
K29.6	Other gastritis	Diagnosis	ICD-10-CM
K29.60	Other gastritis without bleeding	Diagnosis	ICD-10-CM
K29.61	Other gastritis with bleeding	Diagnosis	ICD-10-CM
K29.7	Gastritis, unspecified	Diagnosis	ICD-10-CM
K29.70	Gastritis, unspecified, without bleeding	Diagnosis	ICD-10-CM
K29.71	Gastritis, unspecified, with bleeding	Diagnosis	ICD-10-CM
K52.2	Allergic and dietetic gastroenteritis and colitis	Diagnosis	ICD-10-CM
K52.21	Food protein-induced enterocolitis syndrome	Diagnosis	ICD-10-CM
K52.22	Food protein-induced enteropathy	Diagnosis	ICD-10-CM
K52.29	Other allergic and dietetic gastroenteritis and colitis	Diagnosis	ICD-10-CM
K52.8	Other specified noninfective gastroenteritis and colitis	Diagnosis	ICD-10-CM
K52.81	Eosinophilic gastritis or gastroenteritis	Diagnosis	ICD-10-CM
K52.89	Other specified noninfective gastroenteritis and colitis	Diagnosis	ICD-10-CM
K52.9	Noninfective gastroenteritis and colitis, unspecified	Diagnosis	ICD-10-CM
Prurigo Nodularis			
L28.1	Prurigo nodularis	Diagnosis	ICD-10-CM
Systemic Therapies for Atopic Dermatitis			
J7500	Azathioprine, oral, 50 mg	Procedure	HCPCS
J7501	Azathioprine, parenteral, 100 mg	Procedure	HCPCS
J7502	Cyclosporine, oral, 100 mg	Procedure	HCPCS
J7515	Cyclosporine, oral, 25 mg	Procedure	HCPCS
J7517	Mycophenolate mofetil, oral, 250 mg	Procedure	HCPCS

Appendix E. List of Healthcare Common Procedure Coding System, Level II (HCPCS and ICD-10) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
J8610	Methotrexate, oral, 2.5 mg	Procedure	HCPCS
J9250	Methotrexate sodium, 5 mg	Procedure	HCPCS
J9260	Methotrexate sodium, 50 mg	Procedure	HCPCS
Asthma Biologics			
J0517	Injection, benralizumab, 1 mg	Procedure	HCPCS
J2182	Injection, mepolizumab, 1 mg	Procedure	HCPCS
J2356	Injection, tezepelumab-ekko, 1 mg	Procedure	HCPCS
J2357	Injection, omalizumab, 5 mg	Procedure	HCPCS
J2786	Injection, reslizumab, 1 mg	Procedure	HCPCS
Oral Azithromycin			
Q0144	Azithromycin dihydrate, oral, capsules/powder, 1 g	Procedure	HCPCS
Exacerbation Asthma Inhalers (SABA or SAMA)			
J7602	Albuterol, all formulations including separated isomers, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 1 mg (Albuterol) or per 0.5 mg Levalbuterol)	Procedure	HCPCS
J7603	Albuterol, all formulations including separated isomers, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, per 1 mg (Albuterol) or per 0.5 mg Levalbuterol)	Procedure	HCPCS
J7607	Levalbuterol, inhalation solution, compounded product, administered through DME, concentrated form, 0.5 mg	Procedure	HCPCS
J7609	Albuterol, inhalation solution, compounded product, administered through DME, unit dose, 1 mg	Procedure	HCPCS
J7610	Albuterol, inhalation solution, compounded product, administered through DME, concentrated form, 1 mg	Procedure	HCPCS
J7611	Albuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, 1 mg	Procedure	HCPCS
J7612	Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, 0.5 mg	Procedure	HCPCS
J7613	Albuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 1 mg	Procedure	HCPCS
J7614	Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg	Procedure	HCPCS
J7615	Levalbuterol, inhalation solution, compounded product, administered through DME, unit dose, 0.5 mg	Procedure	HCPCS
J7616	Albuterol, up to 5 mg and ipratropium bromide, up to 1 mg, compounded inhalation solution, administered through DME	Procedure	HCPCS
J7617	Levalbuterol, up to 2.5 mg and ipratropium bromide, up to 1 mg, compounded inhalation solution, administered through DME	Procedure	HCPCS
J7618	Albuterol, all formulations including separated isomers, inhalation solution administered through DME, concentrated form, per 1 mg (albuterol) or per 0.5 mg (levalbuterol)	Procedure	HCPCS
J7619	Albuterol, all formulations including separated isomers, inhalation solution administered through DME, unit dose, per 1 mg (albuterol) or per 0.5 mg	Procedure	HCPCS
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, FDA-approved final product, noncompounded, administered through DME	Procedure	HCPCS

Appendix E. List of Healthcare Common Procedure Coding System, Level II (HCPCS and ICD-10) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
J7621	Albuterol, all formulations, including separated isomers, up to 5 mg (albuterol) or 2.5 mg (levalbuterol), and ipratropium bromide, up to 1 mg, compounded inhalation solution, administered through dme	Procedure	HCPCS
J7625	Albuterol sulfate, 0.5%, per ml, inhalation solution administered through DME	Procedure	HCPCS
J7644	Ipratropium bromide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per mg	Procedure	HCPCS
J7645	Ipratropium bromide, inhalation solution, compounded product, administered through DME, unit dose form, per mg	Procedure	HCPCS
K0504	Albuterol, inhalation solution administered through DME, concentrated form, per milligram	Procedure	HCPCS
K0505	Albuterol, inhalation solution administered through DME, unit dose form, per milligram	Procedure	HCPCS
Oral Glucocorticoids			
J7506	Prednisone, oral, per 5 mg	Procedure	HCPCS
J7509	Methylprednisolone, oral, per 4 mg	Procedure	HCPCS
J7510	Prednisolone, oral, per 5 mg	Procedure	HCPCS
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	Procedure	HCPCS
J8540	Dexamethasone, oral, 0.25 mg	Procedure	HCPCS
Maintenance Asthma Inhalers (ICS or LABA or LAMA)			
J7606	Formoterol fumarate, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, 20 mcg	Procedure	HCPCS
J7626	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg	Procedure	HCPCS
J7627	Budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg	Procedure	HCPCS
J7633	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg	Procedure	HCPCS
J7634	Budesonide, inhalation solution, compounded product, administered through DME, concentrated form, per 0.25 mg	Procedure	HCPCS
J7641	Flunisolide, inhalation solution, compounded product, administered through DME, unit dose, per mg	Procedure	HCPCS
Proton Pump Inhibitors			
C9113	Injection, pantoprazole sodium, per vial	Procedure	HCPCS
S0164	Injection, pantoprazole sodium, 40 mg	Procedure	HCPCS
IL-5 mAbs			
J0517	Injection, benralizumab, 1 mg	Procedure	HCPCS
J2182	Injection, mepolizumab, 1 mg	Procedure	HCPCS
J2786	Injection, reslizumab, 1 mg	Procedure	HCPCS
Purine Analogues			
J7500	Azathioprine, oral, 50 mg	Procedure	HCPCS
J7501	Azathioprine, parenteral, 100 mg	Procedure	HCPCS
Systemic Non-Oral or Injectable Glucocorticoids			
C9092	Injection, triamcinolone acetonide, suprachoroidal (Xipere), 1 mg	Procedure	HCPCS
J0702	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg	Procedure	HCPCS
J1020	Injection, methylprednisolone acetate, 20 mg	Procedure	HCPCS
J1030	Injection, methylprednisolone acetate, 40 mg	Procedure	HCPCS
J1040	Injection, methylprednisolone acetate, 80 mg	Procedure	HCPCS

Appendix E. List of Healthcare Common Procedure Coding System, Level II (HCPCS and ICD-10) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
J1094	Injection, dexamethasone acetate, 1 mg	Procedure	HCPCS
J1095	Injection, dexamethasone 9%, intraocular, 1 mcg	Procedure	HCPCS
J1100	Injection, dexamethasone sodium phosphate, 1 mg	Procedure	HCPCS
J1700	Injection, hydrocortisone acetate, up to 25 mg	Procedure	HCPCS
J1710	Injection, hydrocortisone sodium phosphate, up to 50 mg	Procedure	HCPCS
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	Procedure	HCPCS
J2650	Injection, prednisolone acetate, up to 1 ml	Procedure	HCPCS
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	Procedure	HCPCS
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	Procedure	HCPCS
J3299	Injection, triamcinolone acetonide (Xipere), 1 mg	Procedure	HCPCS
J3300	Injection, triamcinolone acetonide, preservative free, 1 mg	Procedure	HCPCS
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	Procedure	HCPCS
J3302	Injection, triamcinolone diacetate, per 5 mg	Procedure	HCPCS
J3303	Injection, triamcinolone hexacetonide, per 5 mg	Procedure	HCPCS
J3304	Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg	Procedure	HCPCS
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	Procedure	HCPCS
Topical Capsaicin			
J7336	Capsaicin 8% patch, per sq cm	Procedure	HCPCS
Systemic Therapies for Prurigo Nodularis			
C9057	Injection, cetirizine HCl, 1 mg	Procedure	HCPCS
C9145	Injection, aprepitant, (Aponvie), 1 mg	Procedure	HCPCS
J0185	Injection, aprepitant, 1 mg	Procedure	HCPCS
J1201	Injection, cetirizine HCl, 0.5 mg	Procedure	HCPCS
J1453	Injection, fosaprepitant, 1 mg	Procedure	HCPCS
J1456	Injection, fosaprepitant (Teva), not therapeutically equivalent to J1453, 1 mg	Procedure	HCPCS
J2212	Injection, methylnaltrexone, 0.1 mg	Procedure	HCPCS
J2315	Injection, naltrexone, depot form, 1 mg	Procedure	HCPCS
J7502	Cyclosporine, oral, 100 mg	Procedure	HCPCS
J7515	Cyclosporine, oral, 25 mg	Procedure	HCPCS
J8501	Aprepitant, oral, 5 mg	Procedure	HCPCS
J8610	Methotrexate, oral, 2.5 mg	Procedure	HCPCS
J9250	Methotrexate sodium, 5 mg	Procedure	HCPCS
J9260	Methotrexate sodium, 50 mg	Procedure	HCPCS
Local Nasal Glucocorticoids			
C9122	Mometasone furoate sinus implant, 10 mcg (Sinuva)	Procedure	HCPCS
J7401	Mometasone furoate sinus implant, 10 mcg	Procedure	HCPCS
J7402	Mometasone furoate sinus implant, (Sinuva), 10 mcg	Procedure	HCPCS
J7626	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg	Procedure	HCPCS
J7627	Budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg	Procedure	HCPCS
J7633	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg	Procedure	HCPCS
J7634	Budesonide, inhalation solution, compounded product, administered through DME, concentrated form, per 0.25 mg	Procedure	HCPCS

Appendix E. List of Healthcare Common Procedure Coding System, Level II (HCPCS and ICD-10) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
J7641	Flunisolide, inhalation solution, compounded product, administered through DME, unit dose, per mg	Procedure	HCPCS
S1090	Mometasone furoate sinus implant, 370 micrograms	Procedure	HCPCS

Appendix F. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool [12.1.2] to investigate the use of dupilumab by indication and age group in the MarketScan Research Databases.

Query period: January 1, 2017 - Most recently available data (September 30, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index requirement: 0 days
Enrollment gap: 45 days
Age groups: 0-<6 months, 6 months-<6 years, 6-<12, 12-<18, 18-<80, 80+ years
Stratifications: Age group, sex, year-month
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Group	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Treatment Episode Gap	Treatment Episode Extension	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Censor Treatment Episode At Evidence Of:
1	Dupilumab use, 7 day gap	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	7 days	0 days	Any	n/a	Yes	*Death; *Data Partner (DP) end date; *Query end date;
2	Dupilumab use, 7 day gap, any indication	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	7 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;
3	Dupilumab use, 7 day gap, atopic dermatitis	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	7 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;

Appendix F. Specifications Defining Parameters for this Request										
4	Dupilumab use, 7 day gap, asthma	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	7 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;
5	Dupilumab use, 7 day gap, chronic rhinosinusitis	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	7 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;
6	Dupilumab use, 7 day gap, eosinophilic esophagitis	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	7 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;
7	Dupilumab use, 7 day gap, prurigo nodularis	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	7 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;
8	Dupilumab use, 0 day gap	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	0 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;
9	Dupilumab use, 0 day gap, any indication	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	0 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;
10	Dupilumab use, 0 day gap, atopic dermatitis	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	0 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;

Appendix F. Specifications Defining Parameters for this Request										
11	Dupilumab use, 0 day gap, asthma	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	0 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;
12	Dupilumab use, 0 day gap, chronic rhinosinusitis	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	0 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;
13	Dupilumab use, 0 day gap, eosinophilic esophagitis	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	0 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;
14	Dupilumab use, 0 day gap, prurigo nodularis	Dupilumab	Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	0	0 days	0 days	Any	n/a	Yes	*Death; *DP end date; *Query end date;

Appendix F. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool [12.1.2] to investigate the use of dupilumab by indication and age group in the MarketScan Research Databases.

Inclusion/Exclusion Criteria										
Scenario	Group	Inclusion/ Exclusion Group	Criteria	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Exclude Evidence Of Days Supply If Inclusion/Exclusion Period Includes Dispensings	Evaluation	Number Of Instances The Criteria Should Be Found In Evaluation Period
1	Dupilumab use, 7 day gap	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2	Dupilumab use, 7 day gap, any indication	All dupilumab indication diagnoses	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply		1
3	Dupilumab use, 7 day gap, atopic dermatitis	Atopic dermatitis diagnosis	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply		1

Appendix F. Specifications Defining Parameters for this Request									
4	Dupilumab use, 7 day gap, asthma	Asthma diagnosis	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply	1
5	Dupilumab use, 7 day gap, chronic rhinosinusitis	Chronic Rhinosinusitis diagnosis	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply	1
6	Dupilumab use, 7 day gap, eosinophilic esophagitis	Eosinophilic esophagitis diagnosis	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply	1
7	Dupilumab use, 7 day gap, prurigo nodularis	Prurigo Nodularis diagnosis	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply	1
8	Dupilumab use, 0 day gap	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
9	Dupilumab use, 0 day gap, any indication	All dupilumab indication diagnoses	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply	1
10	Dupilumab use, 0 day gap, atopic dermatitis	Atopic dermatitis diagnosis	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply	1

Appendix F. Specifications Defining Parameters for this Request									
11	Dupilumab use, 0 day gap, asthma	Asthma diagnosis	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply	1
12	Dupilumab use, 0 day gap, chronic rhinosinusitis	Chronic Rhinosinusitis diagnosis	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply	1
13	Dupilumab use, 0 day gap, eosinophilic esophagitis	Eosinophilic esophagitis diagnosis	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply	1
14	Dupilumab use, 0 day gap, prurigo nodularis	Prurigo Nodularis diagnosis	Inclusion	Any	n/a	-183	0	Evaluation period should search for evidence of days supply	1
International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360. NDC codes are checked against First Data Bank's FDB MedKnowledge®.									

Appendix G. Specifications Used to Define Baseline Characteristic Parameters in this Request

Covariates

Covariate Number	Covariate	Care Setting	Principal Diagnosis Position	Code Category	Evaluation Period Start	Evaluation Period End	Exclude Evidence Of Days Supply If Covariate Includes Dispensings	Number Of Instances In Evaluation Period
Indications								
1	Any indication	Any	n/a	Diagnosis Code	-183	0	n/a	1
2	Atopic dermatitis	Any	n/a	Diagnosis Code	-183	0	n/a	1
3	Asthma	Any	n/a	Diagnosis Code	-183	0	n/a	1
4	Chronic rhinosinusitis	Any	n/a	Diagnosis Code	-183	0	n/a	1
5	Eosinophilic esophagitis	Any	n/a	Diagnosis Code	-183	0	n/a	1
6	Prurigo Nodularis	Any	n/a	Diagnosis Code	-183	0	n/a	1
67	No indication (NOT covar1)	n/a	n/a	Combo covariate	n/a	n/a	n/a	1
Prior Treatments								
7	Topical glucocorticoids	Any	n/a	Drug Code	-183	-31	Evaluation period should search for evidence of days supply	1
8	Topical calcineurin inhibitors	Any	n/a	Drug Code	-183	-31	Evaluation period should search for evidence of days supply	1
9	Other topical prescription therapies	Any	n/a	Drug Code	-183	-31	Evaluation period should search for evidence of days supply	1
10	Systemic therapies for atopic dermatitis	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1
11	Asthma biologics	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1
12	Oral azithromycin	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1
13	Exacerbation asthma inhalers (SABA or SAMA)	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1

Appendix G. Specifications Used to Define Baseline Characteristic Parameters in this Request

Covariates

Covariate Number	Covariate	Care Setting	Principal Diagnosis Position	Code Category	Evaluation Period Start	Evaluation Period End	Exclude Evidence Of Days Supply If Covariate Includes Dispensings	Number Of Instances In Evaluation Period
14	Oral glucocorticoids	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1
15	Zileuton	Any	n/a	Drug Code	-183	-31	Evaluation period should search for evidence of days supply	1
16	Montelukast	Any	n/a	Drug Code	-183	-31	Evaluation period should search for evidence of days supply	1
17	Maintenance asthma inhalers (ICS, LABA, LAMA combinations)	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1
18	Proton pump inhibitors	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1
19	IL-5 mAbs	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1
20	Purine Analogues	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1
21	IL-13 mAbs	Any	n/a	Drug Code	-183	-31	Evaluation period should search for evidence of days supply	1
22	Systemic non-oral or local injectable glucocorticoids	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1
23	Topical capsaicin	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1
24	Topical vitamin D analogues	Any	n/a	Drug Code	-183	-31	Evaluation period should search for evidence of days supply	1
25	Systemic therapies for prurigo nodularis	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1

Appendix G. Specifications Used to Define Baseline Characteristic Parameters in this Request

Covariates

Covariate Number	Covariate	Care Setting	Principal Diagnosis Position	Code Category	Evaluation Period Start	Evaluation Period End	Exclude Evidence Of Days Supply If Covariate Includes Dispensings	Number Of Instances In Evaluation Period
26	Local nasal glucocorticoids	Any	n/a	Drug Code Procedure Code	-183	-31	Evaluation period should search for evidence of days supply	1
Recent Treatments								
27	Topical glucocorticoids	Any	n/a	Drug Code	-30	-1	Evaluation period should search for evidence of days supply	1
28	Topical calcineurin inhibitors	Any	n/a	Drug Code	-30	-1	Evaluation period should search for evidence of days supply	1
29	Other topical prescription therapies	Any	n/a	Drug Code	-30	-1	Evaluation period should search for evidence of days supply	1
30	Systemic therapies for atopic dermatitis	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
31	Asthma biologics	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
32	Oral azithromycin	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
33	Exacerbation asthma inhalers (SABA or SAMA)	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
34	Oral glucocorticoids	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
35	Zileuton	Any	n/a	Drug Code	-30	-1	Evaluation period should search for evidence of days supply	1
36	Montelukast	Any	n/a	Drug Code	-30	-1	Evaluation period should search for evidence of days supply	1
37	Maintenance asthma inhalers (ICS, LABA, LAMA combinations)	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1

Appendix G. Specifications Used to Define Baseline Characteristic Parameters in this Request

Covariates

Covariate Number	Covariate	Care Setting	Principal Diagnosis Position	Code Category	Evaluation Period Start	Evaluation Period End	Exclude Evidence Of Days Supply If Covariate Includes Dispensings	Number Of Instances In Evaluation Period
38	Proton pump inhibitors	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
39	IL-5 mAbs	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
40	Purine Analogues	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
41	IL-13 mAbs	Any	n/a	Drug Code	-30	-1	Evaluation period should search for evidence of days supply	1
42	Systemic non-oral or local injectable glucocorticoids	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
43	Topical capsaicin	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
44	Topical vitamin D analogues	Any	n/a	Drug Code	-30	-1	Evaluation period should search for evidence of days supply	1
45	Systemic therapies for prurigo nodularis	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
46	Local nasal glucocorticoids	Any	n/a	Drug Code Procedure Code	-30	-1	Evaluation period should search for evidence of days supply	1
Concomitant Treatments								
47	Topical glucocorticoids	Any	n/a	Drug Code	0	30	Evaluation period should search for evidence of days supply	1
48	Topical calcineurin inhibitors	Any	n/a	Drug Code	0	30	Evaluation period should search for evidence of days supply	1
49	Other topical prescription therapies	Any	n/a	Drug Code	0	30	Evaluation period should search for evidence of days supply	1

Appendix G. Specifications Used to Define Baseline Characteristic Parameters in this Request

Covariates


Covariate Number	Covariate	Care Setting	Principal Diagnosis Position	Code Category	Evaluation Period Start	Evaluation Period End	Exclude Evidence Of Days Supply If Covariate Includes Dispensings	Number Of Instances In Evaluation Period
50	Systemic therapies for atopic dermatitis	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
51	Asthma biologics	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
52	Oral azithromycin	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
53	Exacerbation asthma inhalers (SABA or SAMA)	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
54	Oral glucocorticoids	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
55	Zileuton	Any	n/a	Drug Code	0	30	Evaluation period should search for evidence of days supply	1
56	Montelukast	Any	n/a	Drug Code	0	30	Evaluation period should search for evidence of days supply	1
57	Maintenance asthma inhalers (ICS, LABA, LAMA combinations)	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
58	Proton pump inhibitors	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
59	IL-5 mAbs	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
60	Purine Analogues	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
61	IL-13 mAbs	Any	n/a	Drug Code	0	30	Evaluation period should search for evidence of days supply	1

Appendix G. Specifications Used to Define Baseline Characteristic Parameters in this Request

Covariates

Covariate Number	Covariate	Care Setting	Principal Diagnosis Position	Code Category	Evaluation Period Start	Evaluation Period End	Exclude Evidence Of Days Supply If Covariate Includes Dispensings	Number Of Instances In Evaluation Period
62	Systemic non-oral or local injectable glucocorticoids	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
63	Topical capsaicin	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
64	Topical vitamin D analogues	Any	n/a	Drug Code	0	30	Evaluation period should search for evidence of days supply	1
65	Systemic therapies for prurigo nodularis	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
66	Local nasal glucocorticoids	Any	n/a	Drug Code Procedure Code	0	30	Evaluation period should search for evidence of days supply	1
Healthcare Utilization								
n/a	Medical utilization	Any	n/a	n/a	-183	-1	n/a	n/a
n/a	Drug utilization	Any	n/a	n/a	-183	-1	n/a	n/a

Appendix H. Design Diagram of Cohort Entry Requirements



*Inclusion Criteria

Window 1: None, any indication, atopic dermatitis, asthma, chronic rhinosinusitis, EoE, prurigo nodularis (one cohort per indication)

**Baseline Characteristics

Window A: Indications (atopic dermatitis, asthma, chronic rhinosinusitis, EoE, prurigo nodularis, any indication, no indication)

Window B: Prior treatments (topical prescription therapies, systemic therapies, oral corticosteroids, inhaled corticosteroids, LABA, leukotriene modifying agents, intranasal corticosteroids)

Window C: Recent treatments (same categories as above)

Window D: Concomitant treatments (same categories as above)

Window E: Healthcare and drug utilization metrics

***Episode Gap

Will assess 7 day, 14 day, 21 day, 28 day, and 35 day treatment gaps (repeat each set of indication -based cohorts per treatment gap)

Strata

- 1) Sex
- 2) Age group (0 -6 mos, 6 mos -5 yrs, 6-11 yrs, 12-17, 18-79, 80+ yrs)
- 3) Year -month